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SUMMARY
An exaggerated postprandial lipaemic response has long been implicated as a risk factor for 
coronary heart disease (CHD). The extent and duration of this postprandial response is 
regulated by lipoprotein lipase (LPL). It is also known that the fatty-acid composition of the 
diet can affect LPL activity. In this study, we therefore hypothesised that chronic dietary 
intakes of n-3 polyunsaturated fatty acids {n-3 PUFA) and monounsaturated fatty acids 
(MUFA) would modulate LPL activity, possibly by influencing gene expression.
The objective of the 2 dietary intervention studies performed was to determine the feasibility 
of increasing dietary n-3 PUFA and MUFA intakes using fatty acid-modified, commercially 
produced foods in a free-living environment. The first study was a 3-week trial in which 9 
middle-aged male volunteers consumed a variety of eicosapentaenoic acid (EPA)- and 
docosahexaenoic acid (DHA)-enriched foods. The second study was a 2-month trial in 
which 43 male volunteers increased their dietary MUFA (oleic acid) intake by replacing 
saturates, using olive oil-enriched foods. Significant increases in EPA+DHA {P < 0.001) 
and oleic-acid (P < 0.001) intakes were observed and the quality of the foods was excellent. 
These findings support the use of fatty acid-modified foods as a suitable vehicle through 
which to achieve changes in dietary composition.
Few effects on postprandial lipid metabolism were found as a result of altering intakes of 
n-3 PUFA or MUFA. This suggests that adaptive responses to modified diets develop over 
a longer period of time than was investigated here. However, a significant reduction in 
plasma total cholesterol (P < 0.02) and LDL cholesterol (P < 0.001) concentrations was 
observed following substitution of MUFA for saturated fatty acids. Therefore, 
MUFA-enriched diets are a suitable alternative to low-fat, high-carbohydrate diets as a 
means of reducing plasma cholesterol levels and CHD risk.
There is strong evidence that dietary fatty acids affect adipose-tissue LPL activity; however, 
to date it is unclear whether these effects are substrate or hormone driven. To investigate if 
the effect is substrate specific, a sensitive competitive RT-PCR method was developed. 
Although no significant changes in LPL gene expression or LPL activity were observed, 
there was a trend for the gene expression values to be higher following the n-3 PUFA and 
MUFA diets.
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CHAPTER 1
1. INTRODUCTION
There is a substantial and consistent body of evidence which suggests that adverse 
dietary habits are a contributory factor in the development of coronary heart disease 
(CHD) (Department of Health (DOH), 1994). According to the evidence the amount 
and type of fat in the diet, significantly influences plasma cholesterol concentrations, 
which in turn are associated with an increased risk of CHD. However, almost all of the 
epidemiological evidence has been determined from fasting lipoprotein 
concentrations, and yet individuals spend a large proportion of the day in the 
postprandial state, where lipid transport is challenged by the absorption of intestinally 
derived lipoproteins following the consumption of a fat-containing meal. Evidence 
suggests that the extent and magnitude of postprandial lipaemia is influenced by diet 
and governs the remodelling of lipoproteins to remnant particles (Sethi et al. 1993). 
Zilversmit (1979) was one of the first to hypothesize that these remnant lipoprotein 
particles are implicated in the pathogenesis of CHD, and since then other researchers 
have demonstrated a significant association with triacylglycerol-rich lipoproteins and 
the progression of CHD (Hodis & Mack, 1995). In this way, an exaggerated 
postprandial lipaemic response may be responsible for the production of an 
atherogenic lipoprotein profile. Lipoprotein lipase (LPL) is a central enzyme in lipid 
metabolism as it is rate limiting in the clearance of lipids from the plasma. LPL 
activity determines both the length and degree of postprandial lipaemia (Eckel et al.
1988) and may therefore be paramount to the development of potentially atherogenic 
lipoproteins. Several studies have shown that LPL activity is altered by diet (Groot et 
al. 1988; Levy et al. 1991; Benhizia et al. 1994; Zampelas et al. 1994a; Harris et al. 
1997), therefore, changing the fatty acid composition of the diet may provide a useful 
tool for changing the lipoprotein profile of the population and so possibly modify their 
risk of CHD.
The focus of this research project is LPL, its gene expression and activity, and the 
effects of dietary changes on LPL and lipoprotein metabolism. This chapter examines
the physiology of LPL, its role in lipoprotein metabolism and the factors which alter 
its gene expression and activity.
1.1 LIPOPROTEIN METABOLISM
Lipoproteins are complex macromolecules made up of TAG, cholesterol, 
phospholipids and specific proteins referred to as apolipoproteins. Their function is to 
transport water-insoluble nutrients from their site of absorption or synthesis to 
peripheral tissues. The apolipoproteins are essential for the correct targetting of the 
lipoproteins to their metabolic sites. Lipid metabolism is broadly divided into 
exogenous and endogenous pathways, which are responsible for the the transport of 
dietary and hepatically derived lipids respectively. The lipoproteins associated with 
these pathways are discussed in the following sections.
1.1.1 EXOGENOUS PATHWAY
1.1. L I Disestion and absorption o f dietary fats
The average western adult consumes anything from 50-100 g fat daily. This fat is 
predominantly made up of triacylglycerol (TAG) with phospholipids contributing 
4-8  g and cholesterol little more than 0.5 g. The digestion and absorption of TAG is 
complex. A brief summary is presented here but a more detailed review is given by 
Carey et al. (1983) and Patsch (1987).
Enzymatic hydrolysis of TAG begins in the mouth and stomach where lingual lipase 
preferentially cleaves the fatty acids from the sn-\lsn-2> position of the TAG molecule 
to generate a diacylglycerol (DAG) molecule and a free fatty acid. Lingual lipase is 
most active on medium- and short-chain triacylglycerols, whereas the hydrolysis and 
absorption of long-chain fatty acids requires the less acidic conditions, lipases, 
detergents and specialised absorptive cells provided by the lumen and mucosa of the 
upper small intestine. A mixture of TAG, DAG, fatty acids, cholesterol esters and 
phospholipids move in to the duodenum and jejunum where they are acted upon by the 
enzymes, pancreatic lipase (PL), cholesterol esterase and phospholipase. The entry of
fat into the duodenum plus the presence of acid stimulates pancreozymin- 
cholecystokinin and secretin release, which induces gall bladder contraction, 
relaxation of Oddi’s sphincter and pancreatic enzyme and bile-acid secretion (Carey et 
a l  1983).
The bile salts facilitate the formation of micelles which solubilise dietary fat and 
enable it to interact with hydrolysing enzymes. PL is activated by a pancreatic 
co-lipase before hydrolysis of TAG can proceed. PL preferentially cleaves the fatty 
acid at the sn~\lsn-2> position of the di- and tri-acylglycerol molecules to create 
2-monoacylglycerol, 2,3-diacylglycerol and fatty acids. 2,3-Diacylglycerol is further 
hydrolysed to 2-monacylglycerol by carboxyl ester hydrolase and PL. Less than 5% of 
ingested fat remains in its di- or tri-acylglycerol form and further hydrolysis of 
2-monoacylglycerol is rare.
2-Monoacylglycerol and fatty acid components of dietary TAG are then absorbed into 
the enterocyte by passive diffusion along a concentration gradient. Rapid estérification 
within the enterocyte maintains the favourable concentration gradient from the lumen 
into the cells. A protein-mediated process may also be involved in the transport of 
fatty acids through the microvillus membrane (Patsch, 1987).
1.1.1.2 Chylomicron formation
Once in the enterocyte, the fate of fatty acids depends on their carbon-chain length. 
Short- and medium-chain fatty acids (with less than 12 carbon atoms) pass through the 
enterocyte into the capillary network, without first being esterified. Here they bind to 
albumin and are transported via the hepatic portal system, as non-esterified fatty acids 
(NEFA), to the liver and other tissues. Free glycerol can pass through the enterocyte in 
a similar manner.
Long-chain fatty acids (with more than 12 carbon atoms) entering the cell are first 
bound to a specific fatty-acid binding protein (FABP), before being re-assembled into 
TAG. FABP facilitates fatty-acid transport from the brush-border membrane through 
the cytosol (Ockner & Manning, 1974) to the smooth endoplasmic reticulum for
estérification to TAG, cholesterol esters and glycerolphospholipids. In this way, FABP 
prevents the accumulation of potentially toxic unbound fatty acids within the cell.
The re-esterification of TAG takes place in the smooth endoplasmic reticulum and can 
occur by either of two pathways: the glycerol-3-phosphate pathway or the 
monacylglycerol pathway. In most tissues, including liver and adipose tissue, TAG is 
re-esterified by the glycerol-3-phosphate pathway. However, as long as 
monoacylglycerol is available, as is the case following a fatty meal, the majority (90%) 
of TAG will be formed by the monoacylglycerol pathway (O’Doherty & Kuksis, 1974) 
in the enterocyte. Before estérification can take place, fatty acids must be activated to 
their CoA derivative by the enzyme CoA ligase. The acylation of sn-2- 
monoacylglycerol to TAG utilises the enzymes monoacylglycerol transferase and 
diacylglycerol transferase.
The newly esterified TAG largely retains its original dietary fatty acid at the sn-2 
position. The fatty acids in the sn-l and sn-3 positions however, are assembled at 
random from the fatty-acid pool absorbed by the enterocyte. The TAG molecules are 
now ready for assembly into chylomicrons.
Cholesterol and cholesterol esters are also important constituents of chylomicrons and 
are derived from either de novo synthesis in the enterocyte or from re-esterified 
absorbed dietary cholesterol. The cholesterol derived from food and endogenous 
sources, such as bile and sloughed cells, is believed to make the greatest contribution 
to postprandial lipaemia (Patsch, 1987). Phospholipids are also required for 
chylomicron formation, although their fatty-acid composition does not necessarily 
reflect dietary intake. This is because the enterocyte can readily synthesize 
phosphatidylcholine which is the predominant phospholipid in chylomicrons.
The apolipoproteins (apo) associated with chylomicrons are apo B-48, A-I, A IV, C-II, 
c  m  and apo E. The enterocyte synthesizes Apo B-48, A-I and A-IV whereas the 
others are acquired after the chylomicron enters the circulation. Only apo B-48 
remains permanently attached to the chylomicron until it is catabolised by the liver.
Apo B-48 is synthesized in the rough endoplasmic reticulum and corresponds to 48% 
of the size of apo B-lOO (Angelin & Rudling, 1992). Apo B-48 is involved in 
establishing the structure of the chylomicron and is essential for the assembly and 
secretion of this lipoprotein (Brewer et al. 1988).
Chylomicrons contain a core of TAG and cholesterol esters wrapped in a surface 
coating of phospholipids, free cholesterol and apolipoproteins. The nascent 
chylomicrons are pinched off the endoplasmic reticulum as vesicles. After further 
modifications in the Golgi apparatus the chylomicrons are released from the cell 
membrane by exocytosis. Chylomicrons are the largest of the lipoprotein species with 
diameters of 80-500 nm, density < 0.96 g/ml and Svedberg flotation (Sf) > 400. The 
size and composition of chylomicrons depends on the amount and type of fat eaten. 
The consumption of small quantities of fat result in the production of small 
chylomicrons and large quantities of fat result in large chylomicrons (Beil & Grundy, 
1980). Polyunsaturates produce larger chylomicrons than saturates (Levy et al. 1991).
After secretion from the enterocyte chylomicrons are taken up into the lymphatic 
system, pass through the thoracic duct and enter the general circulation via the 
subclavian vein to cause postprandial lipaemia.
1.1.1.3 Chylomicron catabolism
Chylomicrons appear in the plasma within an hour of ingesting a fatty meal and are 
usually removed from the plasma 5-8  hours after the last meal. The half-life of 
chylomicrons, in plasma, has been estimated to be 5 minutes (Patsch, 1987). Once 
chylomicrons enter the plasma they are catabolised by a two-step process. The first 
step involves the action of LPL, leading to the formation of TAG-depleted particles, 
termed ‘remnants,’ and the second step involves the receptor-mediated removal of the 
chylomicron renmants.
After secretion, chylomicrons quickly acquire apo C-II, C m  and apo B along with 
phospholipids, and free and esterified cholesterol from circulating HDL. In return.
chylomicrons transfer apo A-I and A-IV to HDL and the lipoprotein-free fraction of 
the plasma (Lefevre et al. 1986). Apo E is synthesized in the liver and gut and to a 
lesser extent in the brain, muscle, ovaries, kidney, spleen and adrenals. The apo Cs are 
synthesized predominantly in the liver (Durrington, 1995). The acquisition of apo C-II 
means activation of LPL is possible. Apo C-II acts as a co-lipase, increasing the 
interaction of the enzyme with its substrate at the interface of the lipoprotein (Sethi et 
al. 1993). LPL is present in the vascular endothelium of tissues with a high 
requirement for fatty acids, including adipose tissue, skeletal muscle, cardiac muscle 
and mammary gland. LPL is anchored to the endothelium by heparan sulphate 
proteoglycans which are integrated into the glycocalyx on the plasma membrane 
(Eckel, 1989). Although LPL is functional at the capillary endothelial surface where it 
is attached, and it is only this LPL that has contact with circulating TAG (Eckel,
1989), the actual synthesis of the enzyme takes place in the parenchymal cells of the 
tissues.
LPL is the rate-limiting step in TAG hydrolysis and its activity is an important 
determinant of the extent and duration of postprandial lipaemia (Eckel et al. 1988). 
Since hydrolysis by LPL is the initial event in the uptake of TAG fatty acids, the 
enzyme controls the availability of an important cellular fuel (Sethi et al. 1993). 
Insulin has important and diverse effects on the action of LPL -  skeletal LPL is 
inhibited and adipose tissue LPL is stimulated by insulin (Sethi et a/. 1993) -  thus 
reflecting the tissue-specific activities in the postabsorptive and postprandial periods 
respectively.
Chylomicrons interact with several LPL molecules resulting in the rapid hydrolysis of 
its TAG and the production of monoacylglycerol and free fatty acids. The hydrolytic 
products are rapidly transported across the endothelium to the parenchymal cells 
where they are oxidised (in muscle) or re-esterified for storage (in adipose tissue). An 
appreciable quantity of free fatty acids escape into the circulation and, bound to 
albumin, they are transported to the liver. If fatty acids are allowed to accumulate, they
inhibit LPL by interfering with the binding of TAG to the enzyme (Eckel, 1989), and 
cause LPL to disassociate from its membrane binding site into the circulation.
The uptake of fatty acids into the tissues is thought to be mediated by acylating- 
stimulating protein (ASP), a 3-protein complex, secreted by adipocytes. ASP 
stimulates increased activity of diacylglycerol acyltransferase, the last enzyme 
involved in TAG synthesis (Yasruel et al. 1991), and thereby increases the rate of 
fatty-acid uptake by the adipocytes following their release from chylomicrons. In this 
way, ASP may play an important role in directing fatty-acid uptake into adipose tissue 
and limiting the amount of free fatty acids escaping into the circulation (Sniderman et 
al. 1997). There is now in vivo evidence in humans that ASP is generated by 
adipocytes in the postprandial period (Sniderman et al. 1997). A report by Cianflone et 
al. (1989) showed that following an oral fat load, plasma ASP levels gradually rose 
and then fell, the changes closely linked in time with the changes in plasma TAG. If 
ASP is involved in TAG clearance a significant increase in the postprandial period 
would be expected. Saleh et al. (unpublished, cited by Sniderman, 1997) demonstrated 
that this was indeed the case. Following an oral fat load, this group found that the 
veno-arterial gradient for TAG was negative, whereas the veno-arterial gradient for 
ASP was positive. This suggests that ASP is generated in response to fatty-acid release 
by LPL and enhanced TAG removal from the blood. The maximal uptake of TAG and 
production of ASP occurred in the second phase of the postprandial period, suggesting 
that TAG removal is dependent on ASP production. In vitro experiments using human 
adipocytes, cultured in mediums containing different factors, were used to determine 
which additions were responsible for increased generation of ASP (Maslowska et al. 
1997). Glucose, fatty acids, VLDL, HDL and LDL were found to have no effect on 
ASP stimulation. Insulin caused a modest but significant increase in ASP, but the most 
profound increase in ASP was seen with the addition of chylomicrons, the effect being 
both time- and concentration-dependent. The mechanisms by which chylomicrons 
produce these effects have yet to be determined. However, it appears that the ASP 
pathway provides the metabolic link between the chylomicron and the adipocyte and 
may be essential for the normal clearance of dietary TAG from the plasma (Sniderman 
etal. 1997).
1.1.1.4 Chylomicron remnant removal
The hydrolysis of chylomicron TAG results in the formation of smaller, 
protein-enriched particles, with a redundant surface coating of free cholesterol and 
phospholipids. As the TAG core shrinks, these surface components, together with apo 
C-n and c  m, are transferred to HDL to maintain the lipoproteins’ stability. It appears 
that the presence of apo C m  is important for preventing premature removal of the 
chylomicron. Apo C m  masks apo E, and so prevents remnant recognition by the 
hepatic receptor (Havel, 1994), and inhibits hepatic lipase (HL), whose lipolytic action 
appears necessary before hepatic uptake (Jackson, 1983). The loss of apo C-II and 
c  m , plus the increasing inaccessibility of core TAG for the LPL-active sites, results 
in cessation of further TAG removal (Sethi et al. 1993), and release of the lipid-poor 
remnant into the circulation for uptake by the liver. Apo B-48 and apo E remain bound 
to the chylomicron remnant and the exposed regions of the apo E allow recognition of 
the remnant particle by hepatic receptors.
Hepatic uptake of chylomicron remnants is thought to be mediated by at least 2 
independent receptors: the LDL receptor and the chylomicron-remnant receptor. The 
LDL receptor (also known as the B 100/E receptor) was identified by Brown & 
Goldstein (1986) and utilises the ligands apo B-lOO and apo E. The chylomicron- 
remnant receptor, more commonly known as the LDL receptor-related protein (LRP), 
has proved more difficult to elucidate. Evidence for the presence of a chylomicron- 
remnant receptor has been demonstrated by a number of studies. Firstly, homozygous 
familial hypercholesterolaemic individuals who lack LDL receptors display normal 
chylomicron-remnant clearance rates (Fredrickson et al. 1978). Secondly, cholesterol 
feeding (Kovanen et al. 1981), saturated fatty acids (Spady & Dietschy, 1985) and the 
administration of bile acids (Angelin et al. 1983) have all been shown to down- 
regulate the LDL receptor, yet sterol loading does not affect chylomicron-remnant 
clearance in macrophages (Sethi et al. 1993). Finally, if chylomicron remnants were 
only cleared by the LDL receptor they would need to compete with LDL for binding. 
The concentration of LDL is much greater than that of chylomicron remnants and yet 
the latter are still removed (Mackness & Durrington, 1992). The LRP recognises apo E
as a ligand molecule, and the slow removal of apo E deficient chylomicron remnants 
(Arbeeny & Rifici, 1984) suggests apo B-48 plays no major role as a receptor ligand.
Several factors are important in regulating chylomicron-remnant removal, these 
include: the apo E phenotype, the activity of HL and the presence of apo C-m. Three 
isoforms of apo E are known; these are denoted E2, E3, E4 with the E3/E3 phenotype 
being the most commonly found (Sethi et al. 1993). Weintraub et al. (1987a) 
demonstrated that postprandial TAG-rich lipoprotein clearance following a retinyl 
palmitate-labelled fat meal was fastest in phenotypes containing the apo E4 allele, 
followed by E3 and E2. The avidity of binding of the apo E alleles to the LRP follows 
the order E4>E3>E2, which explains why homozygotes for E2 have increased plasma 
chylomicron remnants and an increased risk of cardiovascular disease (Sethi et al. 
1993). Havel (1994) proposed that HL facilitates chylomicron-remnant removal. 
Remnant interaction with HL, on the liver-cell surface, increases hydrolysis of residual 
TAG and phospholipid, which facilitates exposure and recognition of apo E, and 
promotes hepatic uptake. The presence of apo C-m inhibits HL activity and blocks the 
apo E recognition sequence.
In addition to the apo E ligand there is strong in vitro evidence that LPL and HL can 
act like ligands and mediate the binding and uptake of lipoproteins into cells 
(Beisiegel et al. 1991; Kounnas et al. 1995; Zambon et al. 1996). LPL has been shown 
to remain associated with the chylomicron remnant once TAG has been hydrolysed 
and the remnant is released into the circulation. Zambon et al. (1996) showed that LPL 
was found bound to TAG-rich lipoproteins (TRL) in postheparin plasma. To verify 
this association of lipases with lipoproteins after hydrolysis, TRL from LPL-deficient 
patients were treated with bovine LPL and HL. After re-isolation, using a sucrose 
density gradient followed by SDS-PAGE and immunoblotting, the bovine enzymes 
were shown to remain associated with the TRL remnants (Beisiegel & Heeren, 1997).
Recent evidence suggests that apo E together with LPL and HL are important 
recognition signals for chylomicron-remnant uptake. Beisiegel & Heeren (1997) 
demonstrated that the uptake of TRL into several cell lines was increased in the
presence of LPL as compared with native TRL from LPL-deficient individuals. The 
addition of HL increased remnant uptake further. Beisiegel & Heeran postulated that 
for optimal catabolism in vivo, both lipases are necessary. Further studies have shown 
that LPL must be in its dimeric form in order to be able to target lipoproteins to their 
receptors, but the enzyme does not need to be catalytically active (Skottova et al. 
1995; Kjapp etal. 1995).
LPL and HL are known to bind to the endothelial surface via proteoglycan molecules. 
It may be that this interaction between lipases and proteoglycans is the mechanism by 
which the lipase-lipoprotein complex binds to the cell surfaces. Several laboratories 
have demonstrated such an interaction (Eisenberg et al. 1992; Beisiegel et al. 1994; 
Kounnas et al. 1995). The binding and uptake of remnants by proteoglycan-deficient, 
Chinese-hamster ovary cells was reduced by 31-80% compared with normal Chinese- 
hamster ovary cells (Beisiegel et al. 1994). This suggests that the binding of remnants 
via apo E, LPL and HL to proteoglycans may be the first step for the cellular uptake 
of these lipoprotein remnants. It appears that the LRP is the main LPL-binding 
receptor on liver cells (Beisiegel et al. 1991).
Originally it was thought that once bound to the receptor, the chylomicron remnant 
was internalised, delivered to hepatic lysosomes and its components completely 
degraded. However, more recent studies suggest that apo E follows an intracellular 
pathway that is different from lipoproteins taken up by the LDL receptor and that apo 
E is recycled rather than being degraded (Beisiegel, 1995).
1.1.2 ENDOGENOUS PATHWAY
1.1.2.1 Very low-densitv lipoprotein metabolism
Very low-density lipoproteins (VLDL) are a heterogeneous group of TRL differing in 
TAG and apolipoprotein content. The liver is the major producer of VLDL although a 
small amount is synthesized and secreted by the gut (Havel, 1997). VLDL are 
continuously secreted and their function is to deliver energy-dense TAG to peripheral 
tissues for storage (adipose tissue) or oxidation (muscle).
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The principal VLDL components, TAG and apo B-lOO, are synthesized in the 
endoplasmic reticulum of the hepatocyte. The nascent VLDL secreted are globular 
particles with a diameter ranging between 25-75 nm (Gibbons, 1990) and a density 
less than 1.006 g/ml (Sf 20-400). The VLDL particle has a hydrophobic, TAG-rich 
core with some cholesterol ester, surrounded by a hydrophilic monolayer of 
phospholipid and free cholesterol. The major structural framework is provided by apo 
B-lOO, which encircles the particle, interacting with the surface lipids and 
hydrophobic core (Gibbons, 1990). Defects in the structure of apo B-lOO or in the 
assembly of apo B-lOO containing lipoproteins results in the failure of hepatic VLDL 
secretion (Brewer et al. 1988). In addition to apo B-lOO, newly synthesized VLDL 
also contains apo C and apo E.
The synthesis and secretion of hepatic VLDL depends upon a complex series of 
intracellular events. However, it appears that the availability of neutral lipids, rather 
than the other components of VLDL, are primarily responsible for controlling the rate 
of VLDL production. Although the synthesis and secretion of apo B-lOO is integrally 
linked, it does not seem to regulate VLDL production (Lewis, 1997), In fact, apo 
B-lOO is produced in excess of the requirements for VLDL synthesis, with up to 70% 
being degraded intracellularly prior to secretion (Lewis, 1997).
Fatty acids for VLDL-TAG synthesis have four possible sources: de novo lipogenesis 
(stimulated by carbohydrate feeding, insulin or excess energy), recycled TAG (derived 
from lipoproteins taken up directly by the liver), plasma NEFA (derived from 
adipose-tissue TAG stores or from LPL lipolysis of circulating lipoproteins) and 
hepatic-cytoplasmic TAG stores (Lewis, 1997). It is difficult to quantify the relative 
contribution of these four sources as they vary with different dietary states. Although 
VLDL-TAG synthesis is essentially driven by the availability of fatty acids, hormonal 
influences are apparent. In vitro (Lewis, 1997) and in vivo (Steiner, 1991; Lewis et al. 
1993 & 1995) experiments have provided evidence that acute hyperinsulinaemia 
suppresses VLDL-TAG and apo B production in humans. However, on removal of 
insulin, VLDL secretion increases. This suggests that insulin suppresses the secretion
11
of VLDL by reducing the supply of NEFA. However, Steiner (1991) noted that if a 
continual supply of NEFA was provided, in the presence of acute hyperinsulinaemia, 
VLDL-TAG production increased. During chronic insulin-infusion periods (24-48 
hours), VLDL secretion is enhanced (Gibbons, 1990; Steiner, 1991) -  an effect which 
may be due to the down regulation of the insulin receptor. Failure of insulin to 
perform its normal function of suppressing HSL and release of NEFA into the 
circulation during the postprandial phase will therefore lead to increased synthesis and 
secretion of VLDL. This is most apparent in insulin-resistant states such as obesity and 
non-insulin-dependent diabetes (NIDDM).
Many factors influence the in vivo effects of insulin on VLDL-TAG production. These 
include the concentration of insulin, the body’s sensitivity to insulin, the presence of 
other hormones and the availability and the nature of the substrates present for TAG 
synthesis. The effect of insulin on the production of VLDL in vivo is thus determined 
by the balance among all these factors (Steiner, 1991).
1.1.2.2 VLDL catabolism
Once secreted, VLDL initially undergo the same changes as chylomicrons; that is, they 
acquire apo C-II, C m  and apo E from circulating HDL and their core TAG is 
hydrolysed by LPL to produce remnant particles which are removed by receptor- 
mediated processes. However, the metabolism of VLDL particles is far more complex 
than that of chylomicrons, varying even between normal individuals because of the 
diverse group of VLDL particles that exist in the plasma (Shepherd & Packard, 1987).
Many discrete subfractions of VLDL exist and these can be isolated on the basis of 
their flotation rate by density-gradient ultracentrifugation. The two most common 
subfractions are VLDLi (Sf 60-400) and VLDL2 (Sf 20-60). The large VLDLi have 
more TAG and less cholesterol and protein than the smaller VLDL2 (Demant et al. 
1988). The metabolic fate of the VLDL depends on the amount and type (includes 
size, lipid and apolipoprotein composition) of VLDL particles produced.
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The size of the VLDL particle depends on the amount of available TAG, with greater 
amounts of TAG producing bigger particles. It has been demonstrated that in the 
postabsorptive state more VLDL2 particles are produced in normotriacylglycerolaemic 
(NTG) individuals, whereas hypertriacylglycerolaemic (HTG) subjects produce more 
VLDLi (Redgrave & Carlson, 1979; Eisenberg, 1987). In the postprandial period the 
increase in VLDL seen in normals is associated with an increase in VLDLi (Griffin, 
1997).
Through a series of delipidation steps involving LPL, HL, lecithin-cholesterol 
acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP), VLDL is 
catabolised. The VLDL progressively loses its TAG core and most of its surface 
phospholipid and apolipoproteins (apo C and E are lost but apo B-lOO remains with 
the lipoprotein particle) and gains cholesterol ester via neutral lipid exchange, so that 
the end product is a complex of solubilised cholesterol and apo B (Packard, 1994). 
During the delipidation process, remnants of different sizes are removed by the LDL 
receptor.
Early studies suggested that a strict precursor-product relationship existed and that all 
the VLDL moved through the intermediate-density lipoprotein (IDL) interval before 
becoming LDL. However, although the metabolism of LDL is closely linked to that of 
VLDL (Packard, 1994), and the majority of VLDL apo B appears in the IDL density 
range (1.006-1.019 g/ml), not all of it becomes LDL (Janus et al. 1980). In fact, both 
VLDL and LDL are heterogeneous species and different forms of VLDL give rise to 
varying LDL products which appear to have distinct structural and metabolic 
properties (Packard, 1994). Further discreditation of the precursor-product relationship 
is provided by evidence that in fasted, normolipidaemic subjects, LDL can be 
produced independently of VLDL (Cohn et al. 1990).
Lipoprotein and hepatic lipases are intimately involved in the delipidation and removal 
of VLDL particles and have an important role in influencing which remnants are 
formed and the rate of their subsequent removal. In vitro studies have shown that 
chylomicrons and large VLDL are the preferred substrates of LPL, whereas HL prefers
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smaller VLDL and IDL (Nicoll & Lewis, 1980). Work by Stalenhoef et al. (1984) 
demonstrated that when trace-labelled VLDLi-TAG was reinjected into LPL-deficient 
individuals it failed to degrade to IDL and LDL. The authors suggested that LPL must 
be the key rate-controlling step in the conversion of VLDLi to VLDL2 because the 
delipidation of VLDLi by LPL results in the formation of VLDL2 . It is possible that 
the activity of the lipase may influence the size of the remnant formed and therefore 
the rate of its subsequent removal. Demant et al. (1988) postulated that if the lipase is 
functioning normally the residence time of VLDLi in the circulation should be short, 
thus minimising the opportunity for cholesterol ester enrichment from HDL by 
exchange for TAG. However, if LPL activity is reduced then this favours cholesterol 
ester enrichment, which results in larger remnants within the VLDL-density range. 
Karpe et al. (1993a) have demonstrated that individuals with HTG have lower 
postheparin LPL activities than NTG. They have also shown that VLDLi are elevated 
postprandially in NTG and to a greater extent in HTG. Postprandial VLDL% levels are 
unchanged. This suggests that the clearance of VLDL is reduced, possibly as a result 
of competition between chylomicrons and VLDL for LPL (Bjorkegren et al. 1996). 
Metabolic studies by Demant et al. (1988) showed that VLDLi from HTG individuals 
catabolise to remnants in the VLDLi-density range, but little of this VLDL-apo B ends 
up as LDL. Other studies of human-deficiency syndromes have shown that the 
conversion of IDL to LDL requires the intervention of HL. These studies showed that 
in the absence of HL, the conversion of VLDLi to VLDL2 was unimpaired, but the 
transfer of apo B through VLDL2 to IDL and LDL was greatly diminished (Demant et 
fl/. 1988).
1.1.2.3 VLDL and postprandial livaemia
The increase in plasma TAG after a meal has been shown to be derived from both 
exogenous (chylomicrons) and endogenous (VLDL) sources by measuring the relative 
contributions of both apo B-48 and apo B-lOO particles to the postprandial increase in 
TAG (Cohn etal. 1993; Karpe etal. 1993a; Schneeman etal. 1993).
Schneeman et al. (1993) noted that after feeding a mixed meal the concentration of 
TAG, cholesterol, apo B-lOO, apo B-48 and apo E increased substantially in the TRL
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fraction. They found that 80% of the postprandial increase in lipoprotein-particle 
number was accounted for by apo B-lOO, but that only 50% of the TAG was carried by 
these particles. Similar results were found by Karpe et al. (1993a). In contrast, Cohn et 
al. (1993) reported that 80% of the TAG was carried in the apo B-48-containing 
particles. The elevation of apo B-lOO-containing particles can only reflect either 
enhanced hepatic secretion of VLDL, reduced degradation of VLDL or a combination 
of both. Enhanced secretion might occur as a result of augmented hepatic uptake of 
fatty acids derived from chylomicron remnants. Cohn et al. (1990) reported a 50% 
increase in the secretion of apo B-lOO particles in the fed state as compared to the 
fasted state. However, this would be counteracted by a fall in the supply of free fatty 
acids from adipose-tissue lipolysis. Free fatty acid levels do not usually increase after 
the ingestion of mixed meals (Lewis et al. 1990) because insulin inhibits the HSL 
hydrolysis of adipose-tissue TAG. Furthermore, the close correlation found by 
Schneeman et al. (1993) between the increment in apo B-48 and apo B-lOO after the 
meal suggests that the reduced efficiency of chylomicron clearance is closely coupled 
to accumulation of VLDL particles. It is therefore very unlikely that hepatic secretion 
would be stimulated by a less efficient removal of chylomicron remnants. It is more 
likely that VLDL synthesis contributes to postprandial VLDL accumulation only to a 
limited extent (Karpe et al. 1993a). Thus, the correlation between the postprandial 
increment in apo B-48 and apo B-lOO (Sf 60-400 fraction), together with the reduced 
plasma concentrations of apo B-lOO in the Sf 12-60 fraction, supports the notion of 
delayed degradation of VLDL during postprandial lipaemia (Karpe et al. 1993a; 
Bjorkegren et al. 1996), due to preferential clearance of chylomicrons by LPL. Work 
by Van Beek et al. (1998) supports this preferential clearance of apo B-48-containing 
particles. They demonstrated that at low levels of LPL activity (< 120 mU/ml) only 
apo B-48-containing particles disappeared from the plasma, but at higher 
concentrations of LPL activity both apo B-containing particles were removed at a 
similar rate. The authors suggest that the presence of apo B-48 lipoproteins hampers 
the removal of apo B-lOO lipoproteins. Further evidence supporting delayed VLDL 
clearance is provided by Potts et al. (1991) who reported that after a fat-rich meal the
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clearance of chylomicron TAG into human subcutaneous tissue was enhanced, 
whereas that of VLDL-TAG was reduced.
1.1.2.4 LDL metabolism
It has already been established that LDL are formed as a result of VLDL delipidation. 
The transformation involves the progressive loss of TAG and the eventual transfer of 
surface lipid (cholesterol and phospholipid) and apo E and C to HDL. This leaves a 
particle with a cholesterol ester-enriched core and an apolipoprotein of predominantly 
B-lOO (Nestle, 1987).
In normals, LDL is predominantly cleared by the LDL receptor. Although most tissues 
display this receptor, the liver is the major site of LDL catabolism. Other mechanisms 
of LDL removal do exist and these assume considerable importance in LDL receptor- 
deficient individuals (Nestle, 1987). Normally, between 33% and 6 6 % of the LDL 
pool is removed through the activity of the LDL receptor (Slater et al. 1984). In 
humans this is shown directly by comparing the rates of removal of injected normal 
LDL with those of a modified LDL, which cannot bind to the LDL receptor. The 
removal rate of the modified LDL is approximately 30% that of the native LDL (Slater 
et al. 1984). Also, individuals who completely lack the LDL receptor still manage to 
clear a third of their LDL (Nestle, 1987).
The LDL binds to its receptor via a binding domain in the apo B-lOO molecule. The 
receptor and lipoprotein are both internalised. Whilst the receptor is recycled back to 
the cell membrane, the lipoprotein is carried to lysosomes where the apo B and 
cholesterol esters are hydrolysed to their constituent molecules. The release of free 
cholesterol inhibits the enzyme HMG-CoA reductase from synthesizing any new 
cholesterol and also down-regulates the LDL receptor, restricting further influx of 
cholesterol. Conversely, the receptor-independent uptake of LDL does not limit the 
uptake of LDL nor regulate the synthesis of cholesterol, and this can contribute to the 
cholesterol overloading of the cell (Nestle, 1987).
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LDL can be separated by size on polyacrylamide gels into 3 or 4 bands: large LDL are 
described as subclass pattern A and small, dense LDL are described as subclass 
pattern B. Density-gradient ultracentrifugation is used to fractionate LDL into at least 
3 subclasses of varying size and density: LDL-I, LDL-II and LDL-IQ (density range 
1.025-1.060 g/ml). Where larger LDL-I and LDL-II predominate pattern A is seen, 
while a high concentration of smaller, denser LDL-DI generates pattern B (Packard,
1994).
It has been recognised for some time that TAG metabolism influences the structure 
and metabolic function of LDL and that the extent of this effect depends on an 
individuals’ triacylglycerolaemic status (Packard et al. 1984). Austin et al. (1990) 
showed that individuals with plasma TAG above 1.1 mmol/1 were more likely to 
express the pattern B phenotype for LDL, whereas at lower plasma TAG 
concentrations the pattern A LDL phenotype was expressed. In support of this, Griffin 
et al. (1994) found that small, dense LDL-m showed a significant positive association 
with plasma TAG when levels were above 1.5 mmol/1.
Caslake et al. (1992) examined the relationship between plasma TAG and LDL by 
measuring the turnover of radio-labelled LDL in 25 healthy adults. The result was that 
LDL associated with subclass pattern A was cleared rapidly from the circulation 
whereas LDL associated with subclass pattern B was removed relatively slowly. As 
the plasma TAG levels rose, the proportion of pattern B LDL increased and the 
fractional catabolic rate (FCR) fell. Shepherd & Packard (1987) noted, whilst 
investigating the VLDL-LDL conversion, that LDL derived from TAG-rich VLDLi 
exhibited a slow FCR, whilst that produced from TAG-poor VLDL2 had a rapid 
clearance rate. They suggested that when hepatic TAG synthesis is enhanced, in 
normal subjects, an increased amount of large VLDLi are produced and the plasma 
TAG levels rise. As VLDLi are converted to LDL, which is inefficiently removed, 
LDL cholesterol levels rise (Packard, 1994). So it appears that when plasma TAG 
levels are low, the LDL formed is associated with subclass pattern A and is quickly 
removed. However, when plasma TAG levels are high, more VLDLi are produced
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giving rise to LDL associated with subclass pattern B, which are more slowly 
removed.
Further support for the relationship between TRL and the different LDL subclasses is 
provided by a number of studies. Karpe et al. (19936) investigated the postprandial 
TRL responses in a group of men with premature coronary atherosclerosis (subdivided 
into HTG and NTG) and healthy controls. The results showed that, compared to the 
NTG and healthy controls, the HTG group had a larger area under the plasma TAG 
time-response curve, lower postheparin LPL and higher HL activities and a greater 
percentage of small, dense LDL apo-B. The magnitude of the TRL response (to the 
oral fat load) was positively correlated with the small, dense LDL apo-B 
concentration. The LPL activity correlated with the light LDL constituents. The 
authors proposed that LPL activity and the TRL response to a fat load can determine 
the type of LDL produced. When normal or high LPL activity levels preside there is 
rapid conversion of VLDL to LDL, and the low levels of VLDL-TAG reduce the 
possibility for LDL modulation. A high plasma LPL activity coupled with a high 
plasma concentration of light LDL could therefore be a sign of an efficient plasma 
TAG transport system. On the other hand, impaired LPL activity will increase the 
residence time of TAG-rich VLDL, which in turn will promote the acquisition of TAG 
by LDL through neutral-lipid exchange. Once enriched with TAG, LDL becomes a 
favourable substrate for HL, the action of which reduces particle size. In this way a 
deficiency of LPL and raised HL activity can work together to promote the formation 
of small, dense LDL.
Griffin et al. (1994) investigated the relationships between plasma TAG and LDL 
subfractions in patients with and without coronary artery disease (CAD). The results 
showed that patients with CAD and patients post-myocardial infarction had greater 
levels of plasma TAG, VLDL-cholesterol and small, dense LDL, compared to 
controls. The investigators went on to show that the proportion of variability in LDL 
subfractions could be explained by plasma TAG concentrations. At low levels of TAG 
(<1.5 mmol/1) all LDL subfractions showed a positive trend with increasing plasma 
TAG. As the TAG rose above 1.5 mmol/1 LDL-I and LDL-II decreased at the expense
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of LDL-in. Both LDL-I and II assumed strong negative associations with TAG while 
the positive association between TAG and LDL-IH became stronger. The authors 
suggested that at TAG levels >1 .5  mmol/1 more VLDLi are produced which give rise 
to smaller, more slowly removed LDL. As the VLDLi particles stay in the circulation 
for longer they also promote the heteroexchange of TAG for cholesterol esters in LDL, 
with the resultant action of HL converting LDL-II into LDL-m. Due to this, perhaps 
fasting plasma VLDLi levels are the most appropriate marker of postprandial lipaemia 
in relation to LDL subclasses (Griffin, 1997).
The relevance of these findings is that a predominance of small, dense LDL particles 
has been associated with a 4-fold increase in risk of CAD and a 6 -fold increase in risk 
of myocardial infarction (Griffin et al. 1994). The atherogenic potential of LDL-m 
comes from evidence that it does not bind as well to the LDL receptor as LDL-II 
(Kleinman et al. 1987). The increased residence time in the circulation allows a 
greater proportion of the LDL-m molecules to infiltrate the arterial wall and become 
trapped in the sub-endothelial space. LDL is also known to bind to arterial-wall 
proteoglycans, which may initiate cholesterol deposition in the arterial wall. Anber et 
al. (1996) found that the LDL-proteoglycan complex formation was greatest in those 
individuals with LDL-m levels above 100 mg/dl. de Graaf et al. (1991) have shown 
that smaller LDL are more susceptible to oxidation than their larger counterparts, 
possibly because they contain less soluble antioxidants. Oxidative damage is thought 
to be a critical step in the initiation and progression of atherosclerotic lesion 
development. Oxidised LDL is taken up by macrophages in a rapid, uncontrolled 
manner.
1.1.3 HDL METABOLISM
HDL are synthesized directly by the liver and intestine (Brewer et al. 1988) or are 
formed in the plasma as disc-shaped particles during the lipolysis of VLDL and 
chylomicrons (Norum, 1992). The nascent HDL are secreted as a discoidal bilayer of 
phospholipids, apolipoproteins and unesterified cholesterol with no core lipid. The 
protein component is predominantly made up of apo A-I and apo A-II. Upon entering 
the circulation the nascent HDL takes up free cholesterol (from peripheral cells and
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circulating TRL and their remnants), other apolipoproteins (apo A IV, C-II, C-m, & 
E), phospholipids and TAG. The free cholesterol is esterified by the rate-limiting 
enzyme LCAT which is located on the HDL and requires apo A-I as its co-factor. The 
initial formation of cholesterol ester by nascent HDL, generates small spherical HDL3 
particles which, as they accumulate more cholesterol ester appear to be transferred into 
the less dense HDL2a particles. HDLia are the major recipient of TAG from circulating 
TRL. On acquiring TAG, in exchange for cholesterol ester, the HDL2a become the less 
dense HDLiy. The enrichment of HDLib with TAG leads to its catabolism by HL and 
conversion to HDL3 . The regenerated HDL3 is then able to repeat the cycle by 
accepting more cholesterol (Grundy & Vega, 1987). Evidence for HL in this 
conversion comes from subjects who lack HL who have raised HDL2 levels 
(Breckenridge et al. 1982). Also, in normals, HDL2 levels are inversely correlated and 
HDL3 levels directly correlated with postheparin HL activity (Nestle, 1987).
1.1.3.1 Reverse cholesterol transport
HDL plays a central role in regulating the flux of lipid and protein constituents 
between the different lipoproteins during their catabolism. In this way the formation of 
HDL is greatly influenced by the circulating levels of, and interaction with, other 
plasma lipoproteins.
The rate of transport of LDL cholesterol into peripheral cells generally exceeds the 
tissue cholesterol requirements. Most cells are unable to oxidise cholesterol and so 
cholesterol must be returned to the liver for elimination in the bile. The return of 
cholesterol from the tissues to the liver is termed ‘reverse cholesterol transport’. This 
pathway is less understood than the pathways by which cholesterol reaches the tissues, 
but seems to play an important role in the development of atherosclerosis. HDL has 
many features which make it very likely that it is intimately involved in this reverse- 
transport process (Durrington, 1995). There is now considerable evidence that a large 
percentage of cholesterol, initially transferred from peripheral cells on to HDL, 
ultimately returns to the liver via chylomicron and VLDL remnants. There is also 
evidence to suggest that during this transfer there is reciprocal enrichment of HDL 
particles with TAG. This reciprocal crossing-over of cholesterol ester and TAG is
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catalysed by an enzyme complex and CETP. Some cholesterol is taken up directly by 
the liver as HDL2 , but most is transferred onto chylomicrons and VLDL remnants. 
These remnants are then removed by hepatic receptors. In humans, at least 80% of the 
cholesterol esters formed initially on HDL are transported to other lipoproteins, and 
estimates suggest that at least 1500 mg of cholesterol is metabolised daily via this 
route (Durrington, 1995). The significance of disturbances in this pathway to the 
aetiology of atherogenesis is important. It is clear that any perturbations which lead to 
increased transfer of cholesterol onto chylomicrons and VLDL, or which result in 
impaired removal of these lipoproteins, will result in accumulation of cholesterol- 
enriched remnants.
Evidence that disturbances in TRL metabolism affect the size and concentration of 
HDL, and ultimately the return of cholesterol to the liver, is provided by a number of 
experiments looking at the postprandial response to a meal. In particular, the 
magnitude of the response has a profound effect on the size and concentration of HDL. 
Patsch et al. (1983) showed that in NTG subjects those with the lowest HDL 
cholesterol (HDL-C) and HDL2 level and the highest fasting TAG level had the 
greatest postprandial TAG response. Further studies went on to demonstrate that 
during postprandial lipaemia HDL2 was enriched with TAG at the expense of 
cholesterol ester, and that those individuals with the lowest HDL2 levels had the 
greatest TAG enrichment and loss of cholesterol ester (Patsch et al. 1984). In vitro, 
these TAG-enriched HDL were rapidly converted to HDL3 by HL (Patsch et al. 1984). 
The authors proposed that individuals with normal fasting lipids and high levels of 
HDL2 have a faster clearance rate of TRL than those with lower HDL2 levels (Patsch 
et al. 1983). They suggested that if LPL activity is high, postprandial TAG will be 
cleared quickly, very little transfer of TAG and phospholipids occurs, and HDL2 
particles will be regenerated. However, if LPL activity is low then postprandial 
lipaemia will be more pronounced, allowing greater interactions between HDL2 and 
TRL, and substantial transfer of TAG and phospholipids to HDL2 and cholesterol ester 
to chylomicrons and VLDL (Patsch, 1987). In this case, HL would delipidate the 
HDL2 to form HDL3 , which are more rapidly removed from the circulation, and 
therefore would not be available for cholesterol uptake and HDL2 formation. These
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suggestions were supported by O’Meara et ah (1992) who noticed similar results when 
studying males with low HDL levels. They found that low HDL levels were associated 
with both normal and hypertriacylglycerolaemia. However it was the HTG individuals 
who had the most pronounced postprandial-TAG response, and the greatest TAG 
enrichment of HDL particles. LPL activity was also positively correlated with HDL 
levels.
Raised levels of large HDL (HDL2b+a) have been inversely correlated with coronary 
heart disease (CHD) risk in a number of case-control studies (cited by Griffin & 
Zampelas, 1995). However, HDL2 is probably not the reverse cholesterol transport 
vehicle per se, but represents a cholesterol-enriched product of an efficient reverse- 
transport system (Griffin & Zampelas, 1995). Although it has not been proved that 
HDL is cardioprotective, low levels of HDL (< 1 mmol/1) are considered detrimental 
in terms of CHD risk, possibly because they represent a compromised pathway for 
cholesterol excretion (Griffin & Zampelas, 1995).
1.1.3.2 Neutral lipid exchange
Neutral lipid exchange and remodelling of HDL/LDL involves the lipases LPL and HL 
as well as CETP. The concentration of TRL dictates the direction of transfer of 
cholesterol ester between the lipoproteins (Griffin, 1997). If LPL activity is low the 
concentration of TRL increases, which promotes the exchange of TAG from 
VLDL/chylomicrons for cholesterol ester from LDL/HDL. This reciprocal exchange of 
TAG and cholesterol ester is achieved by CETP.
In human plasma, most of the CETP is found associated with HDL (Tall, 1993). 
During TRL catabolism, the substrates required by LCAT (phospholipids and 
cholesterol) are transferred into HDL. CETP functions to redistribute cholesterol ester, 
derived from LCAT activity, from its site of synthesis (HDL) to less dense TRL. The 
net transfer occurs predominantly into particles with the lowest cholesterol ester:TAG 
ratio (Tall, 1986). In exchange, the HDL particle becomes enriched with TAG. 
Increased CETP activity is seen with a high saturated-fat diet and may also occur 
because of increased concentrations of acceptor lipoproteins (VLDL, chylomicrons) in
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the plasma. Increased activity results in a greater transfer of cholesterol ester from 
HDL/LDL to VLDL/chylomicrons and increased reciprocal enrichment with TAG. 
The large HDL/LDL, which make good substrates for HL, are hydrolysed to small, 
dense particles which are rapidly removed from the circulation in the case of HDL, or 
are susceptible to oxidative modification and slow removal, if LDL.
The CETP mechanism for switching HDL2 into atherogenic small, dense HDL3 
assigns HDL a central role in the pathogenesis of atherosclerosis. The driving force for 
the switch being TAG-rich lipoprotein metabolism. Under normal physiological 
conditions, as long as the synthesis and removal of TRL is not hampered, CETP levels 
do not become raised and do not encourage rapid TAG-enrichment of HDL/LDL (Tall,
1986).
I.2 DIETARY FATTY ACIDS
Diet has long been suspected of being a factor in the development of CHD. Affluent 
countries, whose diets tend to be rich in total fats, saturated fatty acids (SEA) and 
cholesterol have a higher incidence of CHD than poorer countries. Although other 
factors such as obesity, exercise and genetics are important, dietary saturated fat and 
cholesterol appear to be the main determinant of plasma cholesterol levels (Grundy,
1987). Numerous epidemiological studies have reported a positive relationship 
between plasma cholesterol levels and CHD mortality. In particular, a consistent 
finding is the observation of a positive relationship between calories from SEA in the 
diet, plasma cholesterol levels and rates of CHD mortality (McNamara, 1992). Some 
of the strongest evidence for such a relationship is provided by the Seven Countries 
Study (Keys, 1970). This was a longitudinal, prospective study of middle-aged men 
(from different populations), which examined the relationship between diet, plasma 
cholesterol and other risk factors with CHD rates. The 15-year mortality data for
II,579 middle-aged men showed a direct correlation between percentage calories from 
SPA and CHD mortality rates (Keys et al. 1986). In a comparable analysis of dietary 
and mortality data, Hegsted & Ausman (1988) reported similar findings. Neither study
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demonstrated a negative correlation between percentage calories from polyunsaturated 
fatty acids (PUFA) and CHD mortality. In fact, the data indicated that the differences 
in intakes of PUFA between those who developed CHD and those who did not were 
very small and inconsistent. Other studies have either reported a higher incidence of 
CHD (Garcia-Palmieri et al. 1980; Gordon et al. 1981), no difference (Kromhout & 
Coulander, 1984), or a lower incidence (Shekelle et al. 1981) of CHD with greater 
intakes of PUFA. To date, no populations consuming a high percentage of their energy 
intakes as «-5 PUFA have been found (Grundy, 1987).
There is little consistent evidence of an association between monounsaturated fatty 
acid (MUFA) intakes and risk of CHD and no formal trial has reported of the effects 
of MUFA on CHD (Oliver, 1997). In the Seven Countries Study (Keys, 1970) 
Mediterranean populations were found to have a lower incidence of CHD, yet their 
diets contained 40 % calories as fat (mostly from olive oil). At the time it was 
concluded that the low rates of CHD were due to low intakes of saturated fat. In 
contrast to this Posner et al. (1991) found a significant positive association between 
the incidence of CHD and the proportion of dietary calories from total fat and MUFA, 
even after adjustment for other risk factors.
In the 1970s, Bang et al. (1976) and Dyerberg et al. (1975) hypothesized that the low 
incidence of CHD in Greenland Eskimos was due to increased intakes of marine oils 
consisting of long-chain n-3 PUFA. Similar findings were found in epidemiological 
studies in the Netherlands (Kromhout et al. 1985) and in Chicago (Shekelle et al.
1985). The Multiple Risk Factor Intervention Trial (MRFIT) found that n-3 fatty-acid 
consumption correlated inversely with all-cause and coronary mortality (Dolecek & 
Grandits, 1991). However, other investigators (Curb & Reed, 1985; Vollset et al. 
1985; Lapidus et al. 1986) found no relationship between n-3 PUFA intakes and 
incidence of CHD. A major difference appears to be in the habitual amount of fish 
consumed. In the studies where a protective effect of fish was found, habitual fish 
consumption was low with a few subjects eating fish twice a week or more (Shekelle 
et al. 1985; Kromhout et al. 1985). By contrast, the studies in which no protective 
effect was found, habitual fish intake was high and few subjects rarely or never ate
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fish (Curb & Reed 1985; Vollset et al. 1985). It is therefore possible that moderate 
amounts of fish consumption are protective, but larger amounts provide no additional 
protection. This consensus was further supported by the Harvard Health Professionals 
Follow-up Study (Ascherio et al. 1995), which provided fairly convincing evidence 
that increasing fish consumption beyond 1 to 2  servings per week offers no additional 
health benefit.
In summary, epidemiological data strongly suggest that CHD mortality and dietary fat 
are intimately related. Saturated-fat intakes are believed to determine plasma 
cholesterol levels and n-3 PUFA is thought to protect against CHD. The evidence for a 
protective role for n-6 PUFA and MUFA remains debatable. Despite these findings, 
epidemiological studies do not prove that SFA directly cause CHD. Other studies are 
needed to elucidate the mechanisms by which fatty acids exert their actions.
For many years research has focused on how the type and amount of dietary fatty acids 
influence plasma lipoprotein levels. It was assumed that SFA raised and PUFA 
lowered plasma total cholesterol levels. However, detailed studies of the effects of 
specific types of fatty acids on different lipoprotein classes have demonstrated that this 
is a gross oversimplification. It is now known that n-3 PUFA exert different effects to 
n-6 PUFA, that not all SFA increase plasma cholesterol levels, that MUFA are not 
neutral and that different dietary fatty acids have unique effects on the metabolism of 
specific plasma lipoproteins (McNamara, 1992). The next few sections examine the 
way in which fatty acids influence the metabolism of lipoproteins.
1.2.1 SATURATED FATTY ACIDS
In the 1960s several investigators (Keys et al. 1965; Hegsted et al. 1965) looked at 
how serum cholesterol levels were affected by the major nutrients of the diet. The 
studies, in normal humans, compared cholesterol responses to different fatty acids, 
with those to low-fat, high-carbohydrate intakes. The authors concluded that 
carbohydrates have a neutral effect on total cholesterol levels and that MUFA, when 
exchanged for carbohydrates, are also neutral. Compared to carbohydrates and MUFA,
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SFA raised and PUFA lowered serum cholesterol levels. Since then other metabolic 
studies have proven that SFA raise serum cholesterol levels relative to other nutrients.
However, the hypercholesterolaemic actions of SFA do not extend to all the fatty acids 
in this classification. For instance, medium-chain fatty acids (C8:0-C12:0) are 
absorbed directly into the portal vein and are not involved in lipoprotein metabolism 
(McNamara, 1992). The longer-chain SFA, lauric acid (C12:0), myristic acid (C14:0) 
and palmitic acid (C l6:0) all raise total and LDL cholesterol whereas stearic acid 
(C l8:0) does not (McNamara, 1992). The reason for this ‘neutral’ effect of stearic acid 
is not clear. The absorption of stearic acid from naturally occurring fats is known to be 
normal in humans (Bonanome & Grundy, 1989) so impaired absorption is not a factor. 
However, one possible explanation for the lack of effect on plasma cholesterol levels 
could be that stearic acid is rapidly converted in vivo to oleic acid, whereas palmitic 
acid is not (Grundy & Denke, 1990).
In more recent years, our understanding of cholesterol transport via lipoproteins has 
advanced, and changes in total cholesterol per se do not indicate which lipoproteins 
are primarily being altered. For whole population studies, serum levels of total 
cholesterol correlate highly with concentrations of LDL cholesterol (LDL-C) (Grundy 
& Denke, 1990). Most investigators agree that the lipoprotein fraction most affected 
by saturated fat is the LDL-C level. The mechanism whereby SFA raise LDL-C is not 
completely understood. Presumably these lipids must act by changing the hepatic LDL 
receptor activity, the LDL-C production rate or both. Isotope kinetic studies of LDL 
apo B-lOO support delayed receptor-mediated clearance (Shepherd et al. 1980). It is 
not known definitively how SFA reduce LDL receptor-mediated activity but it is 
possible that they exert their action by redistributing cholesterol to various cellular 
compartments which favour inhibition of receptor synthesis (Grundy & Denke, 1990). 
It is well documented that LDL receptor activity is regulated by the sterol content of 
the cell; recently, a model explaining how fatty acids alter LDL receptor activity by 
modulating cellular sterol content was proposed (Daumerie et al. 1992; Spady et al. 
1993). This model assumes that both dietary cholesterol and fatty acids alter the size 
of the cellular sterol regulatory pool through their activity in driving the estérification
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enzyme acylCoArcholesterol acyl transferase (ACAT). When a fatty acid such as 
palmitic acid is absorbed, sterol estérification is partially inhibited, the size of the 
cholesterol ester pool is reduced and the cholesterol regulatory pool is expanded. As a 
consequence of this expansion, LDL-receptor mRNA concentrations are reduced and 
LDL-receptor activity is partially suppressed. In contrast, when oleic acid (the 
preferred substrate for ACAT) is delivered to the cell, cholesterol is shifted away from 
the regulatory pool into the cholesterol ester pool and LDL-receptor activity is 
increased. Alternatively, enrichment of cell-membrane phospholipids with SFA could 
interfere with the normal function of LDL receptors at the cell surface, thereby 
reducing the binding or internalisation of circulating LDL (Loscalzo et a/. 1987). 
Evidence for increased apo B synthesis is inconclusive at present.
Apart from increasing LDL-C, SFA also affect other lipoprotein fractions. In 
comparison to high-carbohydrate diets, high-fat and high-SFA diets do not generally 
raise serum TAG levels in the absence of a lipolytic defect. The types of fatty acids in 
dietary TAG may have some influence on the size, but not necessarily the number, of 
VLDL particles secreted by the liver. In general, SFA produce smaller VLDL than 
PUFA, which are more prone to end up as LDL than large VLDL (Norum, 1992). 
HDL-C concentrations are affected by both the amount and type of fat in the diet. 
Although the individual SFAs do exert different effects on HDL-C concentrations, 
these differences are thought to be small (Grundy, 1997) and in general, SFA do not 
lower HDL-C. In one study, myristic acid raised HDL-C to a greater extent than lauric 
or palmitic acid (Zock et al. 1994), yet in another study, palmitic acid increased 
HDL-C relative to myristic acid (Tholstrup et al. 1994). In contrast, stearic acid has 
completely the opposite effect, lowering both LDL-C and HDL-C relative to palmitic 
acid or myristic acid (Tholstrup et al. 1994). The highest HDL-C concentrations are 
found in populations where the diet is rich in both total and saturated fat (Grundy,
1986). However, a high level of HDL-C in populations consuming diets high in SFA 
does not protect individuals against CHD if the LDL-C levels are concomitantly 
increased.
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1.2.2 POLYUNSATURATED FATTY ACIDS
Linoleic acid is the predominant n-6 fatty acid and its cholesterol lowering effects are 
well established. These effects appear to extend to all of the lipoprotein fractions -  
VLDL, LDL, HDL, -  although considerable variability in response exists (Grundy, 
1997). Numerous mechanisms for the hypocholesterolaemic action have been 
suggested. However, the majority of findings indicate that PUFA exert their 
hypocholesterolaemic effects by modifying both the synthesis and catabolism of 
lipoproteins, and only minimally affect endogenous cholesterol metabolism (Grundy 
& Denke, 1990). Human studies found that the VLDL-apo B pool size and production 
rate decreased when PUFA was fed (Cortese et al. 1983). Demacker et al. (1991) also 
showed lower fasting and postprandial concentrations of VLDL on a high-PUFA diet 
compared to a high-SFA diet. The authors suggested that the slower clearance of apo 
B-48 particles on the SFA diet delayed the processing of VLDL particles which 
resulted in an increased fraction being converted to LDL. However, the present state of 
knowledge regarding the effects of n-6 PUFA on VLDL production, intravascular 
processing and catabolism remains limited.
The effects of n-6 PUFA versus SFA on LDL metabolism have been the subject of 
much debate. Combined kinetic data from three studies (Shepherd et al. 1980; Turner 
et al. 1981; Cortese et al. 1983) concluded that exchanging PUFA for SFA in the diet 
results in a significant increase in LDL FCR along with a significant decrease in the 
LDL apo B synthetic rate. A question that remains unresolved is whether the decreased 
apo B production results from a decline in VLDL apo B production, decreased 
conversion of VLDL apo B to LDL, increased receptor-mediated direct removal of 
VLDL and IDL, decreased direct secretion of LDL, or a combination of the above 
(Grundy & Denke, 1990). It is not yet known whether increased LDL catabolism is 
due to increasing LDL receptor number or receptor function. There is evidence that 
increasing membrane fluidity does affect receptor function; whether this is a primary 
mechanism for the hypocholesterolaemic effect of n-6 PUFA or is combined with a 
total increase in LDL receptors is still to be determined (McNamara, 1992). It is also 
possible that replacing SFA with n-6 PUFA in the diet merely removes the inhibitory
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effect of SFA on the LDL receptor. According to the model described previously in 
section 1.2.1, linoleic acid is a better substrate for ACAT than SFA, and therefore 
increases the cell’s cholesterol ester pool size and removes the suppression on the 
LDL-receptor activity.
With respect to other lipoproteins there has been some disagreement regarding the 
effects of n-6 PUFA on plasma HDL levels. It appears that the quantity of n-6 PUFA 
ingested is the determining factor and it is generally accepted that when n-6 PUFA are 
in excess of 10% of calories, decreases in HDL-C are observed (Griffin & Zampelas,
1995). However, when there is an isocaloric exchange of n-6 PUFA for SFA, in the 
range 30-40% energy and between P:S 0.2 and 2.0, plasma HDL-C levels are not 
significantly lowered (McNamara, 1992) although the ratio of HDL2 :HDL3 may alter. 
The mechanism by which n-6 PUFA lower HDL-C concentrations was investigated by 
Shepherd et al. (1978) who compared a low-n-d PUFA diet (P:S 0.2, 40% calories fat) 
with a high-«-d PUFA diet (P:S 4.0, 40% calories fat). From the results the authors 
concluded that n-6 PUFA reduce plasma HDL-C by decreasing apo A-I.
1.2.3 MONOUNSATURATED FATTY ACIDS
Early work by Keys et al. (1965) and Hegsted et al. (1965) concluded that oleic acid 
was neutral in its effect on serum cholesterol levels, even though it reduced serum 
concentrations of cholesterol when exchanged for SFA. For many years, as a result of 
their conclusions, research concentrated on PUFA rather than MUFA.
In 1985, Mattson & Grundy carried out a controlled dietary study investigating the 
effects of SFA, MUFA and PUFA on plasma lipoproteins. They found that when SFA 
were replaced with MUFA or PUFA, total cholesterol and LDL-C levels were 
significantly reduced to a similar extent. Grundy (1986) went on to show that 
high-MUFA and low-fat, high-carbohydrate diets lowered total cholesterol levels to a 
similar extent when compared to a high-SFA diet.The low-fat diet also lowered 
HDL-C and increased TAG levels. Other studies have supported the findings of 
Mattson & Grundy (1985). The Jerusalem Nutrition Study (Berry et al. 1991) found
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that total cholesterol and LDL-C were both lowered on a high-PUFA (14.7-17.2%  
calories) and high-MUFA (14.9-16.9% calories) diet, when the diets were relatively 
low in total fat (32% calories) and SFA and cholesterol were kept constant. The 
percentage reduction in total cholesterol on the MUFA diet (approximately 10%) 
compares with the 13% observed by Mattson & Grundy (1985) and the 12.8% 
observed by Mensink & Katan (1989).
HDL-C does not appear to be lowered when SFA are exchanged with MUFA (Mattson 
& Grundy 1985) or when PUFA are exchanged with MUFA (Dreon et al. 1990; Berry 
et al. 1991; Howard et al. 1995). MUFA-rich diets have been shown to have no effect 
on plasma TAG levels when compared to PUFA-rich diets (Dreon et al. 1990; Berry et 
al. 1991). In contrast to this, Howard et al. (1995) found that plasma TAG levels were 
significantly higher on the high-MUFA compared to the high-PUFA diet. When 
compared to high-SFA diets, MUFA have been found to significantly lower plasma 
TAG levels (Wardlaw & Snook, 1990).
For some time there has been debate over the differential effects of MUFA and PUFA 
on serum lipids. Some investigators arguing that PUFA lower total, LDL and HDL 
cholesterol to a greater extent than MUFA and others arguing that PUFA lower total 
and LDL cholesterol to the same extent as MUFA, and that neither lower HDL-C. 
Dreon et al. (1990) compared a high-PUFA (9.7% calories) with a high-MUFA (14% 
calories) diet. The diets were low in total fat (30% calories) and the SFA content was 
kept constant. This group found no significant differences between the diets for 
plasma TAG, total, LDL, VLDL or HDL cholesterol. In contrast. Berry et al. (1991) 
found that the overall effect of the high-PUFA diet on total cholesterol was 
significantly greater than that of the MUFA diet. In a study where MUFA and PUFA 
were compared in a dose-response fashion (Howard et al. 1995), the investigators 
found that plasma total cholesterol was significantly lower on the highest PUFA diet 
(14% calories) compared to the highest MUFA diet (17% calories). Neither of these 
studies found significant changes in HDL-C between the diets.
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In many of the previous studies small, consistent differences in serum lipids have been 
observed, but have not reached significance because of the limited statistical power of 
the studies. In an attempt to draw together the conclusions of several studies and 
define the statistical differences, Gardner & Kraemer (1995) carried out a meta­
analysis using 14 different studies. To be included, the studies had to have at least two 
intervention diets that varied in amounts of MUFA and PUFA, but were otherwise 
similar in total fat, SFA, fibre and cholesterol. Seven of the studies also included a 
comparable high-SFA diet. The results of the meta-analysis indicated no significant 
difference in total, LDL or HDL cholesterol when oils high in MUFA or PUFA were 
compared directly. Plasma TAG levels were modestly but consistently lower on the 
PUFA compared to the MUFA diet. When SFA were replaced with MUFA or PUFA 
there were significant, but comparable decreases in total and LDL cholesterol. Neither 
type of unsaturated fat significantly changed plasma TAG or HDL-C relative to the 
SFA diets, but there was a trend for the results to be lower with the unsaturated fat. A 
similar meta-analysis including 27 studies came to similar conclusions except that they 
also suggested that LDL-C and HDL-C would be slightly, but not significantly, lower 
if there was a substantial substitution of MUFA with PUFA (Mensink & Katan, 1992).
Although the hypocholesterolaemic effect of MUFA has been accepted, the 
mechanism by which this is achieved has not been found. Grundy (1987) speculated 
that the reduction in LDL was not due to a decrease in VLDL because there was no 
change in plasma TAG and the composition of the LDL was the same (Mattson & 
Grundy, 1985). Grundy concluded that the effect of MUFA must be on the LDL 
receptor. Either MUFA increased LDL-receptor activity or the replacement of SFA 
with MUFA removes inhibition of the LDL receptor. As discussed previously, oleic 
acid is the preferred substrate for ACAT. If the model proposed by Daumerie et al. 
(1992) and Spady et al. (1993) holds true, then this may be the mechanism by which 
MUFA increase LDL-receptor activity.
An additional protective effect of dietary MUFA that is proposed is the relatively low 
susceptibility of the oleic acid-rich cholesterol esters, phospholipids and TAG to lipid 
peroxidation, and thus the oxidative modification of LDL, as compared to n-3 and n-6
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PUFA-rich diets, is less. When oxidative stress was assessed in the Jerusalem 
Nutrition Study it was found that LDL isolated after a PUFA-enriched diet contained 
significantly increased levels of lipid peroxides, as compared to the LDL isolated after 
the MUFA-enriched diet (Berry et al. 1991). In addition, LDL isolated from mildly 
hypercholesterolaemic subjects on a MUFA-enriched diet were found to be less 
susceptible to copper-mediated oxidation, lipid-peroxide formation and LDL-protein 
modification than the LDL isolated from the same subjects on an n-6 PUFA diet 
(cited by Griffin & Zampelas, 1995).
1.2.4 LOW-FAT DIETS
The amount of fat in the diet can play a major role in determining plasma lipoprotein 
levels. A consistent finding from studies comparing high-fat versus low-fat, high- 
carbohydrate diets is that, in addition to a beneficial lowering of total and LDL 
cholesterol there is a less beneficial raising of VLDL-TAG and a lowering of HDL-C 
(Grundy, 1986; Ullman et al. 1991; Howard et al. 1995). Although carbohydrates 
reduce LDL-C to a similar extent as MUFA (Grundy, 1986) they do so in a completely 
different way to fats. Not only do carbohydrates stimulate the hepatic secretion of 
large VLDL, which are less likely to delipidate to LDL (McNamara, 1992), but they 
also reduce the cholesterol content of the LDL particles (Dreon et al. 1994). If low-fat, 
high-carbohydrate diets can influence the size and composition of lipoproteins, this 
could have major effects on lipoprotein metabolism. A study carried out by Dreon et 
al. (1994) looked at the effect of high- and low-fat diets on LDL-subclass patterns. 
LDL-C fell when subjects moved from a high-fat to a low-fat diet. However, those 
subjects with LDL subclass pattern B showed greater decreases in apo B and LDL 
cholesterol than pattern A subjects. Interestingly, 40% of the subjects with pattern A 
converted to pattern B on the low-fat diet. These results would suggest that those 
individuals with the abnormal LDL subclass pattern B may achieve greater benefits 
from dietary modification than their pattern A counterparts.
Although low-fat diets lower plasma cholesterol concentrations, part of this lowering 
is due to a fall in HDL-C. Combined data from 27 well-controlled studies found that 
HDL-C fell by 0.012 mmol/1 for every 1% energy from SFA that was replaced by
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carbohydrate (Katan, 1997). It has been suggested that the effect of carbohydrate on 
HDL-C seen in short-term studies is transient. However, long-term studies have shown 
that the fall in HDL persists (Sandstrom et al. 1992). Epidemiological studies have 
reported lower HDL-C levels in populations that consume low-fat, high-carbohydrate 
diets (Knuiman et al. 1987; West et al. 1990). Whether this is important or not in 
terms of CHD risk depends on whether HDL particles act against atherosclerosis 
themselves or whether they merely indicate the activity of some other factor that 
protects against atherogenesis. There is strong epidemiological evidence for an inverse 
association between HDL concentrations and cardiovascular disease (Katan, 1997). 
Almost anything that lowers HDL raises CHD risk e.g. smoking, obesity, lack of 
exercise, abstinence from alcohol and being male.
1.2.5 POLYUNSATURATED FATTY ACIDS
Dietary n-3 PUFA possess a double bond between carbon atom 3 and 4 proximal to 
the methyl end of the fatty acid. The main species of this lipid class, which occur 
naturally in appreciable amounts, are a-linolenic acid, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). The fatty acids found predominantly in fish oils are 
EPA and DHA. Only these will be discussed.
Numerous metabolic studies have demonstrated that the intake of n-3 PUFA has a 
significant hypolipidaemic effect, with the major response being a reduction in plasma 
TAG levels (Harris, 1989). In addition, studies have also shown that n-3 PUFA bring 
about changes in eicosanoid metabolism, which affect platelet and endothelial-cell 
interactions in the vessel wall, and macrophage metabolism (McNamara, 1992). The 
combined antithrombic and plasma lipid-lowering effects of dietary n-3 PUFA are 
thought to account for the reduced CHD incidence in populations consuming diets 
high in fish oils. The effects of fish oil on human serum lipid and lipoprotein levels 
were reviewed extensively in 1989 (Harris, 1989) and the conclusions of this review 
have not changed (Harris, 1996). The primary effect of n-3 fatty acids is on VLDL 
levels with a concomitant lowering of plasma TAG. This effect has been demonstrated 
in normolipidaemic, hypercholesterolaemic, hypertriacylglycerolaemic, and combined
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hyperlipidaemic patients (Harris, 1989). There appears to be a dose-response 
relationship between changes in plasma TAG levels and the dose of n-3 PUFA 
administered (the larger the dose the greater the TAG reduction). It is also clear that 
the relative decrease in plasma TAG in response to n-3 PUFA intake is positively 
related to the extent of HTG exhibited by the subjects (Harris, 1989). As well as the 
hypotriacylglycerolaemic effects of n-3 fatty acids, the composite data from 
Harris (1989) demonstrate either no change or modest increases in LDL and HDL and 
small increases or decreases in total cholesterol. Another potential benefit of n-3 
PUFA is the maintenance of the hypotriacylglycerolaemic effect when individuals are 
challenged with a high-carbohydrate diet (Harris, 1984).
There are several factors to consider when interpreting total cholesterol and LDL-C 
results. These include: the presence or absence of a lipoprotein disorder and the type 
of disorder, the type of fat used in the control diet, the dose of fish oil given and the 
varying effects of EPA versus DHA (Harris, 1989). Studies in healthy volunteers do 
not show any significant changes in total or LDL cholesterol with modest intakes of 
fish oil, but at very high doses, cholesterol lowering is observed. Some studies where 
lower LDL-C levels were observed with n-3 PUFA feeding did not keep the level of 
SFA constant between the control and n-3 PUFA diets. In this case, the cholesterol 
lowering effect of the n-3 PUFA diet was probably due to the replacement of SFA 
with n-3 PUFA. In normal and hyperlipidaemics, when SFA was kept constant, 
LDL-C levels have been shown to rise (Harris, 1989). In particular, LDL-C increases 
have been demonstrated in HTG and diabetics (Harris, 1989; Radack et al. 1990; 
Kasim-Karakas, 1995a; Morgan et al. 1995). The increases in LDL-C may actually 
reflect changes in the size of the LDL particles, changing from small, dense to large, 
less dense particles with fish-oil feeding. Large LDL are thought to be less atherogenic 
than small LDL (Prince & Deeg, 1997). Long-term studies using n-3 PUFA have 
demonstrated that the increase in LDL-C observed may be transient, as levels returned 
to normal or were lowered when n-3 PUFA supplementation continued beyond 
9 months (Eritsland et al. 1995; Saynor & Gillott, 1992).
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There is some evidence that EPA and DHA do not similarly affect lipoprotein 
metabolism. In his review, Harris (1989) reported that oils rich in DHA lowered 
LDL-C. More recently, Agren et al. (1996) carried out a study where healthy males 
received either a fish diet (EPA 0.38 g + DHA 0.67 g/day), fish-oil supplements (EPA 
1.33 g + DHA 0.95 g/day) or a DHA-oil supplement (DHA 1.68 g/day) for 14 weeks. 
All groups saw a significant lowering of plasma TAG, indicating that both EPA and 
DHA exhibit hypotriacylglycerolaemic properties. The HDL2 :HDL3 ratio was 
significantly raised in all three groups, although the greatest percent change was seen 
in the fish-diet and DHA-oil groups. None of the groups showed a significant change 
in LDL-C although a slight increasing tendency was observed in the fish-diet and fish- 
oil groups. In agreement with Harris (1989) these data suggest that DHA has a LDL-C 
lowering effect or that the presence of EPA has a LDL-C raising effect.
The mechanistic actions of n-3 PUFA are not fully understood but are believed to alter 
the synthesis, composition and catabolism of VLDL. In vitro and in vivo studies have 
shown that n-3 PUFA lower hepatic TAG synthesis and secretion rates by inhibiting 
acyl-CoA: 1,2-diacylglycerol acyltransferase, the last step in TAG synthesis 
(McNamara, 1992). Increased fatty-acid oxidation (Ribeiro et al. 1991) and 
phospholipid synthesis (Benner et al. 1990) have also been reported with n-3 PUFA 
feeding. Together these actions would alter the amount of TAG available for VLDL 
production. Kinetic studies have demonstrated that the primary mechanism for the 
hypolipidaemic effects of n-3 PUFA are suppression of VLDL and TAG synthesis, 
along with an increase in the FCR of VLDL (Nestle et aZ. 1984; Harris et al. 1990; 
Connor & Connor, 1997). Using a stable-isotope method Bordin et al. (1998) 
observed a significant decrease in VLDL-apo B-lOO pool size and production rate with 
modest fish-oil feeding (3 g n-3 PUFA/day). However, hepatic and lipoprotein lipase 
activities did not change with fish-oil feeding and therefore did not suggest a major 
alteration in VLDL catabolism. Studies in humans show that n-3 PUFA produce 
smaller VLDL (Harris, 1990) which could affect the metabolic channelling of VLDL 
into either the LDL or direct-removal pathways. Originally it was believed that the 
smaller TAG-poor VLDL produced with n-3 PUFA feeding were more easily 
converted to LDL. However, the findings of Kasim-Karakas (1995a) suggest that the
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increase in LDL-C seen with n-3 PUFA are mediated through mechanisms other than 
the accelerated conversion of VLDL to LDL.
HDL-C is not uniformly affected by n-3 PUFA. Harris (1989) reported that HDL-C 
increased with n-3 PUFA supplementation in individuals with normal or 
hyperlipidaemia. However, the response is dependent on the dose of n-3 PUFA 
administered. Kasim-Karakas (1995a ) concluded from the literature that, long-term 
intakes of moderate amounts of n-3 PUFA increase, and large doses lower HDL-C 
levels. In those studies investigated by Harris (1989), where more than 10 g n-3 PUFA 
were given per day, 12 demonstrated a decrease in HDL-C, 2 an increase in HDL-C, 
1 reported no change and 1 study did not record HDL-C. A long-term study carried out 
by Saynor & Gillott (1992) demonstrated that HDL-C levels were significantly raised 
by low-dose, n-3 PUFA feeding and remained so at all time points over the 7-year 
investigation. It has already been mentioned that the amount of fat in the diet affects 
HDL-C levels. Mori et al. (1994) carried out a study using diets with either 40 or 30% 
energy as fat supplemented with 1.32 g EPA/day as either fish or fish oil capsules. 
When the diet contained 40% fat, the addition of both fish and fish oil increased total, 
LDL and HDL cholesterol, and decreased plasma TAG. The 30% fat diet (no n-3 
PUFA) reduced total, LDL and HDL cholesterol and marginally increased plasma 
TAG levels. However, on adding the fish to the 30% fat diet, plasma HDL-C increased 
and TAG decreased significantly. Thus it appears that when n-3 PUFA are added to a 
low- fat, high-carbohydrate diet, the adverse effects on HDL and TAG are impeded. In 
support of this, Agren et al. (1996) also found that HDL-C was higher and TAG lower 
in those subjects who consumed fish or fish oil with a low-fat diet (30-34% energy as 
fat). An increase in the HDL2 :HDL3 ratio and the apo A-I concentration is observed 
with n-3 PUFA feeding (Blonk et al. 1990; Agren et al. 1996), suggesting that n-3 
PUFA encourage the production of the large, cardioprotective HDLi molecules.
1.2.6 DIETARY FATTY ACIDS AND POSTPRANDIAL METABOLISM
Since the work of Zilversmit (1979) much attention has been focused on the response 
of plasma lipoproteins during the absorption of dietary fat (i.e. during the postprandial
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phase). This interest is borne out by the accumulating evidence that postprandial 
plasma TAG and TRL are closely related to atherogenic risk (Bergeron & Havel, 
1997). Most individuals spend the greater part of the day (approximately 17 out of 
every 24 hours) in a postprandial state where their plasma TAG levels are elevated 
above fasting (Williams, 1997). The fasting state therefore provides little information 
on the postprandial handling of TRL. An exaggerated plasma TAG response to a 
fat-containing meal reflects either an over-production of TRL (chylomicrons and or 
VLDL) or the slower clearance of TRL. If dietary fatty acids can alter the 
concentration of postprandial plasma TAG then they may have an important role to 
play in modulating postprandial lipoprotein metabolism. The evidence suggests that it 
is the elevated TAG concentration that dictates the direction of neutral lipid exchange 
and the formation of either beneficial or atherogenic lipoproteins and lipoprotein 
remnants.
There are a number of physiological and dietary factors which affect postprandial 
lipaemia, these include: age, gender, exercise, BMI, LPL activity, insulin and glucose 
metabolism, dietary-fat load, fatty-acid meal composition and habitual dietary-fat 
composition. These were extensively reviewed by Roche & Gibney (1995). In brief, 
postprandial TAG concentrations are greater in older compared to younger volunteers 
and lower in women compared to men. Higher levels of LPL activity have been 
reported in younger compared to older subjects and males appear to have slightly 
lower LPL activities than women. Exercise has been shown to reduce the postprandial 
lipaemic response and is associated with higher levels of LPL activity. Obese 
individuals demonstrate higher postprandial TAG responses than normal-weight 
individuals and this may be related to insulin resistance. Some of the dietary factors 
which affect postprandial lipaemia will be discussed individually.
1.2.6.1 Oral-fat load
The amount of fat consumed at any one meal can vary widely between individuals, 
but is usually in the range of 0-50 g (Dubois et al. 1998). As might be expected, 
increasing the fat content of a meal results in a more marked postprandial lipaemia.
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Cohen et al. (1988) gave three test meals of 40 g, 80 g and 120 g fat to 12 NTG men, 
and found that the plasma TAG response was dose related. Similarly, Murphy et al. 
(1995) reported a step-wise increase in the plasma TAG area under the time-response 
concentration curves following the consumption of a 20 g, 40 g or 80 g fat load. In 
their study, Dubois et al. (1998) were particularly interested in discovering whether or 
not there was a level at which dietary fat did not evoke a postprandial response. Eight 
nomolipidaemic males were randomly fed, on separate occasions, 5 mixed meals 
containing 0 g, 15 g, 30 g, 40 g or 50 g fat. The amount of carbohydrate and protein 
remained constant for all meals, because the ratio of fat to carbohydrate in test meals 
has been shown to influence the postprandial response. Following ingestion of the 
meals there was a step-wise increase in the postprandial rise of chylomicron and serum 
TAG for the 4-fat containing meals, although no change was observed following the 
non-fat meal. The authors also proposed that a threshold amount of fat must be 
consumed to promote significant remodelling of lipoproteins postprandially. They 
reported that 15 g fat per meal was the threshold dietary level. Therefore if fat 
ingestion at a meal is kept low (below 15 g), the subsequent postprandial TAG 
response is small, and the potential for remodelling lipoproteins into a more 
atherogenic form is limited.
1.2.6.2 Fatty-acid composition of test meal
Postprandial lipaemia is known to be affected by meal composition and in particular 
the type of fatty acids within the meal. There are a number of studies reported in the 
literature which have measured such effects. Before making any comparisons between 
studies it is important to consider the following factors which are known to influence 
the postprandial response to a meal, and therefore may complicate interpretations:
• total fat and other nutrient content of the meal
• feeding schedule
• number of meals given
• meal form (solid versus liquid)
• route of administration (oral versus intravenous)
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The magnitude of the postprandial lipaemic response appears to be related to the 
degree of fatty-acid saturation. Zampelas et ah (1994a ) gave three test meals of 
different fatty acid composition to volunteers on three separate occasions. The oils 
used in the test meals were high in either SFA, n-6 PUFA or n-3 PUFA. Fasting lipid 
and hormone levels were similar for each study day. The postprandial TAG response 
was highest with the SFA meal, lowest with the n-3 PUFA meal and intermediate with 
the n-6 PUFA meal. Weintraub et al. ( 1988) on the other hand found no difference in 
the postprandial response to a SFA or n-6 PUFA meal. However, this group used 
different solid foods and oils for the n-6 PUFA and SFA test meals, which may have 
influenced the postprandial handling of the TRL. There also appears to be conflicting 
evidence for the hypotriacylglycerolaemic action of n-3 PUFA when given in a test 
meal. Harris et al. (1988) found no difference in the postprandial response to either a 
n-3 PUFA or SFA test meal. A more recent study by Yahia & Sanders (1996) found 
that when a test meal containing olive oil and MaxEPA was given, the postprandial 
TAG response was significantly lower than when a similar test meal without MaxEPA 
was given. The TAG lowering effects observed postprandially when n-3 PUFA are fed 
are probably due to changes in the synthesis and/or removal of chylomicron-TAG. An 
increased clearance of TAG may result from increased lipolysis via LPL. Zampelas et 
al. (1994a ) observed significantly higher postheparin LPL activities 12 hours after 
feeding the n-3 PUFA meal. Alternatively, n-3 PUFA may inhibit TAG synthesis 
during chylomicron formation by inhibiting lipogenic enzymes in the enterocyte 
(Murthy etal. 1990).
The postprandial responses to MUFA-containing meals have produced conflicting 
results, de Bruin et al. (1993) compared the postprandial response to two fat 
emulsions, one prepared with soybean oil and the other olive oil. No carbohydrate or 
protein was included in the test meals. They reported no difference in the plasma TAG 
response between the meals, although, the retinyl palmitate response was greater 
following the olive-oil meal. The authors suggested that olive oil either increases the 
number of newly secreted chylomicrons or that olive-oil chylomicrons and their 
remnants are removed more slowly than those derived from soybean oil. Another 
study compared the postprandial TAG, apo B-48 and retinyl ester responses in
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60 volunteers given test meals in which SFA were progressively replaced by MUFA. 
The test meals contained 12, 17 and 24% energy as MUFA, with PUFA remaining 
constant. No significant differences were found postprandially between the test meals 
(Zampelas et al. 1994Z?; Jackson et al. 1995) suggesting that MUFA-enriched 
chylomicrons are handled in a similar way to SFA-enriched chylomicrons.
Based on these studies it appears that similar postprandial lipaemic responses are 
observed when meals consisting of SFA, MUFA or n-6 PUFA are fed, but attenuation 
of lipaemia occurs when the meal contains n-3 PUFA.
1.2.6.3 Fatty-acid composition ofbacksround diet
The habitual fatty-acid intake appears to have more of a profound effect on 
postprandial lipaemia than the fatty-acid composition of the test meal ingested. 
Weintraub et al. (1988) randomly fed three different metabolic isocaloric diets rich in 
either SFA, n-6 PUFA or n-3 PUFA to normolipidaemic subjects for 25 days. The diet 
provided 42% energy as fat and the cholesterol and MUFA content of the 3 diets was 
kept constant. The postprandial lipoprotein levels were highest for SFA, intermediate 
for n-6 PUFA and lowest for n-3 PUFA regardless of the test meal given. When the 
test meal contained the same fat as the background diet the postprandial TAG 
responses for the n-6 and n-3 PUFA diets were lower than when the test meal 
contained predominantly SFA. A similar study carried out by Harris et al. (1988) also 
demonstrated that the n-3 PUFA background diet produced significantly lower TAG 
responses than the SFA diet regardless of the type of fat given in the test meal. Again, 
the n-3 PUFA test meal tended to produce a blunted and more prolonged postprandial 
response compared to the SFA meal. However, in contrast to Weintraub’s findings, the 
postprandial TAG response following the n-6 PUFA diet was slightly higher than the 
SFA diet. Two possible explanations for these differences are that the SFA diet 
contained more MUFA (as % energy) than the n-6 PUFA diet and almost half of the 
SFA were stearic acid. Another study (Demacker et al. 1991), which fed diets high in 
n-6 PUFA or SFA for 9 days, found that not only did increasing the PUFA content of 
the diet reduce the postprandial plasma TAG response, but that the 24-hour 
concentrations of apo B-48 were 43% lower. The authors concluded that n-6 PUFA-
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rich diets accelerate the clearance of chylomicrons and reduce the exposure of the 
arterial wall to potentially atherogenic chylomicron remnants. Further evidence for the 
postprandial hyoptriacylglycerolaemic effects of n-3 PUFA was provided by Brown & 
Roberts (1991) who demonstrated that even when a low dose (5g fish oil equivalent to 
1.7g n-3 PUFA/day) of n-3 PUFA was fed for 6 weeks, attenuation of the postprandial 
lipaemic response occurred. Williams et al. (1992) who gave 2.7 g/day n-3 PUFA 
found a similar response. A more recent study (Agren et al. 1996) looked at the 
specific effects of EPA and DHA on the postprandial response to â standard test meal. 
When EPA and DHA were included in the diet the TAG response to the test meal 
(measured as area under the curve) was significantly lower after, compared to before 
the diet, and was significantly different from the change in the control group (whose 
diet was similar barring the omission of n-3 PUFA). The extent of the TAG lowering 
was greatest with the higher n-3 PUFA dose (2.28 g compared to 1.05 g/day). When 
DHA only was added to the diet the postprandial TAG response tended to be lower 
than before the diet, but the change was not significant. However, the baseline values 
were somewhat lower in this group, which may have decreased the magnitude of the 
response.
In a recent review, it was reported that when low-fat, high-carbohydrate diets were 
consumed the postprandial response was greater than before the diet commenced 
(Roche & Gibney, 1995), and that the increased postprandial triacylglycerolaemia was 
due to increased hepatic VLDL production. Harris et al. (1984) demonstrated that the 
fasting HTG effect associated with low-fat diets could be prevented by adding 
n-3 PUFA to the diet. A more recent study investigated whether or not these effects 
were also present in the postprandial phase (Roche & Gibney, 1996). First the group 
confirmed that the HTG effects of low-fat diets were prevented by a low dose of 
n-3 PUFA (EPA 0.44 g + DHA 0.36 g/day) as fasting plasma TAG concentrations 
were not significantly altered. However, the investigators observed that the 
postprandial TAG response, following a standard test meal, was significantly higher in 
the fish-oil supplemented, low-fat group compared to the low-fat group without fish- 
oil supplementation. In contrast, the group that ate a high-fat diet with fish-oil
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supplementation showed a reduced postprandial TAG response. The implications of 
this in terms of CHD risk are not yet known.
The findings of these studies highlight that the effects of background diet on 
postprandial metabolism are more easily distinguished, possibly because adaptational 
responses to altered diet develop over weeks, months and years rather than hours. If 
this is the case, it may be that the studies conducted to date have been too short to 
reveal the full extent of changes in lipoprotein metabolism (Williams, 1997). Support 
of this statement is provided by a recent study which measured the postprandial 
responses to standard meals in subjects living in Southern and Northern Europe, 
whose diets closely reflected the typical diets of their country (Zampelas et al. 1998). 
The 2 groups (Southern and Northern individuals) were given a high-SFA (17% 
energy as SFA, 12% as MUFA and 5% as PUFA) and a high-MUFA (5.4% energy as 
SFA, 24.1% as MUFA and 4.6% as PUFA) test meal on 2 separate occasions. No 
significant differences in the postprandial TAG response was seen between the two 
meal types or between the 2 groups. However, there were significant differences in the 
patterns of postprandial response between the Northern and Southern Europeans. The 
postprandial response curves indicated that TAG values reached a peak earlier and 
returned to baseline values more quickly in the Southern compared to the Northern 
Europeans. These response patterns were reflected in the apo B-48 measurements and 
would suggest that in the latter stages of the postprandial period, chylomicrons and 
their remnants are cleared more quickly in the Southern Europeans. Whether this 
evidence has any significance in terms of CHD risk remains unknown, but these 
findings are consistent with the observation that elevations in late postprandial TAG 
values, between 6 and 10 hours after a meal, have been identified as a significant risk 
factor for CHD in a number of case-control studies (Groot et al. 1991).
The exact mechanism by which n-3 PUFA exert their hypotriacylglycerolaemic effect 
is not exactly known, although it must involve either a reduced synthetic rate of TRL, 
increased catabolic rate or a combination of both. There is no evidence of reduced fat 
absorption associated with fish-oil feeding. However, the re-synthesis of TAG in the 
enterocyte, post-absorption, may be reduced in a similar way to that shown in the liver
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by inhibiting lipogenic enzymes (Harris, 1989: Murthy et al. 1990). If this is the case 
n-3 PUFA may exert their effect by reducing both VLDL and chylomicron synthesis.
It is known that chylomicrons compete with VLDL for LPL-mediated removal. 
Following n-3 PUFA feeding, when VLDL synthesis is diminished, chylomicrons may 
have a greater opportunity to interact with LPL, thereby accelerating their clearance. 
For this mechanism to explain the attenuated, postprandial TAG response, it assumes 
that LPL is saturated prior to n-3 PUFA intervention and becomes less saturated. 
However, LPL does not become saturated until plasma TAG concentrations reach 
5 mmol/1 (Brunzell et al. 1973). This suggests that in NTG individuals, chylomicrons 
will continue to be hydrolysed at the same rate, regardless of the reduced VLDL 
output. However, in the HTG individual, when LPL is likely to be saturated, removal 
of VLDL from the circulation (following n-3 PUFA administration) may enhance 
chylomicron catabolism. There is also little evidence from human studies that 
enhanced LPL activity mediates increased chylomicron catabolism (Harris et al. 1988, 
Weintraub et al. 1988), although animal studies differ from this (Groot et al. 1988; 
Van Heek & Zilversmit, 1990; Levy et al. 1991; Benhizia et al. 1994). Furthermore, 
there is evidence that chylomicrons produced on diets rich in n-6 and n-3 PUFA are 
better substrates for LPL in vitro and are hydrolysed faster than chylomicrons 
containing SFA (Groot et al. 1988; Levy et al. 1991). Finally, results from an 
intravenous fat-tolerance test, following 4 weeks of fish-oil or placebo supplements, 
showed no difference in the rate of fat clearance (Harris & Muzio, 1993). The authors 
concluded that as LPL activity was not altered, the lower TAG responses observed 
postprandially with the fish-oil supplements, were not due to increased chylomicron 
removal. However, the lipid particles in the intravenous fat emulsion are of different 
size and chemical composition to chylomicrons, which will have influenced their 
clearance rate. Furthermore, intravenous fat emulsions do not stimulate glucose- 
dependent insulinotrophic polypeptide (GIF), postulated to be important in mediating 
increased LPL activity in response to fat-containing meals (Murphy et al. 1995).
43
1.3 LIPOPROTEIN LIPASE
Lipoprotein lipase is the rate-controlling enzyme responsible for the hydrolysis of 
TAG in chylomicrons and VLDL. During the hydrolytic process, LPL is intimately 
involved in the remodelling of TRL and thus plays a pivotal role in lipoprotein 
metabolism (Santamarina-Fojo & Brewer, 1994). LPL is synthesized and secreted 
primarily by adipocytes and muscle cells but functions at the luminal surface of the 
capillary endothelium of extrahepatic tissues. Here the catalytically active LPL, a 
homodimeric glycoprotein, is anchored to the luminal plasma membrane via heparan 
sulphate proteoglycan molecules (Busca et al. 1998). The enzyme requires the 
co-factor, apo C-II for activation, and this is found associated with chylomicrons, 
VLDL and HDL (Wang et al. 1992).
1.3.1 MOLECULAR BIOLOGY AND STRUCTURE
The human LPL gene has been cloned and characterised. The locus for the LPL gene 
is located on the p22 region of chromosome 8 and spans 30 kilobases (Bensadoun,
1991). The mRNA-specifying sequence is divided into 10 exons. The first exon 
encodes the 5’ flanking untranslated region of the mRNA, the 27 amino-acid, signal 
peptide and the first two amino acids of the mature peptide. The next 8 exons encode 
the mature protein and the 10th exon codes for the 3’ untranslated region (Davies, 
1994). Experiments using labelled LPL complimentary DNA (cDNA) probes have 
identified 2 mRNA species of 3350 and 3750 nucleotides (nt) in humans (Bensadoun,
1991). Approximately 175 nt upstream of the translation initiation codon, the mRNA 
includes a 1425 nt region which codes for a 475 amino-acid preprotein and a 
termination codon. This is followed by the untranslated 3’ region (1557 or 1952 nt 
long) and then the poly A tail (Bensadoun, 1991). From the pre-protein a 27 amino- 
acid signal peptide is removed to give rise to the 448 amino-acid LPL protein. The 
mature monomeric LPL contains approximately 7-8% carbohydrate due to 
N-glycosylation and has a predicted molecular weight of 55 kDa (Auwerx et al. 1992). 
The active LPL consists of a homodimer which is in equilibrium with the less active 
monomeric form (Auwerx et al. 1992).
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LPL belongs to the gene family which includes hepatic and pancreatic lipase and there 
is much sequence homology between these lipases (Bensadoun, 1991). Although the 
structure of LPL is not known, the elucidation of the three-dimensional 
crystallographic structure of human PL (Winkler et al. 1990), the high degree of 
similarity in disulfide linkages and sequence homology between LPL and PL have 
provided a possible model for the structure of LPL (Busca et al. 1998). LPL can be 
separated into two folding domains, a larger amino-terminal (comprising residues 
1-312) and a smaller carboxyl-terminal (comprising residues 313-448). The amino- 
terminal domain includes the catalytic triad (residues aspartate^^ ,^ histidine^" \^ 
serine^ ^  ^ [asp-his-ser]), the lid covering the catalytic triad (residues 216-239) and the 
binding site for apo C-II (residue 314). The carboxyl terminal domain includes 2 sites 
for the binding of LPL to the LRP (residues 380-384 & 404-430) and a lipid-substrate 
binding site (tryptophan cluster residues 390, 393, 394) which confers substrate 
specificity to the lipase (Busca et al. 1998). The carboxyl terminal is thought to be 
involved in the initial interaction of LPL with lipoproteins (Santamarina-Fojo & 
Brewer, 1994). Both amino- and carboxyl- domains contribute to the heparin-binding 
properties of the enzyme and these findings indicate that multiple sites are involved in 
the interaction between LPL and glycosaminoglycans present in the endothelial vessel 
wall (Santamarina-Fojo & Brewer, 1994).
1.3.2 FUNCTIONS OF LPL
LPL’s primary function is to hydrolyse the core TAG of circulating lipoproteins to 
their constituent fatty acids. In doing so, LPL is responsible for directing fatty-acid 
utilisation according to the metabolic demands of the tissues. As a consequence of its 
actions, LPL is involved in the remodelling of chylomicrons, VLDL and HDL -  this 
has important implications in terms of remnant removal and production of atherogenic 
lipoproteins. The preferred substrates for LPL are long-chain triacylglycerols although 
it does hydrolyse monoacylglycerols and phospholipids, but at a much slower rate 
(Eckel, 1989). The enzyme shows stereospecificity for the sn-\ and sn-?> ester bonds.
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It is thought that the initial interaction of LPL with its lipid substrate, mediated by the 
carboxyl-terminal domain, results in a conformational change that leads to opening of 
the LPL lid and exposure of the hydrophobic-lid residues. Repositioning of the lid 
probably leads to the formation of a cleft lined by the hydrophobic side chains of 
amino acids which are part of the lipase backbone or the amphipathic helices of the 
lid. The fatty acid chains bind to this hydrophobic region permitting access of the TAG 
substrate to the catalytic site and its subsequent hydrolysis (cited by Santamarina-Fojo 
& Brewer, 1994).
In vivo, LPL appears to preferentially hydrolyse the larger, more TAG-rich 
lipoproteins (Levy et al. 1991). However, this rapid clearance of chylomicrons over 
VLDL may be a function of capillary size. Chylomicrons, being larger than VLDL, 
will occupy a larger area within the capillary lumen and therefore will have a greater 
chance of interacting with LPL than the smaller VLDL (Goldberg, 1996).
In performing its hydrolytic function, LPL is intimately involved in the remodelling of 
lipoproteins and the preservation of anti-atherogenic particles. LPL is responsible for 
the conversion of VLDL to IDL and chylomicrons to remnants. The enzyme also 
regulates HDL-C levels by generating surface lipids and apolipoproteins for transfer to 
HDL. Defective LPL activity reduces TAG hydrolysis in the periphery and leads to 
more postprandial TAG being available for neutral-lipid exchange between 
VLDL/chylomicrons and HDL/LDL. This would favour the production of 
pro-atherogenic lipoproteins (small dense HDL/LDL and cholesterol ester enriched 
VLDL/chylomicron remnants) (Goldberg, 1996).
In addition to this primary function, LPL is also involved in targeting lipoproteins to 
their receptors and facilitating their uptake into cells (Beisiegel & Heeren, 1997) (see 
section 1.1.1.4). LPL is a ligand for the LRP and several laboratories have confirmed 
that the carboxyl terminal domain of LPL binds to the LRP and aids removal of 
chylomicrons and possibly VLDL (Goldberg, 1996).
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1.3.3 GLYCOSYLATION. SYNTHESIS AND SECRETION
LPL functions at the luminal surface of the vascular endothelium, but, these cells 
neither synthesize nor degrade LPL. Instead, LPL, a secretory glycoprotein, is 
synthesized in the membrane-bound ribosomes attached to the rough endoplasmic 
reticulum (RER) of parenchymal cells. Here the nascent polypeptide is 
co-translationally glycosylated at amino acids Asn and Asn (Hide et al. 1992). 
The N-linked carbohydrate moiety of LPL then undergoes a series of modifications 
involving the removal of glucose and mannose molecules. The resulting mannose-rich 
structure is transported to the Golgi complex where the oligosaccharides are further 
modified (addition and removal of mannose, additions of galactose and sialic acid) by 
Golgi-resident enzymes to produce a variety of complex oligosaccharide side chains 
(Braun & Severson, 1992). The glycoproteins are then sorted in the trans-Golgi for 
delivery to lysosomes or incorporation into secretory vesicles for delivery to plasma 
membranes.
A number of experiments have clearly demonstrated that glycosylation of the LPL 
molecule is required for catalytic activity (Semenkovich et al. 1990; Busca et al. 1995) 
and for release from the endoplasmic reticulum (Busca et al. 1995). Firstly, adipocytes 
incubated with tunicamycin (an antibiotic) showed reduced LPL catalytic activity 
because tunicamycin blocks N-linked glycosylation by inhibiting the synthesis of 
dolichol-linked oligosaccharides (Braun & Severson, 1992). Secondly, site-directed 
mutagenesis at Asn resulted in the production of catalytically inactive LPL (Busca 
et al. 1995). However, it is not only glycosylation that is important for catalytic 
activation -  the subsequent processing of the oligosaccharide chains is also essential. 
Ben Zeev et al. (1992) demonstrated that when cells were incubated with glucosidase 
inhibitors there was a marked reduction in LPL activity but no change in LPL mass. 
He concluded that carbohydrate trimming in the RER was necessary for full catalytic 
activity of the enzyme. Other structural or amino acid changes to the enzyme can 
affect its intracellular processing and secretion. For instance replacement of Gly by 
Glu leads to a mis-sorted protein which is diverted to lysosomes rather than secretion 
(cited by Busca et al. 1998). Deletion of the last 61 or 21 amino acids produces
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truncated proteins which are not efficiently secreted by the expressing cells and remain 
in the RER (Busca et al. 1998). Mutations of the 3 amino acids of the catalytic triad 
results in loss of triolein- and tributyrin- hydrolysing activity, but retains normal 
heparin affinity and intralipid binding properties (Santamarina-Fojo & Brewer, 1994).
Newly synthesized LPL, stored in secretory vesicles, are translocated by a cAMP 
stimulated process to the cell surface where they bind to heparan sulphate- 
proteoglycan (HSPG) receptors (Auwerx et al. 1992). Once here, LPL is either 
released into the medium (for translocation to the vascular endothelium) or 
internalised via the HSPG receptor for degradation or recycling back to the surface 
(Braun & Severson, 1992). Protein secretion from cells occurs either by a constitutive 
or regulated mechanism. Constitutive refers to a process in which proteins are secreted 
as they are synthesized, without intracellular accumulation. Secretion is regulated if 
newly synthesized proteins are stored in secretory vesicles until the cell receives a 
stimulus whereupon large amounts of protein are secreted at a much higher rate than 
the protein synthetic rate (cited by Braun & Severson, 1992). Experiments in mouse 
adipose cell lines (Bensadoun, 1991) show that the time course of LPL activity 
secretion is biphasic. The first phase is regulated and the second is constitutive. Both 
active and inactive forms of LPL are secreted in vitro and several investigators have 
independently shown that 70-80% of the newly synthesized LPL is degraded before 
appearing in the medium (Bensadoun, 1991). Incubation of cells with heparin 
markedly reduces the amount of inactive LPL appearing in the medium (Auwerx et al.
1992) suggesting that heparin protects LPL from proteolytic degradation (Eckel, 
1989). Little is known about the mechanism by which LPL is released in vivo from the 
parenchymal cell surface. It is known that LPL binds to HSPG molecules at the cell 
surface. HSPG consist of a negatively charged glycosaminoglycan (heparan sulphate) 
attached to core proteins which are components of cell membranes and extracellular 
matrix (Braun & Severson, 1992; Goldberg, 1996). LPL is bound ionically to HSPG 
molecules, some of which are covalently attached to the cell membrane by a glycosyl- 
phosphatidylinositol membrane anchor. Heparin displaces LPL bound to all HSPG 
molecules and phosphatidlyinositol-specific phospholipase C (PI-PLC) displaces LPL 
bound to phosphatidylinositol-anchored HSPG. It is possible that heparin or PI-PLC
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may be involved in the release of LPL from the parenchymal cell surface (Braun & 
Severson, 1992).
LPL is translocated, by unknown mechanisms, across the interstitial space to 
functional HSPG binding sites on the luminal surface of vascular endothelia, where 
TAG hydrolysis takes place. Endothelium-bound LPL activity is regulated by the 
factors that influence transcription, translation, translocation to the endothelium and 
release of endothelial LPL into the circulation. This is further discussed below.
1.3.4 REGULATION OF LPL
The central role played by LPL in TAG metabolism implies that its regulation will 
have important physiological consequences in terms of NEFA distribution, lipoprotein 
modulation and LPL-mediated remnant removal (Zechner et al. 1997). LPL is 
regulated in a tissue-specific manner by mechanisms which affect either gene 
transcription, mRNA stability, mRNA translation or post-translation processes 
(Ranganathan et al. 1995). Although all these levels of control are important, the 
mechanisms involved are not fully understood. Expression of LPL not only varies 
between tissues (Ranganathan et al. 1995) but can also vary between different sites of 
the same tissue (Amer et al. 1991). This section primarily focuses on the regulation of 
LPL in adipose tissue.
1.3.4.1 Nutrient Regulation
It is known that LPL is displaced from its endothelial binding sites by the 
accumulation of free fatty acids, which inhibit the interaction of LPL with apo C-II, 
with the substrate interface and with heparin (Taskinen & Kuusi, 1987). Whilst 
studying the possibility of fatty acid feedback control of LPL in vivo, Peterson et al. 
(1990) found a positive correlation between plasma LPL activity and plasma NEFA in 
humans during infusion of a TAG emulsion. This suggests that when fatty acids are 
generated more rapidly by LPL than can be assimilated by the local tissues, the 
enzyme is dissociated from its HSPG binding sites into the circulation. In this way 
fatty-acid feed back is controlling the rate of TAG catabolism and the supply of fatty
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acids to the tissues. Further evidence for this mechanism was provided by Karpe et al. 
(1992) who demonstrated a high degree of parallelism between postprandial 
chylomicron-derived fatty acids and postprandial plasma LPL activity in 44 subjects. 
Linoleic acid was the parameter that showed the strongest association to plasma LPL, 
which supports the hypothesis that unsaturated fatty acids appear to have a greater 
capacity to dissociate LPL than saturated fatty acids (cited by Karpe et al. 1992). A 
more recent study (Ez-Zoubir et al. 1996) suggests that fatty acid feedback control of 
LPL is due to post-translational processing of the enzyme. Their experiments, using 
adipocytes, demonstrated that LPL gene expression increased and LPL activity 
decreased after exposure to long-chain fatty acids. The effect of the fatty acids 
appeared to be more dramatic on LPL-secreted activity rather than on LPL-cellular 
activity. LPL protein synthesis and protein content were not significantly changed on 
exposure to the fatty acids. Together these results imply that LPL was prevented from 
undergoing intracellular processing and release from the cells. The authors postulate 
that this could provide an additional mechanism for controlling the entry of fatty acids 
into adipocytes.
The reciprocal effects of fasting in adipose tissue and cardiac muscle, where LPL 
activity is reduced and increased respectively, represents an example of tissue-specific 
regulation of LPL. Previous studies investigating the regulation of LPL have 
consistently found an increase in adipose-tissue LPL activity after feeding and a 
decrease after fasting (Eckel, 1989). There is conflicting evidence for the pre- and 
post-translational regulation of adipose-tissue LPL by feeding.
The studies carried out in animals and humans when comparing fed to fasted state 
either find no change in LPL mRNA, LPL protein synthesis and LPL mass (Ong & 
Kem, 1989), an increase in LPL mRNA (Enerback et al. 1988; Ladu et al. 1991), or a 
decrease in LPL mRNA and protein synthesis with no change in enzyme mass 
(Doolittle et al. 1990). The majority of the studies indicate that LPL mRNA, synthetic 
rates and enzyme mass do not account for the changes in enzyme activity, suggesting 
that regulation of LPL must be post-translational. Doolittle et al. (1990) observed 
predominantly high mannose LPL (endoplasmic-reticulum bound) in the fasting state
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and high complex-carbohydrate LPL (Golgi bound) in the fed state. They proposed 
that newly synthesized LPL was redistributed into either a secretory pathway (during 
feeding) or an intracellular degradative pathway (during fasting) which would account 
for the constant enzyme mass observed in the fasted state. More recently it has been 
demonstrated that during fasting, adipose tissue LPL is present in an inactive form that 
is converted into an enzymatically active state during feeding (Bergo et al. 1996).
Other examples of tissue-specific activity are demonstrated by the selective 
stimulation of LPL activity in brown adipose tissue on exposure to the cold and the 
dramatic increase in mammary-gland LPL activity with a corresponding decrease in 
adipose-tissue LPL activity during lactation (Braun & Severson, 1992).
The studies performed in this thesis have focused on the effects of altering the 
background dietary content of fatty acids on LPL gene expression and LPL activity. A 
number of studies have investigated the effects of feeding and fasting on LPL activity, 
but far fewer have separated the effects of specific nutrients from those of feeding in 
general. Table 1.1 draws together the results of some animal studies that have looked 
at the response of LPL activity and mass, and the level of LPL mRNA to varying 
dietary compositions.
These animal studies generally agree that PUFA and MUFA stimulate adipose tissue 
and postheparin LPL activity to a greater extent than SFA. Differences between n-3 
and n-6 PUFA are less clear and may be affected by the study design and method of 
measuring LPL activity.
One study (Erskine et al. 1994) reported no difference in LPL activity between a 
high-fat and high-carbohydrate diet. In contrast, the study by Benhizia et al. (1994), 
found that LPL activity was significantly higher on the control diet (low-fat) than the 
high-fat test diets (lard and lard + com oil). These studies were similar in terms of 
duration and percentage energy from fat, carbohydrate and protein. The low-fat, 
high-carbohydrate diets both contained only com oil as their source of fat. However, 
the methods used for determining LPL activity were different.
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Table 1-1 Animal studies showing the effects of diet on LPL
Author Experimental Design Results
Groot et al. 
(1988)
Rats fed meals containing either 
palm or sunflower oil.
Postheparin LPL activity 
significantly higher in the 
sunflower oil-fed rats.
Van Heek & 
Zilversmit 
(1990)
Rabbits fed diets containing 
coconut or olive oil for up to 49 
days.
Postheparin LPL activity three 
times higher in the olive oil-fed 
rabbits.
Baltzell et al. 
(1991)
Rats fed lard, com oil or menhaden 
oil- enriched diets for 2 weeks. 
Animals killed in the fasted state.
Adipose-tissue LPL activity not 
significantly different for the three 
diets, although values highest in the 
com oil-fed animals.
Levy et al. 
(1991)
Rats fed diets containing safflower, 
coconut, MCT oils or normal chow 
for 3 months. Animals killed in the 
fed state.
Adipose-tissue LPL activity 
significantly higher on the 
safflower-and coconut-oil diets 
compared to the chow, and 
significantly lower on the MCT 
diet.
Inadera et al. 
(1992)
Rats maintained on a normal or 
high- calorie chow diet. Animals 
killed in the fasted state.
Postheparin plasma and adipose 
tissue LPL activities significantly 
higher in the rats fed the high- 
calorie chow. Adipose-tissue LPL 
mRNA was lower in the normal 
chow-fed rats.
Murphy et al. 
(1993)
Rats fed diets containing mixed, 
maize or fish oils for 2 weeks. Rats 
killed in the fed state.
Adipose-tissue LPL activity higher 
(NS) and LPL mRNA significantly 
higher in the fish oil-fed rats.
Erskine et al. 
(1994)
Rats fed a high-fat or high- 
carbohydrate diet for 2-3 weeks. 
Animals killed in the fasted state.
No differences in adipose-tissue 
LPL activity, LPL mass or LPL 
mRNA reported between the diets.
Benhizia et 
al. (1994)
Rats fed a lard, lard + com oil or 
lard + fish-oil diet for 16 days. Fat 
provided 50% of the calories. 
Control rats fed normal chow (10% 
fat). Animals killed in the fed state.
Lard + fish oil diet increased 
adipose-tissue LPL activity (NS) 
compared to the control diet and 
significantly compared to the lard 
and lard + com oil diets.
Abbreviation: NS, not significant
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Human studies do not reflect the findings of animal studies. Several studies found no 
significant difference in postheparin LPL activities when subjects were fed diets rich 
in SFA, n-6 PUFA or n-3 PUFA (Weintraub et al. 1988; Harris et al. 1988; Nozaki et 
al. 1991; Bordin et al. 1998). However, 2 groups (Weintraub et al. 1988; Bordin et al. 
1998) did report higher LPL activity values on the n-3 PUFA diet. Kasim-Karakas 
et al. (19956) found a small significant increase in postheparin LPL activity after 
n-3 PUFA supplementation and Zampelas et al. (1994a) showed increased postheparin 
LPL activity 9 hours following consumption of an n-3 PUFA-enriched meal.
The reason for the discrepancy between animal and human studies may be due to the 
lack of precision and specificity of postheparin LPL measurements. These 
measurements include both LPL from skeletal and adipose tissue, whilst the animal 
studies report adipose-tissue LPL activities. If the activating effects of n-3 PUFA are 
localised to the adipose tissue then the postheparin measurements will not detect these 
single-site responses (Williams, 1997). A more recent study (Harris et al. 1997) 
measured preheparin LPL activities in plasma after n-3 supplementation and found 
that LPL activity was significantly higher in healthy and HTG subjects fed n-3 PUFA. 
Whether or not this endogenous circulating LPL activity reflects in vivo lipolytic 
potential remains to be determined. It is also possible that smooth muscle is more 
important in the regulation of plasma TAG levels than adipose-tissue LPL or 
postheparin LPL (Zechner et al. 1997).
Little work has been carried out into the effects of diet on LPL mRNA in humans.
1.3.4.2 Hormonal Régulation
LPL activity levels during feeding and fasting are most likely regulated by a complex 
array of factors, such as insulin, glucagon and glucocortoid levels as well as 
sympathetic innervation (Doolittle et al. 1990).
LPL activity in adipose tissue has been shown to correlate well with the prevailing 
plasma insulin level (Kem et al. 1988; Baltzell et al. 1991; Inadera et al. 1992). This is 
illustrated by low LPL activity during insulin-deficiency states such as fasting (Kem et
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al. 1988), insulin-dependent diabetes mellitus (IDDM) (Taskinen & Nikkila, 1979), 
high LPL activity when insulin levels are elevated, such as after a meal and after 
IDDM treatment with insulin (Taskinen & Nikkila, 1979). Despite this induction of 
LPL activity after administering insulin, there is still controversy surrounding how and 
where it exerts its effects. Studies using cultured rat adipocytes have demonstrated that 
cells respond to insulin with an increase in LPL activity, protein synthesis and mRNA 
(Ong et al. 1988). In contrast, Semenokovich et al. (1989) found an increase in LPL 
activity without an increase in mRNA. A detailed study carried out by Raynolds et al. 
(1990) found that the addition of insulin to cultured rat adipocytes stimulated an 
increase in LPL activity and steady state LPL mRNA in a time dependent manner. 
Nuclear run-on transcription assays, performed to assess whether or not insulin had 
affects on LPL mRNA transcription, found no significant difference in the level of 
newly synthesized RNA transcripts between insulin-treated and untreated adipocytes. 
The authors concluded that insulin does not regulate LPL gene expression by altering 
LPL gene transcription but most likely prolongs mRNA stability. In vitro studies using 
isolated human adipocytes or whole adipose tissue have failed to observe increases in 
LPL activity in response to physiological concentrations of insulin (Kem et al. 1985) 
demonstrating that there are important species differences in LPL regulation. 
Together, these findings suggest that insulin probably regulates LPL at post­
transcription and/or post-translation levels and that in humans insulin mediates its 
effects indirectly.
Other postulated hormonal regulators of LPL include thyroxine, GIP, oestrogen, 
tumour necrosis factor (TNF), and in addition certain dmgs affect LPL activity. 
Fibrates have been used as lipid-lowering dmgs in hypertriacylglycerolaemia and 
hypercholesterolaemia for many years. They act by promoting TAG-rich lipoprotein 
catabolism by stimulating LPL activity and decreasing VLDL synthesis possibly 
through activation of peroxisome proliferator-activated receptors (Gmndy & Vega, 
1987; Schoonjans etal. 1997).
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1.3.5 MEASUREMENT OF LPL
There are many methods available for the measurement of LPL which provide 
information on gene transcription, protein synthesis and activity of the enzyme both 
systemically and at specific tissue sites.
1.3.5.1 Measurement of mRNA
Measuring mRNA provides information on which tissues express a particular gene and 
can give some indication of the physiological function of the encoded protein. 
Secondly, gene-expression data gives an indication of the cells potential for protein 
synthesis and therefore information about possible enzyme activity. Thirdly, it enables 
the determination of factors which regulate the expression of the gene, such as 
nutrients, hormones, and the environment. A general finding is that the metabolic 
regulation of LPL in adipose and muscle tissue is not fully explained by changes in its 
mRNA (Bengtsson-Olivecrona & Olivecrona, 1992).
There are 3 methods available for measuring mRNA: Northern blotting, RNase 
protection and reverse transcription polymerase chain reaction (RT-PCR). 
Quantitation of mRNA by Northern blotting and RNase protection involves using 
labelled cDNA probes to specific sequences within the target mRNA. RNase 
protection is approxiamtely 10 times more sensitive than Northern blotting. PCR is a 
technique for the rapid amplification of a selected region of DNA. The addition of a 
reverse-transcription step enables the technique to be applied to RNA. The method 
depends on the generation of oligonucleotide primers complimentary to the known 3’ 
terminals of the selected portion of DNA to be amplified. Both the forward and 
reverse strands of the DNA template act as templates for the synthesis of new 
complementary strands. The DNA/cDNA is denatured, the primers anneal to their 
complimentary 3’ terminal and extend along the length of the DNA/cDNA. By 
repeating this process for a finite number of cycles the amount of DNA increases in an 
exponential manner. The sensitivity of the technique means that investigation of 
mRNA expression is possible even when the material available is extremely limited 
(Chesters, 1996; Chesters, 1998).
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RT-PCR has been used by a number of investigators to measure LPL mRNA in small 
samples of human tissue and has been successfully performed in human muscle and 
adipose tissue (Levesque et al. 1994; Laville et al. 1996). The development of new 
techniques for the quantitative measurement of LPL mRNA in this laboratory is 
ongoing and is discussed in further detail in Chapter 3.
1.3.5.2 Measurement of LPL Mass
Radiolabelled methionine has been used to assess tissue synthetic rates of LPL. The 
methods generally employ immunoprécipitation followed by measurement of the 
labelled LPL by SDS-polyacrylamide gel electrophoresis. Protein-synthesis 
measurements give an estimation of how much LPL is being made at a given time. A 
study in diabetics demonstrated that increased LPL activity was accompanied by an 
increase in LPL synthesis and LPL immunoreactive mass (Simsolo et al. 1992). The 
availability of antibodies against LPL has enabled the development of more sensitive 
and accurate methods for the determination of LPL mass. Several investigators (Ikeda 
et al. 1990; Peterson et al. 1992; Kawamura et al. 1994) have measured plasma 
immunoreactive mass (IR-mass) by enzyme-linked immunoabsorbant assays (ELISA) 
and found that the measurement of IR-mass correlates well with postheparin LPL 
activity values (Ong et al. 1988; Peterson et al. 1992; Vilella et al. 1993).
1.3.5.3 Measurement o f LPL Activity
LPL activity can be measured in specific tissues or in postheparin plasma. The 2 main 
approaches used to estimate tissue LPL activity are to measure total activity or to 
measure heparin-releasable activity. Acetone-ether preparations of adipose tissue are 
used to measure total tissue LPL activity (Nilsson-Ehle, 1987). In this preparation, 
LPL is stabilised, the lipid is removed and HSL is inactivated. The disadvantage of 
this method is that recovery of the enzyme activity on extraction is not always 
complete (Bengtsson-Olivecrona & Olivecrona, 1992).
Heparin is known to release LPL from its HSPG binding sites and several protocols 
for the release of LPL from tissue pieces using heparin have been described
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(Bengtsson-Olivecrona & Olivecrona, 1992). The activity recovered is assumed to be 
the sum of endothelial LPL and some intracellular LPL which has been secreted. 
Postheparin plasma lipase measurements are the most commonly used assessment of 
LPL activity because the method is quick and easy to perform, and reproduce. The 
method involves the administration of a bolus dose of heparin (100 lU/kg body 
weight) intravenously. The heparin releases potentially active lipase from the capillary 
endothelium into the circulation. Maximal lipase activity can be measured in the 
plasma collected 5-15 minutes after the heparin injection. There are several 
disadvantages of this method:
1) It is not specific to LPL because postheparin plasma contains hepatic lipase, 
monoacylglycerol hydrolase and phospholipase in addition to LPL. However, 
95% of the TAG lipolytic activity in postheparin plasma is due to LPL and HL 
(Huttunen et al. 1975).
2) It is not site specific because heparin releases LPL bound to all endothelial 
sites (adipose tissue and muscle). This may explain why postheparin plasma 
activities do not always correlate with the enzyme activities measured in the 
tissue beds (Eckel et al. 1988).
3) Postheparin LPL is a single measurement which gives no information about its
metabolic regulation (Eckel et al. 1988).
4) The release of LPL and HL into the plasma results in substantial lipid 
hydrolysis which perturbs lipid levels and may alter lipase activities 
(Eckel et al. 1988).
Several methods have been published for the selective measurement of LPL and HL 
but most involve quantifying the release of free fatty acids from a labelled triolein 
source. The main problems encountered with these methods relate to the type of 
substrate used and the method of differential-enzyme inhibition chosen.
There are two approaches to the selective measurement of LPL and HL, either to use 
assay conditions which favour one of the enzymes, by exploiting their different 
physio-chemical properties, or to use antibodies that inhibit the activity of one
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enzyme. LPL is inhibited by 1 M NaCl and protamine sulphate (Krauss et al. 1974); 
both are agents to which HL is resistant (Henderson et al. 1993). In addition, LPL 
requires apo C H for activation and prefers a pH of 8.2. In contrast, HL has a pH 
optimum of 8.8, shows reduced activity in the presence of heat-inactivated serum 
(Nilsson-Ehle, 1987) and is inhibited by SDS (Baginsky & Brown, 1979). Antiserum 
is used to immunoinhibit HL (Huttunen et al. 1975) and allow the measurement of 
LPL. The SDS methods used to inhibit HL and allow the measurement of LPL have 
been found to correlate well with immunochemical methods (Baginsky & Brown, 
1979; Henderson et al. 1993) although the activity values tend to be about 30% higher 
(Nilsson-Ehle, 1987).
Both LPL and HL can be separated by heparin-Sepharose affinity chromatography and 
then individually measured under their optimal assay conditions (Boberg et al. 1977). 
Cretan et al. (1977) found the results obtained after immunochemical inhibition of HL 
correlated well with those obtained following heparin-Sepharose separation. However, 
recovery of the enzyme is not always complete and the method is laborious 
(Bengtsson-Olivecrona & Olivecrona, 1992).
The selective measurement of HL is achieved by including 1 M NaCl in the substrate 
to inactivate LPL. Total lipase activity is measured using a substrate containing a low 
concentration of NaCl. The LPL activity in the sample can then be indirectly estimated 
as the difference between the total lipase and HL activities. However, subtraction 
procedures, for the measurement of LPL, are comparatively imprecise because the 
optimal requirements of both enzymes cannot be achieved in a single assay system 
(Nilsson-Ehle, 1987; Henderson et al. 1993). Suppression of LPL by protamine 
sulphate is known to be variable and may affect HL activity (Nilsson-Ehle, 1987). 
Huttunen et al. (1975) found a good correlation with their immunochemical method 
and the protamine-sulphate method employed by Krauss et al. (1974). However, 
Cretan et al. (1977) reported a poor correlation between both their immunochemical 
and heparin-Sepharose methods and their protamine-sulphate method. For this reason, 
the preferred measurement of HL is by 1 M NaCl inhibition of LPL.
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The substrates commonly used for the measurement of LPL and HL are long-chain 
triacylglycerols emulsified with phospholipids or other surface-active components 
such as gum arabic (Bengtsson-Olivecrona & Olivecrona, 1992). Labelled TAG are 
often used because they increase the sensitivity and precision of the method. The 
amount of TAG substrate required tends to vary between systems because it is the area 
of the oil-water interface which is important for lipolysis rather than the molar 
concentration of TAG (Nilsson-Ehle, 1987). However, in general, both lipases require 
a TAG-substrate concentration in excess of 5 g/1 for maximal catalytic activity 
(Henderson etal. 1993).
The type of emulsifier used to stabilise the substrate is an important consideration 
when assaying LPL and HL. Lecithin-stabilised emulsions are readily attacked by LPL 
but are not suitable for HL unless sonicated in the presence of albumin (Ehnholm et al. 
1984). Gum-arabic stabilised emulsions are the substrate of choice for the analysis of 
HL and are also suitable for LPL. Comparisons between the gum-arabic and 
lecithin-stabilised emulsion methods (Ehnholm et al. 1984; Henderson et al. 1993) 
found higher lipase activities against the gum-arabic emulsions although the results 
demonstrated that the two methods were highly correlated for both lipases.
Preheparin measurements provide an estimate of actual circulating levels of LPL. 
Eckel et al. (1988) found that pre- and postheparin LPL activities were correlated 
suggesting that preheparin values were a measure of TAG hydrolytic potential. 
However, other researchers have not found significant correlations between these 
parameters (Karpe et al. 1992; Watson et al. 1995a). The absence of significant 
correlations between pre- and postheparin LPL suggests that the plasma and 
endothelial pools are not in equilibrium, possibly because of the avid uptake of 
circulating LPL by the liver (Watson et al. 1995a). Measuring preheparin LPL activity 
has proved problematic because the plasma levels are so low that the methods 
employed are at the limits of their sensitivity and are relatively imprecise.
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In the work described in this thesis, postheparin plasma and heparin-releasable, 
adipose-tissue LPL activities were determined, together with adipose-tissue LPL 
mRNA using competitive RT-PCR.
1.3.6 LPL AND DISEASE
Deficiency or reduced activity of LPL is observed in a number of clinical situations 
including Type I hyperlipoproteinaemia, diabetes and obesity. The association between 
LPL and these disease states is briefly discussed in this section.
Familial-LPL deficiency is an autosomal, recessively inherited disorder which usually 
presents itself in childhood. Homozygotes for the condition are extremely rare with an 
incidence of approximately 1 in 10 ,^ whilst the incidence of the heterozygous state is 
about 1 in 500 (Davies, 1994). LPL deficiency is characterised by massive HTG due to 
the accumulation of chylomicrons. LDL and HDL levels are normally low whilst 
VLDL levels vary (Davies, 1994). The clinical symptoms associated with this disorder 
may include: pancreatitis, abdominal pain, eruptive xanthomas, hepatomegaly, 
retinopathy, recent memory loss, depression and dyspnoea.
The pathogenesis of LPL deficiency can be due to either the presence of circulating 
inhibitors or molecular defects of apo C-II or LPL. Apo C-H is the co-factor essential 
for LPL activation. In the absence of apo C-II, normal LPL is secreted but it is unable 
to hydrolyse circulating TRL. At least 36 different mutations of the LPL gene have 
been reported (Davies, 1994), giving rise to a functional deficiency of LPL. The 
defects can occur because of the following:
• mis-sense (point) mutations -  one nucleotide is replaced by another
• frameshift mutations -  deletion of a single nucleotide alters the 
reading frame in the sequence
• sequence and splicing defects
• gross changes in the DNA sequence -  insertion, deletion or 
duplication of base pairs
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Depending on the site of the defect, an individual may produce catalytically inactive 
LPL which may or may not be able to bind to the endothelium, or the LPL protein 
synthesized may be truncated, preventing its secretion from the cell (Olivecrona & 
Bengtsson-Olivecrona, 1990). Heterozygotes for LPL deficiency generally have LPL 
activities half that of normals and may present with HTG, combined hyperlipidaemia 
or hypercholesterolaemia depending on the defect displayed. The finding that 
homozygotes and heterozygotes have variable phenotypic expression may in part 
explain why LPL deficiency is not always associated with an increased risk of CHD 
(Davies, 1994).
Hormones, such as insulin, play an important role in lipoprotein metabolism and 
through abnormalities in their secretion or action may participate in the 
pathophysiology of lipoprotein aberrations and possibly the atherogenic risk associated 
with disorders such as HTG, diabetes and obesity (Kissebah & Schectman, 1987). 
Over 30 years ago it was demonstrated that untreated diabetes was associated with 
HTG and low postheparin LPL activity, which was reversed on treatment with insulin 
(Bagdade et al. 1967). This suggested that there was a link between LPL activity, 
insulin levels and HTG. Since then it has been demonstrated that insulin can increase 
LPL activity by increasing transcript stability or by modifying post-translation 
processes (Frayn & Coppack, 1992).
The normal functions of insulin are to stimulate glucose uptake, and in the adipose 
tissue, suppress fat mobilisation and stimulate activation of LPL and lipogenesis. Loss 
of insulin sensitivity, as observed in diabetes and obesity, results in activation of HSL 
with a subsequent release of NEFA. NEFA released from adipose tissue will be 
delivered to the liver and will augment the secretion of VLDL-TAG, thereby 
contributing to the HTG. The HSL-stimulated release of NEFA during insulin 
resistance may contribute to the product inhibition of LPL at the endothelial surface 
(Frayn & Coppack, 1992) in the same way that LPL-released fatty acids have been 
shown to do so (Karpe et al. 1992). This would release LPL from its endothelial 
binding sites and reduce LPL activity further. Impairment of the normal 
responsiveness of adipose-tissue LPL activity to insulin will result in reduced VLDL
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and chylomicron-TAG hydrolysis. This in turn will impair the normal transfer of 
cholesterol and phospholipids to HDL and encourage the CETP-mediated, neutral- 
lipid exchange of TAG between VLDL and HDL/LDL; the end products are small, 
dense HDL and LDL. Insufficient TAG hydrolysis of VLDL and chylomicrons may 
delay their uptake by hepatic receptors therefore allowing them to reside for longer in 
the circulation. It has been suggested that remnant particles are atherogenic 
(Zilversmit, 1979). From this point of view, complete lack of LPL may be less harmful 
than partial impairment due to insulin resistance, which is illustrated by the lack of 
predisposition to atherosclerosis in Type I hyperlipoproteinaemia (Frayn & Coppack,
1992).
The LPL gene is known to be expressed by macrophages within the vessel wall. It is 
thought that LPL may aid retention of small lipoproteins in the sub-endothelial space 
by acting as a bridge between proteoglycans and lipoproteins. Cell-culture studies have 
shown that active LPL produced by macrophages increases uptake of chylomicrons 
and LDL (cited by Goldberg, 1996). Macrophage LPL activity has also been correlated 
with the propensity to develop atherosclerosis in mice (cited by Goldberg, 1996).
Thus it might be that LPL has a dual role in the development of atherosclerosis. 
LPL-mediated uptake of lipoproteins by the liver may result in enhanced catabolism of 
atherogenic particles and reduced atherosclerosis, whereas synthesis of LPL by cells in 
the arterial wall may promote the atherosclerotic process (Santamarina-Fojo & Dugi,
1994).
1.4 DIETARY ASSESSMENT METHODOLOGY
Part of this research project involved conducting 2 dietary-intervention studies, in 
which information on food intake was collected. A brief review of the problems 
associated with collecting and interpreting dietary information is given here.
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1.4.1 INTRODUCTION
Dietary surveys enable the impact of diet on health and disease to be assessed and 
provide data that can be used as a basis for dietary guidelines and nutritional policy. 
Human dietary experiments are costly and time consuming, and it is therefore most 
important that they are designed and performed in a way that will allow conclusions to 
be drawn that fulfil the aims of the research (Block et al. 1982).
It is often assumed that assessment of habitual food intake is simple to perform, and 
yet the reality is that it is one of the hardest tasks a physiologist can undertake. The 
methods used for assessing dietary intake can be divided into 2 broad categories: 
prospective methods, in which the subject records what they are eating, and 
retrospective methods, in which the subject recalls from memory what they have 
eaten. Prospective methods include weighed dietary records and non-weighed, 
estimated dietary records, whilst retrospective methods include diet histories, 24-hour 
recalls and food-frequency questionnaires.
The biggest obstacle to research on nutritional causes of disease has been uncertainty 
about the validity of existing dietary-assessment methods and the consequent doubt 
concerning the accuracy of the results obtained. The errors incurred in the 
measurement of diet can be random or systematic. Random errors affect the precision 
of a method and in theory can be reduced by increasing the number of observations. In 
contrast, systematic errors remain despite the number of observations made and every 
attempt should be taken to minimise these if reliable and accurate results are to be 
obtained. The accuracy (freedom from both types of error) of the measurement of an 
individual’s habitual food intake is dependent on a number of factors including the 
number of days recorded, the reliability of information obtained about food intake, 
portion size, food composition and the conversion of food intake into nutrient intakes.
A method is valid when it measures exactly what it intended to measure, and this 
degree of accuracy requires complete factual information. Despite the obvious need 
for assurance, few dietary-assessment methods have been fully validated because they 
rely on information given by the subjects themselves, which may or may not be true.
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There is no satisfactory solution to this dilemma and investigators have therefore had 
to use other validation criteria. Some investigators have compared their new methods 
with an existing method that has greater acceptance, whilst others have attempted to 
demonstrate that a method reflects a usual intake by showing that it can produce 
similar results on 2 separate occasions (Block et al. 1982). More recently, objective 
measures for validating dietary assessment have been used . Using analytes of 
biological specimens, these closely reflect dietary intake without relying on reports of 
food consumption. Biological markers are increasingly being used as an independent 
validity check on the presence or absence of systematic bias in a dietary method. 
These include 24-hour urinary nitrogen for protein (Bingham & Cummings, 1985; 
Bingham et al. 1995), and membrane (Dougherty et al. 1987; Tynan et al. 1995) or 
plasma phospholipid (Frost Andersen et al. 1996) fatty-acid composition for dietary 
fatty-acid exposure. The measurement of energy expenditure by the doubly labelled 
water technique has been used to validate reported energy intakes (Schoeller & van 
Santen, 1982; Black, 1997) and comparisons between reported energy intake and 
estimated energy requirements (Goldberg et al. 1991) provide an estimate of the 
degree of under-reporting of energy. The inclusion of several independent validation 
techniques within a dietary survey will help to determine the validity of the dietary 
records and thus lend more support to the findings of the dietary survey.
1.4.2 SOURCES OF ERROR IN DIETARY STUDIES
1.4.2.1 Self-reported dietarv-enersy intake
The subjects ability to accurately record the food they consume greatly influences the 
reliability of the results obtained. One of the biggest and commonest sources of 
systematic error is under-reporting. The incidence of under-reporting has increased 
from 33% in 1982 to 46% in 1992 among women and from 27% to 42% in men 
(Hirvonen et al. 1997). This may have occurred as a consequence of increased public 
awareness of diet and health. Many studies have focused on the identification and 
characterization of those individuals who quantitatively under-report their dietary 
intake. It has been suggested that women (Pryer et al. 1995; Hirvonen et al. 1997) and 
overweight people (Prentice et al. 1986; Lichtman et al. 1992; Hirvonen et al. 1997)
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are more likely to under-report than men and normal-weight individuals. However, 
other investigators (Livingstone et al. 1990; Kortzinger et al. 1997) who observed 
significant under-reporting were unable to distinguish between lean or obese 
individuals. The reasons for under-reporting are not known but are thought to occur 
due to conscious or subconscious changes in normal eating patterns. A recent study 
(Macdiarmid & Blundell, 1997) reported that subjects altered their diet either because 
they were embarrassed or felt guilty about the amount or type of food they were eating, 
or because they found recording their food intake inconvenient. This resulted in them 
not eating their normal diet or omitting foods from their records.
It has been suggested that under-reporting is a greater problem in population surveys 
rather than experimental studies because the higher subject-investigator involvement 
in experimental studies makes people less susceptible to under-reporting than lower 
involvement in survey-type studies (Smith et al. 1994). Under-reporting potentially 
has serious implications for the interpretation of dietary studies especially when 
estimates of energy intake can be inaccurate by 50% or more (Lichtman et al. 1992). 
However, a more recent study (Hirvonen et al. 1997) observed that excluding the 
under-reporters did not change the main conclusions of the dietary survey when 
looking at macronutrient intakes, but caused significant bias when looking at 
micronutrient intakes.
In order to limit the inaccuracies of the results obtained using a specific dietary- 
assessment method, it is important to consider ways to identify biased food records 
and incorporate independent checks on the validity of the food-intake data. The use of 
biomarkers is useful, since they confirm the validity of recorded foods which have 
actually been eaten. The doubly labelled water test is too expensive and complex for 
large surveys but the assessment of urinary nitrogen as a measure of protein intake 
(Bingham & Cummings, 1985: Bingham et al. 1995) and/or the measurement of total 
energy expenditure as a standard for energy intake (Goldberg, 1991; Bingham et al. 
1995; Kortzinger et al. 1997; Black et al. 1997) may be useful. Finally, it is important 
to interpret and evaluate results with caution and to view self-reported food intakes for 
what they are -  estimates of true habitual intake.
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1.4.2.2 Food-vortion sizes
Methods for establishing portion sizes involve weighing foods directly, estimating 
weights visually, or via comparison to visual aids (household measures, photographs 
and food models). Although weighing is precise when scales are calibrated properly, 
they are expensive and subjects find weighing tedious and may compensate by 
decreasing food intake (Mertz & Kelsay, 1984) or by choosing simple, rather than 
composite dishes to weigh. Subjects have great difficulty estimating amounts of food 
they recall consuming in the past and present, as well as those displayed in front of 
them (Young & Nestle, 1995). There are also widely differing interpretations of 
standard small, medium and large portions. Household measures have the advantage 
of familiarity, ease of use and high levels of subject co-operation but they are not 
always calibrated accurately and can result in significant over - or under-estimation of 
portion size (Bingham, 1987). Considerable errors are also produced with volume 
measures and there is individual variability when estimating portion weights as foods 
can be loosely or tightly packed, and some do not conform to measuring devices. 
Portion sizes of some foods, such as pre-packed meals and sliced breads are easier to 
judge than others, such as sliced and grated cheese, pasta and rice. As these foods are 
energy dense this creates a problem in assessing total energy and fat intake. Three- 
dimensional models closely represent actual foods but can cause bias, especially if 
they are of one size, as this may influence subjects to report portion sizes similar to 
that of the model (Bingham, 1987). Robson et al. (1994) compared household 
measures with photographs and found that although both methods incurred large 
errors, the photographs seemed a better alternative and concluded that portion-size 
estimation in recall methods is a major source of measurement error.
It is evident that there is a need for more attention to be given to portion sizes and 
internally consistent reference standards need to be developed for dietary guidance, 
food tables and dietary-intake surveys.
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1.4.2.3 Food tables
All results from dietary surveys are ultimately dependent on the quality of the food 
tables used, unless duplicate samples of food are analysed independently by chemical 
analysis or bomb calorimetry. The obvious limitation with food tables is that they are 
averages of the analysis of food samples from various sources, and as such they have 
limited accuracy when applied in any particular case. In addition, some nutrients 
cannot be accurately assessed by the use of food tables because the food data are 
controversial or incomplete. For example, few tables are able to accurately measure 
sodium, fatty acids, amino acids and some vitamins. There are also inconsistencies 
between food tables due to the use of different chemical-analysis techniques, sampling 
procedures, or factors applied to convert analysed values to nutrients (Bingham, 1987). 
Other variations occur because of changes in farming practices or alteration of product 
ingredients. A study by Guilland et al. (1993) was set up to determine whether 
differences in food-composition databases were an important cause of discrepancy 
between nutrient-intake values calculated by different computerized dietary-analysis 
systems. The investigators compared the results of thirty 7-day food records analysed 
by 3 different centres using their own nutrient database systems. Significant 
differences between the 3 systems were found in the calculation of alcohol, PUFA, 
SFA, linoleic acid, linolenic acid, cholesterol, magnesium, sodium and water. The 
estimates for energy, protein, fat and carbohydrate were not significantly different. 
Analysis of variance showed that the differences in the data obtained by the 3 systems 
were mainly due to the food-composition database used. The authors concluded that 
computerized dietary analysis systems may produce widely different values for most 
nutrients in common foods and that these differences would probably be even greater 
for nutrients on which information is incomplete. These results reinforce the need for a 
reliable and valid food-composition database that is updated regularly.
1.4.2.4 Codins
Another source of error in the analysis of dietary records may arise at the coding stage. 
Imprecise descriptions or illegible handwriting could result in differences in coder 
interpretation. Even when the weights of the food eaten have been recorded, the choice
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of code can vary depending on individual coder interpretation of a description 
(Bingham, 1987), If the portion weight is not established, estimation of portion sizes 
will provide another source of variation. However, some investigators have 
demonstrated that no significant differences in nutrient calculations result from the use 
of different coders (Adelman et al. 1983). The lack of coder effect was attributed to 
the similar training and background of the coders participating in the study. Guilland 
et al. (1993) concluded from their study that the coding variance was much less than 
that of the database.
Recently comparisons have been made between the use of computerised (direct-entry 
computer program DIDO [data in data out]) and manual coding methods (Price et al.
1995). In both methods, ambiguities in coding occurred because subjects did not give 
enough information, had illegible handwriting, gave no information on portion size, or 
were thought to have made omissions from their usual dietary pattern. The errors were 
greater with the manual coding method; there were twice as many incorrect food codes 
in the manually-coded food diaries compared with the DIDO-coded food diaries. Most 
of the incorrect codes were as a result of using different cooking or processing codes 
for the same food, general misguided choice of code and remembering codes 
incorrectly.
Using the DIDO system, the mean time to code and check the 7-day diaries was 58 
minutes, whereas the manual coding, checking and data entry of 7-day weighed intake 
records was reported to take 104 minutes (Sheppard et al. 1990). The coding of diaries 
recorded in household measures is expected to take longer (up to 3 -4  hours) than 
weighed records because coders must assign portion weights to each food as well as 
choose the most appropriate code (Black, 1982). Price et al. (1995) concluded that 
although DIDO is not error-free, the method has greater accuracy, speed, consistency 
and easier data access for checking than the manual method.
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Table 1-2 Number of days of diet record required to ensure that r > 0.9 for energy, 
6 nutrients and the ratio o f PUFA to SFA (P:S) in males and females'^
Nutrient Adult Male (days) Adult Female (days)
Energy 4 6
Protein 6 8
Fat 6 7
Carbohydrate 4 6
SFA 7 6
MUFA 1 0 1 2
PUFA 15 30
Cholesterol 2 0 25
P:S 15 30
Adapted from Nelson et al. (1989).
1.4.2.5 Number of days to record
The number of days of diet recording required to accurately quantitate nutrient intakes 
varies with the nutrient of interest. Individuals vary markedly from day to day in their 
intake of food and nutrients. Daily variations are far greater than weekly or seasonal 
variations, although the latter are still important and should be considered when 
interpreting dietary data that cross seasons. It is usual to keep dietary records for 7 
days based on the assumption that this is the shortest time necessary to cover 
fluctuations in dietary patterns. However, for some nutrients, much longer periods are 
required. Table 1.2 highlights the number of days of diet recording required to 
accurately measure a number of different nutrients.
1.4.2.6 7-day weighed records
When subjects are asked to record what they eat there is always a risk that they will 
alter their normal eating habits, to simplify the task or because they have been made 
more aware of the amount they are eating. Some subjects may also try to impress the 
interviewer and may follow a prescribed diet more strictly if they are being observed 
(Bingham, 1987). This is a problem that occurs with weighed and estimated dietary 
records.
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The 7-day weighed record is generally thought to be the most accurate technique for 
assessing habitual food intake and is often quoted as being the ‘gold standard’. 
However, Livingstone et al. (1990), found discrepancies between the energy intake 
measured by the 7-day weighed record and total energy expenditure estimated using 
the doubly labelled water technique. The systematic error was due to the 
inconvenience of having to weigh everything that was being eaten leading to loss of 
motivation, and omitting or simplifying measurements as a result.
Accuracy and precision are also a problem, with spring balances rarely offering results 
better than ± 5 g (Bingham, 1987). Digital electronic balances are more accurate 
usually to ± 1-2 g but they are also very expensive. The presence of a tare can also 
cause errors in those who have not been properly trained to use it. These errors are 
minimal however when compared to those incurred when the weight of food eaten is 
estimated (Bingham 1987). The portable electronic tape-recorded automatic (PETRA) 
scales were developed to try and overcome some of the problems associated with 
weighed intakes. The PETRA system automatically records a verbal description and 
the weight of the food consumed. The information is not displayed to the user but goes 
into a black box to be retrieved later by the investigator. Operating the scales is simple 
as there is only one button. Simplicity of use and the fact that the patient cannot check 
recorded information reduces the likelihood of interference with habitual intake.
Weighed dietary-record methods are also subject to sampling bias. If the subject 
becomes bored or demotivated because recording their food intake is tedious or 
inconvenient they may drop out of the study. If too many subjects drop out, then the 
analysis on the remaining subjects may not be representative of the group. By splitting 
the periods of observation into comparatively small sections (e.g. 2 x 4-day periods) it 
is possible to minimise the interference in the volunteer’s life, whilst at the same time 
gaining sufficient numbers of observations to minimise random error from daily 
variation in nutrient and food intake, and sample bias due to subject drop-out. 
(Bingham, 1987; Bingham 1995).
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Despite doubts about the accuracy of weighed-intake techniques, they have been 
positively correlated with 24-hour urinary nitrogen (r = 0.69) and potassium (r = 0.73), 
which are two biological markers of food intake (Bingham et al. 1995).
1.4.2.7 7-day estimated record
The biggest disadvantage of the estimated food record is the time taken to code it for 
nutrient analysis (Bingham et al. 1994), although this can be reduced if the DIDO 
computer program is used. The estimated food record method may be impractical for 
large clinical or epidemiological studies because of the high level of co-operation 
required from subjects. This may result in small unrepresentative numbers being 
encouraged to participate (Block, 1982) or problems with high drop-out rates. 
However, compliance with this method is no worse than weighed methods. The 
subjects must be literate and there may be problems coding if handwriting is illegible. 
Subjects may omit certain foods from their records if they don’t carry their diaries with 
them at all times. Inaccurate descriptions of types and quantities of food may be given 
and it is important to realise that if the person recording the food intake is not the 
person who prepares the food, they may find it hard to record meals, especially if 
recipes are involved. Despite this, however, this method removes errors of memory 
associated with recall methods.
When compared to the weighed intake this method has the highest correlation 
coefficients and is able to classify a greater proportion of individual values into the 
correct quartile of distribution. There is no bias in mean intakes of food or nutrients 
and results are almost as good as those obtained from the weighed records (Bingham 
et al. 1994). The method correlates almost as well as the weighed intake method with 
24-hour urinary nitrogen (r = 0.65 for estimated record versus r = 0.69 for weighed 
method) which means that some confidence can be placed in the results obtained by 
7-day estimated diaries (Bingham et al. 1995).
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1.5 AIMS OF THIS RESEARCH PRO TECT
This literature survey stresses the importance of the metabolic role of LPL in 
lipoprotein metabolism. LPL may affect CHD risk because it is the rate-limiting 
enzyme in the clearance of TAG from chylomicrons and VLDL. The speed at which 
these liporoteins are remodelled influences the production of atherogenic particles. In 
this way, LPL has a central role to play in the development of CHD. Indirectly, the 
effect of diet on LPL activity may therefore be an important factor in the development 
of CHD and its associated complications.
Since the 1980’s, nutritional guidelines, for the UK, have predominantly focused on 
reducing dietary intakes of SFA, in an attempt to reduce plasma total cholesterol levels 
and risk of CHD (DHSS, 1984). More recently, in addition to reducing dietary SFA, 
more attention has been given to increasing intakes of n-3 PUFA (DoH, 1994). 
Achieving these targets will depend on how easy it is for the population to make these 
dietary changes, and many social, environmental and psychological factors are 
involved in influencing whether an individual makes that change or not. Dietary 
intervention studies should therefore focus on achieving government dietary 
recommendations by using methods which are appropriate and acceptable to the whole 
population. The 2 dietary intervention studies carried out in this project tried to 
address both these issues, by using ‘normal’ manufactured foods, rather than 
supplements, to achieve the dietary and biochemical changes recommended.
Thus the aims of this research project are:
1) To investigate the feasibility of increasing the dietary intake of long-chain 
n-3 PUFA and MUFA, using ordinary foods fortified with these fatty acids, in 
free-living individuals.
2) To investigate the in vivo effect of these dietary manipulations in humans on 
fasting and postprandial lipid and hormonal metabolism.
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3) To investigate how changes in diet affect LPL gene expression as well as LPL 
activity in humans.
In pursuing these aims the following experimental work was performed:
The effect of long-chain n-3 PUFA supplementation on fasting and postprandial lipid 
and hormonal metabolism was investigated in humans. A dietary intervention study 
was performed comparing an n-3 PUFA-enriched diet with an identical control diet. 
n-3 PUFA enrichment was achieved by incorporating n-3 PUFA into ordinary foods 
during the manufacturing process. At the end of each manipulation period, changes in 
fasting and postprandial responses to a standard test meal were measured.
The effect of substituting SFA with MUFA on fasting and postprandial lipid and 
hormone metabolism was investigated in humans. A dietary-intervention study was 
performed comparing a high-MUFA diet with a high-SFA control diet. The level of 
MUFA intake aimed to reflect the intake currently consumed in Crete and other 
Mediterranean countries (18-23% energy), and the SFA intake reflected the current 
UK dietary intake (16-17% energy). MUFA enrichment was achieved by using olive 
oil-based cooking and spreadable fats together with manufactured foods, whose 
extrinsic fat content was replaced with olive oil. At the end of each intervention 
period, changes in fasting and postprandial responses to a standard test meal were 
measured.
Work was performed to develop a competitive RT-PCR method, including the 
construction of a synthetic LPL competitor RNA, for the measurement of LPL mRNA 
in human adipose tissue. The question of whether diet {n-3 PUFA, MUFA and SFA) 
alters LPL gene expression was addressed.
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CHAPTER 2
2. MATERIALS AND METHODS
2.1 MATERIALS
All general chemicals were supplied by Fisons, Loughborough or BDH, Poole and 
were Analar grade unless otherwise stated. Specific chemicals ordered include:
Radiochemicals
Glycerol Tri (9,10(n)-^H) oleate
^^ I^-Insulin
Molecular Biology Grade Products
Guanidine isothiocyanate
Sarkosyl
Phenol
2-Mercaptoethanol
Lauryl sulphate
Isoamyl alcohol
Diethyl pyrocarbonate 
Cobas Mira Analysis Kits
TAG analysis kit (Unimate 5)
Cholesterol kit (Unimate 5)
Supplier
Amersham International pic., Amersham, 
UK.
Amersham International pic., Amersham, 
UK.
Gibco BRL (Life Technologies), Paisley, 
UK.
BDH, Poole, UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Aldrich, Gillingham, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
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Glucose kit (Unimate 5 HK)
HDL reagent
Lipid-control serum
Control-serum N
NEFA C kit
Seronorm lipid 
Others
BSA (essentially fatty-acid free)
Triolein
L-a-phosphatidylcholine 
Trizma base
Heparin (porcine, sodium salt)
Optiphase safe
Lignocaine hydrochloride injection B.P. 
(2 % w/v)
Medium 199 (containing 25 mM HEPES 
buffer, Earles salts and L-glutamine) 
Nunclon multiwell plates
5 ml and 10 ml lithium heparin tubes
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
Roche Diagnostic Products Ltd., Welwyn 
Garden City, UK.
WAKO Chemicals (Alpha Laboratories), 
Eastleigh, UK.
Nycomed, Birmingham, UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Wallac Uk, manufactured by Fisons 
Chemicals, Leicester, UK.
Antigen Pharmaceuticals Ltd., Roscrea, 
Ireland.
Gibco BRL (Life Technologies), Paisley, 
UK.
NUNC A/S, Kamstrup DK4000,
Roskilde, Denmark.
L.I.P. Equipment & Services Ltd.,
Shipley, UK.
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5 ml fluoride oxalate tubes L.I.P. Equipment & Services Ltd.,
Shipley, UK.
LP3 tubes L.I.P. Equipment & Services Ltd.,
Shipley, UK.
14 ml sterile Falcon tubes Greiner Labortechnik Ltd., Dursley
15 ml opaque centrifuge tubes Sarstedt Ltd., Leicester, UK.
Polycarbonate centrifuge tubes Nalge - Sybron Corporation, Rochester,
(12 X 101 mm) USA.
Cannulae (Y-CAN 19 g) Simcare Ltd., Lancing, U.K.
2.2 METHODS
2.2.1 COLLECTION OF PLASMA SAMPLES
All blood samples were collected into lithium heparin tubes, except those due for 
glucose analysis, which were collected into fluoride oxalate tubes. The blood tubes 
were centrifuged at 553 x g for 10 minutes in a bench-top centrifuge, the plasma 
removed, aliquotted and stored at -20°C until required for analysis.
2.2.2 SEPARATION OF TRL AND TPL FRACTIONS FROM PLASMA USING 
THE CAMLAB ULTRACENTRIFUGE
TRL (flotation density d < 1.006 g/ml) and TPL (flotation d > 1.006 g/ml) fractions 
were prepared using a modified procedure of Grundy & Mok (1976).
Sodium chloride solution, density 1.006 g/ml, was made by dissolving 9.6 g NaCl in 
1 litre of reverse osmosis (R.O.) water. The density was adjusted with the use of a 
digital density meter, DMA 35 (Paar Scientific Ltd., London). Blood was collected 
and the plasma removed as described in section 2 .2 .1 .
a) TRL and TPL procedure for n-3 PUFA samples (Chapter 4)
Plasma (3.5 ml) was placed in a polycarbonate centrifuge tube (12 mm x 101 mm) and 
overlayered with 3.5 ml NaCl solution (d = 1.006 g/ml) using an automated
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Finnpipette (Lifesciences International, UK). The tubes were centrifuged at 20,000 
rpm in a Camlab refrigerated high-speed centrifuge 4239R (Camlab, Cambridge, UK.) 
at 24°C for 99 minutes (including acceleration and deceleration). The cumulative ‘g ’ 
force of this spin was 4.31 x 10^  gmax-min.
b) TRL and TPL procedure for MUFA samples (Chapter 5)
This procedure was carried out by another investigator. Plasma (5 ml) was transferred 
to a glass bottle containing no anticoagulant and stored at 4°C overnight. Using 
thick-walled polycarbonate tubes (38 ml), 3.5 ml of plasma was overlayered with
3.5 ml of NaCl solution (d=1.006 g/ml) using an automated Finnpipette. These were 
then ultracentrifuged in a 50.2 Ti rotor (Beckman, UK.) at 4.83 x 10  ^ gmax.min in a 
Beckman L7-65 ultracentrifuge (MSB Scientific Instruments, UK.) at 24°C.
The TRL fraction (seen as a fine, cream layer on the surface of the liquid) was isolated 
using a glass Pasteur pipette and aliquotted into LP3 tubes. If the amount of TRL 
removed was greater than 1.2 ml, the TPL fraction was made up to 5.8 ml with 0.16 M 
NaCl. The TPL fraction was mixed and aliquotted. All samples were stored at -20°C 
until analysis.
2.2.3 AUTOMATED ANALYSES ON THE COBAS MIRA PLUS
Prior to analysis, all defrosted plasma samples were vortex mixed and centrifuged at 
1700 X g for 10 minutes in a Beckman J6  centrifuge, to precipate any fibrin, which 
interferes with accurate pipetting by the analyser.
2.2.3.1 Measurement of plasma triacylslycerol
Plasma TAG levels were measured by an automated, enzymatic, spectrophotometric 
technique on the Cobas Mira Plus analyser (Roche Products Ltd., UK.). The kit used 
was supplied by Roche Diagnostic Products Ltd., and the quality control (QC) was 
supplied by Nycomed., Birmingham, UK. The principle of this assay is described in 
the following equations and involves the use of enzymes LPL, glycerol kinase, 
glycerol phosphate oxidase and peroxidase:-
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Triacyglycerol —> glycerol + fatty acids 
Glycerol + ATP glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2 —> dihydroxyacetone phosphate + H2O2 
H2O2 + 4-chlorophenol + 4-aminophenazone —> quinoneimine derivative
The red-coloured quinoneimine derivative absorbs at 500 nm. The colour intensity 
measured is directly related to the triacylglycerol concentration in the sample. The 
intra-assay coefficient of variation (CV) was 1.5% at 2.2 mmol/1 and the inter-assay 
CV was 4.5% at 2.2 mmol/1. The linearity of the assay was 8  mmol/1 and any samples 
with concentrations greater than this were diluted with 0.15 M NaCl.
2.2.3.2 Measurement o f plasma total cholesterol
Plasma total cholesterol was measured on the Cobas Mira analyser using a kit supplied 
by Roche Diagnostic Products Ltd., UK. and a QC supplied by Nycomed., 
Birmingham,UK. The total cholesterol assay is an enzymatic colorimetric test 
involving the enzymes cholesterol esterase, cholesterol oxidase and peroxidase:-
Cholesterol ester + H2O cholesterol + fatty acids 
Cholesterol + O2 —> cholest-4-en-3-one + H2O2
H2O2 + 4-chlorophenol + 4-aminophenazone quinoneimine derivative
In the presence of peroxidase the hydrogen peroxide catalyses the oxidative coupling 
of phenol and 4-aminophenazone to form a red-coloured quinoneimine derivative. The 
colour intensity measured is directly proportional to the concentration of cholesterol in 
the sample. The intra-assay and inter-assay CV was 2.03% and 4.2% at 7.5 mmol/1 
respectively.
2.2.3.3 Measurement of HDL and LDL cholesterol
HDL-C analysis was carried out using the TPL fraction collected as described in 
section 2.2.2, aScb. HDL-cholesterol was measured on the Cobas Mira Plus analyser. 
The kit and QC used were supplied by Roche Diagnostic Products Ltd, UK.
78
Prior to cholesterol analysis, samples and QCs were treated with a reagent containing 
phosphotungstic acid and magnesium chloride to precipitate out apolipoprotein B 
containing lipoproteins (LDL and VLDL). After centrifugation at 5955 x g for 2 
minutes in a microcentrifuge, the supernatant was removed and used for cholesterol 
analysis using the total cholesterol kit and method described in section 2.2.S.2. The 
standard used for this assay was diluted (1:2.5) with 0.15 M NaCl prior to cholesterol 
analysis, to allow for the diluting effect of the precipitating reagent on the samples.
LDL-C was calculated from total cholesterol and HDL-C according to Friedewald’s 
formula (Friedewald et al. 1972):
LDL -  C (mmol /1) = Total serum cholesterol - HDL-C +
Total TAG 
2.2
The intra-assay and inter-assay CV was 2.8% and 4.2% at 2.24 mmol/1 respectively for 
HDL-C.
2.2.3.4 Measurement of plasma NEFA
Plasma NEFA was analysed on the Cobas Mira using a kit made by WAKO Chemical 
GmbH, Germany and supplied by Alpha Laboratories Ltd., Eastleigh, UK. The assay 
employs an enzymatic colorimetric method involving the enzymes acyl-CoA 
synthetase, acyl-CoA oxidase and peroxidase:-
NEFA 4- ATP + CoA —> acyl-CoA + AMP + PPi
Acyl-CoA + Ü2 —> 2,3-trans-enoyl-CoA + H2O2
H2O2 + 3-methyl-N-(p-hydroxyethyl)aniline -t- 4-amino-antipyrine
-> purple-coloured adduct
The purple-coloured adduct can be measured colorimetrically at 550 nm. The intensity 
of the colour formed is proportional to the NEFA concentration. The intra-assay CV 
was 1.7% at 0.5 mmol/1 and the inter-assay CV was 6.7% at 0.5 mmol/1.
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Ascorbic acid existing in the samples would be expected to cause interference due to 
its biological role as an antioxidant and known ability to react with hydrogen peroxide. 
The presence of added ascorbate oxidase in the reaction mixture completely removes 
all ascorbic acid from the sample.
The level of NEFA within a sample will increase if allowed to stand at room 
temperature. Sample preparation prior to analysis was, therefore, carried out on ice to 
minimise this occurrence.
Heparin is known to stimulate the activity of LPL, which acts upon the TAG 
associated with blood lipoproteins, to release free fatty acids. For this reason blood 
collected into heparinized containers is not ideally suited to this test. However, since a 
large number of analytes were being measured from the blood samples collected 
during the postprandial study day, heparin-coated blood tubes were used. Assay 
validation, carried out by another investigator in this laboratory, demonstrated that 
blood samples collected into EDTA or heparin coated tubes showed no significant 
differences between the NEFA levels observed.
2.2.3.5 Measurement o f plasma slucose
Plasma glucose was measured on the Cobas Mira using a kit and QC supplied by 
Roche Diagnostic Products Ltd, UK. This is an enzymatic photometric assay which is 
read in the UV spectrum. The principle of the assay is described in the following 
equations and involves the enzymes hexokinase and glucose-6 -phosphate 
dehydrogenase:-
D-glucose D-glucose-6 -phosphate + ADP
D-glucose-6 -phosphate + NAD^ —> D-gluconate-6 -phosphate + NADH + H^
The formation of NADH is directly related to the concentration of glucose in the 
sample and is measured at 340 nm. The intra-assay CV was 0.5% at 4.09 mmol/1 and 
the inter-assay CV was 1.05% at 4.09 mmol/1.
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2.2.4 MEASUREMENT OF PLASMA INSULIN
Insulin was measured by another investigator using a Radioimmunoassay (RIA) 
method originally described by Albano et al. (1972) and modified by Flatt & Bailey 
(1981).
This double-antibody RIA technique involves the incubation of plasma samples with 
an antiserum, raised to porcine insulin in the guinea pig, and a fixed amount of 
radiolabelled insulin. Competition occurs between the radiolabelled and unlabelled 
insulin, where the level of radiolabelled insulin bound to the insulin antibody is 
dependent on the plasma insulin concentrations. The unbound radiolabelled insulin is 
removed after adding guinea pig IgG antiserum. This binds to the primary antibody 
and causes the precipitation of the antibody-antigen complex which is accelerated by 
the presence of polyethylene glycol. The radioactivity of the precipitate is measured. 
Insulin concentrations were expressed as pmol/1. A QC was run in each assay. The 
intra-assay CV was 9.03% at 35 pmol/1 and the inter-assay CV was 10.7% at the same 
concentration.
2.2.5 ISOLATION OF RNA FROM ADIPOSE TISSUE
This technique is based on a method reported by Chomczynski & Sacchi (1987). In the 
preparation of all solutions autoclaved diethylpyrocarbonate (DEPC) treated water was 
used. The DEPC treatment involved adding 1 ml DEPC per litre of milli Q water, 
holding the water at 37°C overnight and then autoclaving. All solutions and pipette 
tips were autoclaved before use and all glassware was baked at 180°C for at least 12 
hours to destroy RNases.
Denaturing solution ‘D ’ and the phenolic solution were made using the chemicals 
shown in Table 2.1. Three millilitres of the ‘D ’ solution and 21.6 |il 
p-mercaptoethanol were added to a sterile Falcon tube and placed on ice. Phenolic 
solution (4 ml) was added to a separate Falcon tube and kept on ice.
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Table 2-1 Preparation of the denaturing solution ( ‘D ’) and the phenolic solution for  
use in total RNA extraction from adipose tissue
Denaturing Solution (‘D ’) Phenolic Solution
250 g Guanidine thiocyanate (GTC) 300 pi 2 M Sodium acetate, pH 4
293 ml DEPC water 3 ml Phenol (fresh, water saturated)
17.6 ml 0.75 M Sodium citrate, pH 7 700 pi Chloroformiisoamylalcohol (24:1)
26.4 ml 10% (v/v) Sarkosyl
Reagents mixed and held at 65°C 
to fully dissolve the GTC
Reagents mixed at room temperature
Adipose tissue was collected from the paraumbilical region under local anaesthetic 
(5 ml 2% (w/v) Lignocaine) using a 12-gauge biopsy needle attached to a 20 ml 
syringe. The procedure involved making a small incision (2-5 mm) in the skin using a 
scalpel. Approximately 3-5  cm of the biopsy needle was inserted into the adipose 
tissue through the incision and using a forward and backward motion, adipose tissue 
was aspirated by creating a partial vacuum using the syringe. This was repeated until 
sufficient tissue had been collected.
Once removed from the body, the adipose tissue was deposited into the Falcon tube 
containing ‘D ’ solution and p-mercaptoethanol. The phenolic solution was added to 
this, and the mixture was shaken vigorously for 20 seconds. The tubes were stored on 
ice for 15 minutes before being centrifuged at 6148 x g for 20 minutes at 4°C in a 
Camlab refrigerated high speed centrifuge, model number 4239R.
Following centrifugation, the upper aqueous phase (containing the RNA) was 
removed, placed in a fresh, sterile Falcon tube, and an equal volume of isopropanol 
was added. The tubes were left at -20°C for 1 hour or more, to aid extraction and 
precipitation of RNA. Following this, the tubes were re-centrifuged at 6148 x g for 20 
minutes at 4°C and the supernatant was decanted and discarded. The remaining pellet 
was dissolved in 300 pi ‘D ’solution (without p-mercaptoethanol) and transferred to a 
sterile 1 ml microfuge tube. The tubes were centrifuged at 4135 x g for 20 minutes at
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room temperature in a microcentrifuge and the supernatant discarded. The RNA 
containing pellet was washed with 300 pi of 75% (v/v) ethanol, centrifuged at 4135 x 
g for 20 minutes at room temperature, and left to dry for 30 minutes. The cleaned 
RNA pellet was resuspended in 25 pi of 0.5% (w/v) sodium lauryl sulphate (SDS) and 
stored at -80°C until analysis.
2.2.6 HUMAN ADIPQSE-TISSUE EXPLANTS
Adipose tissue was taken from human volunteers by needle biopsy as described in 
section 2.2.5, and placed into a 20 ml tube containing prewarmed (37°C) medium 199. 
The tubes were centrifuged at 1700 x g for 5 minutes at 37 °C in a Beckman J6  
centrifuge to pellet any blood (red blood cells) mixed in with the adipose-tissue 
sample. Explants of the adipose tissue were cut under a dissecting microscope to 
approximately 1 mm  ^using tweezers and a scalpel. However, the irregular structure of 
the tissue led to unevenly sized explants being cut. Approximately 15-20 explants 
(plus medium 199) were transferred to each well of a multiwell plate held at 37°C on a 
dry block heater. After 45 minutes of cutting, the medium 199 surrounding the 
explants was removed and replaced with 1 ml fresh medium 199. The multiwell plate 
containing the explants was transferred to an incubator and rested for 90 minutes at 
37°C. The medium 199 surrounding the explants was removed, replaced with 0.5 ml 
fresh medium 199 and the explants were incubated for a further two hours at 37°C. At 
the end of this period, 5 p.1 heparin (2 U/5 pi) was added to each well and the explants 
incubated for 40 minutes at 37°C. Heparin releases LPL from the tissue into the 
medium. At the end of the final incubation period the medium (containing LPL) was 
removed, aliquotted into LP3 tubes and stored at -80°C. The wet, drained adipose- 
tissue explants were weighed before disposal. The LPL activity of the medium was 
measured using the assay described in section 2.2.7.
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2.2.7 LIPOPROTEIN LIPASE ASSAY
LPL activity was measured by a modified method of that described by Nilsson-Ehle & 
Schotz (1976). The method involves the detection of ^H-labelled free fatty acids, 
formed by hydrolysis of a ^H-labelled triolein-substrate emulsion, catalysed by LPL, as 
depicted in the equation below:
Glycerol ^H-trioleate ^H-oleic acid + glycerol
To enable LPL activation and to prevent product inhibition of the enzyme, cofactor 
apo C n  (heat-inactivated serum) and a fatty-acid acceptor (albumin) were included in 
the assay system.
2.2.7.7 Préparation of ^H-triolein-slycerol emulsion
^H-triolein (50 pi), triolein (250 pi) and phosphatidyl choline (80 pi) were placed in a 
sonication vial. Solvents were evaporated from the triolein by passing a stream of 
nitrogen over the sonication vial for 2 hours in a dark fume cupboard. Glycerol (5 ml) 
was added and the solutions vortex mixed. Emulsification was carried out by 
intermittent sonication (10-20 second blasts) using a Soniprep 150 ultrasonic 
disintegrator (MSE Scientific Instruments) at an amplitude setting between 2-4. 
Between sonications the glycerol emulsion was vortex mixed and cooled on ice for 15 
minutes. A homogeneous emulsion was produced when no trace of oil was visible on 
the surface (approximately 4 -5  hours of sonicating and cooling). The emulsion was 
transferred to a glass tube, wrapped in silver foil (to prevent photolytic destruction) 
and stored for up to 6  weeks at room temperature. The linearity of the reaction for each 
emulsion was checked by a dose-response curve, using standards prepared from fresh, 
unpasteurised cows milk (section 22 .13 ).
2.2.7.2 Preparation of 0.2 M and 4 M NaCl Tris buffers
50 mM Trizma base containing 2 lU/ml heparin and either 0.2 M or 4 M NaCl was 
made up in a volumetric flask with R.O. distilled water. The pH was corrected to 8.1 
using 1 M HCL or NaOH and then stored at -20° C until required for use.
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2.2.7.3 Préparation of milk standards and quality controls
Fresh unpasteurised cows milk (Loseley, Guildford, UK.) was centrifuged at 553 x g 
for 1 0  minutes, in a bench-top centrifuge, to separate the cream from the skimmed 
milk. The cream layer was removed and the skimmed milk was filtered through glass 
wool to remove any other fat. The milk standards were either a 1 in 10 dilution or a 
1 in 4 dilution of the skimmed milk, diluted using 0.2 M NaCl-Tris buffer (pH 8.1). 
The 1:10 milk standard was further diluted 1 in 3, with 0.2 M NaCl-Tris buffer (pH
8 .1 ), and used as a quality control.
2.2.7.4 Preparation of apo C-II source
Venous blood from human volunteers was collected into tubes without anticoagulant, 
allowed to clot at room temperature for 2 hours and centrifuged at 553 x g for 10 
minutes in a bench-top centrifuge. The serum was removed, pooled and heated in a 
water bath at 62°C for 10 minutes, to inactivate the lipases present. The heat- 
inactivated serum was then aliquotted and stored at -80°C.
2.2.7.5 Collection of postheparin plasma samples
Volunteers were given a bolus dose of intravenous heparin (7500 lU) at a distant site 
to where blood would be collected. Blood was collected 5 and 15 minutes postheparin 
administration into lithium heparin tubes. Samples were immediately centrifuged at 
553 X g for 10 minutes in a bench-top centrifuge, and the plasma removed, aliquotted 
and stored at -80°C. Plasma samples were defrosted and centrifuged at 1700 x g for 
10 minutes in a Beckman J6  centrifuge prior to analysis of lipase enzyme activity, to 
precipitate any fibrin present.
2.2.7.6 Preparation of the substrate emulsion
The substrate emulsion was prepared fresh on the day of assay by adding either 0.2 M 
or 4 M NaCl-Tris buffer (pH 8.1), containing 0.3% (w/v) BSA (essentially fatty-acid 
free), to heat-inactivated human serum and ^H-triolein-glycerol emulsion in the ratio 
4:1:1. The substrate emulsion was vortex mixed and incubated at 37°C for 10 minutes 
before being added to the reaction tubes.
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2.2.7.7 Assay protocol
The protocol described here is for LPL activity in postheparin plasma. Variations in 
the assay according to the sample being analysed are discussed separately. LPL 
activity is inhibited by 1 M NaCl (final concentration), but HL is not. LPL activity in 
postheparin plasma samples is determined by carrying out identical reactions in 0.2 M 
and 4 M NaCl (initial concentration). The difference between the enzyme activities in 
0.2 M NaCl (representative of total lipase activity) and 4 M NaCl (hepatic lipase 
activity only) is assumed to be that of LPL.
An outline of the assay protocol used is shown in Table 2.2. The assay tubes were 
initially set up on ice, to prevent the enzymatic reaction occurring prematurely. 
Postheparin plasma (20 |xl) was pipetted, in duplicate, with either 80 |xl 0.2 M 
NaCl-Tris buffer (pH 8.1) or 4M  NaCL-Tris buffer (pH 8.1).
One hundred microlitres of substrate emulsion (containing either 0.2 M or 4 M 
NaCl-Tris buffer (pH 8.1) with BSA (0.3% w/v), ^H-triolein-glycerol emulsion and 
heat-inactivated serum) was added to the appropriate reaction tubes and mixed for 
10 seconds. The enzymatic reaction was started by incubating the tubes at 37°C, in a 
shaking water bath, for 30 minutes. At the end of this period the tubes were placed 
back on ice and 3.25 ml of organic solvent (chloroform, heptane and methanol in the 
ratio 1.25:1:1.41 by volume) followed by 1.05 ml 0.1 M K2CO3 (adjusted to pH 10.5 
with saturated boric acid) were added to all tubes to stop the reaction and extract the 
free fatty acids into the upper methanolic phase. The tubes were vigorously vortex 
mixed to aid extraction of the fatty acids and centrifuged at 1700 x g for 1 0  minutes in 
a Beckman J6  centrifuge. Part of the aqueous layer (500 |il) was removed and added to 
a scintillation vial containing 4 ml optiphase safe and 75 pi glacial acetic acid. The 
glacial acetic acid is a neutralising agent which reduces chemiluminescent light 
intensity. The vials were inverted several times and left for a minimum of 1 hour in the 
dark before being counted for radioactivity on a Wallac 1410 beta counter. Each tube 
was counted for 5 minutes using a preset programme.
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Table 2-2 Lipase Assay Protocol
Reagents Tubes
Totals Blanks Milk
Standards
QC PHP Expiant
Medium
0.2 M/4 M 
NaCl-Tris 
Buffer (pH 8.1)
2.45 ml 1 0 0  pi 90-10 pi 80 pi
Milk standard - - 10-90 pi - - -
Milk/plasma
QC
1 0 0  pi
Test PHP - - - - 2 0  pi -
Test explant 
medium
1 0 0  pi
Substrate
emulsion
1 0 0  pi 1 0 0  pi 1 0 0  pi 1 0 0  pi 1 0 0  pi 1 0 0  pi
Mix and incubate at 37°C for 30 mins (PHP/Milk standards), or 45 mins for explants
K2CO3 - 1.05 ml 1.05 ml 1.05 ml 1.05 ml 1.05 ml
Organic
solvent
3.25 ml 3.25 ml 3.25 ml 3.25 ml 3.25 ml
Vortex mix and centrifuge at 1700 x g for 10 minutes
Abbreviations: PHP, postheparin plasma
Blank incubations containing 100 pi of either 0.2 M or 4 M NaCl-Tris buffer (pH 8.1), 
instead of postheparin plasma, were included in each assay as a measure of 
background free fatty acids. These values were subtracted from the sample counts. A 
milk-standard QC was included in each assay to monitor and correct for inter-assay 
variation. A maximum of 84 tubes was handled in any one assay.
The intra-assay CVs were 4.9% at 70 mU/ml, 5.9% at 118 mU/ml and 6.2% at 
248 mU/ml. The inter-assay CV were 12.4% at 155 mU/ml and 10% at 197 mU/ml 
(milk and plasma samples).
87
The results from the blanks incubations were subtracted from the postheparin plasma 
sample values and the enzyme activity was calculated using the following equation:-
Enzyme activity (pmol oleate.min'^) at 37°C =
(DPM - B la n k ) x - x  ;---------- ;— ^ --------- ;— — x 3 x 4 .9 x  ^
t specific radioactivity o f triolein 0.76
where;
t = incubation time in minutes 
specific radioactivity of triolein = 2170699.34 dpm (varies with each batch)
3 = 3 fatty acids liberated for each triaclyglycerol 
hydrolysed
4.9 = dilution factor (0.5 ml taken from 2.45 ml aqueous 
methanolic phase)
0.76 = partition coefficient for oleate into the aqueous 
methanolic phase
The results were expressed in milliunits (mil) per ml for plasma samples, where one 
mU represents 1 nmol oleate released per minute at 37°C.
2.2.7.8 Assay protocol for LPL activity in human-explant media
The extraction of human adipose tissue and preparation of explant media is described 
in section 2.2.6.
In this assay, 100 pi of explant media was added, in duplicate, to the reaction tubes 
followed by 100 pi of substrate emulsion (see Table 2.2). The substrate emulsion in 
this assay included 0.2 M NaCl-Tris (pH 8.1), containing 3% (w/v) BSA, heat- 
inactivated human serum and ^H-triolein-glycerol emulsion in the ratio 4:1:1. The 
reaction tubes were then incubated for 45 minutes at 37°C, in a shaking water bath. 
The rest of the procedure was identical to that described in section 2.2.1.1. Results 
were expressed as mU mT^  g'^  (wet tissue).
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2.2.8 LIPASE ASSAY VALIDATION
Validation in this laboratory has previously been carried out by Nix (1993). This work 
showed that the lipase enzymes were stable for up to 2 hours at 37°C and that the 
assay was sensitive to 0.02 mU. These results were similar to the findings of 
Nilsson-Ehle & Schotz (1976).
2.2.8.1 Optimal albumin concentration for the lipase assay
LPL and HL enzyme activities are inhibited by free fatty acids. Inclusion of albumin 
into the assay system binds the free fatty acids and prevents product inhibition. 
Nilsson-Ehle & Schotz (1976) observed that the optimal albumin concentration was 
about 1% (w/v). Other investigators have used between 2-10% (w/v) BSA (Huttunen 
et al. 1975; Pykalisto et al. 1975; Blache et al. 1983; Eckel et al. 1988; Hutlin et al. 
1994). Bengtsson-Olivecrona & Olivecrona (1992), on reviewing the literature, 
reported that incubation systems typically contained between 3-6% (w/v) albumin.
The original protocol used in this laboratory only included 0.3% (w/v) BSA in the 
substrate emulsion. This may not be sufficient BSA to prevent fatty-acid product 
inhibition of the lipases. An experiment was therefore set up to investigate the effects 
of including 0.3% and 3% (w/v) BSA, in the substrate emulsion, on the lipase enzyme 
activity levels.
Postheparin plasma (20 pi), taken from a group of men, 9 hours postprandially, and 
different volumes (10, 30, 50, 90 pi) of the 1:10 milk standard were used as the 
enzyme source. Two assays were set up according to the method described previously 
in section 1.1.1.1. The first assay contained 0.3% (w/v) BSA in the substrate emulsion 
and the second assay contained 3% (w/v) BSA in the substrate emulsion.
The results, shown in Figure 2.1, demonstrate that LPL activity was significantly 
higher in the 50, 70, and 90 pi 1:10 milk-standard samples, which had been incubated 
with substrate emulsion containing 3% (w/v) BSA (P < 0.05, P < 0.001, P < 0.0001 
respectively). In support of these findings, LPL activity values (see Figure 2.2) were
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significantly higher in postheparin plasma which had been incubated with substrate 
emulsion containing 3% (w/v) BSA (P < 0.0001),
The LPL activity values from both methods (0.3% and 3% (w/v) BSA) were positively 
correlated (r = 0.76 and 0.84, P < 0.0001 for milk and postheparin plasma samples 
respectively).
In conclusion, future studies should endeavour to find the optimal amount of BSA 
required for their assay system, but as a rule, a minimum of 3% (w/v) BSA should be 
included.
2.2.8.2 Inclusion of serum as the source of apo C-II, in the lipase assay system
Inclusion of a source of apo C-II, such as heat-inactivated serum, is recommended 
when measuring LPL because apo C-II is the co-factor necessary for LPL enzyme 
activation. Nilsson-Ehle & Schotz (1976) noted that although maximal enzyme 
stimulation was achieved with 7.5% (v/v) serum, enzyme activity was still present 
when serum was not included in the system. Bengtsson-Olivecrona & Olivecrona 
(1992) reported that if TAG emulsions were used, LPL would still be active (5-20%) 
in the absence of apo C-II.
It has also been shown that different sources of serum, the length of time that 
substrates are incubated with the serum, and the amount of serum added can all affect 
the activity of LPL (Bengtsson-Olivecrona & Olivecrona 1992; Henderson et al. 
1993). Therefore, it is important that the optimal amount of serum and incubation time 
required, is determined for each new batch of serum.
In contrast to LPL, HL is inhibited by apo C-II and other lipid binding proteins found 
in serum (Bengtsson-Olivecrona & Olivecrona 1992; Henderson et al. 1993). Watson 
et al. (1992) demonstrated that when serum was included in their high-salt assay 
(2 M NaCl, final concentration) LPL activity was greater than when the serum
I
was not included.
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Figure 2-1 Comparison of LPL activity using different concentrations of milk standards with substrate 
emulsions containing either 0.3% or 3% (w/v) BSA. Values are mean (SEM) for 8 samples. Points 
with the same s\'mbol are significantly different from one another: (* P  < 0.05, ** p  < 0.001, 
# P <  0.0001).
@0.3% BSA 
«3%  BSA
15 minute postheparin plasma sample
Figure 2-2 Comparison of LPL activity using postheparin plasma with substrate emulsions 
containing either 0.3% or 3% BSA (w/v). Values are mean (SD) for 32 subjects. # Indicates that LPL 
activities using the 3% (w/v) BSA substrate emulsion were significantly different from the 0.3% (w/v) 
BSA substrate emulsion. (P < 0.0001).
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In this laboratory, serum is included in both the 0.2 M and 4 M NaCl-Tris buffer (pH
8.1) substrate emulsions. Inclusion of serum with the 4 M NaCL-Tris buffer (pH 8.1) 
substrate emulsion (measurment of HL activity) could be preventing total inactivation 
of LPL and inhibiting HL. An experiment was therefore set up to investigate the 
effects of including or not including serum in the assay, on the activities of LPL and 
HL.
Postheparin plasma samples taken from a group of young women, 9 hours 
postprandially, were pooled and used as the enzyme source. The lipase assay protocol 
described in section 2.2.1.1 was followed.
Substrate emulsions containing 0.2 M or 4 M NaCl-Tris buffer (pH 8.1, with 3% (w/v) 
BSA), ^H-glycerol emulsion and either serum or 0.2 M NaCl-Tris buffer (pH 8.1) in 
the ratio 4:1:1 were prepared. Eight duplicates of the same postheparin plasma sample 
were used in each assay (total of 4 assays) together with 2 milk QCs.
The results presented in Figure 2.3 show that exclusion of serum from the assay led to 
higher total lipase and LPL activity values, although this did not reach statistical 
significance. These findings were the opposite to those expected, as it was thought that 
exclusion of serum, and therefore the source of apo C-II, would have resulted in lower 
total lipase and LPL activity values. However, total lipase and LPL activity measured 
in the milk QCs decreased dramatically when serum was excluded from the assay 
(total lipase with serum = 35 (SD 2.2) mU/ml, total lipase without serum = 8.2 (SD 
1.3) mU/ml). These results suggest that there is sufficient apo C-II, to allow activation 
of LPL in postheparin plasma and no apo C-II in the milk QC. Addition or removal of 
serum had no significant effect on the activity of HL (as measured in 4 M NaCl-Tris 
buffer pH 8.1), although there was a trend for the values to be higher when serum was 
not included in the assay.
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Figure 2-3 Total lipase, HL and LPL activity in postheparin plasma, with and without the addition o f 
serum. Values are mean (SD) for 8 samples.
In conclusion, it is recommended that for fiiture studies, serum is not included in the 
assay for measurement o f HL activity and that the optimal amount o f serum required 
is determined for each new batch of heat-inactivated serum produced.
The selective measurement o f LPL usins SDS to inhibit HL
The indirect measurement of LPL (through measuring total activity and HL activity) 
has been criticised because the optimal substrate, pH and activator requirements of  
both enzymes cannot be achieved in a single assay system (Henderson et al. 1993). 
The method employed in this laboratory was originally set up to measure LPL activity 
in adipose tissue, where HL is not present. The method was adapted to allow the 
measurement of LPL and HL in postheparin plasma. However, although this method 
has been adapted to preferentially measure LPL, the method is in fact better suited to 
the specific measurement o f HL, by inhibiting LPL with 1 M NaCl (final 
concentration).
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The selective measurement of LPL is possible when HL is inhibited by antibodies or 
SDS. Several investigators (Baginsky & Brown 1979; Henderson et al. 1993; Watson 
et al. 19956) have demonstrated that a sensitive, specific and reproducible assay, 
involving SDS, can be employed for the measurement of LPL.
An experiment was therefore set up to investigate whether or not SDS inhibited HL in 
postheparin plasma and if LPL activity could subsequently be measured using a 
^H-glycerol lecithin-based emulsion.
Several reactions were set up using a dilution series of SDS ranging from 0-100 mM. 
Equal volumes of postheparin plasma and SDS (different concentrations) were 
incubated for either 30 minutes at 28°C, 30 minutes at 20°C or 1 hour at 26°C. 
Following this incubation period, 40 pi of the postheparin plasma-SDS mixtures were 
used for the measurement of total lipase and HL activity according to the protocol 
described in section 2.2.1.1.
The results (see Figure 2.4) show that at SDS concentrations where there was an 
appreciable inhibition of HL, the activity of LPL was also inhibited. This non-specific 
inhibition meant that SDS was unsuitable for the selective determination of lipoprotein 
lipase using a glycerol lecithin-based emulsion. These results are in contrast to those 
of other researchers (Baginsky & Brown 1979; Henderson et al. 1993). These 
investigators used Intralipid- or gum arabic-stabilised emulsions rather than a glycerol 
lecithin-stabilised emulsion, which is probably the reason for the difference in 
findings.
In conclusion, future work should investigate the use of antibodies, specific to HL, for 
the selective measurement of LPL. In addition, the use of a gum arabic-stabilised 
emulsion, which appears to be a better substrate for both LPL and HL (Henderson et 
al. 1993), should be pursued.
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Figure 2-4 Effects o f SDS on total lipase and HL enzyme activity in human postheparin plasma, a) 
relates to postheparin plasma incubated for 30 min at 28°C, b) relates to postheparin plasma 
incubated for 30 min at 20°C, and c) relates to postheparin plasma incubated for 60 min at 26°C.
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CHAPTER 3
3. COMPETITIVE RT-PCR METHOD 
DEVELOPMENT
.1.] IN TR O m im O N
This chapter describes the development of a competitive reverse-transcription 
polymerase chain reaction (RT-PCR) method for the measurement of LPL mRNA in 
human adipose tissue, including the construction and cloning of a synthetic RNA 
standard (competitor).
LPL is one of the central enzymes involved in lipid metabolism and can be measured 
at many stages in its production and secretion. Chapter 1 summarised these 
measurements, highlighting their advantages and disadvantages and concluded that a 
number of measurements are necessary to obtain an overall picture of the regulation of 
LPL. It is not yet clear whether LPL is secreted in response to changes in circulating 
TAG levels or whether TAG levels are a result of circulating LPL activity. However, 
the measurement of LPL mRNA, together with measurements of LPL activity and 
mass, may go some way to answering these questions.
This chapter focuses on the analysis of adipose-tissue LPL mRNA. Measurements of 
adipose-tissue mRNA may provide information on the amount of LPL mRNA 
synthesized under different dietary conditions and production levels at different 
anatomical sites. The disadvantage of measuring adipose-tissue mRNA is in the 
collection process. Tissue collection is invasive and often, particularly in humans, it is 
difficult to obtain enough tissue to perform all the steps required in the extraction, and 
subsequent measurement, of mRNA levels.
The first measurements of specific mRNA sequences were made using Northern 
blotting, a technique which involves isolating RNA from the cell, chemically 
denaturing (to prevent formation of secondary structures), and separation using gel
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electrophoresis. The RNA is transferred from the gel to a membrane (e.g. 
nitrocellulose) which binds the RNA. The RNA is then fixed to the membrane by heat 
and blotted with a labelled nucleic-acid probe to detect the specific mRNA of interest. 
After washing (to remove unhybridised, labelled probe) the membrane is exposed to 
photographic film. The resulting autoradiograph is developed and the band intensities 
are measured. However, blot techniques are inherently insensitive, because the RNA 
molecules being assayed must be physically attached to the membrane and the 
attachment interferes with the ability to hybridise to labelled probes. Other 
disadvantages with Northern blotting include:
• High background on the autoradiograph (as a result of residual probe 
radioactivity) can interfere with quantitation
• Requirement for large amounts of total RNA
• Time-consuming procedure which is not suitable for large clinical studies
• Potential exposure to radioactivity
• Semi-quantitative method only
The measurement of mRNA LPL in rats (Murphy et al. 1993) and in humans 
(Chapman, 1996) has been studied in this laboratory using the Northem-blot 
technique. Chapman (1996) demonstrated that although human LPL mRNA could be 
detected in 2 p.g of total RNA, realistically >8 p,g total RNA was necessary if reliable 
results were to be obtained. These values were much lower than an equal amount of 
total RNA from rats. A comparison between lean and obese human subjects showed 
that the detection of LPL mRNA was possible in obese subjects but not possible in 
lean subjects, because insufficient adipose tissue was obtained from the latter. It was 
concluded that detection of human LPL mRNA is possible, but only when large 
quantities of adipose tissue are collected. There appears to be a lower ratio of LPL 
mRNA to total RNA in humans than there is in rats (Chapman, 1996) and the level of 
LPL expression and activity in the human is approximately 14% that of rat adipose 
tissue (Chapman et a/. 1998).
97
In order to be able to measure LPL mRNA in small samples of human adipose tissue, 
a technique which is more sensitive, reproducible and quantitative is required. Two 
methods which potentially meet these requirements, the RNase protection assay and 
the polymerase chain reaction (PCR), were considered.
The RNase protection assay is a more direct and sensitive procedure than the 
Northem-blot methodology. In brief, a labelled probe, complementary to the part of 
the specific mRNA under investigation, is hybridised in solution to the total RNA. The 
reaction is then digested with RNase to degrade all single-stranded, unhybridised 
RNAs. Only those nucleic acids which have formed a specific double-stranded hybrid 
remain in solution. The probe, which has been protected in the hybrid, is then 
electrophoresed on a denaturing gel alongside a serial dilution of a standard labelled 
mRNA and quantified by autoradiography. The RNase protection assay is known to be 
10 times more sensitive than Northern blotting because the probe hybridises better to 
the target mRNA, and the background is digested away. However, the method 
involves the use of a radioactive label at all stage of the procedure, which puts the user 
at a higher risk of exposure to radioactivity. As with Northern blotting the method also 
requires large amounts of total RNA and is time consuming.
PCR was first described by Saiki et al. (1985) as a highly sensitive and specific 
method for detecting and quantifying nucleic acids in small tissue samples. When 
combined with a reverse transcription step it can be used to analyse RNA levels. PCR 
is essentially a powerful copying system. Starting with a specific target-nucleotide 
sequence, the PCR process produces millions of identical copies. This reaction is 
depicted in Figure 3.1. The technique is ideally suited to the repetitive analysis of the 
same gene from many individuals. The only requirement is that the original sequence 
information, with which to design the oligonucleotide primers, be available. PCR is an 
exponential process for a finite number of cycles. At some point the reaction becomes 
limited (due to lack of one or more reagents) and the rate of formation of new PCR 
products increase at an unknown, non-exponential rate. After this point, the initial 
concentration of DNA cannot be determined by extrapolation (Apostolakos et al. 
1993).
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Figure 3-1 Simplified diagram o f  the reverse-transcription polymerase chain reaction. Double­
stranded cDNA is denatured, oligonucleotide primers anneal to their complementary strand and 
extend along its length. The result is a 2-fold increase in the amount o f  double-stranded cDNA. The 
process is repeated for each cycle o f PCR. T fl, Thermus flavus\ cDNA, complementary DNA.
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The use of competitive PCR or RT-PCR overcomes this problem because the ratio of 
target to competitor templates remains the same, even after the accumulation of 
reaction products has reached a plateau (Gilliland et al. 1990).
Competitive RT-PCR is used to achieve precise quantitation of specific mRNA 
species and involves the co-amplification of a competitive RNA template (which uses 
the same primers as the target RNA template) with the target RNA. Both the target and 
competitor templates must be amplified with the same efficiency and the 
complementary DNA (cDNA) PCR products must be distinguishable from each other 
after amplification. To obtain quantitative information, a constant amount of the target 
RNA is co-amplified with a dilution series of competitor RNA of a known 
concentration. Following competitive RT-PCR, the relative amounts of target cDNA 
versus competitor cDNA can be measured by densitometric analysis. Since the starting 
concentration of the competitor cDNA is known, the initial concentration of the target 
mRNA can be calculated, because the equivalence point between the target and 
competitor cDNA is equal to the amount of target RNA in the original sample (see 
Figure 3.2)
The polymerase chain reaction offers the advantage of being up to a thousand times 
more sensitive than the blot assay (Wang et al. 1989) and involves the use of much 
smaller amounts of RNA than traditional methods.
Before it was known that the Northem-blot methodology was not suitable for the 
measurement of LPL gene expression in human adipose tissue, the adipose-tissue 
biopsy samples, from the n-3 PUFA and MUFA dietary studies (Chapters 4 and 5), 
had already been collected and total RNA extracted. As the amount of total RNA was 
limiting, this factor dictated which method was pursued for the analysis of LPL gene 
expression in these tissue samples.
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Figure 3-2 Schematic diagram of a typical electrophoresis gel following competitive RT-PCR. Lanes 
1-5 show the addition of a 2-fold dilution series of competitor RNA and a constant amount of target 
RNA. Lane 3 indicates the equivalence point between the target and competitor RNA. The arrows on 
the right indicate the size of the competitor RNA (460 bp) and the target RNA (370 bp)
Competitive RT-PCR was the technique chosen for the measurement of LPL mRNA 
in human adipose tissue because:
• RT-PCR is known to be up to 100 times more sensitive than the RNase 
protection assay
• smaller sample sizes can be used
• RT-PCR is less time consuming
• reliable, quantitative information can be obtained
• the method does not involve the use of radiolabels
Aims
This work had three objectives:
1. To develop a competitor-RNA internal standard for use in competitive 
RT-PCR
2. To develop a competitive RT-PCR method for the analysis of LPL mRNA in 
adipose tissue
3. To measure LPL mRNA in adipose-tissue biopsies taken from subjects on the 
n-3 PUFA and MUFA dietary studies described in Chapters 4 and 5
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3.2 MATERIALS AND GENERAL PROCEDURES
All general chemicals were supplied by Fisons, Loughborough, UK or BDH, Poole, 
UK and were Molecular Biology grade unless otherwise stated. All restriction 
endonucleases and buffers were supplied by Promega Corporation, Maddison, USA or 
Amersham International Pic, Little Chalfont, UK. Other materials and their source are 
listed below:
Materials
pBluescript® IISK+ phagemid 
Ligase buffer 
T4 DNA ligase 
JM109 competent cells 
Ampicillin
Ethidium bromide
Agarose
Polaroid black and white print film 667
Polaroid positive/negative film 665
5-bromo-4-chlor-3-indoyl-|3-D-galactoside 
Isopropyl-p-D-thiogalactopyranoside 
DNA quantitation standards (phageX, DNA)
Primers
Tryptone
Agar
Source
Stratagene Ltd., Cambridge, UK. 
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA. 
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Immunogen International Ltd., 
Sunderland, UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Sigma Chemical Company Ltd., Poole, 
UK.
Stratagene Ltd., Cambridge,UK. 
Stratagene Ltd., Cambridge, UK.
Gibco BRL (Life Technologies), Paisley, 
UK.
Gibco BRL (Life Technologies), Paisley, 
UK.
Unipath Ltd., Basingstoke, UK.
Unipath Ltd., Basingstoke, UK.
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Yeast
Tris
PolyATract® system 1000 
Wizard™ plus maxipreps DNA 
purification system
RiboMAX™ large scale RNA production
systems, SP6, T3, T7
Wizard® plus SV minipreps DNA
purification system
Access RT-PCR system
Biphenol chloroform ISA
Petri dishes
1 Kb DNA ladder
Prep-A-Gene DNA purification kit
Microcon^^ microconcentrators 
Whatman filter paper
Unipath Ltd., Basingstoke, UK. 
Boehringer Mannheim GmbH, Germany. 
Promega Corporation, Madison, USA. 
Promega Corporation, Madison, USA.
Promega Corporation, Madison, USA.
Promega Corporation, Madison, USA.
Promega Corporation, Madison, USA. 
Camlab Ltd., Cambridge, UK.
Gibco BRL (Life Technologies), Paisley, 
UK.
Gibco BRL (Life Technologies), Paisley, 
UK.
Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK.
Amicon Ltd., Stonehouse, UK.
Whatman International Ltd., Maidstone, 
UK.
3.2.1 GENERAL PROCEDURES
3.2.1.1 1 X Tris acetate ÏTAE) buffer 
Tris 48.4 g
0.5 M EDTA, pH 8.0 20 ml
Glacial acetic acid 11.42 ml
Made up to 10 litres with milli Q water. Adjust pH to 8.3.
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3.2.1.2 Luria-Bertani (LB) medium
Tryptone 10 g
Yeast 10 g
NaCl 5 g
Made up to 1 litre with reverse osmosis (R.O) water and autoclaved to sterilise. Stored 
at room temperature.
3.2.1.3 LB-asar (solid medium)
Tryptone 10 g
Yeast 5 g
NaCl 10 g
Agar 15 g
Made up to 1 litre with R.O water and autoclaved to sterilise. Stored at room 
temperature.
3.2.1.4 Ampicillin antibiotic stock
Ampicillin powder 10 mg
Nuclease-free water 1 ml
Dissolve ampicillin powder in water. Filter sterilize using a 0.2 )Lim filter. Aliquot and 
store at -20°C. Stock concentration 10 mg/ml.
3.2.1.5 LB-medium with antibiotic
A 500 ml bottle of sterile LB-medium was opened in a flow cabinet. The neck of the 
bottle was flamed and 2.5 ml of ampicillin (stock 10 mg/ml, see section 3.2.1.4) was 
added. This provided a working antibiotic concentration of 50 ng/ml. The solution 
may be stored for up to 1 month at 4°C in the dark.
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3.2.1.6 LB-asar plates with antibiotic
Pre-sterilised solid LB-agar was stored at room temperature. When required, the solid 
LB-agar was melted by heating in a steamer or a microwave. The liquid LB-agar was 
allowed to cool until hand hot (approximately 55°C). Working inside a flow hood, the 
neck of the bottle was flamed and 2.5 ml of ampicillin (stock 10 mg/ml, see section 
3.2.1.4) was added to 500 ml liquid LB-agar. The solution was mixed and the neck of 
the bottle flamed before pouring the required amount of LB-agar into the sterile Petri 
dishes. The plates were allowed to set and dry, in a laminar flow hood, before 
replacing the lids. The plates were then wrapped in clingfilm and stored, medium 
surface facing down, at 4°C.
3.2.1.7 Oranse G loadins dye
Orange G dye 0.02 g
Formamide 10 ml
0.5M EDTA, pH 8.0 200^1
Mixed and stored at room temperature in a foil-lined container. Three microlitres of 
Orange G loading dye per 10 j L i l  sample was used for gel electrophoresis.
3.2.1.8 Ready to load 1 Kilobase (Kb) DNA ladder 
1 Kb DNA ladder (1 ^ig/|Lil) 10 | i l  
Nuclease-free water 90 |xl
Orange G loading dye 30 |xl
Mixed and stored at room temperature. Eight microlitres of this DNA marker were 
used for gel electrophoresis.
3.2.1.9 Asarose sel préparation and sel electrophoresis
Different percentage gels were used to resolve small or large DNA/RNA fragments. 
In this work 1% (w/v), 1.8% (w/v), 2% (w/v) and 3% (w/v) agarose gels were used. 
The agarose gel was made by dissolving the required amount of agarose in 100 ml
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1 X TAE buffer and boiling in a microwave for 2 -5  minutes (depending on the 
concentration of agarose). The molten agarose was left to cool slightly before 3 |xl 
ethidium bromide (10 mg/ml) was added and swirled to mix. The agarose was allowed 
to cool to a hand-hot temperature before being poured into the gel mould. The gel was 
left to set at room temperature, wrapped in clingfilm, and stored at 4°C until required 
for use.
The prepared gel cast was placed in a gel tank, and sufficient buffer (1 x TAE) to fill 
the electrode chambers and cover the gel by a depth of 1-2 mm, was added. Samples 
were loaded into the gel and all gels were run at 3-5  v/cm for 1.5-2,5 hours, 
depending on the degree of band resolution required.
3.3 COMPETITIVE RT-PCR METHOD DEVELOPMENT 
FOR THE ANALYSIS OF LPL GENE EXPRESSION
To carry out competitive RT-PCR, a competitor or ‘standard’ RNA, which utilises the 
same primer sequence as the target RNA but yields a product of a different size, must 
be synthesized. Production of a competitor RNA was achieved by performing an 
RT-PCR experiment using 3 primers (2 sense primers joined together and 1 anti-sense 
primer) to delete a small section within the target sequence. The resulting PCR 
product (competitor) was cloned and used for RNA transcription. Once a competitor 
RNA had been synthesized, the wild type or ‘target’ RNA could then be co-amplified 
with a series of known concentrations of the competitor RNA using the same primers. 
The equivalence point between the target cDNA and competitor cDNA (as measured 
by densitometry) is equal to the number of molecules of target RNA in the initial 
sample.
This section describes how suitable primers were selected and modified to enable 
construction of an LPL competitor RNA using RT-PCR followed by DNA extraction, 
cloning and transcription. The LPL competitor RNA was then used in competitive
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RT-PCRs to measure LPL mRNA, in total RNA and mRNA samples extracted from 
adipose tissue.
3 .3 1 CONSTRUCTION OF LPL COMPETITOR nPNA 
3.3.1:1 Selection o f  primers
In order to develop suitable primers for PCR, the sequence o f the gene o f interest 
must be known. There are a number o f software programmes available for identifying 
potential primers for different genes. The cDNA sequence o f the gene o f interest can 
be copied into these programmes. In this case, primers for LPL mRNA were 
identified using Genejockey for Apple Macintosh. The parameters used to select the 
primers were as follows: amplicon (template) sequence size o f between 200 and 450 
base pairs (bp); G + C content 50-60%; primer length 18-20 bp; melting temperature 
greater than 72°C.
From the list o f primers selected by Genejockey, 2 upstream primers (separated by 
80 bp) and a shared downstream primer were chosen. These enabled the production o f  
the required target and competitor product. To help identify contaminating genomic 
DNA, only those primers which spanned several introns were chosen. This is 
advantageous when working with RNA because if  any contaminating DNA is 
replicated, it appears as a large molecular weight product (size o f the amplicon plus 
the intermediate introns) rather than the 442 bp product expected.
The primers chosen from Genejockey were as follows: 
upstream I 5 ’-GACACTTGCCACCTCATTCCCG-3 ’
upstream 2 5’-GGAATGTATGAGAGTTGGGTGC-3’ 
downstream 5 AAAGACGACTCGGGGCTTCTGC-3 ’
Primers ‘upstream 1’ and ‘downstream’ were used to amplify the target amplicon 
(442 bp in size). All 3 primers were used to construct a competitor product 362 bp in 
size (442 bp minus the 80 bp sequence between the 2 upstream primers).
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The full LPL-cDNA sequence, together with its 10 exon boundaries and the 3 primer 
sequences chosen, are shown in Figure 3.3.
Once the primers were selected, Genejockey was used to identify which restriction 
endonucleases would cut in the competitor amplicon sequence and which would not. 
Restriction endonucleases make double-strand breaks at specific recognition 
sequences within DNA molecules. They enable DNA molecules to be cut (restricted) 
in a reproducible fashion to provide a distinct pattern of fragment sizes. These 
enzymes can be used to demonstrate the specificity of PCR by confirming the identity 
of the PCR product. Restriction endonucleases are also essential for cloning (see 
section 3.3.2).
Restriction-enzyme recognition sequences can also be attached to primers so that they 
are incorporated into the PCR products. This is particularly useful if these PCR 
products are subsequently cloned. The following enzymes were identified as having 
restriction sites in the multicloning site (MCS) of the cloning vector pBluescript SK+, 
but not in the LPL competitor amplicon sequence: EcoR V, Cla I, Xba I, Sac H, Kpn I, 
Xma I. This was necessary because these enzymes were involved in the construction 
of the LPL competitor RNA.
The enzymes were also checked for isoschizimers (restriction enzymes having the 
same recognition sequence, but derived from a different bacterial species), e.g. Xma I 
and Sma I both recognise the sequence CCCGGG.
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1 CCACTTCTAG CTGCCCTGCC ATGGGGTTTA AAGGGGGAGT TGGTGAGGGG
5 1 CAAACCGCGG CTCCAGCCCT GTGGAGGGTG GGGGTGAGGG GGGTGATGAG
1 0 1 TCGGTCCGCG CCTTGCAGCT GGTGGAGAGG GAGGGGGGGG GAGATGGAGA
1 5 1 GCAAAGCCCT GCTCGTGCTG AGTGTGGGGG TGTGGGTGGA GAGTGTGAGG
2 0 1 GCCTCCCGCG GAGGGGTGGC GGGGGGGGAG ÇAAAGAAGAG ATTTTATGGA
2 5 1 CATCGAAAGT AAATTTGCCC TAAGGAGGGG TGAAGAGAGA GGTGAGGAGA
3 0 1 CTTGCCACCT CATTCCCGGA GTAGGAGAGT GGGTGGGTAG GTGTGATTTG
3 5 1 AATCACAGCA GCAAAACCTT GATGGTGATG GATGGGTGGA GGGTAAGAGG
4 0 1 AATGTATGAG AGTTGGGTGC GAAAAGTTGT GGGGGGGGTG TAGAAGAGAG
4 5 1 AACCAGACTC CAATGTCATT GTGGTGGAGT GGGTGTGAGG GGGTGAGGAG
5 0 1 CATTACCCAG TGTCCGCGGG GTAGAGGAAA GTGGTGGGAG AGGATGTGGG
5 5 1 CCGGTTTATC AACTGGATGG AGGAGGAGTT TAAGTAGGGT GTGGAGAATG
6 0 1 TCCATCTCTT GGGATACAGC GTTGGAGGGG ATGGTGGTGG GATTGGAGGA
6 5 1 AGTCTGACCA ATAAGAAAGT GAAGAGAATT AGTGGGGTGG ATGGAGGTGG
7 0 1 ACCTAACTTT GAGTATGCAG AAGGGGGGAG TGGTGTTTGT GGTGATGATG
7 5 1 CAGATTTTGT AGACGTCTTA GAGAGATTGA GGAGAGGGTG GGGTGGTGGA
8 0 1 AGCATTGGAA TGCAGAAAGG AGTTGGGGAT GTTGAGATTT AGGGGAATGG
8 5 1 AGGTACTTTT GAGGGAGGAT GTAAGATTGG AGAAGGTATG GGGGTGATTG
9 0 1 CAGAGAGAGG AGTTGGAGAT GTGGAGGAGG TAGTGAAGTG GTGGGAGGAG
9 5 1 CGCTCCATTC ATGTGTTGAT GGAGTGTGTG TTGAATGAAG AAAATGGAAG
1 0 0 1 TAAGGCCTAC AGGTGGAGTT GGAAGGAAGG GTTTGAGAAA GGGGTGTGGT
1 0 5 1 TGAGTTGTAG AAAGAAGGGG TGGAAGAATG TGGGGTATGA GATGAATAAA
1 1 0 1 GTCAGAGCCA AAAGAAGGAG GAAAATGTAG GTGAAGAGTG GTTGTGAGAT
1 1 5 1 GCCCTACAAA GTCTTCCATT AGGAAGTAAA GATTGATTTT TGTGGGAGTG
1 2 0 1 AGAGTGAAAC GGATAGGAAT GAGGGGTTTG AGATTTGTGT GTATGGGAGG
1 2 5 1 GTGGCCGAGA GTGAGAAGAT GGGATTGAGT GTGGGTGAAG TTTGGAGAAA
1 3 0 1 TAAGACCTAC TGGTTGGTAA TTTAGAGAGA GGTAGATATT GGAGAAGTAG
1 3 5 1 TCATGTTGAA GGTGAAATGG AAGAGTGATT GATAGTTTAG GTGGTGAGAG
1 4 0 1 TGGTGGAGCA GTGGGGGGTT GGGGATTGAG AAGATGAGAG TAAAAGGAGG
1 4 5 1 AGAGACTCAG AAAAAGGTGA TGTTGTGTTG TAGGGAGAAA GTGTGTGATT
1 5 0 1 TGCAGAAAGG AAAGGGAGGT GGGGTATTTG TGAAATGGGA TGAGAAGTGT
1 5 5 1
1 6 0 1
CTGAATAAGA
GCATGTGAAT
AGTGAGGGTG
TC
AAAGTGGGGG AATGTAGAGA AGAAAGAAGG
Figure 3-3 Full cDNA sequence o f human lipoprotein lipase. LPL contains 10 exons and 9 introns. 
The exon boundaries are identified by a emboldened underlined letter (e.g. Ç). The coloured 
sequences correspond to the upstream 1, upstream 2 & downstream primers respectively, as identified 
by Genejockey.
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3.3.1.2 Modification o f  primers for the production o f  the LPL competitor cDNA
By joining together the base-pair sequences o f the upstream primers 1 and 2, a 44 bp 
sense primer was produced. In a PCR experiment, this 44 bp sense primer, together 
with the downstream (anti-sense) primer, would yield a cDNA fragment o f 362 bp. To 
facilitate the cloning o f this LPL competitor-cDNA fragment, the restriction 
recognition sequences for Cla 1, EcoR V and Xba 1 were added to the 5’ end o f the 
44 bp sense primer, and restriction-récognition sequences for Sac 11, Kpn 1 and Xma 1 
were added to the 5’ end o f the anti-sense primer. These primers yielded a 387 bp 
cDNA fragment.
The final sequence for the modified sense and anti-sense primers are shown below, 
where red corresponds to the restriction-enzyme recognition sequences, and blue, 
green and pink correspond to the ‘upstream 1’, ‘upstream 2’ and ‘downstream’ primer 
sequences respectively:-
Primer name CBMU1U2
5’-ATCGATATCTAGACACTTGCCACCTCATTCCCGGGAATGTATGAGAGTT
GGGTGC-3’
The sense primer for constructing LPL competitor cDNA (includes upstream primers 
1 & 2 and restriction-récognition sequences for 3 restriction endonucleases).
Primer name CBDIM
5’-CCGCGGTACCCGGGAAAGACGACTCGGGGCTTCTGC-3’
The anti-sense primer for constructing LPL competitor cDNA (includes downstream 
primer and restriction-récognition sequences for 3 restriction endonucleases).
In an RT-PCR experiment, primers CBMU1U2 and CBDIM produced a 387 bp LPL 
competitor-cDNA fragment. The construction o f the LPL competitor, using the above 
primers only, is shown schematically in Figure 3.4.
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Figure 3-4 Summary of the PCR-mediated synthesis of the LPL competitor RNA, from Schneeberger 
& Zeillinger (1996). Primers CBMU1U2 & CBDIM  were used to construct an LPL competitor-PCR 
amplicon. The sequences a,c & d on the primers are complimentary to the sequences a,c & d on the 442 
bp LPL cDNA. m & n correspond to the restriction enzyme recognition sequences added to the 5 ’ end 
of the primers. During the first PCR the primer CBMU1U2 can anneal at sequence a or c. However, 
only those primers that anneal at sequence c will extend along the length of the LPL cDNA. After the 
third PCR the 80 bp sequence b is deleted from and the sequences m & n are incorporated into the final 
PCR product.
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The primers used to amplify both the LPL target and competitor in the competitive 
RT-PCR experiments are listed below:-
Primer name CBLUl 
5’-GACACTTGCCACCTCATTCCCG-3’
The sense primer used in competitive RT-PCR. Used to amplify the LPL target and 
competitor cDNA.
Primer name CBLDl
5’-AAAGACGACTCGGGGCTTCTGC-3’
The anti-sense primer used in competitive RT-PCR. Used to amplify the LPL target 
and competitor cDNA.
3.3. L 3 Production o f  LPL competitor cDNA bv RT-PCR usim  primers CBMU1U2 &
CBDIM
Human adipose tissue, taken from a number o f patients undergoing abdominal 
surgery, was collected and the total RNA extracted and pooled according to the 
method described in Chapter 2, section 2.2.5. The concentration (calculated from 
absorbance at 260 nm), purity (260:280 ratio >1.8) and the integrity (by gel 
electrophoresis) o f the RNA was checked.
RT-PCR was carried out using the Access RT-PCR system. Each reaction tube set up 
for RT-PCR contained the reagents, primers and total RNA as shown in Table 3.1. 
The reaction tubes were placed in a Hybaid Onrn-E thermal cycler and PCR thermal 
cycling was performed according to the following conditions:
One cycle o f reverse transcription for 45 min at 48°C and denaturing o f reverse- 
transcription enzyme for 2 min at 94°C followed by 40 cycles o f denaturing o f cDNA 
for 30 sec at 94°C, annealing of primers for 1 min at 50°C and extension o f  
oligonucleotide for 2 min at 68°C.
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Table 3-1 RT-PCR protocol using the Access RT-PCR system, CBMU1U2 & CBDIM
primers and total RNA
Reagents (concentration) Volume (pi) per 
reaction
Final concentration per 
reaction
Nuclease-free water 32.0 -
AMV/ZyZ 5X reaction buffer 10.0 IX
dNTP mix (10 mM each of dATP, 
dCTP, dGTP and dTTP
1.0 0.2 mM
MgS0 4  (25 mM) 2.0 1 mM
AMV reverse transcriptase (5 U/pl) 1.0 0.1 U/pl
Tfl DNA polymerase (5 U/pl) 1.0 0.1 U/pl
CBMU1U2 primer (50 pmol/pl) 1.0 1 pM
CBDIM primer (50 pmol/pl) 1.0 1 pM
Total RNA sample (varies) 1.0 -
Total volume 50.0 -
The reaction products (10 pi PCR product + 3 pi Orange G loading dye) were run out 
on a 1.8% (w/v) agarose gel (see section 3.2.1.9). A 1 Kb DNA ladder was run in an 
adjacent lane to confirm the size of the PCR product.
An endonuclease restriction digest of the PCR products was carried out to check the 
specificity of the reaction. Aliquots (10 pi) of PCR product were mixed with 1 pi of 
each of the restriction endonucleases (stock concentration of 5-10  U/pl) (shown in 
Table 3.2) and incubated overnight at 37°C. These enzymes are known to cut in the 
LPL competitor-cDNA amplicon sequence to produce distinctive patterns (see Table 
3.2). The digested PCR products were run out on a 1.8% (w/v) agarose gel (see section 
3.2.1.9) to check that the correct-size fragments had been produced (see Figure 3.5). 
This confirmed that the primers were amplifying the correct sequence of the LPL 
mRNA.
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Table 3-2 Restriction endonucleases used to cut the 387 bp, LPL competitor-cDNA 
amplicon in a reproducible fashion to provide a distinct pattern of fragment sizes
Restriction Endonuclease Fragment sizes (bp) expeeted from the PCR product 
(387 bp LPL competitor cDNA)
Hae in 136 117 67 67
Hinc n 306 81
Hinf I 272 91 24
Hpa II 189 155 31 12
Pvu n 331 56
Figure 3-5 Agarose gel electrophoresis showing the restriction digests of the 387 bp LPL competitor 
cDNA using the restriction endonucleases Hae III, Pvu II, Hinf I, Hpa II and Hinc II (lanes 2 -6  
respectively). Lanes 1 & 7 correspond to the 1 Kb DNA ladder. The arrows indicate the size of the PCR 
fragments produced following restriction.
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Once it had been confirmed that the primers (CBMU1U2 & CBDIM) were amplifying 
the correct sequence of the LPL gene, a second identical RT-PCR was performed. To 
help facilitate the ligation of the LPL competitor into a suitable vector, the PCR 
reaction products (50 pi) were incubated overnight at 37°C with the restriction 
endonucleases Xba I (1 pi) and Kpn 1(1 pi). These enzymes cut the LPL competitor 
cDNA at the restriction recognition sites of the 5’ and 3’ ends to produce a cDNA 
(370 bp in size) with single-strand overhangs (‘sticky ends’). The whole contents of 
the digestion (52 pi + 18 pi orange G loading dye) were mn out on a 1.8% (w/v) 
agarose gel (see section 3.2.1.8) alongside a 1 Kb DNA ladder to ensure that digestion 
had taken place.
3.3.1.4 DNA purification of the LPL competitor cDNA
Once digestion was confirmed, the 370 bp, LPL competitor-cDNA band was excised 
from the agarose gel under UV light (this procedure was carried out quickly in order to 
prevent the DNA being damaged by the UV light). The gel slice was placed in a 
microcentrifuge tube and briefly centrifuged in order to bring down the gel slice and 
enable its volume to be roughly estimated.
A ‘Prep-A-Gene’ DNA-purification kit was used to purify the DNA. Firstly the 
amount of Prep-A-Gene matrix required to bind all the DNA present was calculated 
(5 pi matrix for each pg DNA). Based on the volume of the gel slice, plus the amount 
of Prep-A-Gene matrix required for DNA binding, 3 volumes of Prep-A-Gene 
DNA-purification kit binding buffer (containing sodium perchlorate) was added and 
the mixture gently agitated to dissolve the gel slice. To assist dissolving, the 
microcentrifuge tube was held at 37°C for 5 minutes. The calculated amount of 
Prep-A-Gene matrix was added and the sample mixed gently by flicking the tube or 
vortexing briefly. This was followed by 5-10  minutes incubation at room temperature. 
During this time, frequent agitation by end-over-end rocking assisted DNA-to-Prep-A- 
Gene matrix binding. The DNA-containing Prep-A-Gene matrix was pelleted by 
centrifuging for 30 seconds in a microcentrifuge. The supernatant was removed with a 
pipette and the pellet (containing the bound DNA) was gently resuspended in
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DNA-purification kit binding buffer (volume added being equivalent to 25 times the 
amount of matrix used originally). The sample was centrifuged for 30 seconds to pellet 
the matrix and the supernatant discarded. The pellet was washed with 25 times matrix 
volume of prepared-wash buffer, followed by centrifugation for 30 seconds and 
removal of the supernatant. This wash process was then repeated. After the second 
wash and centrifugation the supernatant was discarded and the matrix pelleted firmly 
by further brief centrifugation. All traces of the supernatant needed to be removed 
because high concentrations of ethanol and salts can inhibit the enzymes involved in 
restriction digestion and ligation procedures.
Once the pellet was completely free of all wash buffer, the bound DNA was eluted by 
resuspending the Prep-A-Gene matrix pellet in 1 pellet volume of elution buffer, and 
incubating at 37-50°C for 5 minutes. The sample was centrifuged for 30 seconds to 
make a solid pellet and the DNA-containing supernatant was transferred to a clean 
tube. The supernatant was briefly re-centrifuged to check for, and if necessary to 
remove, any traces of matrix. A portion of the eluted cDNA (2 pi) was run out on a 
1.8% (w/v) agarose gel (see section 3.2.1.9) alongside a 1 Kb DNA ladder and a series 
of DNA quantitation standards to confirm both the size and concentration of the 
cDNA. This LPL competitor cDNA (370 bp in size) was then ready for ligation into a 
suitable vector (see section 3.3.2.2).
3.3.2 CLONING OF LPL COMPETITOR cDNA
The next stage in synthesizing the competitive RNA template involved cloning the 
purified cDNA fragment extracted. Cloning involves a number of procedures which 
employ 2 main types of enzymes: restriction endonucleases and ligases. First, a 
cloning vector (essentially a circular piece of DNA), which possesses just 1 restriction 
site for a particular endonuclease, is converted into a linear molecule by treatment with 
that enzyme. This is the essential manipulation required to prepare the cloning vector 
for insertion of the DNA fragments to be cloned. DNA ligases are responsible for 
joining together DNA fragments prepared by restriction. To be ligated, a pair of ends 
must be compatible, which means they must be flush (‘blunt’) ended, or they must 
both have single-strand overhangs (‘sticky’ ends) that are able to base pair. Once the
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cDNA of interest has been ligated into the linearised cloning vector it is known as 
recombinant DNA. Newly constructed recombinant DNA molecules are introduced 
into host cells, which are normally a strain of Escherichia coli (E. coli). This process 
of putting DNA into a cell is known as transformation. Within the host cells, the 
recombinant DNA molecules replicate and are passed on to progeny cells when the 
host cells undergo cell division. Continued replication of the host cells results in 
clones, each one containing identical copies of the recombinant DNA molecule.
Following transformation and cloning it is necessary to identify which colonies 
contain recombinant DNA molecules, as not all cells will take up recombinant DNA, 
and some will take up self-ligated vector that contains no insert. Identification of 
colonies makes use of the genes carried by the cloning vector. The vector used in these 
experiments, pBluescript SK+, contains the Ampicillin-resistance gene (amp*^ ) for 
antibiotic selection of the vector. This means that only bacterial cells containing the 
pBluescript SK+ vector will grow in the presence of the antibiotic ampicillin. This 
allows distinctions between transformed cells which contain the vector and 
untransformed cells which do not contain the vector. However, it does not distinguish 
between transformed cells containing recombinant DNA (vector + insert) and cells 
without recombinant DNA (vector but no insert). Instead, this is achieved by 
blue/white colour screening, through inactivation of p-galactosidase activity. 
pBluescript SK+ contains the lacZ gene, which codes for the first 146 amino acids of 
P-galactosidase. This is the enzyme responsible for converting lactose to glucose plus 
galactose in the normal E. coli bacterium. The segment coded by the lacZ gene is not 
sufficient to catalyse the conversion by itself, but it can complement a host-encoded 
fragment to produce an active enzyme. Host bacterial strains that carry lacZAMlS and 
lacl^ on a F’ episome will enable enzyme activation. The enzyme activity can be 
assayed in the presence of 5-bromo-4-chlor-3-indolyl-p-D-galactoside (X-gal) which, 
although colourless, is converted to an intense blue product as a result of p- 
galactosidase activity. Isopropyl-p-D-thiogalactopyranoside (IPTG) is also included 
with X-gal because it is needed to switch on expression of lacZ. pBluescript SK+ 
vector with no inserts (in the MCS) will grow as blue colonies on the appropriate
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strains of bacteria because there is no disruption of the lacZ gene-coding region. 
However, pBluescript SK+ vectors that do have inserts in the MCS will grow as white 
colonies on appropriate strains of bacteria, because the inserts disrupt the coding 
region of the lacZ gene and prevent enzyme activation. Therefore recombinants are 
amp'^  and lacZ  and non-recombinants are amp'^  and lacZf.
Once there is confirmation of recombinant DNA presence, large-scale cultures are 
prepared, the recombinant DNA is extracted from the bacterial cells and RNA is 
transcribed from it. The following sections describe in detail the construction, 
transformation and extraction of recombinant DNA.
3.3.2.1 Restriction digest o f the clonins vector
The cloning vector used in these experiments was pBluescript SK+. This is a 
phagemid (a plasmid with a phage origin of replication) cloning vector (see Figure 
3.6). The restriction endonucleases used to cut pBluescript SK+ were Kpn I and Xba I. 
These enzymes cut at specific sites to produce a linear vector with single-strand 
overhangs which are base-pair compatible with the LPL competitor-cDNA fragment to 
be inserted.
The restriction digest was carried out as follows:
5 p.1 pBluescript SK+ (1 |ig/pl)
1.5 |xl 10 X multicore buffer 
1 |il Kpn I enzyme
1 |Lil Xba I enzyme
9.5 pi nuclease-free water
Incubate at 37°C overnight
The completed reaction was run out on a 1% (w/v) agarose gel (see section 3.2.1.9) 
alongside a 1 Kb DNA ladder, and some undigested pBluescript SK+ in order to check 
that digestion had taken place. Two DNA bands were observed, 1 corresponding to the
118
N ael
F lO ri
,ac
'Am\
[CS'
S a d  X3 |  
_ BssHH
ColE I Origin
Where:-
MCS
LacZ
Amp 
FI Ori
ColEl Origin 
Nae I 
BssH n  
Kpn I 
Xba I 
Sac I
= Multiple cloning site flanked by T3 and T7 
promoters
= This portion of the lacZ gene provides 
a-complementation for blue-white colour selection of 
recombinant phagemids
= Ampicillin resistance gene for antibiotic selection of 
the phagemid vector
= Fl(+) filamentous phage origin of replication 
= Plasmid origin of replication 
= Nae I endonuclease restriction site 
= BssH n  endonuclease restriction site 
= Kpn I endonuclease restriction site 
= Xba I endonuclease restriction site 
= Sac I endonuclease restriction site
Figure 3-6 Diagrammatic representation of the phagemid vector pBluescript SK+ (2.96 Kb).
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size of the restricted pBluescript SK+ (2878 bp), and the other corresponding to the 
size of the sequence (82 bp) between Kpn I and Xba I. The DNA band corresponding 
to the size of the restricted pBluescript SK+ was excised from the gel and the DNA 
extracted using the Prep-A-Gene DNA-purification kit as described in section 3.3.1.4.
The extracted DNA was quantified on a 1% (w/v) agarose gel (see section 3.2.1.9) 
alongside DNA quantitation standards. The concentration was also determined 
spectrophotometrically at absorbance 260 nm.
3.3.2.2 Lisation reaction involvins the clonins vector and the LPL competitor cDNA
To carry out the ligation reaction, the size and approximate concentration of both the 
vector (see section 3.3.2.1) and LPL competitor-cDNA insert (see section 3.3.1.4) 
were calculated:
Size of digested pBluescript SK+ = 2.878 Kb
Concentration of digested pBluescript SK+ = 200 ng/p.1
Size of LPL competitor-cDNA insert = 0.37 Kb
Concentration of LPL competitor-cDNA insert = 5 ng/|xl
An insert:vector molar ratio of 1:1, 2:1, 3:1 is usually used. In these experiments 
100 ng of vector and a 1:1 and 2:1 insert:vector ratio was used. The amount of insert 
(ng) per nanogram of vector was calculated using the following equation:
ng vector x Kb size of insert x molar ratio of insert = ng insert
Kb size of vector vector
The ligation reactions were set up as shown in Table 3.3. A sample (2 |xl -f- 3 \il 
orange G loading dye) of the ligation reactions were run out on a 1% (w/v) agarose gel 
(see section 3.2.1.9) alongside a 1 Kb DNA ladder to check that the ligation was 
successful. The size of the recombinant DNA band expected was 3.248 Kb.
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Table 3-3 Ligation reaction protocol.
The amount of reagents used were calculated from the equation shown above. Tubes 1 
and 2 have a 1:1 and 2:1 insert.'vector ratio respectively. Tubes 3—5 are control tubes. 
Tube 3 controls for contaminating insert DNA, tube 4 controls fo r  uncut or self ligated 
vector DNA and tube 5 controls for contaminating vector DNA
Reagents (concentration) Tube Number (volumes in pi)
1 2 3 4 5
Restricted pBluescript SK+ DNA 
(200 ng/|ll)
0.5 0.5 0.5 0.5 0
LPL competitor-cDNA insert (5 ng/|il) 2.5 5.0 0 0 2.5
10 X ligase buffer 1.0 1.0 1.0 1.0 1.0
T4 DNA ligase (4 weiss U/pl) 0.5 0.5 0.5 0 0.5
Nuclease-free water (to 10 pi) 5.5 3.0 8.0 8.5 6.0
Incubated at 4°C overnight
If ligation had not been successful 2 products, 1 of 2.878 Kb and the other 0.37 Kb, 
would have been seen.
3.3.2.3 Preparation of competent cells
Once the recombinant DNA has been constructed it can be introduced into host 
bacterial cells. Before this is possible, the host cells must be made competent, which 
essentially means opening up gaps within the cell’s walls so that the recombinant 
DNA can pass through and become trapped within the cells.Competent cells were 
prepared as follows: A fresh culture was made by innoculating 500 ml LB medium 
with E. coli XLl-Blue MRF cells in glycerol (gift from Dr J.Rockett, University of 
Surrey) and incubating at 37°C overnight (16 hours) in a shaking incubator.
An aliquot of this E. coli XLl-Blue MRF culture (1 ml) was taken and incubated with 
100 ml fresh LB medium and 100 p-1 tetracycline (15 mg/ml in ethanol) at 37°C with 
shaking for 3 hours (or until the absorbance at 590 nm was 0.3). The resulting culture 
was placed on ice for 10 minutes and then centrifuged at 1500 x g for 5 minutes to
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pellet the cells. The supernatant was discarded and the pellet resuspended in 10 ml 
100 mM MgCL (freshly prepared). This was left on ice for 20 minutes followed by 
centrifugation at 1500 x g for 5 minutes. Due to cell fragility at this stage, the 
supernatant was carefully removed and the pellet gently resuspended in 5 ml 100 mM 
CaCl2 and 15% glycerol (0.75 ml glycerol + 4.25 ml 100 mM CaCl2). Aliquots were 
taken and stored for 1 hour at 4°C before being transferred to the -80°C freezer.
33.2.4 Transformation and clonins
Competent E. coli XLl-Blue MRF or JM109 cells (200 pi) were thawed on ice. 
Recombinant DNA (10 ng) from the ligation reaction (see section 3.3.2.2) was added 
to the competent cells and mixed by gently swirling the pipette tip. This mixture was 
left on ice for 30 minutes. The recombinant DNA-competent cell mixture was placed 
in a waterbath (42°C) for 45-60 seconds, and then cooled on ice for 2 minutes. After 
cooling, the mixture was added to 3 ml of LB medium and incubated for 45 minutes at 
37°C in a shaking incubator (approximately 150 revolutions per minute [rpm]).
The agar-ampicillin plates (see section 3.2.1.6) were brought to room temperature and 
spread with 50 pi (50 mg/ml) X-Gal and 100 pi (0.1 M) IPTG, to enable blue/white 
colour screening, and allowed to dry at 37°C. The culture was removed from the 
shaking incubator and 100 pi of the transformation mix was spread onto each prepared 
agar plate using a sterile spreader. After inoculation the plates were left to grow up 
overnight in an oven at 37°C.
3.3.2.5 Assessment of the overnight growth usins a miniprep to extract the DNA 
The next step was to check if the white colonies, which had grown up overnight, 
contained the recombinant DNA.
Using a sterile picker, individual colonies ( those which were white or white with a 
pale blue centre) were picked and placed in 5 ml LB medium with 25 pi ampicillin 
(10 mg/ml, see section 3.2.1.4) and incubated overnight at 37°C in a shaking
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incubator. A miniprep was carried out using a simple method (Zhou et al. 1990) as 
follows:
The overnight culture (1.5 ml) was microcentrifuged for 10 seconds to pellet the cells 
and all but 50-100 pi of supernatant was decanted. The cell pellet was resuspended in 
the residual supernatant by high-speed vortexing. Next, 300 pi of TENS solution (TE 
buffer, 0.1 M NaOH and 0.5% (w/v) SDS) was added and the sample vortex mixed 
until the mixture became sticky. Following this, 150 pi of 3 M sodium acetate, pH 5.2 
was added and vortex mixed for 2 -5  seconds. This was microcentrifuged for 2 
minutes to pellet cell debris and chromosomal DNA. The supernatant was transferred 
to a clean tube and mixed with 0.9 ml 100% ethanol which had been pre-cooled to - 
20°C. After centrifuging for 2 minutes to pellet the plasmid DNA and RNA, the 
supernatant was discarded and the pellet washed twice in 1 ml of 70% (v/v) ethanol. 
The pellet was allowed to dry thoroughly before being resuspended in 20-40 pi 
nuclease-free water.
In order to check that the phagemid DNA contained the LPL competitor-cDNA 
fragment, a restriction digest was performed. The sequence between Kpn I and Xba I 
in the phagemid corresponds to the LPL competitor-cDNA fragment that was inserted, 
therefore these restriction endonucleases were used to cut this section out of the 
phagemid. The following reagents were incubated together for two hours at 37°C:
15 pi phagemid DNA, 1 pi Kpn I, 1 pi Xba I, 2 pi 10 x multi-core buffer & 1 pi 
RNase
RNase was added to destroy any RNA contamination, which on a gel would present as 
low molecular-weight smearing and could interfere with the detection of the LPL 
competitor-cDNA fragment. Five microlitres of the digested products were loaded 
alongside a 1 Kb DNA ladder into a 1% (w/v) agarose gel (see section 3.2.1.9).
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Figure 3-7 Agarose gel electrophoresis following the restriction digest of the cloned recombinant DNA 
(pBluescript SK+ phagemid DNA with LPL competitor-cDNA insert) using Kpn I and Xba I restriction 
endonucleases. Lanes 1 & 15 show a 1 Kb DNA ladder. Lanes 2-14 show recombinant DNA grown 
from single colonies. The bands seen at 2878 bp and 370 bp correspond to the digested phagemid and 
LPL competitor-DNA respectively.
The presence of 2 bands, 1 corresponding to the size of the LPL competitor-cDNA 
(0.37 Kb)and the other corresponding to the size of digested pBluescript SK-f (2.878 
Kb), confirmed successful transformation and cloning (as shown in Figure 3.7).
33.2.6 Maxiprev of recombinant DNA
Once the correct-size bands were detected on the gel, the remaining volume (3.5 ml) 
of overnight culture (see section 3.3.2.5) was added to 500 ml LB medium containing
2.5 ml ampicillin (10 mg/ml, see section 3.2.1.4) and incubated overnight in a shaking 
incubator at 37°C. Using Promega’s ‘Wizard Plus maxiprep DNA purification system’ 
a maxiprep was performed on the resulting culture according to the protocol described 
below:
The culture was transferred to a container suitable for centrifugation and the cells were 
pelleted by centrifuging at 5000 x g for 10 minutes in a Beckman J6 centrifuge at 
room temperature. The supernatant was discarded and the remaining pellet was 
resuspended in 15 ml cell-resuspension solution (50 mM Tris-HCL, pH 7.5 + 10 mM 
EDTA 4- 100 |ig/ml RNase A) by pipetting up and down. Next, 15 ml of cell lysis 
solution (0.2 M NaOH +1% (w/v) SDS) was added and gently mixed by inverting the 
container. Cell lysis was complete when the solution became clear and viscous 
(20 minutes). Neutralisation solution, 15 ml of 1.32 M potassium acetate, pH 4.8 was 
then added and immediately mixed by gently inverting the centrifuge bottle. The
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sample was centrifuged at 14000 x g for 15 minutes in a J2-21 Beckman centrifuge at 
22-25°C in a rotor at room temperature. The supernatant was carefully removed and 
filtered through a Whatman Filter paper into a clean 50 ml screw-cap tube so that the 
volume could be recorded. Isopropanol at room temperature (half the volume of the 
supernatant) was added to the supernatant and mixed by inversion. The tubes were 
centrifuged at 14000 x g for 15 minutes at 22-25°C and the supernatant discarded. 
The DNA pellet (which was not visible) was resuspended in 2 ml 1 x TAE buffer and 
left on ice for 30 minutes to allow the DNA to dissolve.
Wizard maxiprep DNA-purification resin (10 ml) was added to the DNA solution and 
mixed by swirling. A wizard maxicolumn was inserted into a vacuum manifold port 
(Promega) and the resin-DNA mixture was transferred into the column. A vacuum was 
applied so that the resin and DNA mix were pulled into the maxicolumn. Whilst still 
applying a vacuum, 25 ml of column-wash solution (80 mM potassium acetate +
8.3 mM Tris-HCL, pH 7.5 + 40 pM EDTA + 55% (v/v) ethanol) was added to the 
maxicolumn. This was followed by 5 ml 80% (v/v) ethanol to wash the bound DNA. 
The vacuum was allowed to draw for an additional minute after the ethanol had passed 
through. The maxicolumn was inserted into a 50 ml screw-cap tube and centrifuged at 
1300 X g  for 5 minutes in a benchtop centrifuge with a swing-out rotor. The 
maxicolumn was returned to the vacuum and the resin was dried by applying the 
vacuum for a further 5 minutes. Following this, the maxicolumn was transferred to a 
clean 50 ml screw-cap tube and 1.5 ml of preheated (65-70°C) sterile water was 
added. After 1 minute, the tube was centrifuged at 1300 x g  for 5 minutes. The final 
eluate was removed and filtered (0 . 2 2  pm syringe filter) to clear the eluate of any 
white resin fines.
The phagemid DNA was cleaned by carrying out an overnight ethanol precipitation. 
One third volume of 3 M sodium acetate pH 5.2 followed by 2 volumes of absolute 
ethanol was added to the phagemid DNA and left at -20°C overnight. The mixture was 
centrifuged at top speed in a microcentrifuge for 20 minutes. The supernatant was 
discarded and the DNA pellet was washed with 70% (v/v) ethanol. The ethanol was
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removed and the DNA pellet allowed to dry before being resuspended in nuclease-free 
water. The concentration of the phagemid DNA was checked spectrophotometrically 
at absorbance 260 nm.
33.2 .7  Linearisation of phasemid DNA
Linearisation of phagemid DNA is necessary prior to transcription of RNA, so that 
only the sequence of interest (the LPL-competitor sequence) is transcribed. The vector 
was linearised downstream of the T3 promotor site, using a restriction endonuclease 
which cut at a recognition site shortly after the end of the sequence of interest. The 
enzyme chosen cut only once in the vector and did not cut in the LPL-competitor 
sequence.
Two linearisations were carried out using the restriction endonucleases Kpn I and 
Nae I, as follows:
10 pi phagemid DNA
3.0 p i  10 X buffer
5.0 pi restriction endonuclease
12.0 pi DEPC water
Incubated at 37°C for 6  hours
The linearised phagemid was cleaned up by adding an equal volume of Bi-phenol: 
chloroform:isoamylalcohol (25:24:1, buffered to pH 8.0) and centrifuged for 
5 minutes. The aqueous layer was removed, an equal volume of 
chloroform:isoamlyalcohol (24:1) was added and the mixture centrifuged for 
2 minutes. The aqueous layer was removed and transferred to a clean tube where 
0.1 volume 3 M sodium acetate and 2 volumes of absolute ethanol were added before 
precipitating DNA overnight at -20°C. The mixture was centrifuged for 20 minutes to 
pellet the DNA. The DNA pellet was washed in 80% (v/v) ethanol, allowed to dry and 
resuspended in nuclease-free water. The linearisation reaction was checked by running 
some of the eluted DNA on a 1% (w/v) agarose gel (see section 3.2.1.9) alongside a 
1 Kb DNA ladder and DNA quantitation standards.
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33.2.8 Transcription
This was carried out using the Ribomax large-scale, RNA production system and 
utilised the T3 promotor site which is located on the pBluescript SK+ vector, just 
upstream from the MCS. The reaction was set up as follows, adding the reaction 
components in the order listed:
T3 Transcription 5 x buffer 20 pi
rNTPs (25 mM ATP, CTP, GTP, UTP) 30 pi
Linear phagemid template (5 pg) in nuclease-free water 40 pi
Enzyme mix 10 pi
Final Volume 100 pi
The reaction components were gently mixed together and incubated for 2 -4  hours at 
37°C. Following this, the DNA template was removed by the addition of RNase-free 
DNase, at a concentration of 2 U/pg DNA template, and incubated for 30 minutes at 
37°C. The RNA was extracted by adding 1 volume of TE-saturated bi-phenol: 
chloroform:isoamylalcohol (25:24:1, pH 4.5) and centrifuging at top speed for 
2 minutes. The aqueous layer was removed and mixed with 1 volume of 
chloroform:isoamylalcohol (24:1). After centrifuging for 2 minutes the aqueous layer 
was removed and mixed with 0.1 volume of 3 M sodium acetate (pH 5.2) and 
1 volume of isopropanol. This was left on ice for 5 minutes before centrifuging at top 
speed for 10 minutes to pellet the RNA. The pellet was washed twice in 70% (v/v) 
ethanol and allowed to dry before being resuspended in nuclease-free water. The 
concentration and purity was determined spectrophotometrically at absorbance 260 
and 280 nm.
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Table 3-4 Restriction endonucleases used to cut the 362 bp LPL competitor-cDNA 
PCR product and their expected fragment sizes
Restriction Endonuclease Fragment sizes (bp) expected from the PCR product 
(362 bp LPL competitor cDNA)
Ban I 322 40
Hinf I 272 80 1 0
Msp I 187 155 2 0
To confirm that the LPL competitor-RNA sequence had been transcribed, an RT-PCR 
experiment was set up. This used the reagents and conditions described in section 
3.3.1.3, except that the total RNA was replaced with LPL competitor RNA (100 ng/pl) 
and the primers CBMU1U2 and CBDIM were replaced with the primers CBLUl and 
CBLDl. A restriction digest was carried out on the PCR products, to confirm the 
specificity of the primers, using the enzymes shown in Table 3.4. The digested 
products were then visualised by gel electrophoresis, as shown in Figure 3.8.
Once the sequence of the LPL competitor RNA was confirmed, the stock LPL 
competitor RNA was diluted. Using nuclease-free water, a 10-fold serial dilution was 
carried out to give a series of working concentrations (1 pg-100 ag/pl). These were 
aliquotted and stored at -80°C until required.
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Figure 3-8 Agarose gel electrophoresis showing the restriction digest of the 362 bp LPL competitor 
cDNA PCR product using the restriction endonucleases Msp I, Hinf I and Ban I. Lane 1 shows a 1 Kb 
DNA ladder, lane 2 shows the undigested 362 bp LPL competitor-PCR product, lanes 3-5  show the 
digested LPL competitor-PCR products following digestion with Msp I, Hinf I and Ban I respectively. 
The arrows indicate the size of the DNA fragments produced.
3.3.3 OPTIMISATION OF THE RT-PCR USING PRIMERS CBLUl & CBLDl
3.3.3.1 RT-PCR usins total RNA extracted from surgically removed adipose tissue
Total RNA used in section 3.3.1.3 was used for the optimisation of the RT-PCR 
conditions for the ‘target’ primers CBLUl and CBLDl. Although these primers had 
worked satisfactorily with the LPL competitor RNA, it could not be presumed that 
they would work with total RNA, where there are other RNAs present besides the 
mRNA of interest. Initially an RT-PCR was set up according to the protocol described 
in Table 3.5.
PCR cycling was carried out as follows in a Hybaid Omn E thermal cycler: 1 cycle of 
reverse transcription (RT) for 45 min at 48°C and denaturing of RT enzyme for 2 min 
at 94°C, followed by 40 cycles of denaturing of cDNA for 30 sec at 94°C, annealing of 
primers for 1 min at 50°C and extension of oligonucleotide for 2 min at 6 8 °C. This 
experiment was repeated, altering one parameter at a time, until the optimum MgS0 4  
concentration, annealing and extension temperatures and number of cycles were
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determined. The optimal conditions determined for this set of primers were: 1 cycle 
RT for 45 min at 48°C and denaturing of RT enzyme for 2 min at 94°C followed by 
28 cycles of denaturing of cDNA for 30 sec at 94°C and combined annealing and 
extension for 2.5 min at 70°C using 1 mM MgS0 4 .
To determine the optimal number of cycles required for a total RNA sample, a series 
of identical reaction tubes were prepared according to tube number 2 in Table 3.5. 
PCR cycling was carried out as above except, after 23 cycles, 1 reaction tube was 
removed from the cycler and a further tube was removed after each additional cycle 
(up to 30 cycles). Following agarose gel electrophoresis the products were visualised 
and photographed on positive-negative film (see Figure 3.9). The band densities were 
measured on the negative film using a Shimadzu dual-wavelength, flying-spot scanner 
and plotted against the number of cycles (see Figure 3.10). This enabled the 
exponential (log) and plateau phases of the reaction to be determined.
Table 3-5 RT-PCR protocol using the Access RT-PCR system, CBLUl & CBLDl 
primers and total RNA extracted from adipose tissue. Tubes examine the effect of 
increasing the concentration ofMgS04 . Tube 5 is a negative control containing kit
reagents and primers only
Reagents (concentration) Tube Number (volumes in |xl)
1 2 3 4 5
Nuclease-free water 33 32 31 30 33
AMN/Tfl 5X buffer 1 0 1 0 1 0 1 0 1 0
dNTPs (10 mM of each) 1 1 1 1 1
MgS0 4 ( 2 5  mM) 1 2 3 4 2
Tfl DNA polymerase (5 u/|il) 1 1 1 1 1
AMV-Reverse transcriptase (5 u/p.1) 1 1 1 1 1
CBLUl + CBLDl primers 
(50 pmol/)Lil each)
2 2 2 2 2
Total RNA 1 1 1 1 -
Total volume 50 50 50 50 50
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Figure 3-9 RT-PCR carried out using total RNA and primers CBLUl and CBLDl for 23-30  cycles, in 
order to demonstrate the exponential nature of the PCR reaction. The intensity of the DNA band 
increases with increasing PCR cycle number. Lanes 1 & 10 show a 1 Kb DNA ladder. Lanes 2 -9  show 
the 442 bp target LPL-PCR products produced at 23-30 cycles respectively.
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Figure 3-10 Graphical representation of the PCR-product band densities measured at 23-30  PCR 
cycles, to demonstrate the exponential nature of the RT-PCR reaction.
33.3.2 RT-PCR usins total RNA extracted from adipose tissue obtained by needle 
biopsy
Throughout the RT-PCR method development, total RNA from surgically acquired 
adipose tissue was used, since this provided a large source of RNA which could be 
used for the whole study. However, the dietary studies described in this thesis used 
adipose tissue obtained by needle biopsy (as described in Chapter 2, section 2.2.5). It 
was therefore necessary to check that the RT-PCR conditions optimised in section
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3.3.3 were transferable to total RNA extracted from needle-biopsy adipose tissue. An 
RT-PCR experiment was set up according to tube number 2 of Table 3.5. Two 
samples of needle-biopsy, adipose tissue total RNA were used, 1 that had been stored 
at -80°C for more than 1 year, and 1 that was freshly extracted.
The RT-PCR conditions were the same as those used initially in section 3.3.3.1. The 
PCR products were visualised by gel electrophoresis. However, the results obtained 
from this and subsequent repeat experiments were ambiguous, as sometimes a signal 
was seen and other times it was not.
Inhibitors of PCR have been documented and include ionic detergents such as SDS 
and Sarkosyl (Weyant et al. 1990). Other chemicals used in template collection and 
preparation such as heparin and phenol (Beutler et al. 1990) have also been shown to 
inhibit PCR. All the total RNA used in these RT-PCR experiments had been dissolved 
in 0.5% (w/v) SDS (see Chapter 2, section 2.2.5). Work by Loffert et al. (1997) 
demonstrated that at concentrations of 0.01% (w/v), SDS inhibited PCR to the extent 
that no product could be seen by gel electrophoresis. These findings might explain the 
lack of product seen in RT-PCR experiments herein. However, it does not explain why 
sometimes PCR products were seen and other times they were not.
Ideally, a lithium chloride (LiCl) precipitation step, to recover RNA without 
precipitating the SDS, should be used when SDS is included in RNA extraction 
(Adamovicz & Cause, 1995). However, the LiCl must subsequently be removed by 
ethanol precipitation because it interferes with reverse transcription (Adamovicz & 
Cause, 1995). Re-extraction of the RNA using ethanol precipitation and/ or centrifugal 
ultrafiltration can also be used to help reduce PCR inhibitors (Roux, 1995). This 
procedure was not carried out because re-extraction always results in loss of some 
nucleic acid and there was not sufficient sample to allow for this loss.
At the same time that these problems were experienced, another investigator was 
extracting mRNA rather than total RNA from adipose tissue. The mRNA extraction 
method contained no chemicals known to interfere with RT-PCR and subsequent
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RT-PCR experiments, using this mRNA, demonstrated that the conditions described 
previously in section 3.3.3 were transferable.
At this stage, the inability to eliminate the RT-PCR inhibitors from the total RNA 
samples meant that further RT-PCR method development, using total RNA, could not 
be pursued. It was, therefore decided that it would be more appropriate to optimise the 
competitive RT-PCR method for the analysis of LPL gene expression in mRNA 
samples extracted from adipose tissue. One advantage of using mRNA rather than 
total RNA is that small changes in LPL gene expression are more likely to be detected 
because ribosomal and transfer RNAs are absent. In order for this method to be 
successful, and meaningful RT-PCR results to be obtained, the concentration of 
mRNA needs to be known. Work by another investigator using mRNA extracted from 
small quantities of liver had found that the concentration of the mRNA could be easily 
measured using a microspectrophotometer. It was initially assumed that this would 
also apply to adipose-tissue mRNA.
3.3.4 EXTRACTION OF mRNA FROM ADIPOSE TISSUE
Adipose tissue from 5 volunteers (see Table 3.6, page 140 for details) was removed by 
needle biopsy according to the procedure described in Chapter 2, section 2.2.5. 
Instead of placing the tissue into ‘D ’ solution the tissue was immediately placed in 
liquid nitrogen. The mRNA was then extracted using the PolyAtract system 1000 kit.
In brief, 41 pi p-mercaptoethanol (48.7% (v/v)) and 1 ml of the GTC extraction buffer 
(4 M guanidine thiocyanate & 25 mM sodium citrate, pH 7.1) was added to a 
homogeniser tube. A measured amount of adipose tissue (< 0.125 g) was added to the 
homogeniser tube and the tissue homogenised until no visible fragments remained.
Based on the tissue mass used, the amount of biotinylated oligo (dT) probe 
(50 pmol/pl) and streptavidin magnesphere paramagnetic particles (SA-PMPs) 
required was estimated from the chart displayed in the manufacturer’s manual. Two 
millilitres of dilution buffer (10 mM Tris-HCL, pH 7.4 + 1 mM EDTA + 0.25% SDS
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(w/v) + 6 X SSC) preheated to 70°C and 41 pi of p-mercaptoethanol (48.7% (v/v)) was 
then added to the homogenate and mixed by inversion.
Following this, the required amount of biotinylated oligo (dT) probe was added to the 
homogenate, mixed thoroughly by shaking, and incubated at 70°C for 5 minutes. The 
homogenate was then transferred to a clean tube and centrifuged in a J2-22 Beckman 
centrifuge at 1 2 0 0 0  x g for 1 0  minutes at room temperature.
During the centrifugation the required volume of SA-PMPs was transferred to a 50 ml 
conical screw-cap tube and placed in a magnetic stand. The magnetic stand was placed 
in a horizontal position so that the SA-PMPs collected at the tube side. The storage 
buffer was poured off by tilting the tube and the magnetic stand, so that the solution 
ran over the captured particles. The SA-PMPs were then resuspended in an equal 
volume of SSC 0.5X solution (75 mM NaCl + 7.5 mM sodium citrate, pH 7.2) and re­
captured using the magnetic stand. This procedure of capturing the SA-PMPs, pouring 
off the storage buffer and resuspending in fresh buffer was repeated a total of 3 times. 
After the third wash the SA-PMPs were resuspended in the original volume of SSC 
0.5X solution.
Once the centrifugation was complete, the homogenate supernatant was removed 
using a sterile 5-ml pipette and added to the SA-PMPs in SSC 0.5X solution. The 
mixture was mixed by inversion and incubated at room temperature for 2 minutes. The 
SA-PMPs were captured using the magnetic stand in the horizontal position until the 
homogenate cleared. The supernatant was poured off over the SA-PMPs and the 
particles were resuspended in 1 ml SSC 0.5X solution. The contents were transferred 
to one of the RNA tubes supplied, the SA-PMPs were captured by the magnetic stand 
and the SSC 0.5X solution was removed carefully using a pipette. The SA-PMPs were 
resuspended in SSC 0.5X solution, and the wash procedure repeated twice. After the 
final wash the SSC 0.5X solution was removed and the remaining particle cake was 
resuspended in 80 jil of nuclease-free water to elute the mRNA. The SA-PMPs were 
captured on the magnetic stand and the liquid containing the eluted mRNA was 
removed using a pipette. This procedure of resuspending the SA-PMPs in nuclease-
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free water, capturing the SA-PMPs on the magnetic stand and removing the liquid 
containing the eluted mRNA was repeated 3 times until there were 4 x 80 |xl aliquots 
of eluted mRNA. The mRNA was pooled, aliquotted and stored at -80°C until 
required for analysis.
3.3.5 COMPETITIVE RT-PCR USING mRNA FROM ADIPOSE TISSUE
A series of RT-PCR experiments were carried out to optimise the conditions for use 
with adipose-tissue mRNA. These included determining the MgS0 4  concentration, 
annealing temperature and the optimum number of cycles necessary for competitive 
RT-PCR.
Although competitive RT-PCR does not have to be run in the log phase, Pannetier 
et al. (1993) cautioned that competitive RT-PCR may not provide accurate results 
when the data are collected well after the plateau phase. Also at higher cycle numbers 
there is an increased likelihood of non-specific bands and high molecular weight 
smearing, which can interfere with quantitation. Using the Access RT-PCR system, 8  
reaction tubes were set up to contain the reagents shown:
REAGENT (concentration) VOLUME ( i^l)
Nuclease-free water 31.0
A M V /^ 5 X  buffer 10.0
dNTPs (10 mM of each) 1.0
MgS0 4  (25 mM) 2.0
AMY reverse transcriptase (5 U/^il) 1.0
Tfl DNA polymerase (5 U/|il) 1 0
CBLUl + CBLDl primers (50 pmol/|xl each) 2.0
Sample mRNA (varies) 1.0
Total volume 49.0
Ten-fold dilutions (1 ng-100 ag/|il) of the LPL competitor RNA (prepared in section
3 .3 .2 .8 ) were defrosted and 1 |Xl of each dilution was added to an individual reaction
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tube. A negative control, containing kit reagents and primers only, was also prepared. 
PCR cycling was carried out as follows: 1 cycle of RT for 45 min at 48°C and 
denaturing of RT enzyme for 2 min at 94°C, followed by 26 cycles of denaturing of 
cDNA for 30 seconds at 94°C and combined annealing and extension for 2.5 min at 
70°C.
The PCR products (10 |Lil + 3 |il orange G loading dye) were run on a 1.8% (w/v) 
agarose gel (see section 3.2.1.9) and photographed on positive film. The photograph 
enabled the approximate equivalence point between the target and competitor to be 
determined. Using this information, a second RT-PCR was carried out using the same 
conditions, but this time a 2-fold serial dilution (10 pg-0.156 pg/jLil) of LPL 
competitor RNA was used. The PCR products were run on a 1.8% (w/v) agarose gel, 
photographed on positive-negative film and the band densities measured on the 
negative film using a Shimadzu dual-wavelength, flying-spot scanner. A 10-fold and 
2-fold RT-PCR experiment was carried out on each mRNA sample extracted in 
section 3.3.4. The conditions for each sample were the same, except that the 2-fold 
serial dilution range of LPL competitor RNA varied according to the results from the 
10-fold reactions. A total of 3 x 2-fold competitive RT-PCR experiments were 
performed on each mRNA sample.
A typical photograph of a 10-fold and 2-fold competitive RT-PCR are shown in 
Figures 3.11 and 3.12.
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Figure 3-11 Competitive RT-PCR using a 10-fold serial dilution of the 362 bp LPL competitor RNA 
and a constant amount of the 442 bp target LPL mRNA. Lanes 1 & 10 contain a 1 Kb DNA ladder. 
Lanes 2 -9  contain a 10-fold serial dilution of the LPL competitor RNA ranging from 1 ng-100 ag. The 
approximate equivalence point is between lanes 4 & 6 (10 pg-100 fg).
442
362
Figure 3-12 Competitive RT-PCR using a 2-fold serial dilution of the 362 bp LPL competitor RNA and 
a constant amount of the 442 bp target LPL mRNA. Lanes 1 & 10 contain a 1 Kb DNA ladder. Lanes 
2-8  contain a 2-fold serial dilution of the LPL competitor ranging from 100 fg-1.56 fg. Lane 9 is the 
negative control.
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3.3.5.1 Data Processing
Once the band densities were measured the data was handled in the following manner:
1) The nucleotide ratio of target to competitor was determined as follows:
LPL target bp : LPL competitor bp = 442 : 362 = 1.22
2) To correct for the difference in size of the 2 PCR products (the higher the 
number of nucleotides the more ethidium bromide is taken up), the target band 
density was divided by the ratio determined above, to give a corrected 
target-band density value.
3) The ratio of corrected target to competitor band density was determined.
4) The results were expressed as number of molecules of LPL mRNA. Therefore 
the weight of 1 mole of LPL competitor RNA was determined thus:
362 bp (size of competitor) x 343 (mean molecular weight of an RNA base)
= 1 mole (g)
1 mole of competitor (g) = 6.023 x 10^  ^molecules
From this, the number of molecules equal to the amount of LPL competitor 
RNA (pg/jLil) added to each reaction tube was calculated.
5) The corrected target:competitor density ratio was plotted versus the 
reciprocal number of molecules of LPL competitor RNA added, as shown in 
Figure 3.13.
6 ) Using the equation Y = MX + C (where Y equals the ratio of corrected target 
to competitor band density and X equals the reciprocal number of molecules of 
competitor RNA initially added to the reaction), when Y equals 1, X equals 
the reciprocal number of molecules of ‘target’ LPL mRNA.
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7) The results generated were divided by the concentration of mRNA (ng/|Lil) and 
expressed as the number of molecules of LPL mRNA / ng mRNA.
The results for the competitive RT-PCR experiments using the 5 mRNA samples are 
shown in Table 3.6.
CL,
11’
y = 3E-h07x + 0.409 
= 0.995
O.OOE+00 4.00E-08 8.00E-08 1.20E-07 1.60E-07 2.00E-07
Amount of competitor RNA added (expressed as reciprocal number
of molecules)
Figure 3-13 A typical graph plotting the ratio of corrected target to competitor band density versus the 
reciprocal number of molecules of competitor RNA added to the initial reaction. Using the equation for 
a straight line (y = mx -t- c), when the ratio of corrected target to competitor band density (y) equals one, 
X equals the reciprocal number of molecules of ‘target’ LPL mRNA amplified initially in the RT-PCR.
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Table 3-6 LPL expression in human adipose tissue measured by competitive RT-PCR. 
Results are expressed as mean (SD) number of molecules of LPL mRNA/ng mRNA. 
The concentration of each mRNA sample (ng/pl) and the number of competitive RT- 
PCR experiments performed is recorded. Data on the age, sex and BMIfor each
subject is shown
Subject Number Age BMI ng mRNA per Number of molecules of LPL
and Sex (kg/m^) |Xl sample mRNA /ng mRNA
Mean SD
1 Male 30 2 1 . 8 0.43 3.85 X 10*’ 8.76 X 10"
2 Male 59 25.5 1 . 1 0 3.89 X 10" 1.39x10"
3 Female 25 24.8 0.40 7.07 X 10^ 6.57 X 10"
4 Female 27 2 1 . 1 1.80 2.54 X 10" 2.83 X 10"
5 Female 35 32.4 6.18 1.70 X 10" 1.76 X 10"
3.3.6 METHOD USING mRNA FROM ADIPOSE TISSUE
The results from Table 3.6 demonstrate that the RT-PCR method was both sensitive 
and reproducible. However, at this point a number of problems came to light which 
affected the quantitation of the PCR products. Firstly, it was noticed when visualising 
the PCR products that a non-specific band was apparent between the target and 
competitor band (see Figure 3.14).
Secondly, the concentration of the mRNA from adipose tissue was much lower than 
that from liver tissue of similar weight, and was below the sensitivity threshold of the 
microspectrophotometer. This meant there was no reliable reference point against 
which to standardise the results, and so the results from the different samples could 
not be compared. The LPL gene expression results (see Table 3.6), expressed per ng 
mRNA were therefore not valid. In an attempt to overcome these problems a number 
of experiments were carried out.
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Figure 3-14 Competitive RT-PCR using a 2-fold serial dilution of the 362 bp LPL competitor RNA and 
a constant amount of 442 bp target LPL mRNA. The faint non-specific band can be seen between 
442 bp and 362 bp.
3.3.6.1 Concentrating the mRNA samples to enable spectrophotometnc 
measurements
The most important problem was the inability to accurately measure the concentration 
of the mRNA samples used. The availability of microconcentrators enables nucleic 
acids to be concentrated by centrifugal ultrafiltration. Using this approach it was 
possible that the mRNA samples could be concentrated enough to then be measured 
spectrophotometrically. Following the manufacturers instructions, 120 |Lil of sample 
mRNA was added to a model 100 Microcon microconcentrator reservoir, placed in a 
vial and centrifuged for 15 minutes at 500 x g. The reservoir was removed, inverted 
into a new vial and re-centrifuged for 2  minutes at 1 0 0 0  x g to recover the nucleic 
acid. Sample mRNA (1.5 pi) was recovered and resuspended in 28.5 pi of nuclease- 
free water. Seven microlitres of this was used to measure the concentration of the 
sample on the Genequant II microspectrophotometer. Despite concentrating the 
sample, the optical-density (OD) reading was still below the sensitivity threshold of 
the spectrophotometer. Resuspending the sample in a smaller volume of water would 
have left insufficient sample to carry out the RT-PCR experiments. It was therefore 
decided that measuring the concentration of mRNA extracted from small samples 
(< 0.125g) of adipose tissue was not feasible at this stage. In order to measure the 
concentration of adipose-tissue mRNA, further investigations involving larger tissue
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samples, the use of different volumes of water for eluting mRNA and the use of 
different-sized microconcentrators would be necessary. Limited tissue availability 
prevented these investigations.
3.3.6.2 Measurement of an endosenous standard usins RT-PCR
Having discovered that the PCR results could not be expressed against the 
concentration of mRNA, it was thought that they could be expressed against the 
amount of an endogenous internal standard. Endogenous standards are also known as 
housekeeping genes. In brief, housekeeping genes are genes that are constitutively 
expressed at a constant level and therefore give an indication of the number of cells 
present. Examples of housekeeping genes include p-actin, p-2-microglobulin and 
glyceraldehyde-3-phosphate dehydrogenase. The transcription of a housekeeping gene 
should not be affected by external stimuli and thus its quantity remains constant 
throughout the cell cycle. Ideally this should be investigated first, as it appears that a 
number of housekeeping genes are up/down regulated by certain external stimuli 
(Siebert, 1993). Housekeeping genes can be used to correct for differences in RNA 
integrity. For example, if 50 pg of 2 mRNA samples is added to a PCR and the target 
gene values are quantitated at 25 fg and 50 fg respectively and the housekeeping gene 
is quantitated at 50 fg and 100 fg respectively the final normalised values are 2 for 
both samples (Cause & Adamovicz, 1995).
The housekeeping gene chosen was p-actin because working primers were already 
available. These primers produced a 453 bp amplicon and had the following 
sequences:
Sense 5’-TGAGACCTTCAACACCCCAGCC- 3’ named CBBACTU
Anti-sense 5’-TGGATGCCACAGGACTCCAT- 3’ named CBBACTD
The optimal RT-PCR conditions for this set of p-actin primers were determined by 
carrying out a series of experiments altering 1 parameter at a time, as described 
previously in section 3.3.5. The cycling profile for the p-actin primers was identical to 
that of the LPL primers (see section 3.3.5).
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Once these conditions had been determined, an RT-PCR was set up according to 
Table 3.7 using the p-actin primers, the 5 mRNA samples extracted in section 3.3.4 
and the RT-PCR conditions described in section 3.3.5. The PCR products were 
visualised on a 1.8% (w/v) agarose gel as described in section 3.2.1.9. The results 
showed that with 2 of the samples, insufficient PCR products were produced at 
26 cycles to be visualised by gel electrophoresis, and so quantitation was not pursued 
any further.
In theory, the band density for the p-actin PCR product would be determined and the 
LPL-mRNA band density would be expressed against this p-actin value. One of the 
main problems of RT-PCR without the inclusion of a competitor is that the reactions 
must take place in the log phase. Without knowing the concentration of the samples it 
is impossible to know how much target gene or housekeeping gene is being added per 
reaction, and so the log phase for each sample would need to be determined before 
quantitation experiments could be performed. This approach would not be feasible for 
future studies where sample numbers are large. Also, comparisons between samples 
and between PCR experiments would be more problematic.
The only way to overcome this problem would be to develop a P-actin RNA 
competitor and express the number of molecules of LPL mRNA per molecule of 
p-actin mRNA. The use of competitors eliminates the need to know the concentration 
of target mRNA added as the concentration of the competitor is known. Alterations to 
the cycle number used is not of importance because the ratio between target and 
competitor remains the same throughout.
3.3.63 Attempts to improve the sveciftcitv o f the competitive RT-PCR
There are a number of variables that affect PCR specificity. Some of these (Mg^ "^  
concentration, cycle number, annealing temp) have already been optimised for this set 
of primers. Various additives such as Formamide, (1.25-10% (v/v), Sarkar et al. 1990) 
and DMSO, (1-10% (v/v). Hung et al. 1990; Pomp & Medrano, 1991) have been 
shown to increase specificity and product yield when incorporated into the reaction.
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Table 3-7 RT-PCR protocol using the Access RT-PCR system, CBBACTU & 
CBBACTD primers and 5 mRNA samples. Three identical reactions were carried out
on each mRNA sample
Reagents (concentration) Tube Numbers (volumes in |Lil)
1-3 4—6 7-9 1 0 - 1 2 13-15
Nuclease-free Water 32.0 32.0 32.0 32.0 32.0
AMV/T/Z 5X Buffer 1 0 . 0 1 0 . 0 1 0 . 0 1 0 . 0 1 0 . 0
Tfl DNA polymerase (5 u/pl) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
AMV reverse transcriptase (5 u/jxl) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
MgS0 4  (25 mM) 2 . 0 2 . 0 2 . 0 2 . 0 2 . 0
dNTPs (10 mM each) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
CBBACTU primer (50 pmol/pl) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
CBBACTD primer (50 pmol/jil) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
mRNA 1 (unknown) 1 . 0 - - - -
mRNA 2 (unknown) - 1 . 0 - - -
mRNA 3 (unknown) - - 1 . 0 - -
mRNA 4 (unknown) - - - 1 . 0 -
mRNA 5 (unknown) - - - - 1 . 0
Total volume 50.0 50.0 50.0 50.0 50.0
In an attempt to eliminate the non-specific band that was appearing in some 
experiments, an RT-PCR was set up using DMSO and Formamide.Reaction tubes 
were set up as described in Table 3.8. PCR cycling was carried out for 26 cycles 
according to the cycle profile described in section 3.3.5. The PCR products were 
visualised on a 1.8% (w/v) agarose gel. The lanes corresponding to the samples 
containing DMSO 10 and 15% (v/v), formamide 2.5 and 5% (v/v) contained no visible 
bands, suggesting that these chemicals had prevented the PCR from working. The lane 
corresponding to the sample containing 1.25% (v/v) formamide had 2 bands 
corresponding to the size of the target and competitor products. The non-specific band 
was not visible. However, the intensity of the bands was much less than those of the 
reaction without chemical additives.
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Table 3-8 Competitive RT-PCR protocol used to investigate the effect o f the addition 
of formamide and DMSO on the specificity of the RT-PCR reaction
Reagents (concentration) Tube Number (volumes in |xl)
1 2 3 4 5 6
Nuclease-free water 24.0 13.5 31.0 30.0 29.0 31.5
AMV/7y/5X buffer 1 0 . 0 1 0 . 0 1 0 . 0 1 0 . 0 1 0 . 0 1 0 . 0
dNTPs (10 mM each) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
MgS0 4  (25 mM) 2.0 2 . 0 2 . 0 2 . 0 2 . 0 2.0
AMV reverse transcriptase (5 u/|il) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
Tfl DNA polymerase (5 u/pl) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
CBLUl + CBLDl primers (50 pmol/|il each) 2 . 0 2 . 0 2 . 0 2 . 0 2.0 2.0
Subject 5 mRNA (unknown) 0.5 0.5 0.5 0.5 0.5 0.5
LPL competitor RNA (5 pg/p,l) 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0 1 . 0
DMSO (10% v/v) 5.0 - - - - -
DMSO (15% v/v) - 7.5 - - - -
Formamide (1.25% v/v) - - 0.6 - - -
Formamide (2.5% v/v) - - - 1.25 - -
Formamide (5% v/v) - - - - 2.5 -
Total volume 50.0 50.0 50.0 50.0 50.0 50.0
Further consultation of the literature suggested that this non-specific band was 
probably a heteroduplex (Siebert, 1993; Zimmermann & Mannhalter, 1996). 
Heteroduplex formation occurs with the use of competitor fragments that are 
homologous to the target sequence. During the later stages of PCR, when the 
concentration of products is high, target and competitor sequences hybridise to each 
other before the primers have a chance to anneal. This produces an intermediate-sized 
product (Siebert, 1993).
Heteroduplex formation can complicate the quantitation of PCR products, although 
Henco & Heibey (1990) describe a novel approach that actually uses the 
heteroduplexes for quantitation. It is possible that increasing the concentration of 
primers or reducing the cycle number may have helped overcome this problem. The 
addition of 1.25% (v/v) formamide appeared to eliminate the non-specific band.
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However, with the problem of measuring the mRNA concentration unresolved, there 
was little point investigating this further at this stage.
In view of the problems associated with measuring the concentration of the mRNA, 
heteroduplex formation and the length of time it would take to develop a P-actin RNA 
competitor it was decided that investigations into the possibility of obtaining a 
multi-specific ‘standard’ competitor should be made. Such ‘standards’ are known to 
exist, and allow the competitive RT-PCR of both target (e.g. LPL) and housekeeping 
genes even when the mRNA concentration is unknown.
3.4 COMPETITIVE RT-PCR USING A MULTI-SPECIFIC 
INTERNAL STANDARD
A review of the literature showed that Vidal’s group in France (Laville et al. 1996) 
had produced a multi-specific internal standard that included primer sequences for the 
LPL gene and for the housekeeping gene p-2-microglobulin (p-|Xglob).
3.4.1 LARGE-SCALE PRODUCTION OF A MULTI-SPECIFIC INTERNAL 
STANDARD FOR USE IN COMPETITIVE RT-PCR
Vidal’s group (INSERM U449, Faculté de Medicine Alexis Carrel, Lyon) donated to 
us some of their multi-specific standard, sub-cloned in pBluescript KS+.
The RNA multi-specific standard was a 525 bp long synthetic gene, the sequence of 
which corresponded to the juxtaposition of 13 specific sense-primer sequences, 
followed by the juxtaposition of the complementary sequences of 12 specific anti­
sense primers in the same order (Laville et al. 1996). A schematic diagram of this 
RNA multi-specific standard is shown in Figure 3.15.
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Figure 3-15 Organisation of the multi-specific internal standard adapted from Laville et al. (1996), 
A 525 bp long synthetic gene, the sequence of which corresponded to the juxtaposition of 13 specific 
sense-primer sequences, followed by the juxtaposition of the complementary sequences o f 12 specific 
anti-sense primers in the same order.
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The LPL and p-|iglob primers for use with this standard were as follows:
LPL sense primer named CBLPLU 5’-ACACAGCTGAGGACACTTGC-3’
LPL anti-sense primer named CBLPLD 5’-CACTGGGTAATGCTCCTGAG-3 ’ 
P-|Xglob sense primer named CBpGLOBU 5’-CCAGCAGAGAATGGAAAGTC-3’ 
p-|lglob anti-sense primer named CBpGLOBD 5’-GATGCTGCTTACATGTCTCG-3’
These primers produced the following PCR product sizes:
LPL competitor = 267 bp LPL target = 227 bp
p-|iglob competitor = 306 bp P-|Xglob target = 269 bp
Prior to using this multi-specific standard in competitive RT-PCR experiments, the 
phagemid DNA was cloned and RNA transcribed.
3 A. 1.1 Transformation
Firstly, the phagemid DNA was diluted 1:10 to give a working concentration of
16.5 ng/|il. Transformation of competent bacteria {E. coli JM109) was carried out 
according to the method described in section 3.3.2.4. The only difference to the 
method was the omission of blue/white colour screening when plating out the 
competent cells. Single white colonies were picked from the agar plates, placed in 5 
ml LB medium containing 25 |xl ampicillin (10 mg/ml, see section 3.2.1.4) and 
incubated for 4 hours at 37°C. A mini-prep was carried out on the culture produced.
3.4.1.2 Minivrep o f recombinant DNA
The wizard plus SV minipreps DNA-purification system was used according to the 
manufacturer’s instructions. In brief, 1.5 ml of bacterial culture was centrifuged at
10,000 X g for 5 minutes to pellet the bacterial cells. The supernatant was discarded 
and the tube turned upside down to blot off excess liquid. Cell resuspension solution 
(250 pi) was added to the tube and the cells were resuspended by vortexing. The 
resuspended cells were transferred to a clean microcentrifuge tube. Next, 250 pi of cell
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lysis solution was added and mixed by inverting the tube 4 times. This mixture was 
left for 5 minutes until the cell suspension cleared. Following this 10 pi of alkaline 
protease solution was added, mixed by inversion and incubated at room temperature 
for 5 minutes. After the incubation time, 350 pi of neutralisation solution was added 
and immediately mixed by inverting the tube 4 times. The bacterial lysate was then 
centrifuged at 14,000 x g for 10 minutes at room temperature.
The phagemid DNA was purified by first transferring the cleared lysate to a mini-prep 
spin column and centrifuging at 14,000 x g for 1 minute at room temperature. The spin 
column was removed, the flow-through discarded, and the spin column re-inserted into 
the collection tube. Column wash solution (750 pi) was added to the spin column and 
centrifuged at 14,000 x g for 1 minute at room temperature. The flow-through was 
discarded and the spin column re-inserted into the collection tube. A further 250 pi 
column wash solution was added and the tube centrifuged at 14,000 x g for 2 minutes 
at room temperature. The spin column was then transferred to a clean 1.5 ml 
microcentrifuge tube; care was taken not to transfer any of the column wash solution. 
The phagemid DNA was eluted by adding 100 pi nuclease-free water to the spin 
column followed by centrifugation at 14,000 x g for 1 minute at room temperature. 
The spin column was then discarded and the eluted DNA was used to carry out a 
restriction digest.
The restriction endonucleases used were Xho I and BamH I in buffer D (reaction 1) 
and Acc I and Sma I in multi-core buffer (reaction 2). The 2 reactions were incubated 
overnight at 37°C. The restriction digest products were separated by gel 
electrophoresis. The appearance of 2 bands, 1 corresponding to the size of the cut 
phagemid (approximately 2.96 Kb) and the other corresponding to the size of the 
multi-specific standard (approximately 550 bp) indicated that transformation had been 
successful (see Figure 3.16).
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Figure 3-16 Restriction digest of recombinant DNA using restriction endonucleases BamH I and Xho 
I. Lanes 1 & 4 contain 1 Kb DNA ladder. Lane 2 contains restricted recombinant DNA and identifies 2 
bands, 1 corresponding to the size of the multi-specific internal standard (550 bp) and the other 
corresponding to the size of digested pBluescript KS+ (2.96 Kb). Lane 3 contains undigested 
recombinant DNA (pBluescript KS+ plus multi-specific internal standard, approximate size 3.51 Kb).
3.4.1.3 Maxivrep of recombinant DNA
The remainder of the cell culture, grown from the single colony picked (see section 
3.4.1.1), was added to 500 ml LB medium containing 2.5 ml ampicillin (10 mg/ml) 
and incubated at 37°C in a shaking incubator for 16 hours. This culture was used to 
carry out a maxiprep as described previously in section 3.3.2.6. The concentration of 
the purified phagemid DNA produced was determined spectrophotometrically from 
absorbance at 260 nm. A restriction digest was then performed using the same 
enzymes described in section 3.4.1.2 to re-check that the multi-specific standard could 
be excised from the phagemid.
3.4.1.4 Linearisation of phagemid DNA
The phagemid DNA was linearised using the endonuclease BamH I. Phagemid DNA 
(15 |xl, 24 p.g), 3 |xl BamH I and 2 |il Buffer D were incubated at 37°C overnight. The 
linearised product was cleaned as described in section 3.3.2.7 and visualised by gel 
electrophoresis to check that the process was successful. The DNA concentration was 
determined spectrophotometrically from absorbance at 260 nm.
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3.4.1.5 Transcription
RNA transcription was carried out according to the method described in section 
3.3.2.S, except that the DNA template was removed by incubating with RNase-free 
DNase for 2 hours at 37°C. Following transcription, the RNA concentration was 
determined from absorbance at 260 nm. The 260:280 ratio was 1.8. The size of the 
RNA product was checked by gel electrophoresis. To further confirm that the correct 
RNA multi-specific standard had been produced, a RT-PCR was carried out using the 
primers for LPL (CBLPLU 4- CBLPLD). The PCR product was run alongside a 1 Kb 
DNA ladder on a 2% (w/v) agarose gel containing ethidium bromide (see section
3.2.1.9). The band was visualised by UV light and corresponded to 267 bp in size.
The RNA standard was then diluted 10-fold to give working concentrations (1 jil, 
100 ng-100 atg). These were aliquotted out into small volumes and stored at -80°C 
until required.
3.4.2 OPTIMISATION OF THE RT-PCR USING THE LPL AND B-uGLOB 
PRIMERS
RT-PCR was carried out using the Access RT-PCR system. A master mix of all the 
reagents was prepared. The components were added in the following volumes, based 
on the number of samples used, and aliquotted so that each reaction tube contained the 
following:
REAGENTS (concentration) VOLUME (|Lil)
Nuclease-free water 32.0
AMV/ZyZ 5X buffer 10.0
dNTPs (10 mM each) 1.0
MgS0 4  (25 mM) 2.0
AMV reverse transcriptase (5 U/|il) 1.0
Tfl DNA polymerase (5 U/|Lil) 1.0
CBLPLU or CBpGLOBU primer (50 pmol/|xl) 1.0
CBLPLD or CBpGLOBD primer (50 pmol/pl) 1.0
Sample mRNA (unknown) 1.0
Total volume 50.0
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A series of experiments including alteration of the MgS0 4  concentration, annealing 
temperature and cycle number were performed until the optimal conditions were found 
for each set of primers. The log phase for several mRNA samples was also 
determined.
The PCR cycling conditions for both sets of primers were as follows: 1 cycle of RT for 
45 min at 48°C and denaturing of RT enzyme for 2 min at 94°C followed by 28-30  
cycles of denaturing of cDNA for 30 sec at 94°C, annealing of primers for 1 min at 
60°C and extension of oligonucleotide for 2 min at 68°C. The optimal MgS0 4  
concentration was 1 mM per 50 |xl reaction. To confirm that the correct PCR product 
was being produced a restriction digest was carried out using the endonucleases Nco I 
and Pvu II. These produced 132 & 95 bp and 221 & 6 bp fragments respectively.
3.4.3 COMPETITIVE RT-PCR USING THE MULTI-SPECIFIC STANDARD RNA 
AND mRNA FROM ADIPOSE TISSUE
Competitive RT-PCR was carried out on a number of mRNA samples which had 
previously been extracted from adipose tissue according to the method described in 
section 3.3.4. Using the Access RT-PCR system, 8 reaction tubes were prepared as 
described in the section 3.4.2 using the LPL primers (CBLPLU & CBLPLD). The 
volume of nuclease-free water was reduced by Ijxl, so that the final reaction volume, 
after addition of the RNA standard remained at 50 ill.
A second set of identical reaction tubes were prepared except the p-jiiglob primers 
(CBpGLOBU & CBpGLOBD) were used instead of the LPL primers. A 10-fold serial 
dilution (1 ng-100 ag/|il) of the RNA multi-specific standard (prepared in section
3.4.1.5 ) was defrosted and 1 pi of each dilution was added to an individual reaction 
tube, so that each reaction tube contained a different concentration of RNA standard 
(competitor). A negative control, containing kit reagents and primers only, was also 
prepared.
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The reaction tubes were cycled as described in section 3.4.2. The PCR products were 
run on a 3% (w/v) agarose gel (see section 3.2.1.9) and photographed on positive film. 
The photograph enabled the approximate equivalence point between the target and 
competitor to be determined. Based on this information, a second competitive RT- 
PCR was set up using the same reagents and conditions, except that this time, a 2-fold 
serial dilution of RNA competitor (10 pg-0.156 pg/pl) was used. The PCR products 
were visualised by gel electrophoresis, photographed on positive-negative film and the 
band densities measured as described in section 3.3.5.
An example photograph of a 10-fold and 2-fold competitive RT-PCR are shown in 
Figures 3.17 and 3.18.
The 10-fold and 2-fold competitive RT-PCR experiments using both LPL and p-|Xglob 
primers were carried out on 3 different mRNA samples. The cycle number varied 
between samples and the 2-fold serial dilution range for the RNA competitor varied 
according to the results from the 10-fold reactions. The competitive RT-PCR 
experiments using the 2-fold dilution of competitor RNA were repeated for each 
mRNA sample.
3.4.3.1 Data processins
Once the band densities were measured, the data was processed as follows:
1) The nucleotide ratio of target:competitor was determined for each gene thus:
LPL = 227 bp : 267 bp = 0.85
p-|iglob = 269 bp : 306 bp = 0.88
2) To correct for the difference in size of the 2 templates the target band density 
was divided by the ratio determined above, to give a corrected target band- 
density value. Alternatively, the competitor band density can be multiplied by 
the ratio to give a corrected competitor value.
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3) Next, the ratio of the corrected target band to competitor band density was 
calculated.
4) Results were expressed as number of molecules of LPL mRNA per molecule 
of p-iiglob mRNA. The weight of 1 mole of competitor RNA for each gene 
was determined thus:
267 bp (size of LPL competitor) x 343 (molecular weight of 1 RNA base) = 1 mole (g) 
306 bp (size of p-pglob competitor) x 343 = 1 mole (g)
1 mole of LPL/p-|Xglob competitor (g) = 6.023 x 10^  ^molecules
From this, the number of molecules equal to the amount of LPL and p-|iglob 
competitor RNA (pg/pl) added to the RT-PCR experiments can be calculated.
5) The ratio of corrected target:competitor band density was plotted against the 
reciprocal number of molecules of competitor RNA initially used.
6) When the corrected target to competitor band density is equal to one (Y = 1) 
the number of molecules of ‘target’ LPL mRNA (X) used in the experiment 
can be calculated from the equation Y = MX + C (see section 3.3.5.1)
7) The results were expressed as number of molecules of LPL mRNA per 
molecule of p-pglob mRNA.
The results for the mRNA samples of 3 subjects are shown in Table 3.9. These results 
demonstrate that it is possible to detect and quantify LPL mRNA in small samples of 
adipose tissue, although the coefficient of variance may be quite large. However, a 
larger number of samples need to be repeatedly quantified, using competitive 
RT-PCR, before conclusions on the reliability of the method can be drawn.
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Figure 3-17 An example of a competitive RT-PCR reaction using a 10-fold serial dilution of the multi­
specific internal standard RNA (competitor) and a constant amount of sample mRNA. The competitor 
RNA ranges from 100 pg-10 fg for lanes 2 -6  and 7-11 respectively. The arrows on the left indicate the 
position of the LPL competitor (267 bp) and target (227 bp) PCR fragments and the arrows on the right 
indicate the position of the P-2-microglobulin competitor (306 bp) and target (269 bp). The equivalence 
points are between lanes 3 & 4 for LPL and lane 7 -9  for (3-2-microglobulin. Lane 1 shows a 1 Kb DNA 
ladder.
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Figure 3-18 An example of the results of a competitive RT-PCR reaction using primers for the target 
gene, LPL and the housekeeping gene, P-2-microglobulin. The photograph shows a 2-fold serial dilution 
of the competitor RNA over the range 4 pg-125 fg for lanes 2 -7  and 8-13 respectively. The arrows on 
the left indicate the position of the LPL competitor (267 bp) and LPL target (227 bp) PCR fragments 
and the arrows on the right indicate the position of the (3-2-microglobulin competitor (306 bp) and target 
(269 bp) fragments. Lanes 1 & 14 show a 1 Kb DNA ladder.
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Table 3-9 LPL expression in human adipose tissue measured by competitive RT-PCR. 
The results fo r duplicate RT-PCR experiment, plus the mean values are presented for  
each subject. Values are expressed as the number of molecules o f LPL mRNA per
molecule of P-figlob mRNA
Subject Number of molecules of LPL mRNA per molecule p-)iglob mRNA
RT-PCR 1 RT-PCR 2 Mean
1 0.14 0.18 0.16
2 0.16 0.34 0.25
3 0.32 0.43 0.38
3.4.4 COMPETITIVE RT-PCR USING THE MULTI-SPECIFIC STANDARD RNA 
AND TOTAL RNA FROM ADIPOSE TISSUE
The purpose of the work described in this chapter was to develop a competitive 
RT-PCR method to enable the quantitation of LPL mRNA in adipose tissue. Having 
developed such a method it could then be used to investigate the effects of dietary fatty 
acids on LPL gene expression. For the purposes of this thesis, 2 dietary studies were 
carried out: 1 looked at the effects of consuming a high n-3-PUFA diet (Chapter 4) 
and the other looked at the effects of consuming a high-MUFA diet (Chapter 5). 
During both of these dietary studies, adipose-tissue biopsies were collected from the 
human volunteers who took part. Total RNA was extracted from the adipose tissue as 
described in Chapter 2, section 2.2.5. These total RNA samples were available for 
analysis by competitive RT-PCR and could add to the information relating to method 
reproducibility. The results could then help in assessing the effects of dietary fatty 
acids on LPL gene expression (discussed in Chapters 4 & 5).
3.4.4.1 Removal ofSDS. an RT-PCR inhibitor, from the total-RNA samples 
As mentioned in section 3.3.3.2, total RNA resuspended in SDS has been shown to 
inhibit the RT-PCR reaction. Believing the SDS to be the problem, a series of identical 
reaction tubes was set up according to the RT-PCR protocol described in section 3.4.2. 
Instead of using mRNA, the total RNA resuspended in SDS was used. To half of the
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reaction tubes 1 )ll1 of defrosted total RNA was added. The same total RNA was then 
briefly centrifuged (5 seconds) to pellet the SDS, and the supernatant was removed. To 
the other half of the reaction tubes 1 (xl of the supernatant total RNA was added. A 
positive control, using the control RNA and primers provided with the Access RT- 
PCR system, was also prepared. PCR cycling was carried out for 28 cycles according 
to the conditions described in section 3.4.2. The PCR products were visualised by gel 
electrophoresis. The positive control and the reaction tubes containing supernatant 
total RNA produced a PCR product. The reactions containing total RNA, which had 
not been centrifuged, did not produce a PCR product (see Figure 3.19). This suggests 
that the SDS in the total RNA samples was interfering with the RT-PCR and that brief 
centrifugation pelleted the SDS sufficiently to reduce its interference. Following this, 
all total-RNA samples (collected from the n-3 PUFA and MUFA dietary studies) were 
defrosted, briefly centrifuged (5 seconds) and the supernatant removed and aliquotted. 
The concentration of the total RNA was then determined spectrophotometrically by 
measuring the absorbance at 260 nm before refreezing the samples at -80°C. The 
absorption ratio (260:280) was between 1.85 and 2.0 for all samples.
323^
227—
1 2 3 4 .5
Figure 3-19 RT-PCR using total RNA extracted from adipose tissue and resuspended in SDS (lane 2), 
control RNA provided with the Access RT-PCR kit (lane 3) and total RNA extracted from adipose 
tissue followed by a brief centrifugation to precipitate the SDS (lane 4). Lane 1 & 5 shows a 1 Kb DNA 
ladder. The arrows on the left indicate the position of the kit control-PCR fragment (323 bp) and the 
LPL target-PCR fragment (227 bp).
157
3.4A.2 Measurement of LPL sene expression in adipose tissue total RNA, collected 
from two dietary studies, usins competitive RT-PCR
There was not sufficient sample total RNA to analyse both LPL and p-|iglob mRNA, 
so only LPL mRNA was analysed. A series of RT-PCR experiments carried out using 
the total RNA demonstrated that the conditions (annealing and extension 
temperatures, MgS0 4  concentration) were identical to those used in section 3.4.2.
Limited sample dictated that 1 |il of total RNA was used in all reactions regardless of 
its concentration. Ideally, if the concentration for total RNA is known, then this should 
remain constant for every sample analysed by RT-PCR (approximately 100 ng total 
RNA is sufficient for RT-PCR). This reduces the need to vary the reaction cycle 
number for each individual subjects’ sample.
In order to establish that a PCR product could be produced from the 22 total-RNA 
samples collected from the 2 dietary studies, an RT-PCR was carried out using the 
Access RT-PCR reagents described in section 3.4.2, the primers CBLPLU and 
CBLPLD and 1 \l\ of each subjects’ total RNA. PCR cycling was carried out for 23 
cycles according to the conditions described in section 3.4.2.
The PCR products were visualised by gel electrophoresis, and from the individual 
band densities, the optimal number of cycles required for competitive RT-PCR were 
estimated. Competitive RT-PCR was carried out using the Access RT-PCR system, 
total RNA from the n-3 PUFA and MUFA dietary studies and the multi-specific 
standard RNA.
First, a master mix of reagents was prepared based on the number of samples used. 
Each reaction tube contained the following:
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REAGENT (concentration) VOLUME (111)
Nuclease-free water 31.0
AMY/Tfl 5X buffer 10.0
dNTPs (10 mM each) 1.0
M gS04(25mM) 2.0
AMV reverse transcriptase (5 U/jxl) 1.0
Tfl DNA polymerase (5 U/|il) 1.0
CBLPLU & CBLPLD primers (50 pmol/(xl each) 2.0
Sample total RNA (varies) 1.0
Total volume 49.0
A 10-fold serial dilution (1 ng-100 fg/fil) of the multi-specific standard (competitor) 
RNA was defrosted and 1 |Xl of each dilution was added to a separate reaction tube 
(total reaction volume 50 p,l). PCR cycling was carried out as follows: 1 cycle RT for 
45 min at 48°C and denaturing of RT enzyme for 2 min at 94°C followed by 23-28  
cycles of denaturing of cDNA for 30 sec at 94°C, annealing of primers for 1 min at 
60°C and extension of oligonucleotide for 2 min at 68°C.
The PCR products were visualised on a 3% (w/v) agarose gel containing ethidium 
bromide and photographed on positive film. Once the approximate equivalence point 
was determined, the competitive RT-PCR was repeated. This time, a 2-fold dilution of 
the RNA competitor (200 pg-195 fg/|Xl) was used. The PCR conditions were the 
same. The PCR products were visualised on a 3% (w/v) agarose gel containing 
ethidium bromide and photographed on positive-negative film. Two typical 2-fold 
competitive RT-PCRs are shown in Figures 3.20 and 3.21.
Using the negative film, the band densities were measured on a Shimadzu Dual­
wavelength, flying-spot scanner. After correction for the difference in nucleotide 
number, the density ratio of the target band:competitor band was plotted versus the 
reciprocal of the initial amount of competitor RNA in number of molecules (see 
section 3.4.3.1 for calculation). The results were expressed as number of molecules of
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LPL mRNA per ng total RNA. Control experiments that omitted RNA from the 
reaction were included in each RT-PCR and were used to verify the absence of 
contamination. In an attempt to compare samples as accurately as possible, the total 
RNA from both the test and control studies were measured in the same run, using the 
same mastermix of reagents and amounts of competitor RNA taken from the same 
serial dilution.
The 2-fold RT-PCR experiments were repeated twice more for each sample and the 
products from each experiment were run on 2 agarose gels 3% (w/v) in order to test 
the reproducibility of the method. The mean results for these experiments are shown in 
Table 3.10. The mean LPL-mRNA values ranged from 0.60-59.34 molecules x lOVng 
total RNA.
There were no significant correlations between the LPL mRNA values and either age 
or BMI. The overall mean LPL-mRNA value for the n-3 PUFA study was 4.35 (SD 
2.84) X 10^  molecules/ng total RNA, which was lower than the overall mean value for 
the MUFA study, 24.73 (SD 16.24) x 10^  molecules/ng total RNA.
Further discussion of the LPL gene expression results can be found in the relevant 
chapters, 4 and 5.
160
Figure 3-20 An example of a 2-fold competitive RT-PCR reaction using 50 pg-780 fg of the competitor 
RNA (lanes 2-8  respectively). The photograph shows the equivalence point is between lanes 5-7. 
Lanes 1 & 11 show a 1 Kb DNA ladder, lane 10 shows a 100 bp marker and lane 9 is the negative 
control. The arrows on the left indicate the position of the competitor (267 bp) and the target (wild type) 
(227 bp) PCR fragments.
Figure 3-21 An example of a 2-fold competitive RT-PCR reaction using 25 pg-390 fg of the competitor 
RNA (lanes 2-8  respectively). The photograph shows the equivalence point is between lanes 4 -6 . 
Lanes 1 & 10 show a 1Kb DNA ladder, and lane 9 is the negative control. The arrows on the left 
indicate the position of the competitor (267 bp) and the target (wild type) (227 bp) PCR fragments.
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Table 3-10 LPL gene expression in human adipose tissue measured by competitive 
RT-PCR. Values expressed as the mean (SD) number of molecules o f LPL mRNA x 
10  ^per ng total RNA. Subjects 1 -6  were part of an n-3 PUFA dietary study and 
subjects 7-13 were part of a MUFA dietary study where A & B equals the control and 
test periods of the dietary studies respectively. The age and BMI o f the subjects, at the
time o f biopsy, are also shown
Subject
Number
Age
(years)
BMI
(kg/m^)
Number of molecules of LPL mRNA x 10^  
per ng total RNA
Mean SD
lA 54 30.4 7.06 1.11
IB 54 30.2 0.81 0.01
2A 48 29.0 0.60 0.17
2B 48 28.1 7.27 0.15
3A 56 26.2 1.09 0.14
3B 56 26.3 2.64 0.07
4A 53 26.5 5.92 0.70
4B 53 25.6 2.13 0.48
5A 48 23.4 3.33 2.13
5B 48 23.2 6.72 0.35
6A 57 22.9 6.62 3.16
6B 57 22.6 8.05 2.99
7A 58 25.5 10.54 0.70
7B 57 25.4 39.88 18.03
8A 55 24.2 15.84 9.39
8B 55 24.9 59.34 4.71
9A 51 26.7 7.60 4.41
9B 51 26.2 8.46 2.66
IDA 43 25.3 19.49 15.28
l lA 42 30.1 24.04 13.30
12B 56 30.1 31.38 6 3 2
13B 35 25.2 30.68 1.02
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3.4.5 ASSESSMENT OF INTRA- AND INTER-ASSAY VARIATION
No formal quality control was included in the competitive RT-PCR experiments to 
enable the determination of intra- or inter-assay variation. However, each total-RNA 
sample was analysed 2-3  times, and the inter-assay coefficient of variation (CV) 
obtained from these samples ranged from 1.4-78%, with the mean CV for the 
competitive RT-PCR assay being 28%.
To investigate the intra-assay variation, an RT-PCR experiment was set up using the 
multi-specific RNA (50 pg/|il), the LPL primers and the Access RT-PCR reagents 
described in section 3.4.4.2. A master-mix of reagents, RNA and primers was prepared 
and aliquotted into 6 separate tubes. PCR cycling was carried out for 20 cycles 
according to the conditions reported in section 3.4.4.2. The PCR products (10 |Xl + 
3 (Xl OG loading dye) were visualised by gel electrophoresis (x 3), photographed on 
positive-negative film and the band densities measured as described previously 
(section 3.4.4.2). The intra-assay CVs obtained for these 3 gels were 3.3%, 9.5% and 
10.6%.
A second experiment was set up to investigate the inter-assay variation. Using the 
multi-specific RNA (50 pg/jLil), LPL primers and Access RT-PCR reagents described 
in section 3.4.4.2, 6 reaction tubes were prepared separately. PCR cycling was carried 
out, separately for each reaction tube, for 20 cycles as described in section 3.4.4.2. 
The PCR products were visualised by gel electrophoresis (x l), photographed on 
positive-negative film and the band densities measured. The inter-assay CV was 
46.2%.
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3.5 DISCUSSION
3.5.1 ASSESSMENT OF METHODOLOGY
The work described in this chapter can be broadly divided into 2 sections:
1) The construction of an LPL competitor RNA to enable the 
measurement of LPL mRNA in total RNA and mRNA, by 
competitive RT-PCR.
2) The use of a multi-specific internal standard (competitor) for 
measurement of LPL mRNA and p-2-microglobulin in total and 
mRNA, by competitive RT-PCR.
Through out this chapter the methodological problems encountered have been 
discussed as they occurred. However, in brief, the main problems experienced with 
section 1 were:
• the formation of heteroduplexes when quantifying with the 
‘homemade’ LPL competitor RNA
• the presence of SDS, an RT-PCR inhibitor in the total RNA samples
• the inability to measure the concentration of mRNA extracted from 
adipose tissue.
Had there been sufficient tissue sample and time, it may have been possible to 
overcome some of these problems. For instance, if there had been sufficient total-RNA 
sample, the SDS could have been removed by ethanol precipitation or ultrafiltration. 
In fact, it was later discovered that brief centrifugation to precipitate the SDS, 
prevented RT-PCR inhibition. It is recommended that in future, total RNA extracted 
from adipose tissue does not include SDS.
The concentration of mRNA in adipose tissue (approximately 1 ng/(xl) appears to be 
much lower than that of liver (30-40 ng/|il) (J.C. Rockett, personal communication).
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Optimisation of the mRNA-extraction procedure, together with the use of 
microconcentrators, may help to increase the yield of mRNA.
Heteroduplex formation is difficult to prevent when using target and competitor 
cDNAs with similar sequences. Including chemical agents such as formamide into the 
RT-PCR appeared to increase the specificity of the reaction, but at the expense of the 
sensitivity.
To carry out the above experiments a larger quantity of adipose tissue would have 
been required to allow sufficient mRNA or total RNA to be extracted. Obtaining 
adipose tissue is not easy because it relies on volunteers to undergo invasive 
techniques such as biopsy or surgery.
Owing to these problems it was decided that a multi-specific internal standard RNA 
would be used to measure LPL mRNA from adipose tissue, by competitive RT-PCR. 
This multi-specific standard had several advantages: first, it enabled the competitive 
RT-PCR of LPL and a housekeeping gene, and secondly, the competitor RNA 
sequence was completely different to that of the target RNA sequence, so there was no 
risk of heteroduplex formation.
The multi-specific internal standard (competitor) developed by Laville et al. (1996) for 
analysis of LPL mRNA by competitive RT-PCR has been successfully used in this 
laboratory, although further validation of this method is required (see section 3.S.2.6). 
The specificity of the method was checked by carrying out an endonuclease restriction 
digest as described in section 3.4.2.
Initially, the multi-specific standard was used in competitive RT-PCR using mRNA 
extracted from adipose tissue. The results indicated that the method was sensitive and 
reproducible, but the inability to measure the concentration of the mRNA meant that 
each sample had to have its optimum number of PCR cycles determined. This was 
both expensive and time consuming and not ideally suited to the analysis of large 
numbers of samples.
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The analysis of the total-RNA samples from the n-3 PUFA and MUFA dietary studies 
again demonstrated that the method was sensitive, specific and reproducible. 
However, lack of sample prevented the analysis of the p-jiglob housekeeping gene. 
Ideally, this should be included so that correction for differences in RNA 
concentration, due to pipetting and spectrophotometric errors, can be made.
Another criticism of the method is the absence of quality controls. Although the 
individual total-RNA samples were assayed several times, the individual CVs varied 
widely (1.4-78%). The specific intra- and inter-assay experiments showed that the 
intra-assay variation appears to be relatively small in comparison to the inter-assay 
variation. However, analysing the same PCR product on separate agarose gels 
produced different band-density values. These differences are probably due to the 
physical structure of the gel, pipetting errors, and variation in photography and 
densitometric scanning. Even so, these observations highlight the importance of 
standardising each procedure in order to limit such variation.
To reduce the large inter-assay variation it is recommended that each individual RNA 
sample is analysed in triplicate assays, and that the PCR products are visualised on 
two agarose gels. This has been shown, by another investigator to produce reasonable 
CVs and is recommended for use in this laboratory. Campbell & Devlin (1996) 
determined the inter-assay variation of their RT-PCR method by carrying out 
3 separate RT-competitive-PCR assays using RNA isolated from livers and gonads. 
The CVs obtained from these samples were 11.9%, 7.1% and 5 % for the 3-week 
gonad, 1-week liver and 3-week liver, respectively.
Including a quality control, consisting of a known concentration of target and 
competitor RNA, may also help to determine the inter-assay variation.
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3.5.2 FUTURE WORK AND RECOMMENDATIONS FOR THE COMPETITIVE 
RT-PCR METHOD
3.5.2.1 Collection of adivose tissue
The method used for collecting adipose tissue in this thesis involved a needle biopsy 
(as described in Chapter 2, section 2.2.5). The problem with this method is that the 
tissue sample is mixed up with blood and lignocaine and it is difficult to determine the 
weight of tissue. Therefore, standardisation of the tissue weight used for total-RNA 
extraction was not possible.
Following on from the work in this thesis a different approach to adipose-tissue 
collection has been successfully carried out in this laboratory. The method involves 
making a small incision in the skin of the upper part of the buttock with a scalpel, 
following the administration of a local anaesthetic. The adipose tissue is removed 
from the subcutaneous deposits using forceps and scissors, weighed and frozen in 
liquid nitrogen. The tissue removed is less fragmented, less contaminated with blood 
and can easily be weighed before or after freezing. The amount of tissue removed 
ranges from 200-500 mg, which is similar to that removed by needle biopsy. The 
psychological stress experienced by the volunteers appears to be less, as they cannot 
see or feel what is happening.
Competitive RT-PCR has yet to be performed on these samples, but if successful, it is 
recommended that this continues to be the adipose-tissue biopsy method of choice.
3.5.2.2 Extraction of total RNA from adivose tissue
All total-RNA samples used in this thesis were extracted using the Chomczynski & 
Sacchi (1987) method described in Chapter 2, section 2.2.5. The RNA was extracted 
immediately after removing the adipose tissue, which meant that total-RNA extraction 
of paired samples did not happen at the same time. The extraction procedure also 
involved resuspending the RNA in 0.5% (w/v) SDS. Although SDS inhibits RNase 
activity it also inhibits the RT-PCR reaction.
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In future all adipose-tissue samples should be frozen in liquid nitrogen so that 
total-RNA preparation can be carried out at the same time, particularly for paired 
samples. A standard weight of adipose tissue should be used for extraction. Total 
RNA should not be resuspended in SDS or any other RT-PCR inhibitors, unless there 
are steps to remove them before the RNA is used in RT-PCR. All extracted total RNA 
should be aliquotted into small volumes and stored at -80°C. The RNA should not 
undergo repeated freeze thawing, as this shears the RNA and can interfere with 
competitive RT-PCR quantitation. Where possible the same concentration of total 
RNA for all samples should be used in competitive RT-PCR.
Implementing these recommendations should help to standardise the procedure 
between studies and minimise the variation between samples.
3.5.23 Storing the multi-specific standard RNA
Before commencing quantitative competitive RT-PCR a bulk serial dilution (2-fold) of 
the multi-specific standard RNA (competitor) should be prepared and aliquotted into 
small volumes, enough for 1-2 competitive RT-PCR experiments. It is essential when 
comparing competitive RT-PCR data from different samples and different 
experiments that the competitor comes from the same serial dilution. This will help 
prevent variations in the amount of competitor added to the reaction. It is also 
important that the competitor RNA does not undergo repeated freeze thawing as this 
will give false target gene values.
3.5.2.4 Competitive RT-PCR set-up
RT-PCR should be set up in a clean environment away from the preparation of 
phagemid DNA and generation and analysis of PCR products. The competitor RNA 
should not be aliquotted in the same area as the RT-PCR reagents. Pipettes, tips, racks, 
gloves, tubes and lab coats used for PCR set-up should be kept separate from work 
areas handling competitor RNA, PCR products and phagemid DNA. These 
precautions are essential for the prevention of contaminating DNA, which, once 
present, is extremely difficult to remove. The absence of contamination should be 
verified by including control experiments which omit the target and competitor RNA.
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In assays where DNA rather than RNA standards are used there is no control for the 
efficiency of the reverse-transcription step, which is another source of variability 
between samples. It is therefore advisable that the reverse transcription of competitor 
and target genes occurs simultaneously in the same tube.
To reduce tube to tube variation and improve accuracy, a master mix of reagents 
should be prepared for each experiment. Comparative samples should be run 
simultaneously using the same master mix with the same dilution of RNA competitor 
(Apostolakos etal. 1993).
The volumes used for competitive RT-PCR are very small, so it is essential to use 
pipettes which are more accurate at these volumes (e.g. positive displacement p-2 
pipettor), as small differences can cause large variations in the competitive RT-PCR 
results.
3.5.2.5 Use of a reference housekeevins sene
To ensure comparable extraction in a series of samples, endogenous standards 
(housekeeping genes) are usually quantitated in addition to the target gene 
(Zimmermann & Mannhalter, 1996). Even if the same quantity of RNA is used for 
each reaction, the final quantity of PCR product may be greatly affected by pipetting 
technique, differences in RNA integrity and the presence of inhibitors of reverse 
transcriptase (Cause & Adamovicz, 1995). The housekeeping gene also corrects for 
DNA contamination, which can result in misleading spectrophotometric readings and 
incorrect concentration determinations (Cause & Adamovicz, 1995). Ideally, 
amplification of the target and housekeeping gene should take place in the same tube. 
However, separate reactions are usually carried out because housekeeping genes are 
often expressed at such high levels that their amplification inhibits the amplification of 
the target mRNA (Cause & Adamovicz, 1995).
The use of competitive RT-PCR for the analysis of a housekeeping gene overcomes 
the problem of having to operate in the exponential phase of the reaction. Once the 
copy number of the target gene is calculated it is normalised to the copy number of the
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housekeeping gene (Zimmermann & Mannhalter, 1996). However, although 
housekeeping genes can correct for variations in RNA preparation and pipetting errors 
it cannot be assumed that the housekeeping gene will maintain a steady state of 
expression under all circumstances (Zimmermann & Mannhalter, 1996).
3.5.2.6 Validation o f competitive RT-PCR method
Validation of the competitive RT-PCR method using the multi-specific standard has 
been carried out by Laville et al. (1996). However, this work should be repeated in this 
laboratory.
Two experiments need to be performed. The first should examine the amplification 
efficiencies for the target and competitor templates. The amplification efficiency is the 
fraction of the template replicated during each reaction cycle. A variation in 
amplification efficiencies can yield dramatic differences in the amount of product 
formed (Siebert, 1993).
Several factors can affect the efficiency of amplification, these include:
• the sequence being amplified
• the sequence of the primers
• the length of the sequence
• the impurities in the sample.
Other parameters affecting amplification efficiency, such as the concentration of 
dNTPs, MgS0 4 , primers, template, polymerase and PCR-cycle profile, can easily be 
controlled (Wang et al. 1989). However, it appears that the primer sequence has the 
greatest effect on amplification efficiency (Wang et al. 1989).
To carry out an experiment to test the amplification efficiencies approximately equal 
molar quantities of target and competitor RNA should be added to a series of RT-PCR 
reactions. A single reaction tube should be removed after each cycle for a total of 7
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cycles, starting when PCR products were first visualised on an agarose gel. The PCR 
products are visualised by gel electrophoresis and the band densities calculated. The 
logarithm of the amount of amplified target and amplified competitor are graphed as a 
function of the cycle number (Siebert, 1993). The similarity of the slopes at the linear 
portion of the 2 curves is indicative of the similarity of amplification efficiency (Cause 
& Adamovicz, 1995).
The second validation experiment involves cloning the target genes of interest, 
followed by transcription, to produce a synthetic target RNA. Known concentrations 
of the synthetic LPL target RNA are quantified by competitive RT-PCR over a wide 
range of concentrations. The purpose of the experiment is to see if the calculated 
number of molecules of target RNA equals the actual number of molecules of target 
RNA added to the reaction.
3.5.3 CONCLUSIONS
The developmental work described in this chapter has demonstrated that LPL gene 
expression in adipose-tissue biopsies can be successfully measured using competitive 
RT-PCR. To ensure that reliable gene expression data is obtained, further validation of 
the competitive RT-PCR method is required, together with the use of a housekeeping 
gene, inclusion of a QC, standardisation of tissue collection and total RNA extraction 
procedures.
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CHAPTER 4
4. EFFECT OF AN N-3 PUFA 
ENRICHED DIET ON LIPOPROTEIN 
METABOLISM IN NORMAL 
SUBJECTS
4.1 INTRODUCTION
The low incidence of ischaemic heart disease in the Innit population of Greenland 
(Bang & Dyerberg, 1972) and the Japanese population (Hirai et al. 1980) has been 
linked to their habitually high intakes of oily fish. Other epidemiological studies, in 
support of these findings, have also reported an inverse association between n-3 PUFA 
intake and risk of CHD (Kromhout et al. 1985; Shekelle et al. 1985; Dolecek & 
Grandits, 1991). However, few controlled clinical trials have looked at the particular 
effect of dietary fish in the prevention of CHD. One intervention study which 
investigated the effects of fish consumption on the incidence of secondary coronary 
events in a group of men, found that there was a significant reduction in deaths from 
ischaemic heart disease in those men who consumed approximately 290 g fatty fish 
per week (equivalent to 2.3 g EPA/week) (Burr et al. 1989). As there was little 
alteration to the other components of the diet it was concluded that the effect on 
mortality was due to the increase in fish consumption.
Many studies investigating the effects of n-3 PUFA supplementation on lipoprotein 
metabolism have consistently found a lowering of plasma TAG, although the effects 
of these agents on cholesterol and other lipoprotein levels have been varied (Harris, 
1989). In addition to the potential beneficial effects of n-3 PUFA on circulating lipids, 
these fatty acids have favourable haemostatic effects, which may contribute to the 
decreased risk from CHD. These include reduced platelet aggregation (due to 
decreased thromboxane A2 and increased prostacyclin production), reduced blood 
pressure, prevention of ventricular arrhythmias and cardiac arrest, and retardation of
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the growth of atherosclerotic plaques (due to the reduction of platelet-derived growth 
factor) (Connor& Connor, 1997). In addition, postprandial lipaemia, which is known 
to be thrombogenic as it increases activation of factor VII (Silveira et al. 1996), is 
reduced following chronic fish-oil feeding (Harris et al. 1988; Weintraub et al. 1988; 
Brown & Roberts, 1991; Williams etal. 1992).
Despite the apparent consistency in findings in relation to physiological effects of 
n-3 PUFA, the detailed results from many studies are contradictory and difficult to 
compare. The probable explanation for this is the large number of factors which 
determine the extent of the n-3 PUFA effect. These include the population studied, the 
dose of n-3 PUFA ingested, the period of intervention, the source of n-3 PUFA, the 
background diet and the diet during the intervention period. Despite these findings, the 
weight of evidence suggests that n-3 PUFA confer the protective effects associated 
with high fish intakes (Harris, 1989).
There is abundant evidence that HTG and prolonged postprandial lipaemia are 
associated with an increased risk of ischaemic heart disease (Austin, 1991; Patsch et 
al. 1992). Excessive duration or magnitude of postprandial lipaemia results in the 
accumulation of chylomicron remnant particles which become cholesterol enriched as 
a result of transfer of cholesteryl esters from HDL (Sethi et al. 1993). Chylomicron 
remnants have been shown to be atherogenic in both in vivo (Zilversmit, 1979) and 
in vitro systems (Huff et al. 1991) and their impaired removal is thought to be 
responsible for the increased prevalence of coronary artery disease in patients with 
type m  hyperlipidaemia (Durrington, 1995). A further consequence of a prolonged 
residence of TAG-rich lipoproteins in the circulation is the increased transfer of TAG 
onto HDL and LDL and their subsequent hydrolysis by HL, resulting in the formation 
of small, dense HDL and LDL (Sethi et al. 1993).
The n-3 PUFA (EPA + DHA) found in fish oils have potent effects on fasting and 
postprandial TAG metabolism. It has already been mentioned that the chronic 
ingestion of fish oils attenuates the normal postprandial-TAG profile (Harris et al. 
1988; Weintraub et al. 1988; Brown & Roberts, 1991; Williams et al. 1992), although
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the mechanism behind these effects is less clear. Much of the evidence suggests that 
the hypotriacylglycerolaemic effects of n-3 PUFA are due to their ability to suppress 
the synthesis and secretion of VLDL. However, work in this laboratory suggests that 
in addition, these fatty acids may have potent stimulatory effects on adipose-tissue 
LPL.
LPL is the key enzyme involved in the hydrolysis of circulating TAG, the activity of 
the enzyme determining the length and degree of postprandial lipaemia (Eckel et al. 
1988). Studies in animals (Baltzell et al. 1991; Murphy et al. 1993; Benhiza et al. 
1994) have demonstrated that LPL activity levels are higher following n-3 PUFA 
supplementation and this has also been shown in humans (Zampelas et al. 1994a, 
Kasim-Karakas et al. 19956). More recently, Harris et al. (1997) found that 
endogenous, non-heparin stimulated, LPL activity levels were significantly higher in 
healthy and HTG subjects (62% and 68% respectively) following 3 -4  weeks 
supplementation with 3.2 g/day EPA+DHA. In addition, Murphy et al. (1993) have 
shown that LPL gene expression in rat epididymal tissue is significantly increased 
following fish-oil feeding. The authors suggested that this may be due to a direct effect 
of n-3 PUFA on the gene expression of LPL and not via the hormonal stimulation of 
insulin, since insulin levels were unchanged. The concept that intracellular fatty acids 
may directly influence the gene expression of key proteins is an important one and it is 
gaining increasing acceptance. This is demonstrated by the studies showing that 
dietary n-3 PUFA inhibit the rate of transcription of hepatic fatty-acid synthase (Clarke 
& Abraham, 1992), and activate a common cellular signalling pathway to the fibrate 
dmgs, which are potent inducers of LPL activity (Sirtori et al. 1993).
The proposal, that the hypotriacylglycerolaemic effect of n-3 PUFA is in part due to 
the ability of these fatty acids to increase the clearance of circulating TAG via LPL, is 
a controversial one, since most other workers have not observed altered LPL activity 
with n-3 PUFA feeding (Harris et al. 1988; Nozaki et al. 1991). However, this is 
probably due, in part, to the lack of specificity of postheparin plasma LPL 
measurements.
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In many countries the average fish consumption is very low. Moreover, the proportion 
of the population consuming fish is low. Some people do not like to eat fatty fish, 
others have reservations due to the possible toxic effects of pesticides or heavy metals 
in fatty fish. Middle-aged men and women have low intakes, and pregnant and 
lactating women often avoid fatty fish, despite their increased requirements for n-3 
PUFA (Conner et al. 1991). In the UK the average daily fish consumption is 26 g, of 
which only 25% is oily fish. This is equivalent to 0.1 g long-chain n-3 PUFA/day 
(Gregory et al. 1990). According to the present UK recommendations the intake of n-3 
PUFA should amount to at least 0.2 g daily (DoH, 1994). The low intake and low 
proportion of the population who ingest oily fish makes the task of increasing the 
intake of n-3 PUFA difficult. However, advances in food technology have allowed the 
successful incorporation of fish oils into a variety of foods, while still maintaining 
their palatability, acceptability and shelf-life. These manufactured foods offer a 
potential route through which an increase intake of n-3 PUFA may be achieved 
without increasing the intake of oily fish.
Aims
Most studies which have investigated the effects of n-3 PUFA on plasma lipids have 
achieved increased intakes of these fatty acids by using fish, fish oils or fish-oil 
capsules in amounts ranging from 0.5-30 g n-3 PUFA per day (Harris, 1989). The aim 
of the present study was to investigate the feasibility of using normal, manufactured 
foods, which had been enriched with EPA+DHA, to increase the level of these fatty 
acids from habitual levels of 0.1 g/day to 1.8 g/day, without altering dietary habits or 
habitual nutrient intakes. This moderate dose of n-3 PUFA was chosen for a number of 
reasons: firstly, prospective studies have demonstrated that relatively low doses of n-3 
PUFA (2.3 g EPA/week) can reduce the risk of secondary coronary events in men 
(Burr et al. 1989), and other studies using similar doses have reported significant 
hypotriacylglycerolaemic effects (Schmidt et al. 1990; Blonk et al. 1991; Harris et al. 
1991). Secondly, this level of supplementation was considered feasible using the range 
of currently available n-3 PUFA-enriched manufactured foods.
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Another aim of this study was to investigate the effects of these n-3 PUFA-enriched 
foods on the composition of plasma phospholipids, postheparin plasma LPL activity 
and fasting and postprandial lipid, lipoprotein and hormone levels.
Finally, in order to ascertain whether the locus for the effects of these n-3 fatty acids is 
at the level of altered gene expression, LPL mRNA was measured in adipose-tissue 
biopsies. In the past, LPL expression was measured by a specific Northem-blot 
method (Murphy et al. 1993), but this method did not have the sensitivity to measure 
the level of expression in small samples of human tissue (Chapman, 1996). We have 
found that the level of LPL activity and expression in human adipose tissue is 
approximately 14% of that in rat adipose tissue (Chapman et al. 1998). Therefore in 
order to examine the changes in LPL expression in human adipose-tissue biopsies a 
more sensitive method of LPL quantitation, using competitive RT-PCR, was 
developed (See Chapter 3).
176
4.2 METHODS
Before the study commenced, ethical consent was obtained from the Royal Surrey 
County Hospital and the University of Surrey Research Ethics Committees. All the 
volunteers signed an informed consent form at the beginning of the study.
4.2.1 SUBJECT RECRUITMENT
Nine healthy normotriacylglycerolaemic free-living male volunteers were recruited 
from the staff at the University of Surrey, Guildford. A pre-requisite for participation 
in the study was that all subjects satisfied the following criteria:
Age 35-60 years 
BMI 22-30 kg/m^
Alcohol intake < 30 units/week
Habitual fat consumption 35-45% of total energy
Habitual long chain n-3 PUFA intake < 0.2 g/day
Not taking any dietary supplements or following any therapeutic diet
Non-smokers
No history of hyperlipidaemia, alcoholism, endocrine or liver disease
Not aerobically exercising more than 3 x 20 minutes per week
Fasting plasma glucose < 6.5 mmol/1
Fasting plasma total cholesterol < 7 .0  mmol/1
Fasting plasma TAG < 2.2 mmol/1
Haemoglobin >13 g/dl
4.2.2 DIETARY INTERVENTION
The study was a randomised, controlled, single-blind crossover trial which included 2 
periods, each of 22 days duration, of dietary intervention separated by a 5-month 
washout period. During the dietary-intervention phase the volunteers received either 
n-3 PUFA (EPA + DHA)-enriched foods or identical control foods. The food items
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used were bread, biscuits, cake, orange drink, milk shake, low-fat spread, pasta, 
mayonnaise, vinaigrette and milk shake powder. Incorporation of a fish-oil product 
(ROPUFA, Hoffman La Roche Ltd. Basel, Switzerland), either directly, or in a 
microencapsulated form, into the enriched food items during manufacture enabled 
n-3 PUFA enrichment. The EPA and DHA content of all the food items used in this 
study were constant for the stated shelf life (as confirmed by the manufacturers 
Hoffman La Roche). Control foods were prepared and packaged in an identical form 
to the enriched products to allow a blind protocol. The nutritional analysis (as 
provided by Hoffman La Roche) of the n-3 PUFA enriched and control foods are 
shown in Tables 4.1 and 4.2.
The subjects were instructed to incorporate the study foods into their habitual diets by 
exchanging them for similar foods usually eaten. All other foods, except oily fish and 
products containing oily fish, were permitted during the study. The aim of the study 
was for subjects to achieve a mean daily intake of 1.8 g/day of EPA+DHA. As can be 
seen from Table 4.2, the amount of EPA+DHA provided by the study foods ranged 
from 0.01-1.08 g/lOOg. In order to allow the subjects flexibility and choice in the 
foods that could be consumed an exchange system was developed. Each food portion 
was assigned an exchange value, where 1 exchange was equivalent to 0.2 g 
EPA+DHA. Typical food-portion sizes, approximately equal to 0.2 g EPA+DHA, are 
shown in Table 4.3. The subjects were requested to eat 9 exchanges daily in any 
combination in order to achieve a mean intake of 1.8 g EPA+DHA/day. In addition to 
these foods, subjects were asked to consume a 113 g pot of smoked mackerel pate 
{n-3 PUFA-enriched diet) or tuna pate (control diet) per week. These contained 1.6 g 
and 0.3 g EPA+DHA respectively. In order to help guide the subjects, on how to 
incorporate the study foods into their diets, example meal plans were issued.
During the period of the study the subjects were contacted frequently to help 
appropriate food choice, to answer any queries, to monitor body weight and to 
encourage subject compliance.
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Table 4-3 n-3 PUFA-enrichedfoodportion sizes and household measures equivalent
to 0.2 g EPA+DHA
Food Item Portion size Household measure EPA+DHA (g)
Bread 210g 7 slices 0.20
Biscuits 68g 4 biscuits 0.22
Cake 45 g 1/6 th of cake 0.21
Pasta (uncooked) l l Og - 0.20
Low-fat spread 30 g 2 tablespoons 0.20
Mayonnaise 20 g 2 dessertspoons 0.22
Vinaigrette 30 g 2 tablespoons 0.20
Orange drink 400 ml 2 medium glasses 0.20
Milk shake drink 170 ml 1 small glass 0.20
Milk shake powder 35 g 7 teaspoons 0.22
Dietary intake was assessed using the 3-day, weighed food-intake method. Prior to 
commencing the study and following the receipt of instructions and a demonstration 
on using the scales, the subjects were asked to complete a 3-day, weighed-food intake 
(including 1 day of the weekend). The analysis of this was used to represent the 
habitual nutrient intake. Subsequent 3-day weighed food intakes were recorded during 
the 2 periods of dietary intervention, representing the nutrient intakes for the control 
and n-3 PUFA-enriched diets. Data was analysed using the Foodbase nutrient analysis 
program (Version 1.2. Institute of Brain Chemistry and Human Nutrition, London). 
The nutrient and fatty-acid composition of the study foods (control & n-3 
PUFA-enriched) were provided by Hoffman La Roche and added to the Foodbase 
database.
Dietary under-reporting was assessed by comparing recorded energy intakes (using 
3-day, weighed-intake record) with calculated energy intakes (1.27 x basal metabolic 
rate [BMR]) as described by Goldberg et al. (1991). BMR was calculated using the 
equations given by the DoH (1991). This cut-off point was used to determine 
under-reporting because it is the minimum energy requirement for survival, and energy 
intakes below this are rare in healthy free-living individuals (Goldberg et al. 1991).
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A questionnaire was designed to investigate the acceptability and palatability of the 
individual food products. At the end of each intervention period, the volunteers were 
asked to rate the acceptability and palatability of the study food items using a linear 
analogue scale ranging from 0  to 1 0 , where 0  equalled ‘not palatable’ and 1 0  equalled 
‘very palatable’. A similar linear analogue scale was used to assess compliance and 
convenience of the study.
4.2.3 POSTPRANDIAL STUDY
On day 22 of the 2 intervention periods the subjects attended a postprandial study day 
at the University of Surrey. The subjects came into the investigation unit after a 
1 2  hour overnight fast, having been asked not to take any strenuous exercise or 
consume any alcohol on the previous day. A cannula was inserted into the antecubital 
vein of the forearm, and 2 fasted blood samples (20 ml) were taken. The cannula was 
kept patent using sodium citrate between blood sampling. The subjects were then 
given a standard test meal (see Table 4.4 for details of nutrient composition), which 
they consumed within 20 minutes. Following consumption of the meal the subjects 
were allowed free access to water, diet drinks and decaffeinated beverages without 
milk or sugar, but no other food was consumed until the end of the study period.
Blood samples (20 ml) were taken 30 minutes and 60 minutes after starting to eat the 
test meal and thereafter hourly for 8  hours. After 8  hours an adipose-tissue needle 
biopsy was taken, under local anaesthetic, from the paraumbilical region of the 
abdominal wall as described in section 2.2.5, for the analysis of LPL gene expression. 
Following this, a single bolus dose of heparin (7500 lU) was given intravenously at a 
distant site to the indwelling cannula, and further blood samples (5 ml) were collected 
5 and 15 minutes after the injection for the measurement of LPL activity.
4.2.4 PLASMA SEPARATION AND ANALYTICAL METHODS
All blood samples were collected into lithium heparin tubes, except those for glucose 
analysis, which were collected into fluoride oxalate tubes. Plasma was separated by 
centrifugation as described in section 2.2.1, aliquotted into LP3 tubes for different 
analyses and stored at -20°C (samples for lipase analysis were stored at -80°C).
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TRL and TPL fractions were prepared from plasma as described in section 2.2.2a. 
TAG, NEFA, glucose, total and HDL cholesterol were measured 
spectrophotometrically, using automated enzymatic assays on the COBAS Mira Plus 
analyser, as described in section 2.2.3. Glucose, NEFA and total cholesterol were 
measured in plasma. TAG was measured in plasma and both the TRL and TPL 
fractions. HDL-C was determined in the TPL fraction only. LDL-C concentration was 
calculated using Friedwald’s formula (Friedwald et al. 1972) as shown below:
LDL-C = Total serum cholesterol - HDL-C +
Total TAG 
2.2 y
Plasma insulin was measured by another investigator using the radioimmunoassay 
described in section 2.2.4. The insulin to glucose ratio was calculated using the 
homeostasismodel assessment (HOMA) equation (Matthews et al. 1985) as shown 
below:
Fasting insulin (mU /1) X Fasting glucose (mmol /1) 
Insulin resistance = --------------------------
22.5
(where 1 mU/1 is equivalent to 7.5 pmol/1)
LPL activity was measured using the radioactive triolein emulsion technique detailed 
in section 2.2.7. Total RNA was extracted from the adipose-tissue biopsies according 
to the method illustrated in section 2.2.5 and LPL gene expression was measured by 
competitive RT-PCR as described in section 3.4.4.
Plasma-phospholipid fatty acids were determined by Hoffman La Roche.
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Table 4-4 Nutrient composition of standard test meal
Food Quantity 
(g or ml)
Energy
(MJ)
Protein
(g)
Fat
(g)
CHO
(g)
SFA
(g)
MUFA
(g)
PUFA
(g)
Sliced white 
bread
180 1.80 15.1 3.4 88.7 0.73 0.46 1 . 2 1
Cheddar cheese 75 1.28 19.1 25.8 0 . 1 16.37 6 . 0 2 0.35
Flora
margarine
2 0 0.61 0 16.3 0 . 2 3.04 3.86 7.07
Orange juice 250 0.38 1.3 0.3 2 2 NA NA NA
Frosties 50 0.80 2.7 0.3 46.8 0.04 0.03 0.13
Whole milk 150 0.41 4.8 5.8 7.2 3.67 1.35 0.08
Double cream 65 1 . 2 0 1 . 1 31.2 1 . 8 19.58 7.21 0.42
Total - 6.48 44.1 83.1 166.8 43.43 18.93 9.26
% Energy - - 11.4 48.2 40.3 25.2 10.9 5.4
Abbreviation; CHO, carbohydrate.
4.2.5 STATISTICAL ANALYSES
Mean, SD and SEM were calculated for each measurement. Statistical analysis was 
carried out using the statistical package Instat (Macintosh version 2.01 Graph Pad 
Software, San Diego, USA). Paired Student’s t-tests and repeated measures analysis of 
variance were applied to the responses of the subjects to the 2  dietary periods, 
followed by Tukey-Kraemer post-hoc tests, where appropriate. Data was transformed 
before analysis, if necessary to give a normal Gaussian distribution. Total and 
incremental areas under the time-response curves (AUC, lAUC) were calculated using 
the trapezoidal rule on Excel spreadsheets. Differences in time-response curves and 
calculated AUCs were analysed by analysis of variance, followed by Duncan’s 
multiple-range test to locate individual differences and assess the level of statistical 
significance. Correlation coefficients were calculated using the Pearson’s test for 
correlation. Values of P < 0.05 were taken as the lowest level of significance.
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4.3 RESULTS
Nine subjects were recruited and they successfully completed the dietary-intervention 
study. The mean age of the volunteers was 50 (SD 7.2) years with a BMI of 25.7 
(SD 2.6) kg/m^. The anthropometric data for all the subjects, at the beginning of the 
study, are shown in Table 4.5.
Table 4-5 Subject anthropometric details at the beginning o f the study
Subject Age (years) Weight (kg) Height (m) BMI (kg/m^)
1 45 67.6 1.73 22.5
2 56 82.3 1.77 26.2
3 53 82.2 1.79 25.6
4 54 75.5 1.70 26.1
5 57 74.4 1 . 8 22.9
6 34 72.6 1.65 26.6
7 54 78.9 1.61 30.4
8 48 69.5 1.73 23.2
9 49 88.9 1.78 28.1
Mean 50 76.9 1.73 25.7
SD 7.2 6 . 8 0.07 2 . 6
4.3.1 NUTRIENT DATA
The mean nutrient intakes of the subjects on their habitual diet and during the 
2 dietary-intervention periods {n-3 PUFA-enriched & control) are shown in Table 4.6.
There was a significant increase in the energy, fat and carbohydrate intake on the 
n-3 PUFA-enriched and control intervention periods when compared with the habitual 
diet {P < 0.001). However, the 2 intervention periods did not differ in their 
macronutrient content. The percentage energy from fat and carbohydrate were similar 
for all 3 diet periods. However, the percentage energy from protein was lower during 
the 2  intervention periods, although this only reached significance during the control 
dietary phase {P < 0.05).
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Table 4-6 Nutrient composition o f habitual, control and n-3 PUFA-enriched diets as
estimated by 3-day, weighed-food intakes. Values are mean (SD) for 8 subjects
Nutrients Habitual diet 
Mean SD
Control diet 
Mean SD
n-3 PUFA- 
enriched diet 
Mean SD
Energy (MJ) 9.2 1 . 1 1 2 .0 * 1.9 1 2 .0 * 1.3
Protein (g) 81.3 18.1 84.2 15.2 89.3 8 . 6
% Energy Protein 14.6 2 . 1 11.9* 1.7 12.5 1 . 2
Fat (g) 76.5 24.8 1 0 2 .0 * 26.2 105.8* 23.8
% Energy Fat 30.4 9.2 31.9 5.8 33.5 6.4
Carbohydrate (g) 289.8 52.4 409.1* 87.0 396.8* 53.0
% Energy Carbohydrate 49.6 9.2 53.5 6 . 2 52.0 6.5
SFA(g) 27.3 13.7 34.1 9.2 34.6 13.6
% Energy SFA 10.9 5.3 1 0 . 6 2 . 0 10.9 3.9
cfj-MUFA (g) 19.1 6 . 1 34.7® 1 0 . 2 33.1® 11.4
% Energy cw-MUFA 7.7 2 . 2 1 0 .8 ® 2.4 10.3® 3.2
n-6 PUFA (g) 9.0 4.0 14.3 4.8 12.4 6.5
n-3 PUFA (g) 1 . 0 0.4 2.7 0 . 8 3.4 1 . 0
c/5-PUFA (g) 1 0 . 0 4.0 17.0* 5.3 15.8 6.9
% Energy cw-PUFA 4.1 1.5 5.5 2 . 0 5.0 2.3
EPA(g) 0.04 0.03 0.17 0.08 0 .8 6 "^ 0.23
DHA(g) 0.08 0.05 0 . 2 0 0.18 0.50"^ 0.15
EPA + DHA (g) 0 . 1 2 0.07 0.37 0 . 2 2 1.36"^ 0.34
n-6: n-3 ratio 1 0 . 0 6 . 0 5.1* 1.3 3.8* 1.9
P:S ratio 0.46 0.29 0.52 0.17 0.49 0.18
*, 0 ,  #  significantly different from the habitual diet, P < 0.05, P < 0.01, P < 0.001 respectively 
T  significantly different from the control diet, P < 0.001
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The significant increase in total fat during the 2 dietary-intervention periods was 
reflected by an increase in all the fatty acid fractions (SFA, cw-MUFA, cw-PUFA [n-3 
+ n-6 PUFA]). Compared to the habitual diet there was a significant increase in 
cw-MUFA during both intervention diets (P < 0.01) and a significant increase in 
cw-PUFA during the control diet (P < 0.05). Again, the 2 intervention periods did not 
differ in their SFA, cw-MUFA or cw-PUFA content. The percentage energy from 
SFA and cis-PUPA were similar for all 3 diets, however, the percentage energy from 
cw-MUFA was significantly higher on the n-3 PUFA-enriched and control periods 
compared with the habitual diet (P < 0.01). The P:S ratio did not change during the 
3 diet periods. Compared with the habitual diet the n-6:n-3 ratio was significantly 
lower on the 2 intervention diets (P < 0.05).
The quantity of EPA and DHA, when considered separately and together, were 
significantly higher in the n-3 PUFA-enriched, compared with both the control and 
habitual periods (P < 0.001).
The estimated average intake of EPA+DHA during the n-3 PUFA-enriched dietary 
period, as assessed by the 3-day, weighed-food intake, was 1.36 g/day (0.86 g/day 
EPA, 0.5g/dayDHA).
Although there were no significant differences between the mean habitual recorded 
(3-day weighed intakes) and calculated (1.27 x BMR) energy intakes (see Table 4.7), 
the mean habitual recorded energy intakes were lower than the survival minimum. 
This suggests that the subjects were under-reporting their energy intakes, and 
therefore, were incompatible with long-term maintenance of energy balance. Within 
the subject group, 5 volunteers had recorded energy intakes below 1.27 x BMR.
The mean recorded energy intakes during the 2 dietary-intervention periods were 
higher than the calculated intakes, although this only reached significance for the 
n-3 PUFA-enriched diet (P < 0.001), which suggests that there was no detectable 
under-reporting.
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Table 4-7 Comparison of recorded energy intakes (3-day weighed-intake method) 
with calculated energy intakes ( 1.27x BMR) for the habitual, control and n-3 PUFA- 
enriched diets. Values are mean (SD) for 8 subjects
Habitual diet 
Mean SD
Control diet 
Mean SD
n-3 PUFA- 
enriched diet 
Mean SD
Recorded energy intake 
(3-day weighed intakes) 
(MJ/day)
9.2 1 . 1 1 2 . 0 1.9 1 2 .0 * 1.3
Calculated energy intake 
(1.27 X BMR) (MJ/day)
9.4 0.4 9.6 0.4 9.5 0.4
# significantly different from calculated energy intakes, P < 0.001
However, during the control intervention period, 2 subjects underreported their energy 
intakes, whilst none of the volunteers underreported during the n-3 PUFA-enriched 
dietary phase. It must also be remembered that the cut-off levels for under-reporting, 
used here, were the absolute minimum.
4.3.2 PALATABILITY DATA
The palatability assessment scores for the study foods (n-3 PUFA-enriched & control) 
are shown in Table 4.8. There were no significant differences found between the 
n-3 PUFA-enriched (mean 6.9, SD 1.0) and control foods (mean 7.4, SD 0.9).
The mean compliance scores reported by the volunteers (Table 4.9) were not 
significantly different when the n-3 PUFA-enriched and control periods were 
compared, nor when arm 1 and 2  of the study were compared.
The convenience of the 2 study diets, as assessed by a linear analogue scale (Table
4.9), were similar for both the n-3 PUFA-enriched and control diets and for both arms 
of the study. However, the mean scores (range 5.1-5.8) were not high.
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Table 4-8 Palatability scores for the control and n-3 PUFA-enriched foods provided
by Hoffman La Roche, as assessed by linear analogue scales. Values are mean (SD)
for 9 subjects
Food Product Control-product scores n-3 PUFA-enriched product
scores
Mean SD Mean SD
Bread 7.3 2.3 6.9 1 . 8
Biscuits 7.5 1 . 1 8 . 1 1.4
Cake 7.4 2 . 1 7.5 1.9
Pasta 8.7 0 . 6 7.3 1.4
Low-fat spread 7.5 1.7 7.0 2.5
Mayonnaise 7.9 0 . 8 7.5 1 . 1
Vinaigrette 6.9 3.1 6 . 2 2 . 6
Orange drink 8 . 0 1.4 5.9 3.3
Milk shake drink 8.3 2 . 0 7.6 1.5
Milk shake powder 7.2 4.1 6.9 1 . 8
All Foods 7.4 0.9 6.9 1 . 0
Table 4-9 Convenience and compliance scores fo r the control and n-3 PUFA- 
enriched dietary periods, and for both arms of the study. Assessed by using linear 
analogue scales. Values are mean (SD) for 9 subjects
Control diet 
Mean SD
n-3 PUFA- 
enriched diet 
Mean SD
Arm 1 
(both diets) 
Mean SD
Arm 2 
(both diets) 
Mean SD
Convenience 
! Scores 5.7 3.1 5.1 3.0 5.1 3.2 5.8 2 . 8
Compliance
Scores 8.5 1.4 8 . 0 1 . 8 8.7 1.3 7.8 1 . 8
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4.3.3 ANTHROPOMETRIC DATA
Body weight increased during both the n-3 PUFA-enriched and control periods (Table
4.10) and this was found to be significant during the n-3 PUFA-enriched period 
(P < 0.05). The baseline weights for each subject were similar at the beginning of both 
diets and at the beginning of both arms of the study. However, it was found that 
regardless of diet type, there was a significant increase in body weight during arm 1 
compared with arm 2 of the study (P < 0.01), but there was no significant correlation 
between weight gain and change in energy intake (r = 0.29).
4.3.4 FASTING BIOCHEMICAL DATA
There were no significant differences found between the baseline biochemical levels at 
the start of arm 1 or 2  of the study for either diet.
The fasting plasma concentrations of TAG, total and HDL cholesterol, glucose, insulin 
and NEFA, together with the fasting insulimglucose ratios are shown in Table 4.11.
Plasma TAG levels decreased from baseline by 8 % and 3% on the n-3 PUFA-enriched 
and control diets respectively, although this was not significant. The fasting TAG 
concentration was 3% lower following the n-3 PUFA-enriched diet compared to the 
control diet; again, this did not reach significance.
The total-cholesterol concentrations were found to be significantly lower after both 
dietary-intervention periods compared with their respective baseline values (P < 0.05). 
However, the total-cholesterol concentrations after the 2 diets were not significantly 
different from each other. Despite no change in total cholesterol between the 2 diets, 
the HDL-C concentration was significantly higher after the n-3 PUFA-enriched 
compared with the control-intervention period (P < 0.05). There was no significant 
change in LDL-C concentrations after the 2 dietary interventions, although the values 
tended to be higher after the n-3 PUFA-enriched dietary period.
Fasting NEFA concentrations were not significantly different between the 2 diets.
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Table 4-10 Body-weight changes during the control and n-3 PUFA-enriched diets
and during the 2 arms of the study. Values are mean (SD) fo r  9 subjects
Diet/Arm of study Baseline weight 
(kg)
Mean SD
Final weight 
(kg) 
Mean SD
Change in 
weight (kg) 
Mean SD
Control diet 77.6 7.7 78.2 7.5 0 . 6 1 . 0
n-3 PUFA-enriched diet 76.8 6 . 8 78.0* 7.3 1 . 2 1.4
Arm 1 (n = 4 control, n = 5 
n-3 PUFA)
76.9 6 . 8 78.4* 7.1 1.5 1 . 2
Arm 2 (n = 5 control, n = 4 
n-3 PUFA)
77.6 7.7 78.0 7.5 0.4 1 . 1
*, # significantly different from baseline, P < 0.05, P < 0.01 respectively
Table 4-11 Fasting lipid and hormone responses in plasma, and the fasting 
insulin:glucose ratios during the control and n-3 PUFA-enriched dietary periods.
Values are mean (SD) for 9 subjects
Parameter Control diet n-3 PUFA-enriched diet
Baseline 
Mean SD
Day 22 
Mean SD
Baseline 
Mean SD
Day 22 
Mean SD
TAG (mmol/1) 1.58 0.39 1.53 0.63 1.62 0 . 6 8 1.49 0.37
Total cholesterol 
(mmol/1)
5.85 0.67 5.27* 0.54 6.07 0.74 5.52* 0.83
LDL cholesterol 
(mmol/1)
3.73 0.59 3.81 0.87
HDL cholesterol 
(mmol/1)
0.87 0.29 1.04'*' 0.33
NEFA (mmol/1) - - 0.49 0.09 - - 0.48 0.14
Glucose
(mmol/1)
4.97 0.41 5.08 0.18 5.03 0.27 5.51*'*'
\i
0.50
Insulin (pmol/1) - - 87 81 - - 89 58
InsuliniGlucose - - 2.62 2.32 - - 3.03'*' 2.09
Abbreviations: (-), no sample was collected.
* significantly different from baseline, P < 0.05
\j/ significantly different from day 22 of the control diet, P < 0.05
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Compared with the n-3 PUFA-enriched dietary-intervention period, the mean fasting 
glucose concentration was significantly lower at baseline and after the control dietary 
period (P < 0.05). There was no significant difference between the baseline fasting 
glucose concentration and the level after the control-intervention period.
Fasting insulin concentrations were not significantly different between the two dietary 
periods. The fasting insulin:glucose ratio (a measure of insulin resistance) was 
significantly higher following the n-3 PUFA-enriched diet compared to the control 
diet (P < 0.05). Fasting insulin and fasting plasma TAG concentrations were both 
significantly correlated with the insulin:glucose ratio (r = 0.99 and 0.69, P < 0.0001 
and P < 0.002, respectively).
The EPA+DHA incorporation of the plasma phospholipids during the control and 
n-3 PUFA-enriched intervention diets are shown in Figure 4.1 The mean EPA+DHA 
enrichments of the plasma phospholipid fatty acids were not significantly different at 
the start of the 2 intervention periods. There was a significant increase in the 
incorporation of EPA+DHA into the plasma phospholipids during the n-3 PUFA- 
enriched dietary period from day 1 to day 9 (P < 0.001), and a further smaller rise 
from day 9 to day 22 . The latter, although significantly different from baseline 
(P < 0.001), was not significantly different from day 9.
There were no significant differences in the incorporation of EPA+DHA into the 
plasma phospholipids during the control dietary period. Compared to the control 
dietary period, the EPA+DHA enrichment of the plasma phospholipids was 
significantly higher during (day 9) and after (day 22) the n-3 PUFA-enriched 
intervention period (P < 0.001).
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Figure 4-1 Concentrations o f EPA and DHA in plasma phospholipids o f subjects consuming an 
n-3 PUFA-enriched or control diet for 22 days. Values are mean (SD) for 9 subjects. * indicates mean 
values are significantly different from baseline {P < 0.001). # indicates mean values are significantly 
different from those for the control period {P < 0.001).
4.3.5 POSTPRANDIAL BIOCHEMICAL DATA
The postprandial profiles for the mean plasma-, TRL-, and TPL-TAG concentrations 
are shown in Figures 4.2, 4.3 and 4.4 respectively. The patterns of postprandial TAG 
response were similar in all 3 fractions: rising following ingestion of the standard test 
meal and reaching a peak between 120-240 minutes before declining slowly. None of 
the mean TAG levels had returned to baseline values 8  hours after the meal.
There were no significant differences between the mean time to peak, and the peak 
TAG concentrations reached on either diet (Table 4.12). No significant differences 
were observed with the total area or the incremental area under the time-response 
curves (AUC, lAUC) for the TAG responses measured in any of the fractions, for the 
n-3 PUFA-enriched and control diets (Table 4.13). However, there was a tendency for 
the postprandial TAG profiles after the n-3 PUFA enriched intervention period to be 
lower, compared with the control period, although this did not reach significance at 
any point.
193
4
s'o
3I
60 120 180 240 300 360 420 4800
Control 
- • - n - 3  PUFA
Time (minutes)
Figure 4-2 Postprandial plasma TAG responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
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Figure 4-3 Postprandial TRL-TAG responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
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Figure 4-4 Postprandial TPL-TAG responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
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Table 4-12 Time to peak and peak concentration for the TAG responses following the 
control and n-3 PUFA-enriched diets. Values are mean (SD)for 9 subjects
Fraction Control diet n-3 PUFA-enriched diet
Time to peak 
(minutes)
Mean SD
Peak 
concentration 
(mmol/1) 
Mean SD
Time to peak 
(minutes)
Mean SD
Peak 
concentration 
(mmol/1) 
Mean SD
Plasma 195 53 3.22 1.24 2 1 0 1 1 1 3.42 1.09
TRL 203 96 1.70 0.85 218 96 1.47 0 . 6 8
TPL 218 84 1.47 0.34 225 77 1.41 0.32
Table 4-13 Total area and incremental area under the time-response curves for the 
TAG responses following the control and n-3 PUFA-enriched diets. Values are mean
(SD)for 9 subjects
Fraction Control diet n-3 PUFA-enriched diet
AUC lAUC AUC lAUC
(min.mmol 1'^ ) (min.mmol 1'^ ) (min.mmol T^ ) (min.mmol 1'^ )
Mean SD Mean SD Mean SD Mean SD
Plasma 1151 429 418 330 1149 402 433 272
TRL 444 231 245 251 397 226 271 175
TPL 590 137 8 6 105 558 146 83 47
Pearson correlation’s demonstrated that fasting plasma-, TRL- and TPL-TAG values 
were significantly correlated with the AUC for the postprandial TAG-response curves 
in plasma, TRL and TPL (r = 0.691, 0.592 and 0.735 respectively, P < 0.01).
The postprandial total-cholesterol levels were not significantly different at any time 
point (Figure 4.5), although a trend for higher AUCs (Table 4.14) was observed after 
the n-3 PUFA-enriched diet.
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Table 4-14 Total area and incremental area under the time-response curves for the 
plasma total-cholesterol, glucose, NEFA and insulin responses following the control 
and n-3 PUFA-enriched diets. Values are mean (SD)for 9 subjects
Parameter Control diet n-3 PUFA-enriched diet
AUC lAUC AUC lAUC
Total cholesterol 2448 -82 2556 -92
(min.rmnol 1*^ ) (240) (63) (393) (62)
Glucose 2630 193 2865 2 2 2
(min.mmol 1*^ ) (167) (191) (515) (359)
NEFA 172 -64 160 -71
(min.mmol 1'^ ) (38) (59) (57) (73)
Insulin 197369 155633 184807 141905
(min.pmol 1'^ ) (172125) (137240) (124034) (98488)
Plasma glucose responses rose following the standard test meal, reaching a peak at 
30 minutes for both diets (Figure 4.6). The levels fell sharply at 60 minutes and 
continued to fall below the fasting concentration 8  hours after the test meal.
No significant differences were observed in the glucose AUCs and lAUCs for the 2 
diets (Table 4.14), although there was a tendency for the n-3 PUFA-enriched diet 
AUCs to be higher than that of the control diet.
Following the test meal, NEFA concentrations fell during the first 2 hours before 
rising above fasting levels by the end of the 8  hour period (Figure 4.7). There were no 
significant differences between the AUCs and lAUCs for the 2 diets (Table 4.14), 
although there was a tendency for the subjects to show a lower response on the 
n-3 PUFA-enriched diet.
At 60 minutes a significant difference was found between the NEFA responses, with 
the curve for the n-3 PUFA-enriched intervention period falling to a lower level than 
that with the control-intervention period {P < 0.04).
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Figure 4-5 Postprandial plasma cholesterol responses to a standard test meal following the control 
and n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
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Figure 4-6 Postprandial plasma glucose responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
10.6
g  0.4
w
2
I  0
0 60 120 180 240 300 360 420 480
. Control 
n-3 PUFA
Time (minutes)
Figure 4-7 Postprandial plasma NEFA responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for nine subjects. * indicates a 
significant difference between the 2 diets (P < 0.04).
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Figure 4-8 Postprandial plasma insulin responses to a standard test meal following the control and 
n-3 PUFA-enriched dietary periods. Values are mean (SEM) for 9 subjects.
Postprandial insulin responses are shown in Figure 4.8. Following the meal insulin 
concentrations rose sharply to give a peak at 30 minutes, then plateaued to 180 
minutes before falling steadily back towards the fasting values. There were no 
differences between the AUCs and lAUCs for the 2 diets (Table 4.14).
4.3.6 POSTHEPARIN LPL ACTIVITY DATA
Postheparin plasma LPL activities 5 and 15 minutes following the injection of 
heparin, 8  hours after the standard test meal, are shown in Figure 4.9. There were no 
significant differences following the control or the n-3 PUFA-enriched diets for the 
5- and 15-minute LPL activities.
Pearson correlation’s demonstrated that the 15-minute LPL activity values were not 
significantly correlated with the AUC for the postprandial plasma TAG response 
curve (r = -0.1) when all subjects (n = 17) were included. However, when only 11 
subjects were included, this correlation became significant (r = -0.64, P  < 0.04) 
(Figure 4.10, Table 4.15). There was a positive correlation between HDL-C and LPL 
activity (r = 0.381) but this did not reach significance.
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Figure 4-9 Postheparin plasma LPL activities 5 and 15 minutes after injection o f 7500 units o f 
heparin, 8 hours after the standard test meal, following the control and n-3 PUFA-enriched dietary 
periods. Values are mean (SD) for 9 subjects.
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Figure 4-10 The relationship between plasma TAG-AUC and postheparin LPL activity in individual 
subjects following the control and n-3 PUFA-enriched dietary periods, (control diet n = 6, n-3 PUFA 
enriched diet n -  5).
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Table 4-15 Plasma TAG-AUC andpostheparin LPL activity values
Subject Plasma TAG-AUC 
(min.mmol.r^)
Postheparin plasma LPL activity 
(mU/ml)
Control diet n-3 PUFA- 
enriched diet
Control diet n-3 PUFA- 
enriched diet
2 1295 1183
- 1 1 2
118.9 162.5
3 840 927 
+ 87
195.1 156.2
5 933 957 
+ 24
206.2
7 1682 2030 
+ 348
138.4 128.9
8 953 706
-247
216.3 186.2
9 2040 1526
-5 1 4
153.5 181.3
Mean 1291 (482) 1 2 2 2 171.4 163.0
(SD) (484) (39.9) (2 2 .8 )
Results presented are the absolute values for 6 subjects. Values in bold represent the change in plasma 
TAG-AUC from the control dietary period.
4.3.7 LPL GENE-EXPRESSIQN DATA
Although adipose-tissue biopsies were collected from all the volunteers, only 6  
subjects’samples were analysed for LPL mRNA. There were no significant differences 
in LPL expression between the 2 diets, although the values were higher on the n-3 
PUFA-enriched diet (Table 4.16).
It was observed that the subjects who responded to the n-3 PUFA-enriched diet with a 
decrease (or only a very small increase) in fasting TAG levels, had the greatest 
increase in LPL expression. In contrast, the subjects whose fasting TAG levels 
increased the most with n-3 PUFA supplementation showed decreased levels of LPL 
expression (Table 4.16).
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Table 4-16 LPL expression and fasting plasma TAG values following the control and.
n-3 PUFA-enriched dietary periods
Subject LPL expression 
(molecules LPL mRNA x lOVng total 
RNA)
Fasting plasma TAG 
(mmol/1)
Control diet 
Mean SD
n-3 PUFA-enriched 
diet
Mean SD
Control diet n-3 PUFA- 
enriched diet
2 1.09 0.14 2.64 
+1.55
0.08 1.74 1.53
- 0 . 2 1
3 5.92 0.70 2.13
-3 .79
0.48 1 . 0 2 1.42 
+ 0.40
5 6.62 3.16 8.05 
+ 1.43
2.99 1 . 1 2 1.19 
+ 0.07
7 7.06 1 . 1 1 0.81
-6 .25
0 . 0 1 1.80 2.30 
+ 0.50
8 3.33 2.13 6.72 
+ 3.39
0.35 0.96 0.98 
+ 0 . 0 2
9 0.60 0.17 7.27 
+ 6.67
0.15 2.79 1.56 
- 1.23
Mean
(SD)
4.12
(2.83)
4.60 (3.09) 1.57
(0.70)
1.50
(0.45)
Values in bold represent the change in LPL expression and fasting plasma TAG from the control dietary 
period. LPL-expression values (n = 6) are mean (SD), based on 3 competitive RT-PCR experiments.
There was a significant correlation between the change in fasting TAG concentration 
{n-3 PUFA-enriched - control) and the change in LPL gene expression (r = -0.87, 
P < 0.03) (Figure 4.11). In addition, there was a highly significant correlation between 
the change in AUC for the postprandial TAG-response curve (Table 4.15) and the 
change in LPL gene expression (r = -0.96, P < 0.003) (Figure 4.12). There was no 
significant correlation between LPL expression and postheparin LPL activity, nor 
between the changes in these measurements from the control to the test diet. There 
was a negative correlation between BMI and LPL gene expression (r = -0.36), but this 
did not reach significance.
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Figure 4-11 The relationship between the change in LPL expression and the change in fasting plasma 
TAG from the control to the n-3 PUFA-enriched diet (n = 6).
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Figure 4-12 The relationship between the change in LPL expression and the change in the 
postprandial plasma TAG-AUC from the control to the n-3 PUFA-enriched diet (n = 6).
202
4.4 DISCUSSION
This study is one of the first to use normal foods enriched with n-3 PUFA as a means 
to increasing the EPA and DHA content of the diet, and to offer an alternative to 
fish-oil capsules.
The aim of this study was to moderately increase the volunteers daily intake of 
EPA+DHA to approximately 1.8 g. This dose was chosen because similar doses 
(range 1-1.7 g n-3 PUFA/day) have been shown to reduce fasting and postprandial 
plasma TAG levels in studies using fish-oil supplements (Sanders & Roshanai, 1983; 
Blonk et al. 1990; Schmidt et al. 1990; Brown & Roberts, 1991). Also, this level of 
enrichment was considered feasible using currently available enriched, manufactured 
foods.
The results demonstrate that it is possible to increase the daily intake of EPA and 
DHA above the habitual level of 0.1 g/day using the foods available, which is 
consistent with other studies using spreads and fish oil-enriched products (Roche, 
1995; Gustafsson et al. 1996). However, the mean daily intake of EPA+DHA, 
calculated from the weighed food intake, was 1.36 g during the n-3 PUFA-enriched 
dietary period, which did not reach the target intake of 1 . 8  g/day.
The mean palatability scores for the control and n-3 PUFA-enriched foods were not 
significantly different, indicating that the quality of the foods was not responsible for 
the lower than expected intake of n-3 PUFA. Instead, failure to reach the target intake 
was thought to be due to a number of other factors:
Firstly, all of the subjects gained weight and experienced difficulty consuming the full 
number of exchanges required to achieve a daily intake of 1.8 g EPA+DHA. There 
were several reasons for this. To achieve the daily target of 1.8 g EPA+DHA the 
volunteers had to substitute a minimum of 5.45 MJ/day (e.g. 9 x 170 ml milk shake) 
into their habitual diet. As these test foods provided a minimum of half of their daily 
energy requirement failure to adjust their normal eating habits to compensate for these
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test foods inevitably resulted in weight gain. In reality a variety of the study foods 
were eaten which would have contributed more than 5.45 MJ/day to the energy intake. 
Also, several of the study foods provided (e.g. vinaigrette, cakes, milk shake, milk 
shake powder) were not routinely eaten by the subjects. Therefore, addition of these 
foods to the diet may have made it more difficult for the volunteers to reduce their 
consumption of habitual foods, because they were not able to easily swap the study 
foods for similar habitual foods. The most significant weight gain was observed after 
the first arm of the dietary intervention, during which 5 of the subjects were on the n-3 
PUFA-enriched diet. Although all the subjects gained weight in the second arm of the 
study (mean gain of 0.4 kg) this did not reach significance. This could be explained by 
the subjects gaining expertise in exchanging the study foods for their usual foods or 
alternatively the subjects may have become less compliant in the second arm of the 
study. Although there was no significant difference between the compliance scores, 
the mean score was lower during the second arm of the study. Also the convenience of 
the study was rated between 5.1-5.8, which would suggest that the subjects found 
consuming the study foods inconvenient, possibly because they interfered with their 
normal daily activities.
The data obtained in the present study suggest that if fortified foods are to be used to 
achieve n-3 PUFA intakes greater than 1 g per day, then higher levels of enrichment 
are needed together with a wider range of commonly used food products.
The second reason for failing to reach the daily EPA+DHA target was due to the 
limitations of the 3-day, weighed food-intake method, for fatty-acid intake 
determinations. An individual would be required to undertake a weighed-food record 
for a period of 15-30 days (Nelson et al. 1989) in order to accurately measure the 
fatty-acid content of their diet. This was considered impractical and too restricting for 
the volunteers involved. It has been well documented that adherence to dietary 
recording is affected if the period of recording is too long, and that volunteers often 
alter their normal eating habits to simplify the task (Bingham, 1987; Bingham 
et al. 1995). For these reasons 3 days was thought an acceptable number of dietary 
record days to obtain an estimate of the volunteers’ food intakes. Also, accurate
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estimation of dietary fatty-acid intake is restricted by the information available on the 
fatty-acid compositions of foods in current nutrient databases. A recent study (Kelly 
et al. 1999), which compared fatty-acid data obtained from 19 diet diaries with and 
without the use of additional details of foods, recipes, oils and spreads, found small 
but significantly different values for all classes of fatty acid. In our study, the fatty-acid 
composition of the n-3 PUFA-enriched and control foods was directly determined and 
the information manually added to the Foodbase database. However, the fatty-acid 
composition of the other foods consumed relied on the accuracy of the database used 
and the level of information provided by the volunteers. Therefore, the limitations of 
the dietary-intake method must be taken into consideration when interpreting the 
dietary results.
It was also observed that the days in which the fish pate was consumed were not often 
chosen by the subjects for their dietary-recording days. As this source of EPA and 
DHA represented a significant quantity of the n-3 PUFA intake, lack of records for 
this food may explain the lower than expected recorded EPA+DHA intakes.
Lastly, although the subjects were given clear instructions on the procedure for 
recording their food intake, it was evident that under-reporting was taking place. 
Under-reporting is a common occurrence in dietary studies and depending on the 
magnitude, can seriously distort the findings of the study (Bingham, 1987; Hirvonen 
et al. 1997). Inclusion of independent validation techniques, such as 24-hour urinary 
nitrogen, plus para-aminobenzoic acid to verify completeness of the 24-hour urine 
collection, helps to determine the validity of the dietary records, because they reflect 
dietary intake without relying on reports of food consumption. In this study, plasma 
phospholipids and estimated energy intakes calculated as described by Goldberg 
et al. (1991), were used as independent checks of dietary compliance. Using equations, 
estimated energy intakes can be compared to reported energy intakes and it has been 
shown that among free-living persons, energy expenditure levels below 1.27 x BMR 
are rare (Goldberg et al. 1991). Therefore, people whose energy intakes are below this 
cut-off point are defined as underreporters (Hirvonen et al. 1997). In this study
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under-reporting was more prevalent during the collection of habitual dietary 
information than during either intervention period.
It is thought that because plasma phospholipids originate from the liver, their 
fatty-acid composition may reflect tissue-«-5 PUFA levels, and so they would serve as 
a useful marker of n-3 PUFA intake. Several studies have demonstrated that a positive 
dose-dependent relationship exists between dietary n-3 PUFA intake and the levels of 
EPA+DHA which become incorporated into plasma (Blonk et al. 1990), platelet 
(Schmidt et al. 1990; Li et al. 1991) and erythrocyte (Katan et al. 1991) phopholipids. 
For instance, Li et al. (1991) who gave 3, 6  or 9 g/day EPA for 21 days noted 
dose-related gains of 4.5, 5.6 and 7.6% platelet phospholipid EPA (w/w) respectively. 
Similar linear results were seen by Blonk et al. (1990) who gave 1.5, 3 or 6  g/day 
EPA+DHA for 12 weeks and observed dose-related gains of 6.2, 8.26 and 9.78 mole 
% of plasma phospholipid EPA+DHA respectively. EPA appears to be a better marker 
for dietary intake than DHA (Harris, 1989).
In this study there was no significant correlation between recorded EPA+DHA intakes 
and plasma-phospholipid EPA+DHA levels. The studies which have shown a positive 
relationship between n-3 PUFA intake and phospholipid-n-5 PUFA levels used 
fish-oil supplements rather than foods as their source of n-3 PUFA. Also, knowing 
how many fish-oil capsules have been consumed enables a fairly accurate estimation 
of n-3 PUFA intake to be made. In this study, estimation of n-3 PUFA intake was 
reliant on the subjects weighed dietary records, the disadvantages of which have 
already been discussed. Further discreditation to this self-recorded method of 
estimating fatty-acid intake is provided by 1 subject who consumed the lowest 
quantity of EPA+DHA (0.6 g/day) according to the dietary records, yet had the highest 
plasma-phospholipid enrichment of EPA+DHA in the group. In contrast, 1 study 
which used a food-frequency questionnaire to estimate dietary n-3 PUFA intake did 
find significant correlations between recorded intakes of these fatty acids and 
phospholipid levels (Frost Andersen et al. 1996).
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Despite the lack of correlation between recorded n-3 PUFA intake and plasma- 
phospholipid levels, the plasma-phospholipid enrichment data indicated that the 
n-3 PUFA-enriched foods were being consumed. The mean daily intake of 1.36 g 
EPA+DHA found in the present study resulted in a significant increase (5.2 relative % 
above baseline) in EPA+DHA incorporation into the plasma phopholipids. This 
increase compares well with the results of von Schacky et al. (1985), where a daily 
intake of approximately 2 g EPA+DHA, in the form of cod-liver oil, increased the 
EPA+DHA incorporation into the plasma phospholipids by the order of 5%. These 
data suggest that the n-3 PUFA plasma-phospholipid incorporation from enriched 
foods was comparable to that achieved with supplements.
The plasma-phospholipid EPA and DHA levels were highest at day 22 and may have 
continued to increase if the period of n-3 PUFA intervention had been longer. Harris 
et al. (1991) reported that peak levels of fish-oil incorporation into platelet 
phospholipids were achieved after 1 months’ supplementation, with various doses of 
fish oil, and that no further increase occurred during the subsequent 5 months’ 
supplementation. Agren et al. (1990), who used a range (0.25-1.1 g/day) of n-3 PUFA 
doses, noted that platelets achieved maximal EPA incorporation by 5 weeks but that 
DHA levels continued to increase until week 12 of the trial at each dosage level. In 
this study it was observed that n-3 PUFA plasma-phospholipid levels were not 
significantly different at the beginning of both intervention periods, confirming that 
the 5-month washout period was sufficient time for the incorporated EPA+DHA to be 
replaced with fatty acids from the subjects’ habitual diet. This is supported by Blonk et 
al. (1990), who found that the fatty-acid composition of plasma phospholipids 
returned to baseline levels 12 weeks following withdrawal of the n-3 PUFA 
supplements, regardless of the dose of n-3 PUFA given. Agren et al. (1990) also 
recommended that at least 1 2  weeks was required for the platelet fatty-acid 
composition to re-establish its status quo following n-3 PUFA supplementation. It is 
therefore recommended that future dietary studies measure membrane fatty acid levels 
together with plasma phospholipid fatty acid levels in order to be confident that wash­
out periods are long enough.
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The moderate intake of EPA+DHA in this study did not have the expected 
hypotriacylglycerolaemic effects, observed by other studies using low doses of 
n-3 PUFA (1.18 g EPA+DHA/day [Schmidt et a l  1990], 0.49 g EPA+DHA/day 
[Harris et a l  1991], 0.80 g EPA+DHA/day [Roche & Gibney, 1996]) in the form of 
supplements. However, there appears to be a critical quantity, as other studies using 
low doses of n-3 PUFA (0.60 g EPA+DHA/day [Davidson et a l  1988], 0.65 g n-3 
PUFA/day [Lervang et a l  1993]) for an 8 -week period showed no such effect.
The quantity of EPA and DHA consumed is known to be important in determining the 
physiological effects of these fatty acids, as a dose-dependent 
hypotriacylglycerolaemic effect has been repeatedly demonstrated in normal and HTG 
individuals (Sanders & Roshanai, 1983; Blonk et a l  1990; Schmidt et a l  1990; Harris 
et a l  1991). Using the pooled data from these papers (Sanders & Roshanai, 1983; 
Blonk et a l  1990; Schmidt et a l  1990) the reduction in fasting plasma TAG 
concentration can be predicted by the equation Y = -7.67 - 3.05X, where Y is the 
percentage change in fasting plasma TAG concentration and X is the total n-3 PUFA 
intake (Roche & Gibney, 1996). Using this equation and assuming a minimum n-3 
PUFA intake of 1.36 g (i.e. EPA+DHA only) a 14.6% reduction in plasma TAG 
would have been expected in this study. However, compared with baseline values, 
only an 8 % reduction in plasma TAG was observed and compared with the control 
dietary period only a 3% lowering of plasma TAG was seen.
Other studies using similar doses of n-3 PUFA observed greater percentage reductions 
of plasma TAG following n-3 PUFA supplementation (see Table 4.17). Considering 
the level of n-3 PUFA phospholipid incorporation achieved in this study, the expected 
reduction in fasting and postprandial TAG should have been achieved.
The duration of the n-3 PUFA supplementation period is an important consideration 
when investigating the efficacy of n-3 PUFA intervention. Saynor & Gillot, (1992) 
demonstrated that dietary supplementation of 3 g/day of n-3 PUFA for 4 years resulted 
in a time-related reduction in plasma TAG concentrations, and similar findings were 
reported by Schmidt et a l  (1992) who used 4 g n-3 PUFA for 9 months.
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Table 4-17 n-3 PUFA supplementation studies. Dosage of EPA+DHA, duration of
study and percentage change in fasting plasma-TAG levels
Investigator EPA+DHA dose 
g/day
Duration of Study 
(weeks)
% change in 
plasma TAG from 
baseline
Blonk et al. (1990) 1.5 1 2 - 13.9
Brown & Roberts, 
(1991)
1.7
(total n-3 PUFA)
6 -24.8
Roche & Gibney, 
(1996)
0 . 8 16 - 2 1 . 2
Agren et al. (1996) 1.05 14 - 14.7
More recently, a study using a smaller dose of n-3 PUFA (1.05 g/day EPA+DHA) for 
14 weeks also observed a time-related reduction in plasma TAG (Agren et al. 1996). 
Based on this evidence it is possible that had the duration of our study been longer the 
non-significant hypotriacylglycerolaemic effects observed after only 3 weeks may 
have become significant. In support of this, Agren et al. (1996) only observed 
significant plasma TAG reductions following 9 weeks of n-3 PUFA supplementation. 
After 4 weeks supplementation plasma TAG was reduced by 7%, which is similar to 
the 8 % reduction in plasma TAG observed in our study.
Another important consideration is that the form in which the n-3 PUFA is ingested, 
may affect it absorption. A previous study which investigated the effect of a low dose 
of n-3 PUFA (0.72 g/day EPA + 0.36 g/day DHA) incorporated into either a high-fat 
or low-fat spread for a 12-week period, also reported no effect on fasting plasma TAG 
levels (Roche, 1995). However, in that study those individuals consuming the high-fat, 
fish oil-enriched spread had a higher incorporation of n-3 PUFA into the platelet 
phospholipids compared with those subjects ingesting the same quantity of fish oil in a 
low-fat spread. The author suggested that the quantity of other fatty acids in the 
spreads, namely linoleic acid, may have influenced the level of n-3 PUFA 
incorporation into the platelet phospholipids. This data is interesting in relation to the 
food products used in this study, since it may be that fish oil is more readily absorbed
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and incorporated into the platelet phospholipids if it is ingested with a high-fat food. 
Half of the manufactured, enriched foods provided in this study contained less than 5 g 
fat per lOOg and only 3 foods provided more than 40 g fat per 100 g (spread, 
mayonnaise and vinaigrette). It is therefore possible that the lack of biochemical effect 
seen in this study, with a moderately low fish-oil intake (1.36 g/day EPA+DHA), is 
due to the form in which the fish oil was ingested. Further studies on bioavailability, 
and metabolic responses to diets in which n-3 PUFA are produced in different types of 
food, are needed.
In conclusion, the lack of any significant hypotriacylglycerolaemic effects in this study 
may be explained by a combination of the relatively low intake of n-3 PUFA, the short 
duration of the study, the form of n-3 PUFA and the significant weight gain during the 
n-3 PUFA-enriched intervention period.
Despite the lack of a significant effect of the n-3 PUFA intake on TAG measurements, 
effects on fasting and postprandial lipid levels were observed. Fasting total-cholesterol 
levels were significantly reduced following both intervention periods compared with 
their respective baseline values, and compared to the control diet the fasting HDL-C 
concentrations were significantly higher after the n-3 PUFA-enriched diet.
The reduction in total cholesterol after both intervention periods in the present study 
was unexpected as the total energy intake and fat content of the diets were higher than 
the habitual diet; this would be expected to have an adverse effect on total cholesterol 
levels. There are no obvious reasons for these findings; possible explanations include 
under-reporting of habitual dietary intake and alteration of types of food consumed 
during the intervention periods.
The effect of n-3 PUFA on LDL-C are diverse, and depend on the type of fat in the 
diet and whether a lipoprotein disorder is present or not. In reviewing the literature, 
Harris (1989) concluded that in normolipidaemic individuals, when saturated fat was 
kept constant, there was no significant change in LDL-C levels. The LDL-C results in 
the present study are in agreement with the findings of Harris (1989). It has been
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reported that with the majority of placebo-controlled trials, n-3 PUFA supplementation 
increases HDL-C levels by 5-10% (Harris, 1989). hi the present study, the HDL-C 
concentration was 19.5% higher after the n-3 PUFA-enriched diet compared with the 
control diet. The mechanism whereby n-3 PUFA increase HDL levels has not yet been 
elucidated. However, it is believed to be related to the down regulation of the enzymes 
CETP and LCAT (Abbey et al. 1990). Although not determined in this study, other 
studies have demonstrated that the increase in HDL-C is reflected by an increase in the 
HDL2 fraction and a decrease in the HDL3 fraction (Mori et al. 1994; Agren et al. 
1996; Harris et al. 1997). Although not significant, there was a positive correlation 
between HDL-C and postheparin LPL activity, which has been shown by a number of 
other investigators (Patsch et al. 1983; Skottova et al. 1992). These findings could 
suggest that HDL2 are being efficiently regenerated, rather than becoming enriched 
with TAG and hydrolysed to HDL3 .
The significantly lower postprandial NEFA levels at 60 minutes following the 
n-3 PUFA-enriched intervention period, illustrated another potential beneficial effect 
of a low dose , of EPA+DHA. Studies performed by Frayn and co-workers have 
illustrated that high-circulating fasting and postprandial NEFA levels have been linked 
to a number of chronic disease conditions, particularly those associated with insulin 
resistance (Frayn et al. 1996; Frayn et al. 1997).
Following a meal, plasma NEFA concentrations are suppressed by insulin. This is 
appropriate because during the postprandial period the body does not need to mobilise 
its fuel stores. Suppression of plasma NEFA concentrations allows unimpeded glucose 
utilisation by peripheral tissues, removes an important stimulus for hepatic glucose 
production and removes the major stimulus for VLDL-TAG secretion. It is clear 
therefore that any adverse effects of elevated NEFA concentrations will be most 
apparent in the postprandial period (Frayn et al. 1997). Elevated NEFA concentrations 
in the postprandial period lead to an inappropriate maintenance of glucose production 
and impairment of glucose utilisation. Increased delivery of NEFA to the liver may 
reduce insulin binding to hepatocytes, inhibiting hepatic-insulin clearance and leading 
to higher peripheral insulin concentrations. In the long term this may down regulate
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insulin receptors, thus promoting insulin resistance (Frayn et al. 1996). Even amongst 
apparently healthy subjects those showing the least effective suppression of NEFA 
concentrations following a meal also show the greatest prevalence of features of 
insulin resistance (Frayn et al. 1997).
It is possible that the lower levels of NEFA early in the postprandial profile reflect a 
greater insulin-induced suppression of lipolysis during the n-3 PUFA enrichment. The 
resistance of peripheral tissues to the action of insulin has been attributed to the degree 
of saturation of fatty acids in the phospholipids of muscle membranes (Storlein et al. 
1991). In rats fed high-fat diets, insulin sensitivity is impaired and reversed by 
n-3 PUFA feeding (Storlein et al. 1991). hi humans, the lower the proportion of n-3 
PUFA found in skeletal muscle-membrane phospholipids, the greater the insulin 
resistance observed (Borkman et al. 1993). The levels of insulin were unchanged after 
the n-3 PUFA diet in this study, but, this observation may reflect an increase in insulin 
sensitivity due to the postulated incorporation of EPA and DHA into membrane 
phospholipids resulting in reduced NEFA release.
Bordin et al. (1998) found a significant decrease in fasting NEFA concentrations 
following fish-oil supplementation (3 g EPA+DHA/day). They speculated that this 
could be a factor in the plasma TAG decrease, limiting substrate supply for 
VLDL-TAG synthesis. Despite finding no significant changes in basal insulin or 
glucose concentrations they suggested that their results could reflect increased insulin 
sensitivity induced by fish oil.
A significant increase in fasting glucose was observed after the n-3 PUFA-enriched 
diet, although no significant difference was observed in fasting-insulin, postprandial- 
glucose or insulin levels after either of the intervention periods. However, the 
insuliniglucose ratios, a measure of insulin resistance, were signifcantly higher 
following the n-3 PUFA-enriched diet compared to the control diet. This would 
suggest that the subjects were more insulin resistant on the n-3 PUFA diet, which 
could account for the increased plasma glucose concentrations observed. The impact 
of n-3 PUFA intake on glucose metabolism remains controversial. In non-diabetic
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individuals long-term studies showed no deterioration in glycaemic control when 
n-3 PUFA was given daily, and even suggested that n-3 PUFA may protect against the 
development of impaired glucose tolerance and diabetes (Eritsland et al. 1995; 
Feskens et al. 1995; Toft et al. 1995). In studies using n-3 PUFA with NIDDM some 
were associated with a deterioration in glucose homeostasis (Friday et al. 1989; 
Vessby & Boberg, 1990; Borkman et al. 1989), whilst others revealed no impact 
(Popp-Snijders et al. 1987; Hendra et al. 1990). A review of the literature by Heine 
(1993) suggested that many of the studies which found worsening glucose control with 
n-3 PUFA supplementation were not well controlled, were too short-term or that 
energy control was distorted by the administration of energy-dense fish oil without a 
suitable placebo. More recent long-term, double-blind, placebo-controlled studies 
(Connor et al. 1993; Morgan et al. 1995; Puhakainen et al. 1995) using 6 , 5-10, and 
3.8 g/day n-3 PUFA for 6  months, 12 weeks and 6  weeks respectively found no 
association between fish-oil intake and poor glycaemic control in NIDDM.
In the present study, the increased energy intake during both intervention periods 
could explain the increase in fasting glucose observed following the n-3 PUFA- 
enriched diet, as the addition of energy is known to disturb glucose control (Prince & 
Deeg, 1997). However, this does not explain why the glucose levels were unchanged 
following the control dietary period. Whether our findings for glucose-tolerant NTG 
men reflect the adverse effects of a low-dose of EPA+DHA on fasting glucose levels 
is unclear, but they appear to be inconsistent with the apparent enhanced sensitivity of 
the antilipolytic response to insulin suggested by the NEFA findings.
Postheparin LPL activities were not significantly different between the 2 diets 
although the 15-minute value tended to be higher on the control diet. The LPL activity 
values reported here are similar to the values reported by other investigators (Harris et 
al. 1988; Weintraub et al. 1988; Nozaki et al. 1991). The effects of n-3 PUFA on LPL 
activity have produced conflicting results, with some investigators reporting increases 
(Zampelas et al. 1994a; Benhizia et al. 1994; Kasim-Karakas et al. 19956) and others 
reporting no significant differences (Harris et al. 1988; Nozaki et al. 1991; Baltzell et 
al. 1991). The reason for these conflicting results may be due to the lack of precision
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and specificity of postheparin LPL measurements, as the administration of heparin 
releases LPL from both skeletal muscle and adipose tissue.
Only a few studies have directly addressed the impact of tissue-specific LPL activity 
on plasma TAG levels. A few animal studies suggest that the activating effects of 
n-3 PUFA are localised to adipose tissue (Murphy et al. 1993; Benhizia et al. 1994), 
which means that these non-specific, postheparin plasma measurements may fail to 
detect single-site responses. In contrast to this, several reports have suggested that LPL 
in skeletal muscle may be more important than adipose-tissue LPL or LPL in 
postheparin plasma in the catabolism of TAG (Herzberg, 1991; Baltzell et al. 1991; 
Zechner, 1997). For instance, Herzberg (1991) reported that the 
hypotriacylglycerolaemic effect following n-3 PUFA supplementation was partly due 
to an increase in fatty-acid oxidation. They went on to say that for this to be true, there 
must be an increase in muscle-LPL activity to allow for the increased delivery of fatty 
acids to the tissue for oxidation. Their experiments, and those of Baltzell et al. (1991), 
found that following fish-oil feeding in rats, skeletal- and cardiac-muscle LPL activity 
increased but the activity in adipose tissue did not. Further support for this hypothesis 
is provided by experiments where the hypotriacylglycerolaemic effects of exercise or 
hypolipidaemic drugs (fibrates) are associated predominantly with an increase in 
skeletal-muscle LPL activity (Seip er al. 1995; Ohrvall et al. 1995). The reason for 
these tissue-specific differences may be due to the type of mRNA present in these 
tissues. Ranganathan et al. (1995) demonstrated that in humans, muscle expresses 
predominantly the 3.6 kb LPL mRNA species, whereas adipose tissue expresses an 
equal quantity of both the 3.2 and 3.6 kb mRNA species. They also found that the
3.6 kb mRNA form was more efficiently translated into LPL protein and that when 
the 3.2 kb and 3.6 kb cDNAs were transfected into Chinese-hamster ovary cells the
3.6 kb construct demonstrated increased LPL activity and synthesis despite no change 
in levels of LPL mRNA. The functional significance of this difference in the 
3’ untranslated region of LPL mRNA remains to be determined but could suggest that 
LPL’s role in maintaining lipid homeostasis is tissue specific. Further investigations 
into the effect of dietary fatty acids on the expression of these 2 LPL mRNA species.
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within specific tissues, are required if additional insights into the role of LPL in lipid 
metabolism are to be gained.
Regardless of which tissue is more sensitive to LPL activation, postheparin 
measurements are unable to distinguish between changes in the contributions of 
enzyme activities from the 2 tissue types (muscle and adipose). An added 
complication of measuring postheparin LPL is that muscle- and adipose-tissue LPL are 
co-ordinately regulated, so that in the fasted state muscle LPL is more active, and in 
the fed state adipose-tissue LPL is more active. This further complicates the 
interpretation of LPL activities, since the contribution of both tissues depends on the 
time relative to meals. In this study, postheparin LPL was collected 8  hours 
postprandially, when most of the lipid and hormone parameters had returned to 
baseline values. Therefore, it could be argued that our measurements would have a 
greater contribution from muscle LPL rather than adipose tissue. To overcome these 
problems it is recommended that in addition to postheparin measurements, tissue LPL 
activity is also measured and that the collection time point is optimised for the tissue 
of interest.
The negative correlation between postheparin LPL activity and TAG-AUC (n = 6 ) fits 
with the findings of several investigators (Weintraub et al. 19876; Campos et al. 1995; 
Harris et al. 1997). This relationship suggests that postheparin LPL activity levels 
reflect recent exposure to the substrate plasma TAG, with the result that high levels of 
activity effectively clear TAG from the plasma. However, this significant negative 
correlation did not persist when all 9 subjects were included in the analysis. In 
reviewing the literature, Olivecrona & Bengtsson-Olivecrona (1993) and Enerback & 
Gimble (1993) found only a weak or non-existent relationship between plasma TAG 
concentration and postheparin LPL activity levels. Furthermore, the inverse 
relationship appeared to be related to the apo E genotype, with carriers of the allele E2 
demonstrating the relationship whilst individuals with the alleles E3 and E4 showed 
no such correlation (St Amand et al. 1996). Without knowing the genotype of the 
subjects it is impossible to say whether this is the reason for this finding but highlights
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\the complexity of the relationship between enzymes, apolipoproteins and plasma-lipid 
levels.
The values for LPL expression, obtained using the competitive RT-PCR method, 
ranged from 0.6 - 8.05 x 10^  molecules of LPL mRNA per ng/total RNA. These are 
comparable with the values calculated from the paper by Laville et al. (1996). In their 
study, LPL gene expression in human muscle ranged from approximately 7.8-23.4 x 
10^  molecules LPL mRNA/ng total RNA in the basal state and decreased to between 
3-19.8 X 10^  molecules LPL mRNA/ng total RNA following insulin infusion. The 
results of Laville et al. (1996) suggest that LPL expression might be higher in muscle 
tissue than adipose tissue. However, the subjects in that study were young men and 
women (aged 24 ±  1 year) and the difference could be a reflection of the subjects’ age 
or level of physical activity.
The nutritional status of the individual at the time of biopsy is an important 
determinant of LPL activity, and gene expression and must be taken into consideration 
when interpreting results. Farese et a/. (1991) demonstrated that LPL activity levels in 
human adipose tissue and muscle were not significantly different in the fasting state, 
whereas on feeding, adipose-tissue LPL activity rose while activity levels in muscle 
fell. Studies looking at changes in LPL gene expression during feeding and fasting are 
less conclusive. Studies in rats have shown that in adipose tissue, LPL mRNA 
decreases during feeding and increases during a short-term fast (Doolittle et al. 1990; 
Bergo et al. 1996). However, studies in humans have shown no alteration to LPL 
mRNA with feeding (Ong & Kern, 1989). Further studies into the effects of more 
physiological changes in feeding and fasting are warranted in humans. Despite these 
findings, it remains important that if multiple measurements of LPL mRNA are to be 
made, standardised collection times must be employed.
In the present study there was no significant difference in LPL gene expression 
between the 2  diets, although there was a trend for the values to be higher following 
the n-3 PUFA-enriched diet. Also, those subjects who responded with the greatest 
reduction in fasting plasma TAG had the highest absolute levels of LPL mRNA. A
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previous study in rats found significant increases in adipose-tissue LPL gene 
expression following fish-oil consumption (approximately 4 g EPA+DHA/day) for 2 
weeks and supports the view that diet can alter LPL through direct effects on LPL 
gene expression (Murphy et al. 1993). However, in view of the lack of effect on 
plasma TAG response observed in this intervention study, changes in LPL expression 
were not expected. The significant negative relationships between the change in TAG 
levels (both fasting and TAG-AUC) and change in LPL gene expression suggest that 
LPL expression may be a strong determinant of fasting and postprandial TAG levels. 
However, further examination of the underlying causes of LPL expression changes in 
human adipose tissue are needed.
The suggestion that gene expression relates to TAG levels but not to postheparin 
plasma LPL activity in the present study, appears to conflict with the proposal that 
LPL is a main determinant of plasma TAG levels. However, a lack of correlation 
between LPL expression in 1 tissue and postheparin plasma LPL activity can be 
explained on the basis that postheparin measurements are not tissue specific, as 
mentioned earlier. The finding that changes in LPL expression are correlated to 
changes in plasma TAG and not changes in postheparin plasma LPL suggest that LPL 
expression is a longer-term regulator of plasma-lipid levels. LPL expression 
measurements over time, therefore may be more indicative of inefficient plasma TAG 
clearance than measurements of postheparin LPL activity.
The mechanisms underlying the dietary-stimulated changes in LPL gene expression 
warrant further investigation but are possibly related to activation of peroxisome 
proliferator-activated receptors (PPARs). Many nutrients are known to act essentially 
in the same way as steroidal hormones, by binding to soluble nuclear receptors, such 
as PPAR, which then bind to promoters of regulated genes and affect their rate of 
transcription (Gustafsson, 1998).
There are 3 distinct PPARs termed a, ô, and y. Activation of PPARa and PPARy in 
animals and humans results in pronounced TAG-lowering effects due to changes in 
apo C-in and LPL levels respectively (Schoonjans et al. 1997). Activation of PPARa
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in the liver leads to a decreased production of apo C-in, an increased uptake of fatty 
acids by the liver for p-oxidation in peroxisomes and mitochondria and inhibition of 
de novo fatty-acid synthesis. Thus, activation of PPARa by fibrates increases plasma 
TAG clearance and decreases endogenous TAG production (Schoonjans et al. 1997). 
Fibrates have also been shown to induce LPL expression in the liver, the physiological 
significance of which remains unclear, but this may involve clearance of TAG-rich 
lipoproteins (Schoonjans et al. 1996). Activation of PPARy in adipose tissue induces 
increased LPL gene expression and leads to increased LPL activity, which ultimately 
increases plasma TAG hydrolysis. Although fibrates have not been shown to activate 
PPARy in adipose tissue, they do result in the endogenous production of 
prostaglandins which can activate PPARy, thereby increasing LPL gene transcription 
in the adipose tissue (Schoonjans et al. 1996). Together, activation of PPARa and 
PPARy by fibrates leads to increased LPL-mediated hydrolysis of plasma TAG and 
reduced VLDL-TAG production.
As fibrates and n-3 PUFA are known to share very similar pharmacological properties 
(Sirtori et al. 1993), it is quite probable that n-3 PUFA activate PPARa and PPARy in 
a similar fashion. This offers a potential mechanism by which n-3 PUFA, indirectly 
through prostaglandin production, may increase adipose-tissue LPL gene expression.
In conclusion, this study presents evidence suggesting that changes in LPL expression 
may be related to long-term changes in plasma TAG levels. By extension, this implies 
that factors which contribute to attenuation in LPL expression may be important 
factors in determining elevated fasting and postprandial TAG levels, now strongly 
implicated as risk factors for CHD. Further development of the method for measuring 
LPL mRNA will enable the examination of many factors affecting LPL expression and 
thus further elucidation of the role of this gene in regulating plasma TAG levels. 
Future work should involve the use of larger doses of n-3 PUFA and/or the 
administration over a longer time course. Analysis of LPL gene expression on a larger 
number of subjects is recommended if true statistical significances are to be observed. 
The additional measurement of LPL activity in specific tissues will help to
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differentiate between the individual contributions of LPL activity from adipose tissue 
and skeletal muscle.
This study not only confirms that it is possible to increase the daily intake of 
EPA+DHA using fatty acid-modified commercially produced foods, but that these 
foods are an acceptable alternative to supplements and oily fish.
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CHAPTER 5
5. EFFECT OF A MUFA-F.NRTCHF.n 
DIET ON LIPOPROTEIN 
METABOLISM IN NORMAL 
SUBJECTS
S.l TNTKOmimON
In the UK, CHD accounts for 30% of all male deaths and is the single biggest cause of 
death in men aged 45-64 (DoH, 1994). Plasma lipids and especially total, LDL and 
HDL cholesterol have all been correlated with the development of CHD. Until 
recently, fasting TAG concentrations were not considered an independent risk factor 
for CHD, but meta-analysis of population-based prospective studies have shown that 
increased fasting plasma TAG levels are associated with an increased risk of CHD in 
men and women, even after adjustment for HDL-C and other risk factors (Hokanson & 
Austin, 1996). In addition, there is increasing evidence that TAG levels in the 
postprandial state are an important discriminator of the risk of CHD. Repeatedly, 
patients with CHD and their off-spring have been shown to have a more pronounced 
and prolonged postprandial lipaemia than ‘healthy’ controls following ingestion of a 
fat-rich meal (Patsch et al. 1992; Karpe et al. 1994; Uiterwaal et al. 1994). Also, a 
recent prospective study demonstrated that non-fasting serum TAG concentrations 
were a significant predictor of future myocardial infarction (Stampfer et al. 1996). 
Whilst TAG itself is not a component part of the atherosclerotic lesion, elevated 
postprandial TAG concentrations exert their effect by promoting neutral lipid 
exchange between TRLs and LDL/HDL, which encourages the formation of highly 
atherogenic small dense LDL and the catabolism of the large cardioprotective HDL2 
fraction.
Numerous epidemiological and clinical studies have established the 
hypercholesterolaemic role of SFA, in addition to its relationship with development of
220
CHD (Kris-Etherton et al. 1988). The current UK diet is high in total fat (38% energy) 
and SFA (16% energy) and the 1994 COMA report recommends that in an attempt to 
reduce the incidence of CHD, the UK diet should be altered. They recommend that the 
average contribution of energy from fat should be reduced from 38% to 35%, with 
10% being derived from SFA and 6 % from PUFA (DoH, 1994). However, despite 
recognising the potential benefits of MUFA, there are currently no recommendations 
for increasing intakes of these fatty acids. This resistance to increase MUFA is partly 
due to the inconsistent data concerning the effects of MUFA-enriched diets on 
circulating cholesterol concentrations. The Seven Countries Study initially stimulated 
interest in the Mediterranean diet because of the low prevalence of CHD mortality, in 
Cretan middle-aged men, despite high intakes of dietary fat. The traditional 
Mediterranean diet is rich in olive oil, which provides high levels of MUFA, namely 
oleic acid, the levels of which have been negatively correlated with CHD mortality 
(Keys et al. 1986). This negative association has primarily been attributed to the 
hypocholesterolaemic effect of dietary MUFA, which when substituted for SFA, 
significantly reduces total- and LDL-cholesterol concentrations (Mattson & Grundy, 
1985; Mensink & Katan, 1989; Berry et al. 1991; Abbey et al. 1994).
In addition to reducing total cholesterol, and unlike PUFA, which is associated with a 
fall in HDL-C, most studies show that HDL-C is maintained or increased after SFA 
are substituted with MUFA (Becker et al. 1983; Mattson & Grundy, 1985; Mensink & 
Katan, 1989; Berry et al. 1991; Temme et al. 1996). Although reductions in HDL-C 
have been observed, these have not always been significant and are often associated 
with a reduction in total fat and increase in carbohydrate (Sirtori et al. 1986; Nydhal 
et al. 1994; Choudhury et al. 1995; Howard et al. 1995).
Olive oil contains approximately 75% oleic acid together with a small percentage of 
SFA (palmitic and stearic 14%) and essential PUFA (linoleic (LA) and a-linolenic 
(a-LLA) 11%). It also contains tocopherols, p-carotene, squalene and phytosterols. 
Plant sterols are thought to compete with cholesterol for intestinal absorption and in 
high doses have been used to treat hypercholesterolaemia (Truswell & Choudhury, 
1998). Squalene, however, is a precursor of cholesterol, and long-term feeding with
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large doses (1 g/day) have been shown to raise plasma total and LDL cholesterol 
(Miettinen & Vanhanen, 1994). Although olive oil is the principal dietary source of 
MUFA, other sources, which are available include: canola oil (zero-erucic acid 
rapeseed oil) and oleic acid-enriched variants of sunflower or safflower oil. To 
describe these oils as being predominantly MUFA omits details of their fatty-acid 
patterns, which may influence plasma cholesterol levels. For instance, canola oil has 
approximately 60% oleic acid, but it has less SFA (4%), less squalene, more n-6, 
n-3 PUFA (LA 22%, a-LLA 11%) and more phytosterols than olive oil. Recent 
studies have compared the effects of these oleic acid-enriched oils and olive oil on 
lipoprotein concentrations. Lichtenstein and co-workers (1993) compared the effects 
of olive oil and canola oil and found significantly lower total and LDL cholesterol 
concentrations with the canola oil. Perez-Jimenez et al. (1995) compared the effects of 
an oleic acid-enriched sunflower oil and olive-oil diet with a low-fat diet. They 
reported reductions in total and LDL cholesterol following the oleic acid-enriched diet, 
but increases following the olive-oil diet. The authors attributed these responses to the 
differences in plant-sterol composition and non-fatty acid constituents in the oleic 
acid-enriched oil.
The West of Scotland Coronary Prevention Study brought to an end the long-running 
debate about the value of lipid reduction by proving beyond reasonable doubt that 
reducing plasma cholesterol and TAG levels decreases the risk of CHD even when 
there is no evidence of CHD (Shepherd et al. 1995). However, despite this conclusive 
evidence it is neither ethical or cost effective to routinely treat the population with 
drugs in order to reduce the incidence of CHD. Diet, on the the other hand, represents 
a feasible alternative through which modest reductions in plasma cholesterol 
concentrations and disease risk can be achieved. Assessment of dietary intakes reveals 
that although there has been a decline in the amount of fat consumed in the last 
20 years, the percentage of energy from fat has remained constant. Since 1980 the 
proportion of energy from SFA has only fallen from 19% to 16%, and yet the 
availability of low-fat products has increased tremendously (MAFF, 1992, Gregory 
et al. 1990). Evidence from clinical trials has demonstrated that compliance to low-fat 
diets is poor, and have been unsuccessful in achieving significant reductions in
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total-cholesterol levels (Lindholm et al. 1995; Neil et al. 1995). These data suggest 
that the general population is reluctant to follow the low-fat, high-carbohydrate diets 
recommended in numerous reports on diet and health published since the 1980s 
(DHSS, 1984, DoH, 1991). Several researchers have also demonstrated that it is the 
quality rather than the quantity of fat that is important in determining plasma-lipid 
levels (Kris-Etherton et al. 1988). For instance, in 2 populations where the percentage 
of energy from fat was different (25% versus 40%) but the percentage of fat from SFA 
was identical, the cholesterol responses were very similar (Blackburn, 1979). Another 
disadvantage of low-fat, high-carbohydrate diets is their associated increase in plasma 
TAG and decrease in HDL-C, a lipoprotein profile which is not anti-atherogenic 
(Grundy, 1989). Replacing SFA with PUFA has been repeatedly shown to reduce 
cholesterol concentrations, but evidence now demonstrates that when LA is 
incorporated into lipoproteins, especially LDL, they are more susceptible to oxidation 
and may initiate the pathogenesis of atherosclerosis (Reaven et al. 1994; Nenseter & 
Drevon, 1996). For this reason increased intakes of PUFA may not be recommended.
In the light of the potentially hazardous effects of PUFA, consumer resistance and the 
waning enthusiasm for low-fat, high-carbohydrate diets, a diet supplemented with 
MUFA may represent a safe and effective alternative to achieving the government 
targets for reducing SFA and CHD risk levels.
Aims
The primary aim of this study is to assess the feasibility of replacing dietary SFA with 
MUFA using commercially available foods which have been prepared with olive oil, 
in a group of young and middle-aged men. The levels of dietary MUFA intake will 
reflect those currently consumed in Crete and other Mediterranean countries (18-23%  
energy), whilst total fat and the palmitic to stearic acid ratio will remain constant. The 
effects of this diet will be compared with a control diet, whose fatty-acid profile will 
reflect that of the current UK diet.
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Secondly, this study aims to determine whether the 8 -week MUFA dietary 
intervention has beneficial effects on fasting and postprandial lipoprotein and 
hormonal metabolism. In addition, the mechanisms by which dietary MUFA may 
influence postprandial metabolism will be explored and include the measurements of 
plasma and adipose-tissue LPL activity and adipose-tissue LPL gene expression.
Finally, it is hoped that the data obtained from this study will be used in deciding 
whether or not increases in dietary MUFA should be recommended for the UK 
population as a means of reducing risk of CHD.
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5.2 METHODS
5.2.1 SUBJECT RECRUITMENT
Two specific groups of subjects were recruited for this study: 1) healthy middle-aged 
men between 40-60 years, and 2) young men between 18-45 years, who had a first 
degree relative with CHD (defined as either myocardial infarction, angioplasty or 
coronary artery by-pass surgery). Potential volunteers were identified from the local 
population by accessing the computer databases of four GP surgeries in the Guildford 
area. This enabled the screening of clients on the basis of age, sex, medical history, 
smoking habits and family history of CHD. Contact letters were sent out to suitable 
individuals, explaining the nature of the study and inviting them to respond if they 
were interested in taking part. Those who responded were asked to complete a diet and 
lifestyle questionnaire (Appendix I), which was used to assess general eating habits 
and exercise levels. Individuals were excluded if they:
• were smokers
• had any endocrine, cardiovascular or liver disease
• were taking any drug treatment that would affect their plasma-lipid levels
• were vegetarian, following any therapeutic diet or taking any dietary 
supplements
• were travelling often or going on holiday during the intervention period
• were partaking in regular vigorous exercise (> 3 x 30 minutes aerobic 
exercise per week) or participating in team sports for one arm of the study 
only
• were heavy drinkers, > 30 units per week
• were not normally consuming 3 meals/day plus snacks for an average of 5 
out of 7 days
• were having business lunches or socialising more than once per week
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Potential volunteers then provided a fasting blood sample to screen lipid profiles, and 
completed a 4 day unstructured food diary, for analysis of habitual energy and fat 
intake.
Subjects were accepted on to the study if they satisfied the following criteria:
• Fasting total cholesterol < 6.5 mmol/1
• Fasting TAG < 2.5 mmol/1
• Fasting glucose < 6.2 mmol/1
• Haemoglobin >13.2 g/dl
• gamma GT < 1 6 0 1.U/1
• BMI between 20 - 30 kg/m^
• Average total dietary fat intake >35% energy
The initial screening data for 30 middle-aged men (MAM) and 14 young men (YM) 
are shown in Table 5.1.
The study was approved by the ethics committees of the University of Surrey and the 
Royal Surrey County Hospital and all subjects gave their written, informed consent to 
participate.
Table 5-1 Screening anthropometric, fasting lipid, glucose and haemoglobin results 
of subjects recruited. Values are presented as mean (SD)for the indicated number of
analyses
Age
(years)
BMI
(kg/m^)
WHR Choi
(mmol/1)
HDL-C
(mmol/1)
TAG
(mmol/1)
Glue
(mmol/1)
Hb
(g/dl)
MAM
n=30
49.3
(5.4)
26.2
(2 .6 )
0.90
(0.05)
5.60
( 1 .0 2 )
1.06
(0 .2 2 )
1.31
(0.63)
5.52
(0.52)
15.1
(0.74)
YM
n—14
32.6
(5.1)
24.4
(2 .8 )
0 . 8 6
(0.04)
5.56
(1 .1 2 )
1.06
(0.25)
1.30
(0.40)
5.48
(0.72)
15.6
(1.13)
Abbreviations: MAM, middle-aged men; YM, young men; WHR, waist to hip ratio; Choi, cholesterol; 
Glue, glucose; Hb, haemoglobin.
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5.2.2 CHRONIC INTERVENTION STUDY DESIGN
The chronic intervention study was a randomised, single blind cross-over trial in 
which subjects were randomly allocated to receive a MUFA-enriched or control diet 
for 8  weeks, with a 4 -6  week wash-out period, followed by the alternative diet for a 
further 8  weeks. Anthropometric and fasting biochemical measurements were 
collected at baseline 2, 4 and 8  weeks of the intervention period. At the end of each 
dietary arm of the study the postprandial response to a standard test meal was 
measured.
5.2.2.7 The diet
The aim of the control diet was to achieve a fatty-acid intake equivalent to that eaten 
by the UK population (Gregory et al. 1990) (38% energy as fat, 16% SFA, 12% 
MUFA, 6 % PUFA). The aim of the MUFA diet was to achieve a fatty-acid profile 
similar to that of a Mediterranean diet (38-40% energy as fat, 10% SFA, 22% MUFA, 
8 % PUFA), by replacing part of the daily SFA intake with MUFA (cw-oleic acid). The 
intake of PUFA, the n-6 to n-3 PUFA ratio and the ratio of C 16:0 to C l8:0 was kept 
constant between the 2  diets.
The intervention foods were produced in collaboration with food manufacturers and 
retailers. Cretan olive oil was supplied by Elais (Unilever, Greece) and transferred to 
Van den Bergh Foods (Crawley, UK) for blending to produce a test (MUFA) cooking 
fat and margarine. A control (SFA) cooking fat and margarine were also produced. 
The nutrient and fatty-acid composition of the MUFA-enriched and control cooking 
fats and margarines are shown in Tables 5.2 and 5.3. These cooking fats and 
margarines were sent to J. Sainsburys pic. (UK), to replace the extrinsic fat in a 
number of frozen ready meals (e.g. lasagne, seafood tagliatelle, vegetable curry sauce, 
garlic bread), and to Diet and Health Biscuits Ltd. (UK) to make 4 varieties of biscuits. 
The nutrient composition of the modified ready meals and biscuits are shown in Table 
5.4.
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Table 5-2 Nutrient composition o f the Control and MUFA-enriched cooking fa t and
margarine
Control 
cooking fat
Control
margarine
MUFA 
cooking fat
MUFA
margarine
Energy (MJ/lOO g) 0.89 0.72 0.90 0.73
Carbohydrate (g/100 g) - 4.20 - 4.20
Protein (g/100 g) - 0.25 - 0.27
Fat (g/100 g) 99.20 77.60 1 0 0 . 0 0 78.80
SPA (g/100 g) 43.96 34.18 18.33 14.51
cis-MUFA (g/100 g) 35.41 27.00 59.95 47.18
c/5-PUFA (g/100 g) 19.82 15.68 21.73 17.10
Trans-fatty acids (g/100 g) 0.82 0 . 0 0 0 . 0 0 0 . 0 0
Salt (g/100 g) 0 . 0 0 2 . 1 0 0 . 0 0 1.79
Table 5-3 Fatty-acid composition of the Control and MUFA-enriched cooking fa t and
margarine
Fatty acids Control Control MUFA MUFA
(g/ 1 0 0  g) cooking fat margarine cooking fat margarine
C12:0 0.27 0.19 0 . 0 2 0 . 0 0
C14:0 0.81 0.69 0 . 1 1 0.06
C14:l 0.05 0.08 0 . 0 0 0 . 0 0
C16:0 28.48 2 2 . 1 0 1 1 . 8 6 9.53
C16:l 0.19 0.16 0.60 0.48
C17:0 0 . 1 0 0.09 0.09 0.06
C18:0 13.44 10.30 5.64 4.32
C18:l 33.64 25.80 58.72 45.90
C18:2 19.03 15.10 2 0 . 6 8 16.30
C18:3 0.79 0.62 1.04 0.83
C20:0 0.51 0.38 0.41 0.30
C20:l 0.24 0 . 2 1 0.38 0.28
C22:0 0.24 0.30 0.14 0.08
C22:l 0.03 0.05 0.08 0.19
C24:0 0 . 1 1 0 . 1 2 0.06 0 . 0 0
C24:l 0.04 0 . 0 0 0.16 0.30
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The cooking fats and margarines were also used domestically by the volunteers. In 
addition, low-fat meals, supplied by Heinz and J.Sainsburys, were also provided. 
These meals were designed to be accompanied by foods (e.g. potatoes, bread rolls) to 
which the test oils and margarines could be added.
In order to achieve the target daily fatty-acid intakes, all study foods were designed to 
contain multiples of 5 g of MUFA or SPA. Each 5 g MUFA/SFA was referred to as a 
‘lipid unit’, and the number of lipid units provided by the different study foods ranged 
from 1-4. All study foods were clearly labelled with the number of lipid units they 
contained. The establishment of this lipid-unit system ensured that both investigators 
and volunteers were able to control their intake of the correct quantity of study foods.
Prior to commencing the study, all volunteers recorded their habitual dietary intake 
using a 4-day unstructured diet diary. The information from these diaries was used to 
calculate the number of lipid units required to meet the subjects daily requirement of 
MUFA or SFA, and also to identify how the intervention foods could be incorporated 
into the subjects habitual diet without affecting usual dietary energy and fat 
consumption. The volunteers were instructed to achieve their daily lipid-unit target by 
replacing their usual cooking and spreading fats, evening meal and snacks with 
MUFA-enriched or control cooking and spreading fats, recipe meals and snacks. To 
aid compliance, subjects were only required to consume their lipid-unit target for 5 
days of the week, and the other 2 days were ‘free days’. To reach the target fatty-acid 
intake, subjects ate between 6-11 lipid units (equivalent to 30-55 g MUFA/SFA) per 
diet day by choosing the foods they preferred.
Prior to commencing the study, all the volunteers attended an open evening at the 
University, where they watched a study information video and received individual 
dietary advice from registered dietitians. In addition, a copy of the video and a 
handbook, explaining all aspects of the dietary intervention, were supplied for home 
use.
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Regular face-to-face or telephone contact was maintained between the the dietitians 
and the volunteers throughout both arms of the study. The volunteers ordered their 
choice of study foods every 14 days, and these were either collected from the 
University or delivered to the subject’s home.
The subjects were weighed at 0, 2, 4 and 8  weeks of the intervention period by the 
investigators and all subjects weighed themselves daily for the first fortnight of each 
dietary phase, and then once per week thereafter. The number of lipid units was 
adjusted if the subjects gained or lost more than 2  kg over a 2 -week period.
Nutritional assessment was achieved using a 5-day unstructured diet diary during 
weeks 3 and 7 of each arm of the study. Each 5-day diary consisted of 4 diet days and 
1 free day. Household measures, standard food portions and the known weights of the 
intervention food products were used to quantify portion sizes.
All foods prepared for the study were independently analysed for their nutrient and 
fatty-acid composition (Reading Scientific services Ltd., Reading, UK), and this 
information was added to the Foodbase database (Institute of Brain Chemistry, 
London, UK). Following this, the diet diaries were analysed for their nutrient 
composition.
Dietary compliance was assessed using a questionnaire incorporating a linear analogue 
scale filled in during weeks 4 and 8  of each arm of the study. Plasma-phospholipid and 
peripheral-blood mononuclear cell fatty-acid analysis at 0, 2, 4, and 8  weeks of each 
intervention period was also used to assess compliance. Dietary under-reporting was 
assessed by comparing recorded energy intakes (2 x 5-day diet diaries) with calculated 
energy intakes (1.35 x BMR) as described by Goldberg et al. (1991). BMR was 
calculated using the equations given by the DoH (1991). Individuals reporting energy 
intakes below 1.35 x BMR were classified as under-reporters.
Fasting blood samples were collected, following a 12-hour overnight fast, at baseline, 
2, 4 and 8  weeks of each dietary intervention period. Plasma was collected by
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centrifugation at 1700 x g and stored at -20°C. Analytical methods for the 
measurement of total cholesterol, TAG, NEFA, HDL-C, glucose and insulin are 
described in sections 2.2.3 and 2.2.4.
5.2.2.2 Postprandial investisations
At the end of each 8 -week dietary-intervention period the subjects attended a 
postprandial study day at the Royal Surrey County Hospital. The subjects came in to 
the clinical investigation unit, following a 1 2 -hour overnight fast, having abstained 
from alcohol and refrained from strenuous exercise in the 24 hours before the 
postprandial investigation. A cannula was inserted into the antecubital vein of the 
forearm, and 2 fasting blood samples were taken. To ensure the cannula remained 
patent throughout the 9-hour study period, the cannula was flushed with sodium citrate 
between blood samples.
A standard test meal was then consumed within 20 minutes. The test meal consisted 
of 135 g white bread, 36 g strawberry jam and a milk shake composed of 40 g olive 
oil, 40 g dried skimmed milk powder (Tesco, Cheshunt, UK.) and 40 g Nesquick 
strawberry flavoured milk shake powder (Nestle, Vevey, Switzerland), mixed with 
200 ml water (Evian, France). This provided 4.18 MJ, 55% energy from carbohydrate, 
8 % from protein and 35% from fat (5.4% SFA, 24.1% MUFA and 4.6% PUFA). 
Following consumption of the meal the subjects were allowed 200 ml of caffeine-free, 
low-calorie (< 1 kcal/ml) drinks every 2 hours. All other food (including chewing 
gum) and drinks were prohibited until the end of the study period.
Postprandial blood samples were drawn every 30 minutes for the first 2 hours after 
starting to eat the test meal, and thereafter hourly, for a total of 9 hours. Nine hours 
following the test meal, a single bolus dose of heparin (7500 lU) was given 
intravenously at a distant site to the indwelling cannula. Blood samples were drawn 5 
and 15 minutes following the heparin injection for the measurement of LPL activity.
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5 2 2 .3  Adivose-tissue hiospv
On week 9 of each dietary-intervention period a small cohort of volunteers attended 
the Royal Surrey County Hospital for an abdominal adipose-tissue biopsy. Subjects 
abstained from alcohol and refrained from strenuous exercise 24 hours prior to the 
biopsy. On the morning of the biopsy subjects consumed a standard breakfast, 
consisting of 82 g croissants, 20 g butter, 40 g strawberry jam and 250 ml orange juice. 
This provided 3.09 MJ, 45% energy from carbohydrate, 5% from protein and 50% 
from fat. Four hours after consuming this breakfast an adipose-tissue biopsy was taken 
from the paraumbilical region as detailed in section 2.2.5.
Half of the adipose-tissue samples taken were used for the analysis of LPL gene 
expression and the other half were used for the analysis of adipose-tissue LPL activity.
5.2.3 ANALYTICAL METHODS
All blood samples were collected into lithium heparin tubes, except those for the 
analysis of glucose, which were collected into fluoride oxalate tubes. Plasma was 
separated by centrifugation at 1700 x g in a bench-top centrifuge, aliquotted into 
LP3 tubes for different analyses and stored at -20°C (samples for lipase analysis were 
stored at -80°C).
Total RNA was extracted from the adipose-tissue biopsies as detailed in section 2.2.5, 
and analysed for LPL mRNA by competitive RT-PCR as described in section 3.4.4. 
Adipose-tissue explants were prepared as described in section 2.2.6. Postheparin 
plasma LPL activity and heparin releasable, adipose-tissue LPL activity were 
measured using the radioactive triolein technique detailed in section 2.2.7.
The following analytical procedures were carried out by coworkers :-
TRL and TPL fractions were prepared from plasma stored overnight at 4°C following 
the procedure of Grundy & Mok (1976) as described in section 2.2.2b. TAG, NEFA, 
glucose, total and HDL cholesterol were measured spectrophotometrically, using
233
automated enzymatic assays on the COBAS Mira Plus analyser, as described in 
section 2.2.3. Total- and HDL-cholesterol, NEFA and glucose were measured in 
plasma. TAG concentrations were measured in plasma and both the TRL and TPL 
fractions. LDL-C concentrations were determined using Friedwald’s formula 
(Friedwald et al. 1972) (see section 2.2.3.3 ). Plasma insulin was measured as 
described in section 2.2.4. The insulinrglucose ratio was calculated using the 
homeostasismodel assessment (HOMA) equation (Matthews et al. 1985) as shown 
below:
Fasting insulin (mU /1) x  Fasting glucose (mmol /1) 
Insulin resistance = ------------------- ------
22.5
(where 1 mU/1 is equivalent to 7.5 pmol/1)
The fatty-acid composition of plasma total phospholipids and of peripheral-blood 
mononuclear cells (PBMNC) were analysed according to the method described by 
Yaqoob et al. (1995).
5.2.4 STATISTICAL ANALYSES
Mean, SD and SEM were calculated for each measurement. Statistical analysis was 
carried out using the statistical packages Instat (Macintosh version 2.01 Graph Pad 
Software, San Diego, USA) and Data desk 4.1 (Data description Inc, USA). Paired and 
unpaired student’s t-tests and one-way analysis of variance or repeated measures 
analysis of variance were applied to the responses of the subjects to the 2  dietary 
periods, followed by Tukey-Kraemer post-hoc tests, where appropriate. Data was 
transformed before analysis, if necessary, to give a normal Gaussian distribution. 
AUCs (total and incremental) were calculated using the trapezoidal rule on Excel 
spreadsheets. Repeated measures analysis of variance using subject and dietary period 
(control or MUFA-enriched) as the independent variables, was employed to 
investigate differences in the postprandial responses for the analytes measured. 
Correlation coefficients were calculated using Pearson’s test for correlation. Values of 
P < 0.05 were taken as the lowest level of significance.
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5.3 RESULTS
Forty-four subjects were recruited on to the study. One volunteer (YM) dropped out 
before starting the study, due to work commitments. Thirty middle-aged men (MAM) 
and 13 young men (YM) successfully completed both arms of the study.
5.3.1 ANTHROPOMETRIC DATA
The mean age of the MAM and YM was 49.3 (SD 5.4) and 33.1 (SD 5.1) years 
respectively. The MAM had a significantly higher BMI (mean 26.2, SD 2.6 kg/m^) 
than the YM (mean 24.3, SD 2.9 kg/m^) {P < 0.05). The MAM also had a higher waist 
to hip ratio (mean 0.9, SD 0.05) than the YM (mean 0.86, SD 0.04), although this was 
not quite significant (P = 0.052).
The baseline body weights (Table 5.5) for each subject were similar at the beginning 
of both diets, but were significantly higher at the beginning of arm 2  of the study 
(P < 0.001). There was a small, but significant increase in body weight during both the 
control and MUFA-enriched dietary periods (P < 0.001), although there was no 
significant difference between the final body weights between the 2 diets. The changes 
in weight observed were not significantly different between the 2  diets or between the 
2  arms of the study.
5.3.2 DIETARY DATA
The mean nutrient composition of the subject’s habitual, control and MUFA-enriched 
diets are shown in Table 5.6. There were no significant differences between the 
2 groups of men, therefore only the combined subject-group (MAM+YM) results are 
presented.
The intake of energy, protein fat and carbohydrate did not differ significantly between 
the 3  dietary phases, nor was there a difference in the percentage energy from protein, 
fat or carbohydrate.
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Table 5-5 Body-weight changes during the control and MUFA-enriched diets and
during the two arms of the study. Values are mean (SD) for 43 subjects
Body weight (kg)
Baseline 
Mean SD
2  wks 
Mean SD
4 wks 
Mean SD
8  wks 
Mean SD
Control diet 80.6* 11.3 80.7* 1 1 . 2 80.9 11.5 81.3
+0.7
11.7
MUFA-enriched diet 80.3* 1 1 . 1 80.6* 1 1 . 2 80.7^ 11.3 81.4
+1 . 1
11.4
Arm 1 of study 79.8* 1 1 . 2 80.1* 1 1 . 1 80.1^ 1 1 . 1 80.8
+ 1 . 0
11.4
Arm 2 of study 81.1** 11.3 81.3* 11.3 81.5 1 1 . 6 81.9
+0 . 8
11.7
Values in bold represent the change in weight from baseline
(j), #  significantly different from weights at week 8, P  < 0.01, P < 0.001 respectively
\|/ significantly different from arm 1 baseline weights, P < 0.001
There was a significantly higher intake of SFA on the control diet compared to the 
habitual and MUFA-enriched diet (P < 0.001), and the MUFA-enriched diet had a 
significantly lower intake of SFA than the habitual diet (P < 0.001). These significant 
differences were also reflected in the percentage energy from SFA. The intake of 
cis-MUFA, expressed in grammes and percentage energy, was significantly higher on 
the MUFA-enriched diet compared to the control and habitual diets (P < 0.001). 
In addition, during the control diet there was a significantly higher intake of cis- 
MUFA {P < 0.05) and a significantly higher percentage energy from cis-MUFA 
(P < 0.001) than during the habitual diet. The intake of cw-PUFA and the percentage 
energy from cis-FUFA were similar for all 3 diets.
The mean percentage energy from SFA, cw-MUFA and cw-PUFA on the 
MUFA-enriched diet was 10.2%, 17.7% and 6.9% respectively. The mean percentage 
energy from SFA, cw-MUFA and cis-FUFA on the control diet was 15.8%, 12.9% and 
6.7% respectively. This was equivalent to a 6 % decrease in SFA and a 5% increase in 
MUFA during the MUFA-enriched diet, which was significantly different from the 
control diet (P < 0.001).
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Table 5-6 Nutrient composition of the habitual, control and MUFA-enriched diets as
estimated by unstructured food diaries. The values are presented as mean (SD) for 385
subjects
Nutrient Habitual diet 
Mean SD
Control diet 
Mean SD
MUFA-enriched diet 
Mean SD
Energy (MJ) 1 1 . 2 1 2.05 11.31 1.33 11.38 1.19
Protein (g) 88.5 18.9 87.1 14.2 8 6 . 1 13.2
% Energy Protein 13.3 2 . 2 12.9 1.5 12.7 1.5
Fat (g) 117.3 31.3 117.9 17.9 115.8 17.3
% Energy Fat 39.0 5.2 39.2 3.7 38.3 3.6
Carbohydrate (g) 309.0 67.2 326.1 50.4 334.6 43.1
% Energy Carbohydrate 43.3 5.5 45.2 4.0 46.2 4.7
SFA(g) 38.0 11.5 A1.2f 7.0 30.9*^ 6.9
% Energy SFA 12.9 2.7 15.8^ 1.7 1 0 .2 *^ 1 . 8
cis-MUFA (g) 34.1 1 0 . 1 37.0* 5.9 52.2*^ 7.3
% Energy cw-MUFA 1 1 . 2 2 . 0 12.9^ 1.5 177#v 1.7
cis-FUFA (g) 19.4 7.7 2 0 . 1 3.7 20.7 3.4
% Energy cis-FUFA 6 . 6 2 . 2 6.7 0.9 6.9 0 . 8
C16:0 (g) 18.7 5.3 27.5* 3.7 16.9*v 3.3
C18:0 (g) 9.2 2 . 6 1 2 .8 * 1 . 8 78#v 1 . 6
C18:l (g) 28.9 8.7 34.4* 5.4 48.6*^ 7.3
C18:2 (g) 16.5 7.3 18.4 3.5 18.9* 3.2
C18:3 (g) 1 . 8 1 . 0 0.9* 0.3 0 .6 * 0.3
C l6:0 to C l8:0 ratio 2 . 0 0 . 2 2 .2 * 0 . 1 2 .2 * 0 . 1
C18:2 to C18:3 ratio 10.7 5.4 22.4* 6.4 36.4*^ 14.3
“The nutrient data for 38 volunteers are presented here, owing to incomplete habitual diet diary 
information
*, #  significantly different from habitual diet, P < 0.05, P < 0.001 respectively 
\|/ significantly different from control diet, P < 0.001
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The quantity of palmitic (C l6:0) and stearic (C l8:0) acid was significantly higher on 
the control diet as compared to the habitual and MUFA-enriched diets (P < 0.001). 
The habitual diet also contained a significantly higher amount of C l6:0 and C l8:0 
than the MUFA-enriched diet (P < 0.05). Compared to the 2 experimental diets the 
C16:0 to C18:0 ratio was significantly lower on the habitual diet (P < 0.001). There 
were no significant differences in the C l6:0 to C l8:0 ratio between the 2 experimental 
diets.
The intake of oleic acid (C l8:1) was significantly higher on the MUFA-enriched diet 
(P < 0.001) compared to the control and habitual diets, and the intake of C l8:1 was 
also significantly lower on the habitual diet compared to the control diet (P < 0.001). 
The mean intake of C l8:1 on the MUFA-enriched diet was 48.6 g/day, which 
compared to the control diet was a mean increase of 14.2 g.
The quantity of linoleic (C l8:2) and linolenic (C l8:3) acid did not differ between the 
2 intervention diets. However, compared to the habitual diet, the consumption of 18:2 
was higher during the 2  intervention diets, although this only reached significance for 
the MUFA-enriched diet (P < 0.05). The intake of C l8:3 was significantly higher on 
the habitual diet compared to the control and MUFA-enriched diets (P < 0.001). 
The ratio of 18:2 to 18:3 was significantly higher during the 2 intervention periods 
(P < 0.001) and significantly higher on the MUFA-enriched compared to the control 
diet (P <  0.001).
5.3.3 PALATABILITY DATA
The palatability assessment scores for the study foods (control and MUFA-enriched) 
are shown in Table 5.7. There were no significant differences found between the 
individual control or MUFA-enriched products, or between the mean overall scores 
for the control (mean 7.33, SD 0.9) and MUFA-enriched (mean 6.98, SD 0.73) foods. 
The mean food scores ranged from 5.21-8.33. The convenience of the 2 study diets, as 
assessed by linear analogue scale (Table 5.8) were similar for the control and MUFA- 
enriched diets and all mean scores were above 6.4 (range 6.49-8.07).
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Table 5-7 Palatability scores for the control and MUFA-enriched foods provided, as
assessed by linear analogue scales. The values are presented as mean (SD) for 43
subjects
Food Item Control diet MUFA-enriched diet
Mean SD Mean SD
Beef cobbler 6.09 1.99 6.42 1.78
Mariners pie 8.06 1.43 7.26 1.57
Meat lasagne 7.76 2.14 7.00 1.91
Mediterranean pork 8.33 2.08 7.28 2.21
Pasta sauce 8.33 2.08 6.50 2.25
Seafood tagliatelle 7.9 1.44 7.23 2.40
Vegetable curry sauce 7.75 1.86 8.16 1.42
Vegetable lasagne 6.66 2.41 6.71 1.54
Garlic bread 7.27 2.76 7.81 1.86
Margarine 7.53 1.58 6.65 1.83
Cooking fat 7.10 1.82 5.95 1.89
Cherry and coconut biscuits 7.91 1.97 7.76 1.36
Almond and apricot biscuits 7.65 2.13 7.96 1.28
Orange biscuits 6.33 3.07 6.03 2.66
Digestive biscuits 5.21 2.67 6.0 2.91
All foods 7.33 0.90 6.98 0.73
Table 5-8 Convenience scores for the control and MUFA-enriched dietary 
interventions as assessed by linear analogue scales. Values are presented as mean
(SD)for43 subjects
Convenience ratings Control diet MUFA-enriched diet
Mean SD Mean SD
Diet in general 6.98 1.74 6.49 2.49
Using frozen meals 7.84 1.60 8.07 1.68
Reducing high fat foods 6.58 2.47 6.55 2.55
Using the biscuits 7.71 2.29 7.91 2.39
Using the margarine 7.20 2.15 7.37 2.24
Using the lipid unit system 7.72 1.72 7.31 1.84
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Table 5-9 Comparison of recorded energy intakes with calculated energy intakes for  
the habitual, control and MUFA-enriched diets. Values are mean (SD) for 38 subjects
Habitual diet 
Mean SD
Control diet 
Mean SD
MUFA-enriched diet 
Mean SD
Recorded energy intake 
(diet diaries) (MJ/day)
11.21 2.05 11.31 1.33 11.38 1.19
Calculated energy intake 
(1.35 X BMR) (MJ/day)
10.16*^ 0.73 10.25'*' 0.75 10.26* 0.73
(|) significantly different from habitual diet recorded energy intake, P < 0.01 
\|/ significantly different from control diet recorded energy intake, P < 0.01 
# significantly different from MUFA-enriched diet recorded energy intake, P  < 0.001
Compliance to the diet was assessed by asking the volunteers to state how many days 
(out of 5) they managed to achieve their lipid-unit target intake. The mean score 
during the middle of the study was 4.81 (SD 0.46) and 4.67 (SD 0.47) days for the 
control and MUFA-enriched diets respectively. The mean score at the end of the study 
was 4.51 (SD 0.51) and 4.57 (SD 0.5) days for the control and MUFA-enriched diets 
respectively. The mid-diet scores (control + MUFA-enriched) (mean 4.74, SD 0.46) 
were significantly higher than the end-diet scores (mean 4.54, SD 0.50) (P < 0.03).
Under-reporting of dietary intakes was assessed by comparing recorded intakes energy 
(diet diaries) with calculated energy intakes (1.35 x BMR) (Table 5.9). The recorded 
energy intakes for the habitual, control and MUFA-enriched diets were significantly 
higher than the calculated energy intakes for the 3 dietary periods (P < 0.01, 
P < 0.001, P < 0.001 respectively). These findings suggest that the volunteers were 
accurately recording the food they were consuming.
Under-reporting was more evident for the habitual diet, where 32% of the volunteers 
had recorded energy intakes below their calculated energy intakes, compared with 
16% and 7% for the control and MUFA-enriched diets respectively.
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Table 5-10 Effect of consuming the control and MUFA-enriched diets on plasma 
phospholipid fatty-acid composition. Values are mean (SEM) for the indicated number
of analyses
Fatty acid (wt %)
Baseline 1 Month 2 Months
Control
n=19
MUFA
n=23
Control
n=22
MUFA
n=25
Control
n=19
MUFA
n=22
C16:0 36.3 34.8 35.9 35.1 35.0 32.4*"
(0.9) (0.8) (0.6) (0.7) (1.0) (0.7)
C16:l 1.1 1.0 0.9 0.8 1.2 1.3
(0.2) (0.1) (0.2) (0.1) (0.1) (0.1)
C18:0 17.1 17.0 18.1 17.8 17.7 17.1
(0.4) (0.5) (0.6) (0.4) (0.6) (0.4)
C18:l 11.8 12.0 11.7 13.5*'*' 11.7 14.1*'"
(0.5) (0.3) (0.3) (0.4) (0.4) (0.3)
C18:2 23.0 22.9 24.1 23.0 23.9 23.3
(0.6) (0.6) (0.8) (0.5) (0.7) (0.6)
C20:4 5.4 5.7 4.9 5.3 5.7 5.7
(0.3) (0.4) (0.4) (0.4) (0.4) (0.5)
C22:6 0.8 1.1 0.9 0.6 1.0 0.8
(0.2) (0.2) (0.2) (0.1) (0.1) (0.2)
*, #  significantly different from control group, P < 0.05, P < 0.001 respectively 
0 ,  \|/ significantly different from baseline, P < 0.05, P < 0.001 respectively
5.3.4 PLASMA AND MEMBRANE FATTY-ACID ENRICHMENT DATA
The plasma phospholipid and PBMNC fatty-acid enrichment data are shown in Tables 
5.10 and 5.11 respectively. There was no alteration over time in the fatty-acid 
composition of plasma phospholipids from the control subjects. For the subjects on the 
MUFA-enriched diet there was a gradual and significant increase in the proportion of 
oleic acid in the plasma phospholipids (P < 0.001) at 1 and 2 months, almost all of 
which could be accounted for by a decrease in the proportion of palmitic acid 
(P < 0.05).
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Table 5-11 Effect of consuming the control and MUFA-enriched diets on the 
fatty-acid composition of PBMNC total lipids. Values are mean (SEM) for the
indicated number of analyses
Fatty acid (wt %)
Baseline 1 Month 2 Months
Control
n=10
MUFA
n=10
Control
n=8
MUFA
n=12
Control
n=10
MUFA
n=14
C14:0 0.3 0.2 0.3 0.1 0.2 0.4
(0.1) (0.1) (0.1) (0.1) (0.1) (0.1)
C16:0 24.6 23.9 24.6 25.1 25.9 25.1
(1.2) (1.1) (1.5) (1.4) (1.3) (0.8)
C16:l 0.2 0.3 0.2 0.2 0.2 0.4
(0.1) (0.2) (0.2) (0.1) (0.1) (0.1)
C18:0 29.8 29.7 33.4 32.2 33.8 32.0
(1.5) (1.4) (1.3) (1.2) (1.6) 1.2)
C18:l 21.3 22.9 20.4 22.8 20.3 24.5^ (0.8)
(0.8) (1.0) (0.7) (1.0) (1.0)
C18:2 6.3 6.6 7.9 7.0 6.8 7.3
(0.7) (0.4) (0.8) (0.8) (0.5) (0.7)
C20:4 12.7 9.0 10.3 8.7 9.8 7.6
(2.3) (2.1) (2.1) (1.6) (1.9) (1.3)
(|) significantly different from control group, P  < 0.01
The PBMNC from subjects on the control diet showed no changes in the fatty-acid 
composition of total lipid throughout the experimental period (Table 5.11). After 
2 months (but not 1 month) of consuming the MUFA-enriched diet the subjects in the 
MUFA group had a significantly higher proportion of oleic acid in their PBMNC total 
lipid than those in the control group (P < 0.01).
There was a significant correlation between recorded oleic-acid intakes (assessed from 
2 X 5-day diet diaries) and the oleic-acid incorporation into the plasma phospholipids 
at 2 months (r = 0.389, P < 0.02).
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Table 5-12 Baseline fasting lipid and hormone responses in young and middle-aged 
men prior to commencing the control and MUFA-enriched diets. Values are mean 
(SD) for the indicated number of analyses
Control diet MUFA-enriched diet
MAM
n=30
YM
n=13
MAM
n=30
YM
n=13
TAG (mmol/1) 1.69 (0.75) 1.25 (0.37) 1.61 (0.65) 1.22 (0.49)
Total cholesterol 
(mmol/1)
5.49 (1.03) 5.11 (0.96) 5.57 (0.86) 5.48(1.15)
LDL-C (mmol/1) 3.86 (0.94) 3.63 (0.96) 3.95 (0.78) 3.98 (1.25)
HDL-C (mmol/1) 0.86 (0.67) 0.91 (0.21) 0.88 (0.21) 0.94 (0.32)
NEFA (mmol/1) 0.32 (0.19) 0.26 (0.09) 0.34(0.15) 0.44* (0.25)
Glucose (mmol/1) 5.56 (0.67) 5.31 (0.31) 5.32 (0.59) 5.28 (0.45)
Insulin (pmol/1) 51.6 (32.5) 44.6 (16.8) 61.4 (65.2) 42.9 (18.5)
* significantly different from baseline control diet, P < 0.05 
5.3.5 FASTING BIOCHEMICAL DATA
Baseline fasting lipid and hormone levels were not significantly different at the 
beginning of phase 1 or 2 of the study for either diet.
Table 5.12 shows the mean baseline concentrations for plasma TAG, total cholesterol, 
LDL-C, HDL-C, NEFA, glucose and insulin, for the MAM and YM at the beginning 
of the control and MUFA-enriched dietary intervention periods. Although there were 
no significant differences between the MAM and YM for any of the biochemical 
measurements, the YM tended to have lower TAG, total-cholesterol, LDL-C, glucose 
and insulin concentrations and higher HDL-C concentrations than the MAM. 
Compared to the MAM the YM had lower NEFA values at the start of the control diet 
but higher values at the start of the MUFA-enriched diet. The baseline NEFA 
concentrations were significantly higher before the MUFA-enriched diet compared 
with the control diet for the YM (P < 0.05).
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The combined subject-group (MAM+YM) fasting plasma concentrations for plasma 
TAG, total cholesterol, LDL-C, HDL-C, NEFA, insulin and glucose at weeks 0, 2, 4 
and 8 are shown in Table 5.13.
Compared to baseline values there was a significant reduction in total- and LDL- 
cholesterol concentrations at 2, 4 and 8 weeks (Figures. 13)during the MUFA-enriched 
dietary intervention (P < 0.001). The percentage change in total cholesterol and 
LDL-C from baseline was -10.0 (SD 11.8) % and -14.9 (SD 15.4) % respectively for 
the MUFA-enriched diet. Table 5.14 shows that the percentage reduction in total- and 
LDL-cholesterol was greater for the YM than the MAM during the MUFA-enriched 
diet.
Total cholesterol concentrations were significantly lower at the end of the 
MUFA-enriched diet (weeks 4 & 8) when compared to the corresponding weeks of the 
control diet (P < 0.01 and P < 0.02 respectively). LDL-C was also significantly lower 
at the end of the MUFA-enriched diet (weeks 4 & 8) compared to the control diet 
(P < 0.01 and P < 0.001 respectively). Compared to week 8 of the control dietary 
period there was a -5.2% change in total cholesterol and a -9.03% change in LDL-C at 
week 8 of the MUFA-enriched diet (Table 5.15), which is equivalent to a 0.31 mmol/1 
and 0.39 mmol/1 lowering of total- and LDL-cholesterol respectively.
HDL-C concentrations remained unchanged during the MUFA-enriched dietary period 
and tended to increase slightly during the control dietary period (Table 5.13 & 
Figure 5.14). However, the HDL-C concentrations after the 2 diets were not 
significantly different from each other.
Fasting plasma TAG values did not alter significantly during the 2 intervention phases, 
although an increasing trend was observed during the MUFA-enriched dietary period 
(Table 5.13 & Figures. 15). The mean TAG concentration was higher following the 
MUFA-enriched compared to the control diet, although this did not reach significance.
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Table 5-13 Fasting lipid and hormone concentrations during the control and MUFA-
enriched dietary periods. Values are mean (SD) for 43 subjects
Parameter Control diet MUFA-enriched diet
Baseline 2 wk 4 wk 8 wk Baseline 2 wk 4 wk 8 wk
Total
cholesterol
(mmol/1)
5.38
(1.02)
5.17
(0.98)
5.32
(1.08)
5.26
(0.98)
5.54*
(0.94)
4.99
(0.92)
4.97*
(0.96)
4.95*
(0.86)
HDL-C
(mmol/1)
0.88
(0.22)
0.94
(0.18)
0.90
(0.21)
0.91
(0.18)
0.90
(0.25)
0.92
(0.22)
0.90
(0.19)
0.90
(0.18)
LDL-C
(mmol/1)
3.79
(0.94)
3.57
(0.88)
3.70
(0.99)
3.70
(0.92)
3.96*
(0.94)
3.39
(0.81)
3.37*
(0.77)
3.3U
(0.77)
TAG
(mmol/1)
1.56
(0.68)
1.45
(0.62)
1.60
(0.75)
1.53
(0.59)
1.49
(0.62)
1.50
(0.64)
1.54
(0.71)
1.60
(0.83)
NEFA
(mmol/1)
0.30
(0.17)
0.29
(0.16)
0.29
(0.13)
0.52**
(0.19)
0.37
(0.19)
0.30
(0.13)
0.29
(0.12)
0.53**
(0.21)
Glucose
(mmol/1)
5.49
(0.60)
5.49
(0.44)
5.40
(0.49)
5.12
(0.43)
5.31
(0.55)
5.49
(0.32)
5.41
(0.41)
5.25
(0.39)
Insulin
(pmol/1)
49.5
(28.6)
56.5
(44.2)
56.6
(37.3)
72.2
(56.6)
55.8
(55.7)
51.9
(34.2)
56.0
(44.9)
71.9
(44.4)
# significantly different from weeks 2 ,4  & 8 of the MUFA-enriched diet, P < 0.001 
*, (|), \j/ significantly different from control diet, P < 0.02, P < 0.01, P < 0.001 respectively 
** significantly different from baseline values, P < 0.001
Table 5-14 Fasting total- and LDL-cholesterol concentrations at baseline and week 8 
of the control and MUFA-enriched dietary periods for young and middle-aged men. 
Values are mean (SD) for the indicated number of analyses
Control diet MUFA-enriched diet
Baseline 8 wk Baseline 8 wk
MAM
n=30
YM
n=13
MAM
n=30
YM
n=13
MAM
n^30
YM
n=13
MAM
n=30
YM
n=13
Total cholesterol 
(mmol/1)
5.49
(1.03)
5.11
(0.96)
5.34
(0.94)
-1.2%
5.07
(1.10)
-0.3%
5.57
(0.86)
5.48
(1.15)
5.09
(0.79)
-8.0%
4.62
(0.94)
-14.9%
LDL-C (mmol/1) 3.86
(0.94)
3.63
(0.96)
3.76
(0.86)
-0.5%
3.57
(1.06)
-3.2%
3.95
(0.78)
3.98
(1.25)
3.37
(0.77)
-13.8%
3.17
(0.78)
-17.4%
Values in bold represent the percentage change from baseline
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Table 5-15 Absolute and percentage change in fasting total- and LDL-cholesterol 
concentrations. Values are mean (SD)for the indicated number o f analyses
MAM
n=30
YM
n=13
MAM+YM
n=43
Absolute A fasting total cholesterol -0.25 -0.45 -0.31
concentration (mmol/1) (0.63) (0.42) (0.58)
(wk 8 MUFA - wk8 Control)
% A fasting total cholesterol -3.83 -8.38 -5.20
concentration (11.83) (7.80) (10.88)
(wkB MUFA - wk8 Control) x 100
Absolute A fasting LDL-C -0.39 -0.40 -0.39
concentration (mmol/1) (0.61) (0.54) (0.58)
(wk8 MUFA - wk8 Control)
% A fasting LDL-C concentration 
(wk8 MUFA - wk8 Control) x 100
-9.03
(15.99)
-9.02
(13.07)
-9.03
(15.01)
NEFA concentrations (Table 5.13 & Figure 5.16) were not significantly different to 
baseline values at 2 and 4 weeks, but were significantly increased at 8 weeks for both 
diets (P < 0.001). There were no significant differences between the 2 diets.
Fasting glucose concentrations did not significantly change during the 2 intervention 
diets (Table 5.13 & Figures 17), although there was a tendency for the 8-week values 
to be lower than baseline concentrations. There were no significant differences 
between the control and MUFA-enriched diets.
Fasting plasma insulin concentrations tended to increase during both dietary phases 
(Table 5.13 & Figure S. 18),although the final concentrations were not significantly 
different between the 2 diets. The insuliniglucose ratios shown in Table 5.16 
demonstrate that the MAM were more insulin resistant than the YM, although this 
only reached significance on the MUFA-enriched diet (P < 0.05). In the MAM and 
combined subject group, insuliniglucose ratios were significantly lower on the control 
diet compared with the MUFA-enriched diet (P < 0.05 and P < 0.001 respectively).
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Figure 5-13 Fasting plasma total cholesterol concentrations during the 8-week control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects. # indicates a significant 
difference from the baseline MUFA-enriched diet values {P < 0.001). * and ** indicate a significant 
difference between the two diets (P < 0.02, P  < 0.01 respectively).
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Figure 5-14 Fasting plasma HDL-C concentrations during the 8-week control and MUFA-enriched 
dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-15 Fasting plasma TAG concentrations during the 8-week control and MUFA-enriched 
dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-16 Fasting plasma NEFA concentrations during the 8-week control and MUFA-enriched 
dietary periods. Values are mean (SEM) for 43 subjects. # indicates a significant difference from 
baseline values for both diets (P < 0.001).
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Figure 5-17 Fasting plasma glucose concentrations during the 8-week control and MUFA-enriched 
dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-18 Fasting plasma insulin concentrations during the 8-week control and MUFA-enriched 
dietary periods. Values are mean (SEM) for 43 subjects.
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Table 5-16 Insulin:glucose ratios following the control and MUFA-enriched diets.
Values are mean (SD) for the indicated number of analyses
Insulin:Glucose ratio
MAM YM MAM+YM
n=30 n=13 n=43
Control diet 2.04* (1.62) 1.62(0.66) 1.91* (1.41)
MUFA-enriched diet 2.86* (1.81) 1.70 (0.91) 2.51 (1.67)
*, #  significantly different from MUFA-enriched diet, P < 0.05, P < 0.001 respectively 
(|) significantly different from YM, P < 0.05
5.3.6 POSTPRANDIAL BIOCHEMICAL DATA
The postprandial profiles for the mean plasma TAG concentrations for the combined 
subject group are shown in Figure 5.19. Plasma TAG increased steadily up to 180 
minutes after the test meal and continued to increase up to 420 minutes in the control 
group, but levelled off in the MUFA-enriched group. After 420 minutes the TAG 
response fell towards baseline values in both groups, although after 9 hours the 
concentrations did not return to baseline levels. Compared to the control diet the 
postprandial TAG response was higher in the MUFA-enriched group, although this 
did not reach significance.
There were no significant differences in the AUCs and lAUCs between the 2 diets 
(Tables 5.17 and 5.18) nor in the time to peak and peak TAG concentrations (Tables 
5.19 and 5.20).
The individual subject-group postprandial TAG responses for the MAM and YM are 
shown in FigureJ 20, where the magnitude of the postprandial response was lower in 
the YM compared to the MAM, but not significantly so. In both subject groups the 
postprandial response was higher following the MUFA-enriched, compared to the 
control diet.
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There were no significant differences in the AUCs and lAUCs between the 2 subject 
groups or between the diets (Tables 5.17 and 5.18). Compared to the MAM, the YM 
had a higher time to peak, but a lower-peak, plasma TAG concentration (Tables 5.19 
and 5.20) on the control diet, and a lower time to peak and a higher-peak, TAG 
concentration on the MUFA-enriched diet, although this did not reach significance.
The postprandial TRL-TAG responses for the combined subject group are shown in 
Figure5:21. The TRL-TAG response is similar to that for plasma TAG, with a steady 
increase in the TRL-TAG concentration up to 420 minutes followed by a decrease 
towards baseline. After 9 hours the TRL-TAG concentrations did not return to fasting 
levels in either dietary group. The magnitude of the postprandial response was greater 
in the MUFA-enriched compared with the control diet, although this was not 
significant.
There were no significant differences in the AUCs and lAUCs (Tables 5.17 and 5.18), 
nor in the time to peak or peak concentrations (Tables 5.19 and 5.20) between the 2 
dietary groups.
The postprandial TRL-TAG-response curves for the individual subject groups (shown 
in Figure 5.22) demonstrate that the magnitude of the response was greater in the 
MAM compared to the YM.
The AUCs shown in Table 5.17 were significantly higher in the MAM compared to 
the YM for both the control (P < 0.05) and MUFA-enriched (P < 0.01) dietary periods. 
The LAUCs shown in Table 5.18 were significantly higher in the MAM compared to 
the YM on the control diet (P < 0.03) and not quite significantly higher on the 
MUFA-enriched diet (P = 0.065).
Compared to the MAM the YM had shorter times to peak (Table 5.19) and lower peak 
TRL-TAG concentrations (Table 5.20), although these were not significant.
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The combined subject-group postprandial TPL-TAG responses, shown in Figure 5.23 
demonstrate that there was a small increase in TPL-TAG during the 9-hour 
postprandial period. For the first 90 minutes the control diet response was lower than 
the MUFA-enriched diet response, but after this, the 2 dietary responses were very 
similar.
There were no significant differences in the AUCs and lAUCs (Tables 5.17 and 5.18) 
nor in the time to peak and peak TPL-TAG concentrations (Tables 5.19 and 5.20) 
between the diets, although the mean time to peak was 59 minutes shorter following 
the MUFA-enriched diet.
The individual group responses shown in Figure 5.24 demonstrate that the magnitude 
of the TPL-TAG response was lower in the YM compared to the MAM. This was 
supported by significantly lower AUCs (Table 5.17) following both diets (P < 0.001). 
The LAUCs (Table 5.18) were lower in the YM following both diets, but not 
significantly so.
There were no significant differences in the mean time to peak (Table 5.19) nor in the 
mean peak TPL-TAG concentrations (Table 5.20) between the subject groups, 
although the peak concentrations were lower in the YM.
Pearson correlation’s demonstrated that fasting plasma-, TRL-, and TPL-TAG values 
were significantly correlated with the AUC for the postprandial TAG response in 
plasma, TRL and TPL (r = 0.92, 0.90 and 0.87 respectively, all P < 0.0001).
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Figure 5-19 Postprandial plasma TAG responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-20 Postprandial plasma TAG responses to a standard test meal following the control and
MUFA-enriched dietary periods. Values are mean (SEM) for 30 middle-aged and 13 young men.
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Figure 5-21 Postprandial TRL-TAG responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-22 Postprandial TRL-TAG responses to a standard test meal following the control and
MUFA-enriched dietary periods. Values are mean (SEM) for 30 middle-aged and 13 young men.
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Figure 5-23 Postprandial TPL-TAG responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-24 Postprandial TPL-TAG responses to a standard test meal following the control and
MUFA-enriched dietary periods. Values are mean (SEM) for 30 m iddle-aged and 13 young men.
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Table 5-17 Total area under the time-response curves for the TAG responses 
following the control and MUFA-enriched diets. Values are mean (SD)for the
indicated number of analyses
Control-diet AUC 
(min.mmol 1'^ )
MUFA-enriched diet AUC 
(min.mmol 1'^ )
MAM
n=30
YM
n=13
MAM+YM
n=43
MAM
n=30
YM
n=13
MAM+YM
n=43
Plasma 1202 1057 1158 1261 1187 1239
TAG (522) (303) (468) (553) (471) (525)
TRL-TAG 1778* 740 1153 2243* 771 1477
(958) (575) (1099) (1489) (503) (1674)
TPL-TAG 520*^ 348 471 536* 322 476
(126) (83.1) (140) (111) (102) (143)
*, (j), #  significantly different from YM, P < 0.05, P < 0.01, P < 0.001 respectively
Table 5-18 Incremental area under the time-response curves for the TAG responses 
following the control and MUFA-enriched diets. Values are mean (SD)for the
indicated number of analyses
Control-diet lAUC 
(min.mmol 1'^ )
MUFA-enriched diet I AUC 
(min.mmol T^ )
MAM
n=30
YM
n=13
MAM+YM
n=43
MAM
n=30
YM
n=13
MAM+YM
n=43
Plasma 372 347 364 315 396 339
TAG (199) (133) (181) (235) (171) CU9)
TRL-TAG 774* 378 547 747 386 553
(537) (401) (590) (644) (352) (731)
TPL-TAG 48.6 11.8 40.5 29.0 27.9 75.4
(94.1) (72.6) (13.5) (75.9) (80.1) (11.5)
* significantly different from YM, P < 0.03
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Table 5-19 Time to peak for the TAG responses following the control and
MUFA-enriched diets. Values are mean (SD)for the indicated number o f analyses
Time to Peak (minutes)
Control diet MUFA-enriched diet
MAM
n=30
YM
n=13
MAM+YM
n=43
MAM
n=30
YM
n=13
MAM+YM
n=43
Plasma 320 355 331 346 300 332
TAG (112) (90) (106) (134) (98) (125)
TRL-TAG 329 309 323 355 330 348
(126) (114) (122) (119) (101) (113)
TPL-TAG 325 342 330 272 268 271
(123) (90) (113) (160) (106) (145)
Table 5-20 Peak concentration for the TAG responses following the control and 
MUFA-enriched diets. Values are mean (SD) for the indicated number of analyses
Peak concentration (mmol/1)
Control diet MUFA-enriched diet
MAM
n=30
YM
n=13
MAM+YM
n=43
MAM
n=30
YM
n=13
MAM+YM
n=43
Plasma 3.13 2.80 3.04 3.16 3.20 3.17
TAG (1.3) (0.67) (1.15) (1.29) (1.31) (1.28)
TRL-TAG 5.07 2.58 4.32 6.05 2.86 5.14
(2.55) (1.84) (2.61) (3.21) (1.54) (3.16)
TPL-TAG 1.15 0.86 1.06 1.21 0.82 1.09
(0.31) (0.19) (0.31) (0.26) (0.26) (0.32)
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Only the combined subject-group data are presented for the postprandial 
total-cholesterol, NEFA, glucose and insulin responses, as no significant differences 
between the YM and MAM were found.
The postprandial plasma total-cholesterol responses are shown in Figure 5.25. The 
response following the MUFA-enriched diet was lower than the control diet at all time 
points, although this did not reach significance. There were no significant differences 
in the AUCs or the lAUCs between the 2 diets (Table 5.21). However, the AUCs were 
lower following the MUFA-enriched diet and the lAUCs were negative following the 
control diet, and positive following the MUFA-enriched diet.
The postprandial glucose responses are shown in Figure 5.26. Following the standard 
test meal, glucose concentrations rose sharply to give a peak at 30 minutes for both 
diets. The levels then fell steadily to below the fasting concentrations at 300 minutes 
before returning towards baseline values at 9 hours after the test meal. No significant 
differences were observed in the AUCs and lAUCs for the 2 diets (Table 5.21)
Postprandial insulin responses are shown in Figure 5.27. Following the standard test 
meal, insulin levels rose sharply, reaching a peak at 90 minutes following the 
MUFA-enriched diet and 120 minutes following the control diet. The concentrations 
then fell steadily back to baseline values. After 9 hours the insulin concentrations had 
returned to fasting levels. There were no significant differences between the AUCs 
and lAUCs (Table 5.21) between the 2 diets, although there was a tendency for the 
values to be higher following the MUFA-enriched diet.
The postprandial NEFA responses are shown in Figure 5.28. Following the standard 
test meal, NEFA concentrations fell during the first 2 and 3 hours for the 
MUFA-enriched and control diets respectively, before continuing to rise above the 
baseline levels at 9 hours. There were no signficant differences between the AUCs and 
LAUCs for the 2 diets (Table 5.21).
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Table 5-21 Total and incremental areas under the time-response curves for the 
plasma total-cholesterol, NEFA, glucose and insulin responses following the control 
and MUFA-enriched diets. Values are mean (SD) fo r 43 subjects
Control diet MUFA-enriched diet
AUC lAUC AUC lAUC
Total cholesterol 2814 -2.76 2705 2.51
(min.mmol 1'^ ) (533) 93.6) (438) (207)
NEFA 221 -65.1 217 -68.5
(min.mmol 1') (68.5) (72.7) (55.3) (86.4)
Glucose 2924 143 2932 132
(min.mmol 1‘) (225) (299) (248) (222)
Insulin 172388 130639 179694 134138
(min.pmol 1'^ ) (124391) (98874) (94235) (80164)
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Figure 5-25 Postprandial plasma total-cholesterol responses to a standard test meal following the 
control and MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-26 Postprandial plasma glucose responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-27 Postprandial plasma insulin responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Figure 5-28 Postprandial plasma NEFA responses to a standard test meal following the control and 
MUFA-enriched dietary periods. Values are mean (SEM) for 43 subjects.
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Table 5-22 Postheparin LPL activity values 5 and 15 minutes following the control 
and MUFA-enriched diets. Values are mean (SD) for the indicated number o f analyses
Postheparin LPL activity (mU/ml)
Control diet MUFA-enriched diet
MAM
n=30
YM
n=13
MAM+YM
n=43
MAM
n=30
YM
n=13
MAM+YM
n=43
5 minutes 146.5 161.0 151.0 149.5 160.3 153.0
postheparin (37.9) (56.6) (44.2) (35.0) (59.4) (43.9)
15 minutes 178.0* 218.9^** 190.6* 190.4*^ 200.9* 193.9*
postheparin (41.1) (68.0) (53.5) (70.1) (57.2) (46.0)
*, (j), #  significantly different from 5 minute values, P < 0.05, P < 0.01, P < 0.001 respectively 
** significantly different from MAM 15 minute values, P  < 0.05
Postheparin LPL activity values are shown in Table 5.22 and Figure 5.29. The MAM 
had lower mean 5 and 15 minute postheparin LPL activities than the YM, although 
this was only significant at 15 minutes following the control diet. The 5-minute LPL 
values were significantly lower than the 15-minute values in all the subject groups and 
on both diets. The LPL activity values were not signifcantly different between the 2 
diets at either time point.
Pearson product correlations demonstrated that the 15-minute, postheparin LPL 
activity values were positively correlated with fasting plasma HDL-C (r = 0.204), 
although this was not quite significant (P < 0.07). The 15-minute, postheparin LPL 
activity values were also significantly inversely correlated with fasting plasma TAG 
(r = -0.443, P < 0.0001) and AUC-TAG (r = -0.482, P < 0.001). There were no 
significant correlations between change in LPL activity and change in fasting TAG or 
change in AUC-TAG.
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Figure 5-29 Postheparin plasma LPL activities 5 and 15 minutes after injection of 7500 units of 
heparin, 9 hours after the standard test meal, following the control and MUFA-enriched dietary 
periods. Values are mean (SD) for 43 subjects.
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Figure 5-30 Adipose-tissue LPL activities 4 hours after a standard test meal, following the control and 
MUFA-enriched dietary periods. Values are mean (SD), w = 7 for the control diet & n = 6 for the 
MUFA-enriched diet.
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Figure 5-31 Adipose-tissue LPL gene expression values 4 hours after a standard test meal, following 
the control and MUFA-enriched dietaiy periods. Values are mean (SD) for 5 subjects.
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Adipose-tissue, LPL activity results are shown in Figure 5.30. There were no 
significant differences between the 2 experimental diets, although there was a trend for 
the values to be higher following the control diet. Pearson product correlations 
demonstrated that there were no significant correlations between adipose-tissue LPL 
activity and either postheparin LPL activity, fasting plasma TAG or AUC-TAG. There 
was a negative correlation between the change in adipose-tissue LPL activity and the 
change in plasma TAG (r = -0.69), and the change in AUC-TAG (r = -0.69). However, 
these were not significant.
The results for adipose-tissue LPL gene expression are shown in Figure 5.31. There 
were no significant differences between the 2 diets, although the values were higher 
following the MUFA-enriched diet. LPL gene expression was not significantly 
correlated with either postheparin LPL activity, fasting plasma TAG or AUC-TAG.
5.4 DISCUSSION
The aims of this dietary intervention study were 2-fold:
1) To assess the feasibility of increasing the MUFA content of the diet by using 
olive oil-enriched recipe meals, snacks, cooking and spreading fats.
2) To examine the effects of consuming a MUFA-enriched diet on the plasma- 
lipid and hormone concentrations in a group of healthy middle-aged men and a 
group of healthy young men with a family history of CHD.
Together, it was hoped that these findings would provide further evidence upon which
future dietary recommendations could be based, if appropriate.
The 2 subject groups were chosen because, firstly, the majority of comparison trials
investigating the effects of diet on CHD risk factors are carried out in MAM.
Secondly, evidence has shown that males with a family history of CHD, are a ‘high
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risk’ group, especially if their plasma-lipid levels are elevated (Murkherjee & Dastur, 
1994; Uiterwaal etal. 1994; Jousilahti etal. 1996).
The target of the dietary intervention was to maintain the percentage dietary energy 
derived from fat at between 38 - 40%, with 10% from SFA, 20-22% from MUFA and 
8% from PUFA. In contrast, the target for the control diet was 18-20% SFA, 12% 
MUFA and 8% PUFA. In the present study we chose to study free-living volunteers in 
preference to a residential study, as it provided the opportunity to determine whether 
increasing the MUFA content of the diet was feasible and acceptable and whether the 
findings could be directly related to the normal adult UK population. The disadvantage 
of this type of study design is that it results in less frequent contact with the volunteer 
group and difficulties in sample collection and distribution of food supplies, which 
often cause reduction in compliance of the volunteers (Fairweather-Tait, 1996). A 
pilot study, initially carried out by our research group, highlighted that to maintain 
subject motivation, there needed to be close contact with the study co-ordinators, 
individualised dietary counselling, and a wide variety of foods available in order to 
reach the target fatty-acid intakes (Knapper et al. 1996). To aid compliance to the 
study, the volunteers were allowed 2 free days per week from the dietary intervention. 
These days were provided to give the subjects the flexibility of being able to eat away 
from home for social or business reasons, which enabled the subjects to remain 
motivated.
Analysis of the dietary records shows that the intake of energy and the percentage 
energy from fat, carbohydrate and protein did not vary between the experimental diets, 
nor were the values dissimilar to those habitually consumed by the volunteers. The 
mean percentage energy from fat was 39% and 38% for the control and 
MUFA-enriched dietary periods respectively and these values are comparable to those 
quoted for the UK male population (Gregory et a/. 1990). The percentage dietary 
energy derived from SFA and MUFA was significantly different between the 2 
intervention diets, with the percentage energy from SFA, MUFA and PUFA being 
16%, 13% and 7% respectively on the control diet and 10%, 18% and 7% respectively, 
on the MUFA-enriched diet. The intakes of specific fatty acids (C l6:0, C18:0, C18:l,
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C18:2, C18:3) mirrored the changes seen with the major fatty-acid classes. These 
results demonstrate that the 8-week dietary intervention successfully substituted 
dietary cw-MUFA for SFA without affecting total dietary fat or energy intake. The 
‘neutral’ effects of stearic acid (McNamara, 1992) meant that it was important to 
maintain the ratio of C l6:0 to C l8:0 at 2, in order to prevent the 
hypercholesterolaemic effects of palmitic acid being greater on the control than the 
MUFA-enriched diet. Analysis of the dietary records demonstrates that this ratio was 
maintained at 2 during both experimental diets. Despite similar absolute intakes of 
18:2 and 18:3 for both experimental diets the C18:2 to C18:3 ratios were significantly 
higher during the MUFA-enriched diet. Habitual dietary intakes, assessed by a 4-day 
unstructured diet diary, should have reflected a similar fatty-acid profile to that of the 
control diet and yet they were found to be significantly lower for the majority of the 
fatty acids analysed. The most likely explanation for these differences is that accurate 
calculations of fatty-acid intakes from the data provided (4-day diet records) was 
limited by the lack of information on the fatty-acid profiles of commonly eaten foods 
in the Foodbase nutrient database. Recent evidence (Kelly et al. 1999) has 
demonstrated that when direct fatty-acid analysis of foods is made, and the values 
manually entered into the database, the nutrient results obtained are significantly 
different to those analysed using the standard database information. The significant 
correlation found between recorded oleic-acid intakes and oleic-acid incorportaion 
into plasma phospholipids suggests that 10 days worth of diet records was sufficient to 
accurately reflect MUFA intakes.
To establish whether or not the diet records were a true reflection of the volunteers 
actual dietary intake, comparisons between recorded and calculated energy intakes 
were carried out. Recorded energy intakes were significantly higher than calculated 
energy intakes, calculated using the equation 1.35 x BMR. This suggests that the 
volunteers diet-diary records are a true reflection of their actual dietary intake. A 
higher percentage of volunteers appeared to under-report their dietary intake for the 
habitual diet compared with the 2 intervention diets. The most likely explanation for 
this is that the volunteers received fewer instructions for the habitual diet diary, and 
only 4 days were recorded.
264
Palatability assessment scores demonstrated that all the study foods were acceptable 
vehicles through which to achieve the dietary modification and were easily and 
conveniently assimilated into the volunteers diets. Compliance to the study diets was 
excellent, as evidenced by the reports that the volunteers consumed their target 
lipid-unit intake (fatty-acid intake) for 4.74 days out of 5 during the middle of the 
study and 4.54 days out of 5 at the end of the study. However, these values were 
significantly different, which suggests that the volunteers compliance became less 
towards the latter half of the intervention.
Dietary compliance was also assessesed by measuring plasma and membrane 
phospholipids. This study shows that 2 months of consuming a MUFA-enriched diet is 
sufficient to bring about an alteration in the fatty-acid composition of plasma 
phospholipids and PBMNC total lipid. Significant increases in oleic acid were seen in 
the plasma phospholipids and PBMNCs, and this was accompanied by a signficant 
reduction in palmitic acid in the plasma phospholipids. The membrane lipids of 
erythrocytes and platelets should equilibriate with the surrounding plasma, as both 
lack the enzymatic apparatus necessary to synthesize or esterify lipids. Changes in 
dietary fatty acids will affect plasma fatty-acid levels, and maximal changes should 
occur about 4 weeks after the diet has been altered (Tynan et al. 1995). In this way, 
membrane fatty-acid compositions can be used as an indicator of dietary compliance. 
The findings of this present study indicate that the subjects were complying with the 
diet as increases in plasma phospholipid and PBMNC oleic-acid incorporation, at the 
expense of plamitic acid, were observed on the MUFA-enriched diet. Other 
investigators have reported similar alterations in palmitic and oleic acid with MUFA- 
enriched diets (Wardlaw & Snook, 1990; Nydahl etal. 1994; Choudhury et <2 /. 1995).
There was a small, but significant increase in body weight during both the control and 
the MUFA-enriched diets, although there was no difference between the 2 diets. The 
mean weight change over the course of the interventions was 0.7 kg and 1.1 kg for the 
control and MUFA-enriched diets respectively. As there were no significant 
differences between the baseline body weights and weights at weeks 2 and 4 of the 
intervention period, it appears that the majority of the body weight was gained
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between weeks 4 and 8. This period of time also coincided with a reduction in the 
investigator-subject contact, and emphasises how important and essential it is to 
maintain face-to-face contact with volunteers at regular intervals throughout the whole 
of the study, if complete compliance/adherance to the diet is to be achieved. However, 
these changes in body weight are relatively small, can occur on a daily basis due to 
fluctuations in fluid balance, and are unlikely to have altered plasma-lipid and 
hormone responses.
The body weights at the beginning of the first arm of the study were significantly 
lower than the body weights at the start of the second arm, although the change in 
body weights during both arms were similar (1.0 and 0.8 kg for the first and second 
arms of the study respectively). The most likely explanation for the increase in body 
weight prior to starting the second arm of the study was the occurrence of Christmas 
between the end of the first arm and beginning of the second arm of the study.
In general there were no significant differences between the baseline concentrations of 
the lipid and hormone parameters between the control and MUFA-enriched diets, 
which suggests that the 4-week washout period was sufficient in order to return lipid 
and hormone responses to their original concentrations. This is also supported by 
similar fatty-acid distributions in the plasma phospholipid and PBMNC total lipids at 
the start of the control and MUFA-enriched dietary periods. However, there was a 
significantly higher fasting NEFA concentration before the start of the MUFA- 
enriched diet which was due to significantly higher values in the YM only. Evidence 
has shown that NEFA concentrations vary considerably between individuals and this 
is thought to be due to a number of factors including stress levels and exercise (Frayn 
et al. 1996). Therefore an explanation for the higher fasting NEFA levels may be the 
result of the mental stress experienced by the volunteers in expectation of the 
venepunture together with a possible additive effect of the 12-hour overnight fast. 
However, there is no obvious reason why this should be more pronounced in the YM 
compared to the MAM.
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Generally there were few significant changes in the fasting lipid and hormone 
responses between the control and MUFA-enriched diets.
Significantly greater reductions in total cholesterol were observed during the 8-week, 
MUFA-enriched dietary period ( - 8% MAM, -15% YM) than the control period 
(-1.2% MAM, -0.3% YM). This pattern of response was paralleled by LDL-C during 
the MUFA-enriched dietary period (-14% MAM, -17% YM) and the control dietary 
period (-0.5% MAM, -3.2% YM). The lowering of total and LDL cholesterol during 
the control dietary period was not found to be significant and probably reflects dietary 
and lifestyle changes as a result of being part of a nutritional study.
Total and LDL-cholesterol were also significantly lower following the MUFA- 
enriched diet compared with the control diet. In the combined subject group 
(MAM+YM) this was equivalent to a 5.2% (0.31 mmol/1) and 9% (0.39 mmol/1) 
reduction in total and LDL cholesterol respectively.
These results support earlier findings by other research groups where a decrease in 
total cholesterol was observed following the substitution of SFA with MUFA (Mattson 
& Grundy, 1985; Sirtori et al. 1986; Mensink & Katan, 1989; Wardlaw & Snook, 
1990; Berry et al. 1991; Choudhury et al. 1995; Temme et al. 1996). The percentage 
decrease in LDL-C observed by other researchers varies from 5-20% over a range of 
fat intakes from 28-40% dietary energy. This suggests that MUFA when substituted 
for SFA are responsible for the hypocholesterolaemic effect, rather than the amount of 
energy derived from fat. Keys et al. (1965) estimated that for every 1% dietary energy 
in which oleic acid substituted for SFA, serum total cholesterol should fall by an 
average 2.7 mg/dl (approximately 0.067 mmol/1). During the MUFA-enriched diet the 
percentage energy from MUFA (predominantly oleic acid) increased by 4.8% at the 
expense of SFA. Using the above equation this would equal a 0.32 mmol/1 fall in total 
cholesterol, which is similar to what we observed.
Law et al. (1994) have estimated that a 0.6 mmol/1 reduction in LDL-C in MAM 
would produce a corresponding decrease in the risk of CHD of 25-30%. Based on
267
these data, the dietary changes achieved in the present study, if extrapolated to the 
middle-aged male population of the UK, would be expected to reduce their risk of 
CHD by 16.3-19.5%.
The actual mechanisn by which MUFA reduce LDL-C concentrations is not fully 
understood, either they exert their hypocholesterolaemic effect by increasing LDL 
receptor activity or the replacement of SFA with MUFA removes inhibition of the 
LDL-receptor. Daumerie et al. (1992) and Spady et al. (1993) have proposed that oleic 
acid is the preferred substrate for the enzyme ACAT, whose increased activity shifts 
cholesterol away from the cellular sterol regulatory pool in to the cholesterol ester 
pool, which in turn increases LDL receptor mRNA levels and LDL receptor activity, 
thus lowering circulating plasma LDL-C levels.
A non-significant increase in fasting TAG levels was observed during the 
MUFA-enriched dietary period and supported earlier reported findings 
(Seppanen-Laakso et al. 1993; Abbey et al. 1994; Howard et al. 1995; Temme 
et al. 1996). However, other studies in similar volunteer age groups have shown 
reductions in fasting TAG levels (Mattson & Grundy, 1985; Judd et al. 1994; Nydahl 
et al. 1994). It appears that the increase in TAG observed during high MUFA intakes 
is determined by the total percentage energy derived from fat, the age of the volunteers 
and the comparison diet. Low-fat diets tend to cause an increase in plasma TAG levels 
in MAM (Sirtori et al 1986; Dreon et al. 1990; Howard et al. 1995) and reductions in 
YM (Berry et al. 1991; Choudhury et al. 1995). When compared to baseline TAG 
values, Seppanen-Laakso et al. (1993) reported a fall in plasma TAG concentrations 
following the MUFA-rich diet, but when compared to a SFA-rich diet plasma TAG 
values increased after the MUFA-rich diet. Temme et al. (1996) observed a lowering 
of plasma TAG on the MUFA-rich diet when compared to a high palmitic-acid diet 
and an increase in plasma TAG when compared to a high lauric-acid diet. Although 
these inconsistent trends have been observed, only 1 study (Choudhury et al. 1995) 
reported that the changes were significant. A meta-analysis carried out by Gardner & 
Kraemer (1995) concluded that compared to a SFA-rich-diet, fasting plasma TAG 
values would be unchanged or slightly lowered on a MUFA-rich diet. PUFA are
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known to reduce fasting plasma TAG values by inhibiting hepatic lipogenic enzymes 
and VLDL production (Clarke & Abraham, 1992). As this effect has not been 
demonstrated with oleic acid, it is not surprising to find that fasting plasma TAG 
levels were not lowered in the present study.
HDL-C was not significantly altered during the control and MUFA-enriched dietary 
periods, which is in agreement with other investigators (Mattson & Grundy, 1985; 
Sirtori et al. 1986; Wardlaw & Snook, 1990; Berry et al. 1991; Mata et al. 1992; 
Seppanen-Laakso et al. 1993) However, in contrast, some investigators have reported 
decreases in HDL-C concentrations on a MUFA-rich diet (Nydahl et al. 1994; Judd 
et al. 1994; Choudhury et al. 1995). Gardner & Kraemer (1995) in their meta-analysis 
concluded that in comparison to a SFA-rich diet HDL-C would be unchanged or 
slightly lowered on a MUFA-rich diet.
Fasting NEFA concentrations were higher at 8 weeks compared to baseline, 2 and 4 
weeks for both diets. The postprandial study day coincided with the 8-week blood 
sample, where on these occasions, a cannula was inserted into the arm of the 
volunteers under local anaesthetic to enable multiple blood samples to be taken, 
compared with a single venepunture carried out on the other fasting blood sample 
collection days. Evidence has shown stress to increase circulating NEFA 
concentrations through the action of catecholamines on HSL, resulting in 
adipose-tissue TAG hydrolysis (Frayn et al. 1996). In combination with the stress 
level, the nutritional status of the individuals may provide an explanation for the 
elevated NEFA levels since they had fasted for 12 hours prior to the postprandial study 
day.
Glucose levels were similar during the first month and then lower at the end of each 
dietary period, whilst insulin levels were similar during the first month and higher at 
the end of each dietary period. As this occurred in both diets, it tends to suggest that it 
may be a result of the postprandial study day rather than the intervention diets. 
However, we can only speculate about this.
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In general, the results from this study have indicated that there were no significant 
differences in the postprandial responses to the standard test meal following the 8- 
week control and MUFA-enriched dietary periods. The lipaemic responses were 
evaluated using TAG measurements in plasma-, TRL-, and TPL fractions to provide 
an opportunity to determine the contribution of TAG-rich and TAG-poor particles to 
the overall total plasma responses. No significant differences were observed between 
the lipaemic responses between the control and MUFA-enriched diets, although there 
were differences in the responses between the MAM and YM.
Cohn et al. (1988) demonstrated that older male subjects had higher fasting plasma 
TAG concentations, greater postprandial TAG responses and higher peak plasma TAG 
concentrations than younger men. In the present study, the patterns of response to the 
standard test meal were fairly similar for both MAM and YM, except, at all 
postprandial time points the MAM had higher levels of TAG than the YM. Although 
the fasting TAG concentrations were not significantly different between the 2 age 
groups, the higher fasting TAG values in the MAM may have contributed to the higher 
postprandial TAG response observed in this group. However, fractionation revealed 
that this higher postprandial TAG response in the MAM was due to higher levels of 
TRLs, as evidenced by the significantly higher AUCs and lAUCs. Similar findings 
with the postprandial plasma-, TRL-, and TPL-TAG responses in MAM and YM have 
been reported elsewhere (J.M.E. Knapper, personal communication).
These results suggest that, compared with the MAM, the YM have a greater tolerance 
to fat-containing meals, which may reflect a greater capacity for TAG clearance. This 
conclusion is supported by the higher LPL activity values observed 9 hours 
postprandially in the YM compared with the MAM. One can speculate that the lower 
level of LPL activity contributes to the exagerated lipaemia observed in the MAM. In 
order to test this hypothesis directly, it would be necessary to measure LPL activity at 
the height of the postprandial response, which occurs between 3-5  hours after a meal. 
It was not possible to do this as part of this protocol, but the differences found between 
the YM and MAM at 9 hours support a lower activation of this enzyme in older men.
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One conceivable explanation for these findings is the possibility of a developing 
insulin resistance in the MAM, with lower insulin-stimulated LPL activity during the 
postprandial period. However, although fasting and postprandial insulin responses 
tended to be lower in the YM compared to the MAM, these differences were not 
significant. In support of this, fasting insulin:glucose ratios, a measure of insulin 
resistance, were lower in the YM compared to the MAM. However, fasting NEFA 
concentrations were slightly higher in the YM prior to the MUFA-enriched diet, which 
is in conflict with the antilipolytic actions of insulin.
The plasma and TRL-TAG responses, for the combined subject group, were similar 
following the control and MUFA-enriched diet, although at all postprandial time 
points the responses were lower for the control diet. Other investigators (Brouwer et 
al. 1993; de Bruin et al. 1993) have also reported higher postprandial TAG responses 
with olive-oil feeding.
Previous studies have shown that earlier times to reach peak TAG concentrations are 
observed in Southern Europeans habituated to a MUFA-rich diet compared with 
Northern Europeans habituated to a SFA-rich diet (Zampelas et al. 1998). In this 
present study no such pattern was observed, except in the TPL-fraction where lower 
times-to-reach-peak TAG concentrations were seen. Jackson (1997) reported that 
circulating, fasting and 9-hour TPL apo B-48 concentrations, for the YM studied in 
this present trial, were higher for the control diet compared to the MUFA-enriched 
diet. This tends to suggest that MUFA-enriched chylomicron remnants are cleared 
more quickly from the circulation by the liver and peripheral tissues. In agreement 
with these findings the study of Northern and Southern European men (Zampelas et al. 
1998) demonstrated that in the late postprandial phase, plasma TAG and apo B-48 
concentrations were lower in the Southern Europeans, habituated to a MUFA-rich diet. 
The presence of high concentrations of TAG-poor remnants, which predominate in the 
TPL-fraction at the end of the postprandial phase, have been implicated in the 
development of CHD (Karpe et al. 1994). Therefore, a MUFA-enriched diet may 
affect the rate and packaging of the components of the CM particle in the intestinal 
enterocyte and so determine the size of the particles. In turn, this may affect the
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specificity of these particles for the lipolytic enzymes LPL and HL, which determines 
the clearance of the intestinally derived lipoproteins from the circulation.
Postheparin plasma LPL activities, measured 9 hours following the consumption of 
the standard test meal, were not significantly different between the 2 diets. However, 
the values are comparable to those reported by others (Harris et al. 1988; Bordin et al. 
1998. Consistent with our findings, Zampelas et al. (1998) reported lower postheparin 
plasma LPL activity levels in the Southern Europeans compared to the Northern 
Europeans. LPL activities measured 9 hours following the meal reflected the lipolytic 
activities at this time point and this does not discount the possibility that enzyme 
activities may have varied during the postprandial period when TRLs were being 
actively metabolised in the circulation.
Few other studies have reported the effects of MUFA-rich diets on LPL activity levels. 
One animal study which looked at the effects of feeding olive oil or coconut oil to 
rabbits for 49 days found that postheparin LPL activity levels were significantly higher 
in the rabbits fed olive oil compared to those fed coconut oil (Van Heek & Zilversmit, 
1990). This increase in LPL activity was also accompanied by a concurrent decrease in 
the postprandial plasma TAG responses and suggests an increased clearance capacity 
due to increased LPL activity. Heparin releasable, adipose tissue-LPL activity was 
measured to provide information on the contribution of enzyme activity specifically 
from adipose tissue. However, there were no significant differences in the adipose 
tissue-LPL activity levels between the 2 diets. Few other investigators have measured 
heparin releasable, LPL activity in human adipose tissue. Previous work carried out in 
this laboratory (Beety, 1994) reported mean values of 48 (SD 23) mU ml'  ^ mg'  ^ for 
heparin releasable, LPL activity in 7 females. These values are approximately 4 -6  
times higher than the results reported in this present study. It is possible that these 
differences are a reflection of the different subject groups studied, as young females 
have reportedly higher postheparin plasma LPL activity levels than men (Laakso et al.
1987). However, there are aspects of the technique employed for this investigation 
which give cause for concern. It has been suggested that fat cells are extremely fragile, 
and removal of the tissue by aspiration may have resulted in damage to the cell
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structure, and loss of viable enzyme activity. Although every precaution was taken to 
maintain the adipose tissue cells at a constant temperature (37°C), it is possible that 
whilst in transport from the clinical investigation unit, and during the explant cutting 
procedure the temperature fell below this optimum. This may have resulted in cell 
death. Finally, with such low levels of enzyme activity, a more sensitive technique 
than the one used in the present study, is required for the accurate measurement of 
LPL activity in human adipose tissue.
LPL gene expression in adipose tissue was measured to establish whether the cellular 
potential for synthesizing LPL was affected by dietary fatty acids. Again, there were 
no significant differences in the LPL gene expression results between the 2 diets. 
Together, these findings would suggest that LPL activity is not altered by the MUFA 
content of the diet. However, the number of samples used for these measurements 
were small and individual subject variation was high, which makes establishing firm 
conclusions difficult.
Neither adipose tissue-LPL activity nor gene expression were correlated with 
postheparin plasma-LPL activity. In fact, this is not unusual, as others have reported 
poor correlations between postheparin plasma LPL and the enzyme activities 
measured in the tissue beds (Eckel et al. 1988). This is probably because postheparin 
plasma-LPL activity values are not site-specific, but are the sum of LPL released from 
all tissue endothelial sites. Animal studies have generally found that changes in LPL 
mRNA do not account for the changes seen in enzyme activity, because regulation of 
LPL appears to be post-translational (Ong & Kem, 1989; Doolittle et al. 1990).
There was a trend for the peak insulin concentration to be higher and for the insulin 
response to be more prolonged during the early part of the postprandial period after the 
MUFA-enriched diet. This is in agreement with previous studies where a 24% MUFA 
meal exhibited a greater postprandial insulin response than a 12% MUFA meal 
(Jackson, 1997) and where Southern Europeans exhibited a greater postprandial 
response compared to the Northern Europeans (Zampelas et al. 1998). An explanation 
for this finding could be an increased secretion of GIP during the early phase of the
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There was a trend for the peak insulin concentration to be higher and for the insulin 
response to be more prolonged during the early part of the postprandial period after the 
MUFA-enriched diet. This is in agreement with previous studies where a 24% MUFA 
meal exhibited a greater postprandial insulin response than a 12% MUFA meal 
(Jackson, 1997) and where Southern Europeans exhibited a greater postprandial 
response compared to the Northern Europeans (Zampelas et al. 1998). An explanation 
for this finding could be an increased secretion of GIF during the early phase of the 
postprandial period, since insulin secretion has been shown to be modified by GIF in 
the postprandial environment (Morgan et al. 1988). Higher GIF concentrations were 
reported in the Southern Europeans (Zampelas et al. 1998) and were observed for the 
YM, in this present study, in the early part of the postprandial period (Jackson, 1997). 
Similar postprandial plasma glucose and NEFA responses during both diets suggests 
that despite these increases in insulin, the antilipolytic actions of insulin were not 
impaired.
As with the fasting data, there was a trend for cholesterol concentrations to be lower 
following the MUFA-enriched diet during the postprandial test period compared with 
the control diet. This supports earlier findings by Lichtenstein and co-workers (1993), 
where decreases in fasting cholesterol responses were paralleled in the postprandial 
cholesterol responses following an olive oil-enriched diet.
In conclusion, this study showed few significant effects of a MUFA-enriched diet on 
postprandial lipaemia, but did demonstrate that a significant reduction in fasting total 
and LDL cholesterol could be achieved by replacing SFA with MUFA using normal 
commercially produced foods in a free-living situation.
The 1994 COMA report stated that reductions in total and LDL cholesterol could be 
best achieved by decreasing dietary SFA from current levels of intakes of 16% to a 
desired level of 10% of energy (DoH, 1994). The diet used in the present study has 
achieved the same outcome, but without the need for an overall decrease in total fat. 
Evidence from studies aimed at reducing total-fat and SFA intakes have been 
unsuccessful in achieving significant long-term reductions in cholesterol levels
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(Lindholm et al. 1995; Neil et al. 1995). Infact, Oliver (1997) argued that the more 
desirable a diet is in terms of lowering atherogenic lipoproteins, the poorer the dietary 
compliance. The present study demonstrated that compliance to the diet was excellent, 
as was the quality and palatability of the foods provided. This dietary approach, 
therefore offers an alternative to the low-fat diets currently recommended, as a means 
of achieving reductions in SFA intakes, and CHD risk, in the whole population. Future 
studies should look at the longer term feasibility of increasing MUFA at the expense 
of SFA, to see if the hypocholesterolaemic effects noted are sustainable, and if they 
decrease CHD risk.
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CHAPTER 6
6. GENERAL DISCUSSION
The major cause of morbidity and mortality in the western industrialised world is 
CHD (DoH, 1994). Numerous studies have reported a positive relationship between 
plasma cholesterol levels and CHD mortality, and both primary and secondary 
prevention studies have demonstrated that decreasing plasma cholesterol levels 
significantly reduces the risk of CHD and mortality (Scandinavian Simvastatin 
Survival Study Group, 1994; Shepherd et al. 1995). These findings have indicated the 
need for a change in dietary and lifestyle habits in an attempt to reduce the risk of 
premature death. As a preventative measure against CHD, early dietary studies 
focused on reducing plasma cholesterol levels by replacing dietary SFA with PUFA. 
However, concern that PUFA may initiate the pathogenesis of atherosclerosis through 
lipid peroxidation (Reaven et al. 1994; Nenster & Drevon, 1996) shifted the focus of 
research away from these fatty acids towards other dietary factors. The Seven 
Countries Study (Keys, 1970) initially highlighted the potential benefits of MUFA in 
terms of reduced CHD risk, and research by Bang & Dyerberg (1972) first brought to 
attention the anti-atherogenic properties of long-chain n-3 PUFA. Since these early 
observations, evidence of the role of these fatty acids in the pathogenesis, prevention 
and treatment of CHD has accumulated. Dietary guidelines in this country recommend 
that SFA should provide no more than 10% of dietary energy and n-3 PUFA 
consumption should increase from 0.1 g to 0.2 g/day (DoH, 1994). However, few 
large-scale prospective studies have been carried out to support the positive benefits of 
these dietary changes.
The work described in this thesis had 3 objectives:
• To investigate the feasibility of increasing dietary n-3 PUFA and MUFA
intakes using normal foods enriched with the fatty acids of interest
• To establish the effects of chronically increasing n-3 PUFA and MUFA
intakes on fasting and postprandial lipid, hormone and LPL responses
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• To measure LPL mRNA in adipose tissue using a competitive RT-PCR 
method in order to determine whether changes in LPL gene expression are 
responsible for changes in postprandial lipoprotein metabolism
The dietary intervention described in Chapter 4 was a randomised single-blind 
cross-over study. Middle-aged men received either a control or n-3 PUFA-enriched 
diet for 3 weeks, followed by a 5-month washout period before crossing over to the 
alternate diet for a further 3 weeks. This study aimed to increase the intake of 
EPA+DHA from <0.1 g/day to 1.8 g/day using n-3 PUFA-enriched foods 
manufactured by Hoffman La Roche, without changing the percentage energy from 
fat, carbohydrate and protein. Fasting blood samples and adipose-tissue biopsies were 
collected and the postprandial responses to a standard test meal were investigated. The 
dietary intervention described in Chapter 5 was also a randomised single blind 
cross-over study. Middle-aged men and young men with a family history of CHD 
received either a control or MUFA-enriched diet for 8 weeks, followed by a 1-month 
washout period before crossing over to the second diet for a further 8 weeks. This 
study aimed to increase the intake of MUFA from 12% to 20% of dietary energy and 
decrease the intake of SFA from 16% to 10% of energy using MUFA-enriched foods 
manufactured by the food industry, without changing total fat or energy intakes. 
Fasting blood samples and adipose-tissue biopsies were collected and the postprandial 
responses to a standard test meal were investigated. This discussion draws together the 
conclusions from these studies and makes recommendations for future work.
The majority of studies which have investigated increasing dietary intakes of 
long-chain n-3 PUFA have done so by using fish-oil supplements (Harris, 1989; 
Blonk et al. 1990; Roche & Gibney, 1996; Harris et al. 1997). In contrast, studies 
which have looked at increasing intakes of MUFA have used whole foods, although 
many of the trials were carried out in metabolic wards or closed communities, where 
volunteer access to alternative food stuffs was limited (Mattson & Grundy, 1985; 
Berry et al. 1991; Mata et al. 1992). It is therefore difficult to apply the findings of 
these studies to free-living individuals consuming normal food stuffs. To examine 
whether or not the potential benefits of the findings to date are achievable in whole
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populations, dietary intervention studies need to investigate the use of dietary 
strategies which are simple, effective and easy to implement in large groups of free- 
living individuals. Only then will we be able to evaluate how effective dietary change 
is in terms of reducing CHD risk.
The novelty of the dietary intervention studies described in Chapters 4 and 5, is that 
they demonstrated that the fatty-acid profile of the diet of free-living individuals could 
be significantly altered by using commercially produced foods which had been 
enriched with the fatty acids under investigation. The advantage of using these fatty 
acid-modified foods is that they offer an alternative to individuals unable to increase 
their consumption of fish or olive oil, and are possibly more acceptable to the palate of 
the average UK adult. These studies demonstrated that it is technologically possible to 
modify the fatty-acid composition of common foods without any effect on quality or 
consumer acceptability and therefore represent a vehicle through which dietary 
modifications can be achieved easily on a large scale.
Involvement of the food industry provides a direct link to the consumer and a route 
through which dietary recommendations can be quickly assimilated by the public. This 
has already been seen in the margarine industry, which by providing n-6 PUFA 
spreads, did more to increase the awareness of an optimal balance of fatty acids, than 
any government campaign could have hoped for (Gibney, 1997).
The results from Chapter 4 highlighted that the type and number of foods chosen for 
fatty-acid modification are paramount to the success of the study. Several of the foods 
provided in this intervention were not routinely eaten by the volunteers, which made 
substituting them for similar foods and reaching their target daily fatty-acid intakes 
difficult. This study also demonstrated that the season in which the study takes place 
can strongly influence food choice. For instance, vinaigrette, mayonnaise and 
milkshake were consumed more frequently in the second arm of the study than the 
first, which coincided with late spring. These findings, together with those of a high 
MUFA-diet pilot study (Knapper et al. 1996) ensured that a wider variety of foods 
were manufactured for the chronic MUFA dietary intervention study described in
278
Chapter 5. In this study the foods provided included biscuits, frozen recipe meals, 
garlic bread, spreading fats and cooking oils. The results demonstrated that this form 
of dietary manipulation was readily acceptable to all volunteers, as it required little 
effort in the home and could be eaten with the whole family. By allowing other 
members of the family to have access to the study foods, the compliance to and 
convenience of the diet appeared to improve. If dietary intervention studies and public 
health programmes are to be a success, it is essential that ‘healthy’ foods are 
acceptable and suitable for the vast majority of individuals.
Recording dietary intake is an important part of any dietary-intervention study and a 
number of different methods of recording are available. In Chapter 4, a 3-day weighed 
intake method was used, whereas in Chapter 5, two 5-day unstructured food diaries 
were used to assess dietary intake. To confirm the validity of the food records, plasma 
phospholipid fatty-acid composition data was analysed and comparisons between 
reported energy intakes and estimated energy requirements were made. The results 
from the 2 dietary studies suggest that the 5-day, unstructured diet diary used in 
Chapter 5 gave more reliable nutrient data than the 3-day, weighed food-intake method 
used in Chapter 4. The reasons for this are as follows: dietary records are usually kept 
for at least 7 days, based on the assumption that this is the shortest time necessary to 
cover fluctuations in dietary patterns (Bingham, 1987). Other researchers have 
reported that between 15-20 days’ recording is necessary to accurately measure dietary 
PUFA and between 10-12 days to accurately measure dietary MUFA (Bingham, 1987; 
Nelson et al. 1989). Secondly, the plasma phospholipid fatty-acid data from Chapter 4 
demonstrated that the volunteers were consuming the study foods, but the levels of 
EPA+DHA were not correlated with the recorded intake of these fatty acids. These 
results were disappointing, as others have previously shown positive correlations 
between recorded intakes of n-3 PUFA and fatty-acid enrichment of plasma 
phospholipids (Frost Andersen et al. 1996). In contrast to Chapter 4, the phospholipid 
fatty-acid data from Chapter 5 demonstrated a significant correlation between recorded 
intakes of oleic acid and plasma-phospholipid, oleic-acid incorporation levels. Finally, 
comparisons of recorded energy intakes with estimated energy intakes suggested that 
there was more evidence of under-reporting during the n-3 PUFA study (Chapter 4)
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compared with the MUFA study (Chapter 5). The findings from Chapter 4 show that 
recorded energy intakes were not significantly different from estimated energy 
requirements, despite having used the lowest energy cut-off point to maintain 
long-term survival. In contrast, recorded energy intakes were significantly higher than 
estimated energy requirements during all 3 dietary recording periods in Chapter 5. In 
both studies, the volunteers reported that they found recording their food intake one of 
the most inconvenient and intrusive aspects of the study. Other researchers have 
documented that weighed intake methods are particularly inconvenient to subjects and 
often result in omission of foods eaten (Bingham, 1987; Livingstone et al. 1990; 
Macdiarmid & Blundell, 1997). Together, these findings suggest that the unstructured 
food diary method is a convenient and reliable tool for the assessment of dietary fatty 
acids, when the number of recording days is 10 or more. In addition, the fact that 7- 
day unstructured food diaries have been shown to correlate almost as well as weighed- 
intake methods with 24-hour urinary nitrogen (Bingham et al. 1995) suggests that 
these are more suitable as an assessment tool for large dietary studies. However, 
because food diaries take longer to code than weighed intakes (Black, 1982), it is 
recommended that study foods are packaged in standard portions, which will speed up 
the process of coding and will also help reduce the error associated with estimation of 
portion size by subjects.
Small but significant increases in body weight were observed during both the dietary 
intervention studies. The results from Chapter 5 suggest that weight gain was more 
apparent when the contact between subjects and investigators was reduced. It is 
therefore recommended that in future dietary studies, contact is made with the 
volunteers on a weekly or fortnightly basis, in order to motivate subject compliance, 
monitor body weight and adjust dietary intake if appropriate.
The dietary intervention studies described in this thesis illustrate that it is feasible to 
increase the intakes of major (oleic acid) and minor (EPA+DHA) fatty acids using 
conunonly available fatty acid-modified foods. These foods therefore offer a suitable 
alternative to those individuals wishing to increase their intakes of n-3 PUFA or 
MUFA but who are unable to tolerate an increased consumption of fish or olive oil.
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Carrying out a successful dietary-intervention study and significantly changing the 
nutrient composition of the diet was an important aspect of the studies performed in 
this thesis. However, the relevance of these alterations only become apparent if they 
are accompanied by beneficial biochemical changes.
Despite the mean daily intake of 1.4 g EPA+DHA observed in Chapter 4, significant 
hypotriacylglycerolaemic effects were not achieved. Other investigators, using similar 
doses of n-3 PUFA, have observed fasting plasma TAG reductions in the order of 
14-25%, whereas in this study, fasting plasma TAG was only lowered by 8% 
compared with baseline values. The reason for this lack of hypotriacylglycerolaemic 
effect has already been discussed in Chapter 4, but, one important consideration for 
future studies is that the form in which the n-3 PUFA are ingested may affect its 
absorption. Obviously, further studies on bioavailability, and metabolic responses to 
diets in which n-3 PUFA are produced in different types of food are warranted.
The most significant finding from Chapter 4 was an increase in HDL-C levels 
following the n-3 PUFA diet. High levels of HDL-C are believed to be cardio­
protective as they are thought to represent the product of an efficient lipoprotein 
transport system (Griffin & Zampelas, 1995). Increases in HDL-C have been reported 
previously (Harris, 1989), although other investigators have demonstrated increases in 
the HDL2 :HDL3 ratio, rather than total HDL-C per se (Blonk et al. 1990; Abbey et al. 
1990; Agren et al. 1996). The mechanism by which n-3 PUFA increases HDL-C is not 
yet fully understood, but is believed to influence CETP and LCAT activity (Abbey et 
al. 1990). Future dietary studies should endeavour to measure both the HDL-C 
subfractions and CETP activity levels if a more detailed understanding of the specific 
actions of n-3 PUFA on HDL-C are to be gained.
The most significant finding from Chapter 5, was a 5% reduction in total cholesterol 
and a 9% reduction in LDL-C following the MUFA-enriched diet compared to the 
control diet. This effect was brought about by reducing the percentage energy from 
dietary SFA by 6% and increasing MUFA by 5%. These findings suggest that the 
substitution of dietary MUFA for SFA, without changing the percentage energy from
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fat, is a suitable hypocholesterolaemic alternative to low-fat or high-PUFA diets. 
However, since the publication of primary and secondary drug intervention trials, 
which have demonstrated reductions in CHD risk in the order of 25-35% 
(Scandinavian Simvastatin Survival Study Group, 1994; Shepherd et al. 1995), there 
has been some scepticism surrounding the benefit of such small reductions in plasma 
cholesterol through dietary modification, in terms of CHD risk (Dietschy, 1998). 
Conversely, Law et al. (1994) demonstrated that for every 1% reduction in total 
cholesterol there would be a 2% reduction in CHD risk, although the extent of these 
benefits vary with age. For instance, in middle-aged men a 0.6 mmol/1 (approximately 
10%) reduction in total cholesterol would equate to a 25-30% reduction in CHD risk. 
The main advantage of altering dietary fat intake, is that if it occurs from a young age, 
it may help maintain lower plasma cholesterol levels for a longer period of time, thus 
slowing the development of atherosclerotic lesions and death from CHD. However, we 
can only speculate about this because to date, no large, long-term trial reducing total 
and saturated fat for the primary prevention of CHD has been conducted. Drugs are 
currently the primary treatment given to individuals with established CHD, but these 
results would suggest that replacing dietary SFA with MUFA should become part of 
the primary therapy for the prevention of CHD.
The studies described in Chapters 4 and 5 established that the fatty-acid profile of the 
diet can be altered with beneficial outcomes in terms of biochemical changes. These 
studies have also added to the evidence accruing that individual fatty acids behave 
differently, and highlight the need for further exploration of the specific effects of fatty 
acids on disease risk. In particular it would be interesting to investigate the feasibility 
of enriching common foods with both n-3 PUFA and MUFA, to ascertain whether 
beneficial reductions in total cholesterol, LDL-C and TAG can be achieved. The 
source of these fatty acids may also influence biochemical outcomes, as evidenced by 
those studies which have shown that oleic acid-rich sunflower and rapeseed oils are 
more hypocholesterolaemic than olive oil (Seppanen-Laakso et al. 1993; Lichtenstein 
et al. 1993; Perez-Jimenez et al. 1995; Ruiz-Gutierrez et al. 1997). The fact that these 
oils are cheaper than olive oil may encourage their use by the food industry, and so 
enable widespread dietary changes.
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In addition to measuring the fasting biochemical responses to a dietary-intervention 
study, it is now essential that postprandial responses are also investigated. Humans in 
the Western world spend the majority of the day in a postprandial state, and evidence 
has shown that elevated postprandial lipoproteins are implicated in development of 
CHD (Zilversmit, 1979; Groot et al. 1991). LPL is the enzyme involved in the initial 
hydrolysis of TRL and the activity of this lipase may be important in determining the 
efficiency with which individuals clear lipid from their blood, and the length of time 
that their tissues are exposed to potentially atherogenic lipoprotein remnants. 
Furthermore, it has also been demonstrated that a persons’ background diet affects 
their postprandial response to a standard test meal (Harris et al. 1988; Weintraub et al.
1988).
The study described in Chapter 4, showed that there were no significant differences in 
the postprandial responses between a control and n-3 PUFA-enriched diet, although 
the AUCs were lower following the n-3 PUFA diet. This is in contrast to a number of 
other studies, all of which have consistently shown that a background diet containing 
n-3 PUFA attenuates postprandial lipaemia (Harris et al. 1988; Weintraub et al. 1988; 
Brown & Roberts, 1991; Williams et al. 1992; Agren et al. 1996; Roche et al. 1996). 
From these studies it would appear that diets containing 1-2.8 g long-chain n-3 PUFA 
result in a 30% reduction in postprandial lipaemia. These studies used longer 
supplementation periods (6-16 weeks), and it is quite likely that had our study been 
extended, a signficant lowering of postprandial lipaemia would have been observed. In 
view of the current recommendations for long-chain n-3 PUFA, it seems logical that 
future dietary intervention studies should focus on understanding how low doses of 
n-3 PUFA, used long-term, affect fasting and postprandial lipoprotein metabolism.
The results from Chapter 5 showed that there were no significant differences in the 
postprandial responses following a control or MUFA-enriched diet. To date, there has 
been little work carried out into the postprandial handling of chronic intakes of 
MUFA. A study comparing Northern and Southern Europeans habituated to a 
high-SFA or a high-MUFA diet respectively, suggest that Southern Europeans exhibit 
a rapid entry and clearance of TRL, whereas Northern Europeans show a more
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sluggish rise and clearance of TRL (Zampelas et al. 1998). In agreement with these 
findings, our results showed that there was a trend for the chylomicron remnants, as 
measured in the TPL-fraction, to be removed more quickly in the late postprandial 
period following a MUFA-enriched diet. We can only speculate that if this trend had 
been significant that it would suggest that either MUFA-enriched chylomicrons are a 
better substrate for LPL, or that remnants are preferentially cleared by hepatic 
receptors.
The mechanisms responsible for the fatty acid-mediated alterations in postprandial 
lipaemia are not fully understood, but are thought to include either an increased 
clearance or reduced production of TRL. Much of the attention for increased clearance 
of TRL has focused on the activity of LPL. The 2 dietary studies described in this 
thesis did not observe significant changes in postheparin LPL activity with either 
n-3 PUFA or MUFA feeding. However, as there were no significant differences in the 
postprandial responses to the standard test meal, changes in LPL activity were not 
expected. Previous animal studies have shown that LPL activity is increased by both 
n-3 PUFA and MUFA feeding (Van Heek & Zilversmit, 1990; Murphy et al. 1993; 
Benhizia et al. 1994) and thereby enhance TAG clearance. In contrast, human studies 
have generally failed to find that increased postheparin LPL activity was responsible 
for the lower postprandial responses following n-3 PUFA diets (Harris et al. 1988; 
Weintraub et al. 1988; Nozaki et al. 1991) or when comparisons between individuals 
habituated to a high SFA or MUFA diet were made (Zampelas et al. 1998). There are 
2 possible reasons why human studies are not in agreement with animal studies. 
Firstly, measurement of postheparin LPL is not tissue specific, as heparin releases LPL 
from adipose, cardiac and skeletal tissue; yet in the fed state, adipose-tissue LPL 
activity increases whilst skeletal muscle LPL activity decreases (Farese et al. 1991). 
Secondly, many studies measure LPL activity 8-9 hours after the meal, when 
postprandial responses are returning towards fasting levels. LPL activity is known to 
peak 3-5 hours after a meal, and coincides with peak TAG concentrations. It is 
therefore possible that LPL activities are low 8-9  hours postprandially because the 
requirement for lipolysis of TRL has fallen. This may explain why Southern 
Europeans, habituated to a MUFA-rich diet, had lower postheparin LPL activity values
284
than their Northern European counterparts, 9 hours after a test meal -  this was a 
reflection of the low circulating plasma TAG concentrations at this time (Zampelas et 
a l  1998).
In order to test whether increased LPL activity is responsible for the increased 
clearance of plasma TAG following n-3 PUFA- or MUFA-rich diets, LPL would need 
to be measured 3-5  hours after ingestion of a fat-rich meal. As this is not possible 
during a routine postprandial study, alternative methods for the measurement of LPL 
activity have been sought. The measurement of preheparin LPL activity has been 
shown to significantly increase following ingestion of a fat-rich meal and parallels the 
postprandial responses for TAG (Karpe et a l  1992). However, because LPL activity in 
plasma is low a very sensitive method for its measurement is required. Another 
alternative to postheparin measurements of LPL is the analysis of whole tissue or 
heparin-releasable, adipose-tissue LPL activity. Considering that animal studies have 
suggested that the activating effects of PUFA are localised to adipose tissue (Levy 
et a l  1991; Benhizia et a l  1994), tissue measurements of LPL activity would appear 
to be a more specific and appropriate method for establishing LPL’s contribution to 
postprandial TAG clearance. These findings, therefore, do not rule out that increased 
LPL activity is responsible for reduced postprandial lipaemia following n-3 PUFA or 
MUFA feeding, but suggest that postheparin measurements provide limited 
information and that future studies should direct more attention towards the 
measurement of adipose tissue or preheparin plasma LPL activity.
Other possible mechanisms for the increased removal of TAG following n-3 PUFA or 
MUFA feeding have already been discussed in Chapter 1 and include evidence that 
these fatty acids produce larger chylomicrons which are a better substrate for LPL than 
the smaller SFA-rich chylomicrons (Levy et a l  1991). Secondly, it is also known that 
n-3 PUFA, by inhibiting hepatic lipogenic enzymes, reduce the production of VLDL 
particles (Clarke & Abraham, 1992). A high percentage of the particles circulating 
postprandially are known to be derived from endogenous hepatic sources (Schneeman 
et a l  1993). Therefore, a reduction in the output of these particles will not only reduce 
postprandial lipaemia but may possibly reduce the competition for LPL. Finally,
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dietary fatty acids may affect chylomicron synthesis within the enterocyte. Work has 
already demonstrated that n-3 PUFA have inhibitory effects on the lipogenic enzymes 
involved in chylomicron synthesis (Murthy et al. 1990) and it may be that MUFA can 
also influence the molecular processes involved in chylomicron synthesis, assembly 
and secretion. Obviously, further studies are needed to investigate exactly how these 
fatty acids influence the postprandial metabolism of lipoproteins.
Part of the work in this thesis has centred on the measurement of LPL gene expression 
together with the effects of dietary fatty acids on LPL gene expression. Much of the 
previous work carried out in animals and humans has concentrated on the effects of 
dietary fatty acids on LPL activity rather than LPL gene expression. However, 
2 studies in animals have demonstrated that LPL mRNA levels are influenced by 
dietary fatty acids (Murphy et al. 1993; Chapman 1996). Measurement of LPL gene 
expression gives an estimate of the total potential for LPL activity. Our hypothesis is 
as follows: if LPL mRNA levels are directly altered by dietary manipulation, and this 
is transcribed into active enzyme, this could in turn influence an individuals ability to 
clear dietary TAG. The studies performed in this thesis did not find that LPL gene 
expression was significantly altered by dietary n-3 PUFA or MUFA. However, there 
was a trend for LPL expression to be higher following both the n-3 PUFA and MUFA 
diets when compared to the control SFA diet. An important finding from the study 
described in Chapter 4 was that the absolute change in fasting plasma TAG and 
TAG-AUC was inversely correlated with the change in LPL gene expression. This 
suggests that LPL gene expression may be a strong determinant of fasting and 
postprandial TAG levels and may be more indicative of an efficient plasma TAG 
clearance mechanism than postheparin LPL activity measurements. However, this can 
only be speculation, and further examination of the underlying causes of changes in 
LPL gene expression in adipose tissue of human individuals is needed.
The notion that fatty acids can regulate the transcription of genes is a relatively recent 
concept, but one that is gaining increasing favour. Clarke & Abraham (1992) were the 
first group to report that fish oils had a direct effect on gene expression. Their studies 
looked at the regulation of fatty-acid synthase gene expression in rat liver and showed
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that PUFA suppress expression through a 70-90% reduction in the levels of fatty-acid 
synthase mRNA. They suggested that because the changes in enzyme levels in 
response to alterations in dietary fatty-acid intakes occurred so rapidly, the effects 
could not be due to changes in membrane lipid composition with subsequent 
alterations in insulin signalling, but had to be due to a direct effect of the fatty acids 
themselves or their metabolites. In support of this, there is an increasing body of 
evidence that dietary fatty acids, and n-3 PUFA in particular, stimulate the 
transcription of mRNA by activating key regulatory factors associated with these 
genes (Clarke & Jump, 1993).
It is thought that n-3 PUFA may affect gene expression in a similar manner to the 
fibrate drugs, by activating specific PPARs found in adipose tissue and liver. By 
activating PPARa in liver and PPARy in adipose tissue, fibrates increase hepatic 
fatty-acid uptake for ^-oxidation, decrease the production of apo C-HI and increase 
adipose-tissue LPL gene expression and postheparin LPL activity (Schoonjans et al. 
1996; Schoonjans et al. 1997). Together, activation of these PPARs results in 
increased LPL-mediated lipolysis of plasma TAG and reduced VLDL production. If 
n-3 PUFA activate PPARs in the same way that fibrate drugs do, then this could 
represent the mechanism by which increased LPL gene expression is observed in 
adipose tissue and reduced postprandial lipaemia is achieved following fish-oil 
feeding. In the same way MUFA may have similar effects on adipose-tissue LPL gene 
expression. Although Clarke & Jump (1993) have clearly shown that oleic acid does 
not stimulate hepatic fatty-acid synthase gene expression, they did not rule out that it 
may act as a ligand for various PPARs. It has been suggested that dietary fatty acids 
influence lipoprotein metabolism, and therefore various diseases, through a 
combination of interactive mechanisms: first an acute, rapid and direct regulation of 
gene expression, and secondly a long-term adaptive modulation of membrane 
composition which in turn modifies hormonal signalling (Clarke & Jump, 1993). This 
is an exciting area of research identifying the potential mechanisms through which 
dietary fatty acids may influence the expression of a number of genes involved in 
lipoprotein metabolism and warrants further investigation.
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The ability to measure the expression of a number of genes has been made possible by 
the availability of highly sensitive RT-PCR techniques. Previous work carried out in 
this laboratory has shown that the traditional Northem-blot methodology is not 
sensitive enough to reliably measure LPL mRNA in small biopsies of adipose tissue 
(Chapman, 1996). Therefore, the aim of the work presented in Chapter 3, was to 
develop a competitive RT-PCR method that would measure LPL mRNA. Having 
developed the method, it would then be used to investigate whether diet could alter 
LPL gene expression. The results from Chapter 3, demonstrate that a competitive 
RT-PCR method, sensitive and specific to LPL, was successfully developed and in 
addition, it was also shown that this technique was able to reliably quantitate changes 
in LPL gene expression in response to dietary fatty-acid manipulation. However, as 
this was the first time that competitive RT-PCR was carried out in this laboratory a 
number of problems were encountered during the development process. As a 
consequence, various recommendations for future work have been made, some of 
which are currently in use. For instance, the biopsy procedure has now changed so that 
whole pieces of adipose tissue are removed from the body and stored at -80°C. The 
total RNA extraction method has also changed; weighed amounts of adipose tissue are 
used, extraction of paired tissue samples are carried out simultaneously and the use of 
RT-PCR inhibitors has been avoided.
Future work should focus on the measurement of a housekeeping gene in addition to 
the target genes, so that errors in total RNA measurements between samples can be 
erased. PCR is subject to variable results even when the same sample is analysed 
under identical experimental conditions. On account of this variability it is essential 
that all future studies carry out 2-3  repeated measurements on each total-RNA sample, 
and that steps are taken to standardise each stage of the RT-PCR procedure.
Competitive RT-PCR, although only a relatively new technique, is the preferred 
method for the measurement of gene expression, because of its highly sensitive and 
specific nature and because it does not require large amounts of tissue. The 
opportunity to measure any number of genes involved in lipoprotein metabolism are
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now vast, and will enable a greater understanding of how genes are regulated and 
whether nutrients such as different fatty acids have a role to play in this process.
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APPENDIX
DIET & LIFESTYLE 
QUESTIONNAIRE
Nutrition Research Centre 
University of Surrey
The information given in answer to the follovring questions will be 
treated in the strictest confidence.
NAME
AGE
DATE OF BIRTH 
OCCUPATION
Who else lives in your household (please tick)
Wife /  Partner
Children (please give number and ages)
Parents
Friends /  Lodgers
Would vou describe your job as (please tick): 
Sedentary (desk bound)
Semi-sedentary (multi site offices/factory) 
Physically hard (eg builder)
Physically active (eg postman)
Does your work involve frequent travel? (please tick) 
Abroad 
Within the UK 
No regular travel involved
Which of the following storage/cooking facilities c0 vou own and use?
Fridge
Freezer
Microwave
Oven
GriU
Hob
How regularly do you have breakfast?
Always/usually
Sometimes
Never
Weekdays Weekends
Cereal
Toast
Cooked breakfast
Other (please specify)
How do you travel to work? (e.g. walk to station -10 min, train -30 min)
Do vou have a regular mid-moming break and snack? YES /  NO
What does this consist of?(please tick all that apply}
Biscuits 
Chocolate 
Fruit 
Cake 
Crisps 
Scone 
Muffin 
Toast 
Other Please specify.
Do you eat lunch? 
Always/usually 
Sometimes 
Never
Is lunch usually...? (please tick all that apply) 
Homemade 
Pub lunch 
Shop bought 
Canteen meal
On average, how many times per month do you eat the following:
Pub lunch ____________
Business lunch ____________
Which of the following describes your 
typical lunchtime meal?
Cooked meal eg meat, potatoes & veg. 
Sandwich 
Salad
Pasta & sauce 
Snack meal eg soup & bread 
Pie and chips/fish and chips 
Other (please specify)
How many times per week?
Do you have a regular mid-aftemoon break and snack? YES /  NO 
What does this consist of? (please tick all that apply)
Biscuits
Chocolate
Fruit
Cake
Toast
Muffin
Scone
Crisps
Other
Do vou eat an evening meal?
Always
Sometimes
Never
Please specify
How many times per week is this eaten:
At home
In a pub/restaurant
Which of the following c
Chicken
Pork
Beef
Lamb
Turkey
Veal
Fish
0 you eat regularly? (please tick all that apply)
Do you have a regular late evening or bedtime snack? YES /  NO 
What does this consist of? (please tick all that apply)
Biscuits
Fruit
Cake
Toast
Muffin
Scone
Crisps
Other Please specify
Indicate which of the following vou eat once a month or more 1V 1 or would 
rarelv/never eat F X 1
Lasagne 
Fish in sauce 
Casseroles 
Chilli con came 
Pizza 
Curry
Spaghetti Bolognese 
Other pasta dishes 
Other rice dishes 
Egg noodles
What type of cooking oil
Mazola oil 
Sunflower oil 
Flora 
Olive oil 
Lard 
Dripping
Mixed vegetable oil 
Other
do vou use at home?(please tick aU that apply)
Please specify
What tvpe of spread do vou use at home?(please tick all that apply)
Butter
Stork
Flora
Flora lite
Vitalité
Delight
Olivio
Olive gold
Blue band
Other Please specify
What do you use spread on? (please 
Bread/toast 
Scones/tea cakes 
Potatoes 
Vegetables 
Garlic bread 
Crackers/biscuits 
Fruitcake 
Other
tick aU that apply)
Please specify
What tvpe of milk do you use? 
Full fat
Semi-skimmed
Skimmed
Do you eat cheese? YES/NO
If yes, what types of cheese do vou use regularly?Mease tick all that apply)
Cheddar 
Cheshire 
Edam
Cottage cheese 
Stilton 
Brie 
Other Please specify
How many times per week do vou eat cheese?
Once per week or less 
times per week 
or more times per week
Do you eat out at for have a take- away from! any of the following 
restaurants at least once per month? (please tick all that apply)
Pub/Harvester/Beefeater 
Chinese 
Indian 
Fish & Chip 
French 
Pizza Hut etc 
Fast Food eg Burger King 
Italian 
Mexican
Other (please specify) 
Never/rarely eat at any of these
Please tick any of the following vitamin/mineral preparations that you take 
on a regular basis:
Cod liver oil
Multi vitamin and mineral 
Vitamin C 
Brewers yeast 
Ginseng
Garlic supplements
Other Please specify
Do you drink alcohol? YES/NO
If y es. where do you drink?
Pub
Home
Restaurant/Hotel
Are you a regular drinker? YES/NO 
If so. how often do vou drink?
Once a week
- 3 times per week 
-5 times per week
- 6 times per week 
Every day
Once a fortnight 
Once a month or less
What do you drink? (please tick all that apply) 
Beer 
Wine 
Spirits
If 1 unit = 1/2 pint of beer OR 1 glass of wine OR 1 spirit measure
please estimate the number of units you consume per week
CZl
Do you smoke? YES./NO
If yes, how manv per dav?
What exercise do you do?
Walking
Swimming
Squash
Team sports eg.football
Golf
Cycling
Other (please state_________
Duration?
Do you exercise regularly? YES/NO
How often do you exercise? 
Once per week
1-2 times per week
2-3times per week
4 or more times per week 
1-2 times per month 
Do not exercise
THANK YOU FOR YOUR TIME
PLEASE RETURN THIS QUESTIONNAIRE 
IN THE S.A.E PROVIDED
Y
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The objectives of the present study were to determine the feasibility of using manufactured foods, 
enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as a means of 
increasing the intake of these n-3 polyunsaturated fatty acids (PUFA), and to determine the effect of 
the consumption of these foods on postprandial lipaemia and other metabolic responses to a high-fat 
mixed test meal. Nine healthy, normotriacylglycerolaemic, free-living male volunteers (aged 35-60 
years) completed the randomized, controlled, single-blind, crossover study. The study consisted of 
two periods (each of 22 d) of dietary intervention, separated by a 5-month washout period. During 
these two periods the subjects were provided with the manufactured foods enriched with EPA and 
DHA (n-3 enriched) or identical but unenriched foods (control). A mixed test meal containing 82 g 
fat was given to the fasted subjects on day 22 of each dietary intervention period. Two fasting, and 
thereafter hourly, blood samples were collected from the subjects for an 8h  period postprandially. 
Plasma triacylglycerol, total and HDL-cholesterol, non-esterified fatty acids (NEFA), glucose and 
immunoreactive insulin levels, post-heparin lipoprotein lipase (EC 3.1.1.34) activity and the plasma 
free fatty acid and phospholipid fatty acid compositions were measured. A mean daily intake of 1-4 g 
EPA +  DHA (0 9 g EPA, 0 5 g DHA) was ingested during the n-3-enriched dietary period, which was 
significantly higher than the intake during the habitual and control periods (P <  0 001) assessed by a 
3 d weighed food intake. A significantly higher level of EPA -t-  DHA enrichment of the plasma fatty 
acids and phospholipids (P <  0 001) after the n-3-enriched compared with the control intervention 
periods was also found. The energy intake on both of the dietary intervention periods was found to 
he significantly higher than on the habitual diet (P <  0 001), with an increase in body weight of the 
subjects, which reached significance during the n-3 PUFA-enriched dietary intervention period 
(P <  0 04). The palatability of the enriched foods was not significantly different from that of the 
control foods. Significantly higher fasting plasma HDL-cholesterol and glucose concentrations were 
found after the n-3 PUFA-enriched compared with the control intervention period (P <  0 02 and 
P < 0 05 respectively). No significant dififerences were found for the postprandial lipid and hormone 
measurements, except for significantly lower levels of NEFA at 60 min after the n-3-enriched 
intervention period (P <  0 04). Enriched manufactured foods were a feasible vehicle for increasing 
n-3 PUFA intake. However the nature of the foods provided as the n-3 vehicle may have contributed 
to the increased body weight and higher energy intakes which were adverse consequences of the 
intervention. These factors, together with the short duration of the study may have been reponsible 
for the failure to observe significant plasma triacylglycerol reductions in response to daily intakes of 
1 4 g E P A  +  DHA.
n-3 Polyunsaturated fatty acids: Eicosapentaenoic acid: Docosahexaenoic acid
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Epidemiological studies have related the high habitual intakes of fatty fish with a low 
ineidenee of ischaemic heart disease in the Eskimo population of Greenland (Bang & 
Dyerberg, 1972; Bjerregaard & Dyerberg, 1988) and the Japanese population (Hirai et al. 
1980). M any studies have investigated the effects o f supplementation with marine n-3 
polyunsaturated fatty acids (PUFA; especially eicosapentaenoic acid (EPA) and doc­
osahexaenoic acid (DHA)) on hum an plasm a lipids and lipoproteins and have consistently 
found a lowering of plasm a triacylglycerol (TAG) concentrations, although the effects of 
these agents on cholesterol and lipoprotein levels have been varied (Harris, 1989). In 
addition to the potential beneficial effects o f n-3 PUFA on circulating lipids, these fatty 
acids have beneficial haemostatic effects which may contribute to a decreased risk from 
CHD. These include reduced platelet aggregation, reduced blood pressure, decreased 
viscosity and a lower incidence o f cardiac arrhythmias (W eber & Leaf, 1991).
Despite the apparent consistency of findings in relation to physiological effects of 
long-chain n-3 PUFA, the detailed results from  many of the studies are contradictory, and 
difficult to compare. The probable explanation for this is the large number of factors which 
determine the extent o f the n-3 PUFA effect. These include: the population studied, the 
dose o f n-3 PUFA ingested, the period o f intervention, the source o f n-3 PUFA, 
background diet and diet during the intervention period. However despite these problems, 
the w eight o f evidence suggests that n-3 PUFA (EPA and DHA) confer the protective 
effect associated with high fish intakes (Harris, 1989).
In many countries, the average level o f fish consumption is very low. Moreover, the 
proportion of the population consuming fish is low. Some people do not like to eat fatty 
fish, others have reservations due to the possible toxic effects o f pesticides and /o r heavy 
metals in fatty fish. M iddle-aged men and women have low intakes, and pregnant and 
laetating women often avoid fatty fish despite their increased requirements for long-chain 
n-3 PUFA (Conner et al. 1991). In the UK, the average daily fish consumption is 26 g, of 
which only 25 % is oily fish, the primary source of n-3 PUFA (Gregory et al. 1990). 
According to the present UK recommendations the intake of n-3 PUFA should amount to at 
least 0-2 g daily (Department o f Health, 1994). The low intake and low proportion o f the 
population who ingest oily fish makes the task of increasing the intake of n-3 PUFA 
difficult. However, advances in food technology have allowed the successful incorporation 
of fish oils (EPA and DHA) into a variety of foods, while still maintaining their 
palatability, acceptability and shelf-life. The aim of the present study was to investigate the 
feasibility o f using normal manufactured foods, which had been enriched with EPA and 
DHA, to increase moderately the quantity of these long-ehain n-3 PUFA ingested over a 
22 d period. The absorption, effect on the composition of plasm a phospholipids and any 
changes in fasting and postprandial lipids, lipoproteins and hormone levels were 
investigated in nine middle-aged, normotriacylglycerolaemic men with a low habitual 
fatty fish intake.
MATERIALS AND METHODS 
Subjects
Nine healthy normotriacylglycerolaemic m ale volunteers were recruited from  the staff at 
the University of Surrey, Guildford. The average age o f the volunteers was 50 (SD 7-2) 
years (range 35-60  years) with BM I of 25-7 (SD 2-6)kg/m ^ (range 25-30  kg/m ^). The 
volunteers all satisfied the following inclusion criteria: they were between 35 and 60 years 
old, with a BM I between 22 and 30kg/m ^, their habitual fat consumption was between 35 
and 45 % of total energy and their habitual long-chain n-3 PUFA intake was < 0 -5 g /d .
INCREASING n-3 POLYUNSATURATED FAT INTAKE 225
They did not have any previous history of hyperlipidaemia, endocrine or liver disease or 
known alcoholism. Their alcohol intake was <  30 units per week (1 unit =  8 g alcohol) and 
they did not exercise aerobically for m ore than three 20 min sessions per week. None o f the 
volunteers was following any form  of therapeutic, or specialized, diet or taking dietary 
supplements of fatty acids. All subjects had a fasting blood sample collected before 
inclusion in the study for screening. The criteria for inclusion were: glucose <  6 5 mmol/1, 
total cholesterol < 7  mmol/1, TAG <  1-5 mmol/1 and haemoglobin >  130 g/1.
Informed consent was obtained from  each subject at the beginning o f the study and 
ethical consent was obtained from  the University o f Surrey and the Royal Surrey County 
Hospital Research Ethics Committees.
Dietary intervention
The study design was a randomized, controlled, single-blind, crossover study which 
included two periods, eaeh o f 22 d duration, o f dietary intervention using n-3 PUFA 
(E PA -1-DHA)-enriched and identieal eontrol foods; these were separated by a 5-m onth 
washout period. The food items used were bread, biseuits, cake, iee-cream, orange drink, 
m ilk shake, low-fat spread, pasta, mayonnaise, vinaigrette and milk-shake powder. 
Enrichment was achieved by incorporation of a fish-oil product (ROPUFA; Hoffman La 
Roche Ltd, Basel, Switzerland), either directly, or in a microencapsulated form, into the 
enriehed food items during manufacture. The EPA and DHA content o f all the food items 
used in this study were constant for the stated shelf-life (as confirmed by the m anufacturers 
Hoffman La Roche). Control foods were prepared and paekaged in an identical form  to the 
enriched produets to allow a blind protocol. The subjects were requested to incorporate the 
study foods into their habitual diets, exchanging them  for their usual brands, in an attem pt 
to maintain their habitual dietary intake. No foods, except fatty fish or those containing 
fatty fish, were excluded from  their diets. The aim  o f the study was for the subjects to 
achieve a m ean daily intake of 1-8 g E P A -fD H A /d  on the enriched diet. To this end an 
exchange system was used to allow the subjects choice in the foods that could be consumed 
to reach the objeetive. Each food portion was assigned an exchange value, where one 
exchange was equivalent to 0-2 g E P A -1-DHA (Pike et al. 1996). Subjeets were asked to 
consume nine exchanges daily, equal to 1-8 g E PA -t-D H A /d. In addition to these foods, 
subjects were asked to consume a 113 g pot o f smoked m aekerel pâté (enriched diet) or 
tuna pâté (eontrol diet) per week. These contained 1-6 g and 0-3 g EPA 4- DHA 
respectively. During the period o f  study the subjects were contacted frequently to help 
appropriate food choice, to answer any queries and to aid subject motivation, essential to 
the suceess of dietary intervention studies.
At the end o f the 22 d intervention period the subjeets were asked to score the 
acceptability and palatability of the individual food items using a linear analogue seore 
ranging from 0 to 10, where 0 was ‘not palatable’ and 10 was ‘very palatable’. They were 
also asked to score for compliance on a linear analogue scale where 0 was ‘very com pliant’ 
and 10 was ‘not at all com pliant’. Before commencing the study and during the two periods 
of dietary intervention the subjects were asked to eomplete a 3 d  weighed food intake 
(including 1 d o f the weekend). These data were analysed using the FOODBASE nutrient 
analysis program  (Version 1.2; Institute o f Brain Chemistry and Human Nutrition, 
London).
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Protocol o f  postprandial study days
On day 21 o f the intervention period the subjects were asked not to undertake any 
strenuous exercise, and not to consume any alcohol or eat any food after 20-00 hours. On 
day 22 o f the two intervention periods the subjeets were asked to come into the 
Investigation U nit at the University of Surrey after a 12h overnight fast. A cannula was 
inserted into the antecubital vein o f the forearm, and two fasted blood samples were taken. 
The subjeets were then given the test meal which consisted of 180 g white bread, 250 ml 
orange juice, 5 0 g Frosties (Kellogg’s Company of Great Britain Ltd, M anchester, Greater 
Manchester), 150 ml whole milk, 65 ml double cream, 20 g sunflower margarine, 75 g 
Cheddar cheese. The nutritional content o f the test m eal was 6-4M J energy, 43 g protein, 
163 g carbohydrate and 82 g fat, which comprised 43 g saturated fatty acids, 8 g PUFA, 23 g 
monounsaturated fatty acids, 6 g tran^-fatty acids and 2 g other fatty acids. The subjects 
consumed the meal within 20 min. Following the consumption of the meal the subjects 
were allowed free access to water, low-energy drinks and decaffeinated beverages without 
m ilk or sugar, but no food was eonsumed for 8 h.
Blood samples were collected at 30 min and 60 min postprandially, and then hourly for 
8 h. The blood samples were collected into heparinized tubes, except for a 1 ml sample 
which was collected into a fluoride oxalate tube for glucose analysis. The blood samples 
were spun at 7000g, the plasm a was then frozen in portions at —20°, for future analysis. 
The samples for non-esterified fatty acid (NEFA) determination were divided into portions, 
and frozen within minutes to reduce degradation. At 8 h a 7500 lU  bolus quantity of 
heparin was given to the subjects intravenously and 5 ml blood samples were taken at 5 and 
15 min after the heparin injeetion, from  the opposite arm. These samples were treated as 
described for the other samples collected.
Analytical procedures
Preparation o f  triacylglycerol-rich and triacylglycerol-poor lipoprotein fractions. Plasma 
samples were prepared as described earlier. Then 3-5 m l plasm a was overlayered with an 
equal volume of saline (1-006 g NaCFml), and ultracentrifuged for 5-0 x 10^g  (Lindgren 
et al. 1972) at 24° in a 10 ml centrifuge tube to prepare the triacylglycerol-rich lipoprotein 
(TRL) fraction using essentially the method of Grundy & M ok (1976). The top 1-2 ml of 
the upper layer, the TRL fraction, was carefully removed, portioned and frozen at —20° for 
later analysis. The remaining sample (triacylglycerol-poor lipoprotein (TPL) fraetion) was 
mixed, portioned and stored at —20° for future analysis.
M easurement o f  triacylglycerols, non-esterified fa tty  acids, glucose, total and HDL- 
cholesterol. TAG, NEFA, glucose, total and HDL-cholesterol were measured on the 
Cobas-M ira analyser (Roche Produets Ltd, W elwyn Garden City, Herts.) using enzymic 
kits. TAG levels were measured in plasma, TRL and TPL fractions, using an enzymic 
colorimetric kit supplied by Roche Diagnostic Products Ltd (W elwyn Garden City, Herts). 
The plasm a glucose, total and HDL-cholesterol levels were analysed using kits supplied by 
Roche Diagnostie Products L td and plasm a NEFA using a kit supplied by W AKO 
Chemical GmbH (Germany) supplied by Alpha Laboratories Ltd (London). The m ean 
intra-assay CV for the TAG, cholesterol, NEFA and glucose assays were 2-2, 2-4, 2-0 and
4-5 % respectively. The inter-assay CV for the TAG, cholesterol, ÎÆ FA  and glucose assays 
were 7-3, 7-4, 4-0 and 5-4%  respectively.
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M easurement o f  lipoprotein lipase activity. Lipoprotein lipase (EC  3.1.1.34; LPL) 
activity was m easured in 2 0 /d  portions of plasm a taken 5 and 15 min after the 
administration o f an intravenous dose o f heparin. LPL activity was measured with LPL 
activity being inhibited w ith 4 M-NaCl by a modified m ethod described by Nilsson-Ehle & 
Schotz (1976) using the detection of liberated ^H-labelled free fatty acids from ^H-labelled 
triolein substrate emulsion (Amersham International, Bucks.), as the index of triolein 
hydrolysis. The intra- and inter-assay CV were 5 1 and 8-7 % respectively.
Statistical analysis
Mean, SD and SEM were calculated for each measurement. Differences in time response 
curves were analysed by repeated measures ANOVA followed by a Tukey-K ram er test to 
locate individual differences. Differences in the calculated areas under the time v. response 
curves were identified by ANOVA, followed by D uncan’s multiple range test to locate 
individual differences and assess the level o f statistical significance. Values of P  <  0-05 
were taken as the lowest level o f significance.
RESULTS 
Nutrient intake
The mean nutrient intake o f the subjeets on their habitual diet and during the intervention 
diet period (n-3 enriched) and the control diet period (control) are shown in Table 1. There 
were significant increases in the energy, carbohydrate and fat intakes on the n-3-enriched 
and the control intervention periods when compared with the habitual diet (P < 0-001). 
However the two intervention periods did not differ in their m aeronutrient content. The 
quantities of EPA and DHA, when considered separately and together, were significantly 
higher in the n-3-enriehed, compared with both the control, and habitual periods 
(P < 0-001). The estimated average intake of EPA +  DHA during the n-3-enriched dietary 
period was 1-4 g /d  (0-9 g E PA /d, 0-5 g D H A /d), assessed by the 3 d weighed food intake.
Palatability and compliance
There were no significant differences in palatability scores between n-3-enriched (mean 
6-9, SD 1-0) and control foods (mean 7-4, SD 0-9). The mean com pliance scores reported by 
the volunteers were not significantly different when the n-3 enriched (mean 8-0, SD 1-8) 
and the control (mean 8-5, SD 1-4) period were compared. The values indicated good 
compliance and m otivation of the subjects on both intervention periods. Similarly 
convenience scores o f the dietary intervention periods did not reveal any significant 
differences between the two diets, w ith the mean values for the n-3-enriched and control 
periods being 5-1 (SD 3-0) and 5-7 (SD 3-1) respectively. There were also no significant 
differences found for all compliance, convenience or palatability scores recorded in the two 
arms of the crossover study which could have eome about through seasonal differenees.
Plasma and phospholipid fa tty  acid enrichment
The mean EPA -t- DHA enrichments o f the plasma and phospholipid fatty acids were not 
significantly different at the start o f the two intervention periods. There was a significant 
increase in the EPA -t- DHA incorporation into both the plasm a phospholipids and free fatty
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Table 1. The daily macronutrient, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) intakes o f subjects consuming habitual, n-3-enriched and control diets 
(Mean values and standard deviations for nine subjects)
Nutrients
Habitual diet n-3-Enriched diet Control diet
Mean SD Mean SD Mean SD
Energy (MJ) 9-2 11 120*** 1-3 12-0*** 1-9
Protein (g) 81 18 89 9 84 15
Carbohydrate (g) 290 52 397*** 53 409*** 87
Fat (g) 77 25 106*** 29 102*** 26
EPA (g) 004 0-03 0-86***ttt 023 017 0-08
DHA (g) 0-08 0-05 0-50***ttt 0 15 0-20 018
EPA +  DHA (g) 012 0-07 l-36***ttt 0-34 0-37 0-22
Mean values were significantly different from those for the habitual diet: *** P < 0 001. 
Mean values were significantly different from those for the control diet: f t t  R < 0-001.
acids during the enriehed intervention period from  day 1 to day 9 (P  <  0-001), and a further 
smaller rise from  day 9 to day 21, which did not reach significance. There was no 
significant difference in the incorporation of EPA +  DHA into the plasm a phospholipids or 
fatty acids during the control dietary period. The EPA +  DHA enrichment o f both the 
plasm a fatty acids and phospholipids was significantly higher during (day 9) and 
immediately after (day 21) the n-3-enriched intervention period, compared with the control 
period (P  <  0-001) as shown in Fig. 1.
Anthropometric data
Subjects’ mean body weight increased during both the n-3-enriched and the control 
intervention periods by 1-2 (SD 1-4) kg (76-8 (SD 6-8) kg at the beginning, 78-0 (SD 7-3) kg 
at the end o f the n-3-enriched study period) and 0-6 (SD 1-0) kg (77-6 (SD 7-7) kg at the 
beginning, 78-2 (SD 7-5) kg at the end of the control study period); this was found to be 
significant during the n-3-enriched period (P  <  0-04). It was also found that, regardless of 
the diet type, there was a significant increase (P  <  0-007) in the weight during arm 1 (n 5 on 
n-3-enriehed and n 4 on eontrol diet) compared with arm 2 (n 4 on n-3-enriched and n 5 on 
control diet), but there was no correlation between weight gain and energy intake. The 
starting weights o f each subject on two diets were not significantly different.
Fasting biochemical data
The fasting plasm a concentrations of TAG, total and HDL-cholesterol, glucose, insulin and 
the post-heparin LPL activity are shown in Table 2. The fasting concentrations of TAG, 
insulin and the post-heparin LPL activities were not different after the two intervention 
periods. The mean fasting glucose level after the n-3-enriehed intervention period was 
higher than the habitual and after the control diet (P  <  0-05). The total cholesterol 
concentrations were found to be significantly lower after both dietary intervention periods 
compared with the habitual diet (P  <  0-05). The HDL-cholesterol level was also found to
INCREASING n-3 POLYUNSATURATED FAT INTAKE 229
12
10
I
8
6
Q.
Q.
CL
4
D-
2
0
12 18 240 6
T i m e  (d )
Fig. 1. Concentrations of eicosapentaenoic acid (EPA) and docosahexaneoic acid (DHA) in plasma (O, • )  and 
phospholipids (A, À) of subjects consuming an n-3 polyunsaturated fatty acid-enriched diet (O, A) or a control diet 
(# , A) for 22 d. Values are means for nine subjects with their standard errors represented by vertical bars. Mean values 
were significantly different from baseline: *** P < 0 001. Mean values were significantly different from those for the
control period: t t t  P < 0  001.
Postprandial biochemical data
There was no significant difference between the mean postprandial profiles for the TAG 
measured in any o f the fractions (plasma, TRL and TPL fractions). Fig. 2(a) shows the 
postprandial profiles for the mean TRL TAG concentrations. The mean fasting TRL TAG 
levels were lower after the n-3-enriched compared with the control intervention period,
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however this was not found to be significant. The postprandial profiles were very similar 
rising to a peak at 220 (SD 90) min and 202 (SD 96) min after the n-3-enriched and the 
control intervention periods respectively. The mean TRL TAG levels did not return to 
baseline levels 8 h  after the meal for either intervention period. The patterns of postprandial 
TAG response were similar in all three fractions. However there was a tendency for the 
postprandial profiles after the n-3-enriched intervention period to be lower, compared with 
the control period, although this did not reach significance at any point.
Fig. 2(b) shows the postprandial NEFA responses. They followed a normal pattern, 
falling sharply after the consumption of the test meal and gradually rising to above 
postprandial levels by 8 h at the end o f the study. A t 60 min a significant difference was 
found between the NEFA responses, with the curve for the n-3-enriched intervention 
period falling to a lower level compared with the control intervention period (P  <  0 04).
The postprandial total cholesterol, glucose and insulin levels were not significantly 
different at any time point (results not shown). Higher postprandial cholesterol levels were 
generally observed after the control period and higher postprandial glucose levels after the 
n-3-enriched intervention period. These were not significant, and may reflect the different 
fasting values observed for these two variables after the two dietary intervention periods.
DISCUSSION
This study is one of the first to use normal foods enriched with long-chain n-3 PUFA as a 
means of increasing the EPA and DHA content o f the diet, and offers an alternative to the 
use o f fish-oil capsules or fish. The aim was to increase m oderately the subjects’ daily 
intakes o f EPA and DHA (to about 1 8  g /d ). This daily intake was chosen as it has been 
shown to reduce fasting and postprandial TAG levels significantly in studies using fish-oil 
supplements (Schmidt et al. 1990; Harris et al. 1991). It was also a level o f enrichment 
predicted to be achievable using currently available enriched m anufactured foods. Our
Table 2. Mean fasting plasma concentrations o f  triacylglycerol (TAG), total and HDL- 
cholesterol, glucose, insulin and post-heparin lipoprotein lipase (EC 3.1.1.34; LPL) o f male 
subjects after consuming their habitual diet, a control diet or an n-3-enriched diet% 
(Mean values and standard deviations for nine subjects)
Habitual diet «-3-Enriched diet Control diet
Mean SD Mean SD Mean SD
TAG (mmol/1) 154 054 149 0 37 153 063
Total cholesterol (mmol/1) 599 062 552* 083 5 27* 054
HDL-cholesterol (mmol/1) NC 104f 033 087 029
Glucose (mmol/1) 50 04 5-5*t 05 51 02
Insulin (pmol/1) NC 89 58 87 81
Post-heparin LPL 5 min NC 133 34 117 24
(mU)§
Post-heparin LPL 15 min NC 154 26 161 40
(mU)
NC, no collection of sample.
* Mean values were significantly different from those for the habitual diet, P < 0 05.
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Fig. 2. Postprandial concentrations of (a) triacylglycerols (TAG) in the TAG-rich lipoprotein (TRL) fraction 
(mmol/1) and (b) plasma non-esterified fatty acids (NEFA; mmol/1) after a high-fat mixed test meal (82 g fat) 
consumed at time 0. Subjects had been consuming an n-3 polyunsaturated fatty acid-enriched diet (O) or a control 
diet ( • )  for 22 d before the test. Values are means for nine subjects, with their standard errors represented by vertical 
bars. Mean value was significantly different from that for the control period; * P <  0 04.
results showed that it was feasible to increase the daily intake o f EPA and DHA above the 
habitual level o f 0-1 g /d  using the foods available, consistent with other studies using 
spreads and fish-oil-enriched fish products (Roche, 1995; Gustafsson et al. 1996). However 
the mean daily intake of the subjects did not reach the target intake of 1*8 g /d . The mean 
palatability scores for the individual foods were not found to be significantly different
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when the enriched foods were compared with the control foods and these results indicated 
that a range o f n-3-enriched food products are acceptable vehicles through which EPA and 
DHA supplementation can be achieved without the use of capsules or fish.
The mean daily intake of EPA and DHA, calculated from  the weighed food intake, was 
1 4  g /d  during the n-3-enriched dietary period which did not reach the target intake of 
1-8 g /d . Apparent failure to achieve the target intake was thought to be due to a number of 
factors. First the lim itations of the 3 d weighed food intake m ethod for accurate fatty acid 
intake assessment. For an individual to undertake a weighed food record for accurate 
determination of fatty acid content o f their diet, it would require a period of about 27 d (the 
time estimated for accurate determination of cholesterol), which was considered too 
restrictive for the subjects involved with this study, as a level o f precision necessary for a 
metabolic study was not appropriate in the free-living situation and may have altered 
subjects’ food intakes (Bingham, 1987). In addition, the days during which the fish pâté 
was consumed were not often chosen by subjects as their dietary recording days. This 
source of EPA +  DHA represented a significant quantity of the weekly n-3 PUFA intake, 
and lack of a record o f this food intake may explain the lower than expected recorded n-3 
PUFA intake. Lastly, although the subjects were given full, clear instructions on the 
procedure of dietary records it was observed that the subject who consumed the lowest 
quantity of EPA -f-D H A  (0-6 g /d ), according to the dietary records, had the third highest 
enrichment of E P A -1-DHA in the plasm a fatty acids and fifth highest enrichment of 
EPA-}-DHA in the plasm a phospholipids in the group. This sheds further doubt on the 
credibility of self-recorded dietary data as a means o f assessing nutrient intake, particularly 
of these low levels of dietary fatty acids.
The plasm a fatty acid enrichment data indicated that the enriched foods were being 
consumed. It was observed that the plasma EPA-}-DHA fatty acid levels were at their 
highest on day 22 o f the study, and may have continued to increase if  the duration o f the 
intervention periods had been longer. This suggests that the tissue was not saturated by the 
test fatty acids. Harris et al. (1991) reported a peak level o f fish-oil incorporation into 
platelet phospholipids after supplementation for 1 month, with various doses o f fish oil, 
with no increase for the subsequent 5 months of supplementation. It was observed that the 
n-3 PUFA plasm a phospholipid enrichment was not significantly different at the beginning 
of the two intervention periods, confirming that the 5-month washout period was sufficient 
time for the incorporated EPA -}- DHA to be replaced with fatty acids from  the subjects’ 
habitual diet in the plasm a and phospholipids, between study periods. However no data 
were available for the fatty acid enrichment of the membranes, which would be essential to 
assess the true period o f time required for an adequate washout period.
All o f the subjects gained weight and found difficulty consuming the full number of 
exchanges required to achieve a daily intake of 1-8g EPA-}-DHA/d. The main reason for 
this was that several o f the study foods were not routinely eaten by the subjects; for 
example, m ilk shake, vinaigrette, ice-cream, cakes and biscuits. W hen these foods were 
added to the diet, failure to compensate by reduction in other foods led to an increased 
energy intake, accounting for the weight gain observed. The m ost significant weight gain 
was observed after phase 1, during which five of the subjects were on the n-3-enriched diet. 
This difference in weight gain during the two study phases could be explained by the 
subjects gaining expertise in exchanging the study foods for their usual foods during phase 
1, which they used more successfully during phase 2, preventing such a marked dietary 
energy increase. The data obtained in the present study suggest that if  enriched foods are to 
be used to achieve levels o f intake of greater than 1 g /d , then higher levels o f enrichment in 
individual foods, and a wider range of enriched food products, are needed. It would be
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advisable to enrich foods with a higher fat content such as spreads and oils which are used 
habitually in m ost people’s usual diet.
The moderate intake of EPA +  DHA in the present study did not have the expected 
hypotriacylglycerolaemic effect. Previous studies using low doses of n-3 PUFA (0-74 g 
EPA, 0-44 g DHA and 0*34 g EPA, 0 15 g DHA) in the form o f supplements have reported 
a significant TAG-lowering effect (Schmidt et al. 1990; Harris et al. 1991), although there 
seems to be a critical quantity, as studies using very low doses of n-3 PUFA (0 36 g EPA, 
0-24 g DHA and 0-65 g n-3 PUFA) for an 8-week period showed no effect (Davidson & 
Gold, 1988; Lervang et al. 1993).
The quantity of EPA and DHA consumed is known to be important in determining the 
physiological effects o f these fatty acids. Li & Steiner (1991) demonstrated this when they 
gave 3, 6 or 9 g E P A /d  for 21 d, which led to dose-related gains o f 4-5, 5-6 and 7-6 g 
E P A /100 g total platelet phospholipid fatty acids respectively, similar to findings of other 
groups (Blonk et al. 1990; Harris et al. 1991). The m ean daily intake o f 1-4 g /d  found in 
the present study resulted in a significant increase in EPA -f DHA incorporation into both 
the plasma fatty acids and phospholipid fatty acids (changes of 4-3/^g/m l and 5 -2 /ig /m l 
respectively). This compares very well with the data reported by von Schacky et al. (1985) 
which showed that a daily intake of approximately 2 g EPA -f- DHA in the form of cod- 
liver-oil supplements led to an increase o f EPA -t-D H A  incorporation into the plasm a 
phospholipids in the order of 5 jUg/ml. These findings suggest that the n-3 PUFA 
incorporation from the enriched foods was comparable with that achieved with 
supplements and should, therefore, have provided the predicted reduction in fasting and 
postprandial TAG levels.
A previous study which investigated the effect o f 0-72 g E P A /d  and 0-36 g D H A /d  
incorporated into either a high- or low-fat enriched spread for a 12-week period, also 
reported no effect on fasting plasm a TAG levels (Roche, 1995). In that study the platelet 
phospholipid n-3 PUFA incorporation during the 12-week period illustrated that those 
subjects who were consuming the high-fat fish-oil-enriched spread, had a m ore rapid, and a 
higher level o f EPA -(- DHA incorporation into platelet phospholipids, compared with those 
subjects ingesting the same quantity o f fish oils in the form  o f a low-fat spread (Roche, 
1995). These findings are interesting in relation to the enriched foods used in the present 
study, since it may be that the fish oil is more readily absorbed and incorporated into the 
platelet phospholipids if  it is ingested with a high-fat food. The manufactured, enriched 
foods which were used in our study, except for the spread (600 g fat/kg), were low-fat 
foods, with some (bread, pasta and orange juice) being almost fat-free. VOiether the lack of 
a biochemical effect o f our moderately low n- 3 PUFA intake of 1 -4 g /d  could be due to the 
form in which the fish oil was ingested cannot be determined from  this study. Further 
studies on bioavailability of, and metabolic responses to, diets in which n-3 PUFA are 
produced in different types of foods, are needed.
The duration o f supplementation in a study is also an im portant consideration. Saynor 
& Gillott (1992) demonstrated that dietary supplementation with 3 g n-3 P U F A /d  for 4 
years resulted in a tim e-related reduction in plasm a TAG concentrations. These results 
were also supported by Schmidt et al. (1992) with a shorter study period of 9 months. The 
duration o f the present study was relatively short with only a 2 2 d  intervention period, 
however a significant reduction in plasma TAG has been reported after only 1 m onth by 
other groups (Schectman et al. 1989). The lack of a significant reduction in plasm a TAG 
levels in the present study could be explained by the combination of the relatively low 
dose, short duration o f the study and form of n-3 PUFA, and the significant w eight gain 
during the n-3-enriched intervention period.
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The significantly lower NEFA levels at 60 min postprandially after the n-3-enriched 
intervention period illustrated another potential beneficial effect o f the low-dose fish-oil 
intake. Studies perform ed by Frayn et al. (1996) have illustrated that high circulating 
fasting and postprandial NEFA levels may be linked to a num ber of chronic disease 
conditions. The mechanism of their action is unclear. It is suggested that the lower levels of 
NEFA early in the postprandial profile reflect a greater insulin-iPduced suppression of 
lipolysis during the n-3 PUFA enrichment. In the present study the levels of insulin were 
unchanged after the enriched diet, however this observation may reflect an increase in 
insulin sensitivity, due to the postulated incorporation of E P A -1-DHA into membrane 
phospholipids, resulting in a reduced NEFA release. The m echanism of the reduction in 
NEFA requires further investigation.
Despite the lack o f a significant effect o f the n-3 PUFA intake on TAG concentrations, 
effects on fasting and postprandial lipid levels were observed. Higher fasting HDL- 
cholesterol values were found after the n-3-enriched intervention period compared with 
both the habitual diet and the control intervention period, and after both dietary 
intervention periods the total cholesterol levels were reduced. It has been reported that fish- 
oil intervention in placebo-controlled trials generally increases HDL-cholesterol levels by
5 -1 0 %  (Harris, 1989). The mechanism whereby n-3 PUFA increase HDL levels has not 
yet been elucidated. However it is believed to be related to the down-regulation o f the 
enzymes: cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase (EC  
2.3.1.43; Abbey et al. 1990). In reviewing the effect o f n-3 PUFA supplementation on 
LDL-cholesterol levels, Harris (1989) concluded that the effect was negligible in 
normolipidaemic subjects, unless intakes were high. The reduction in total cholesterol after 
both intervention periods in the present study was unexpected as the total energy intake and 
fat content o f both diets were apparently higher when compared with their habitual intake, 
which would be expected to have an adverse effect on total cholesterol levels. Possible 
explanations for the findings are that there was under-reporting o f habitual intakes or that 
subjects altered the types o f foods consumed.
A significant increase in fasting glucose was observed after the n-3-enriched diet, 
although no significant difference was observed in the fasting insulin, postprandial glucose 
or insulin levels after either o f the intervention periods. The effect o f chronic n-3 PUFA 
intake on hypoglycaem ic control is controversial. Some studies of glucose-intolerant and 
type II diabetic subjects have reported a detrimental effect on fasting and postprandial 
glucose control, with no significant effect on insulin levels, using relatively large doses of 
n-3 PUFA (Friday et al. 1989; Vessby & Boberg, 1990). Other less-controlled studies 
which have also shown this effect, have been criticized, with the negative effect on glucose 
metabolism  being explained by the extra energy supplied by increased fat intake (Borkman 
et al. 1989). W hether our findings for glucose tolerant normotriacylglycerolaemic men 
reflect adverse effects o f low-dose EPA -f DHA on fasting glucose levels is unclear, but 
they appear to be inconsistent with apparent enhanced sensitivity of the anti-lipolytic 
response to insulin suggested by the NEFA findings.
This study has illustrated that it is feasible to use manufactured enriched foods as a 
means of increasing the EPA -1- DHA intake in a free-living population. The foods were 
found to be palatable and well tolerated, but a greater level o f incorporation of 
EPA -I- DHA into the foods would be preferable for future studies. A significantly higher 
incorporation of EPA -f- DHA into the plasm a fatty acids and phospholipids indicated that 
these long-chain n-3 PUFA were absorbed, although the efficiency of absorption could not 
be determined. The m oderately low dose (1 4  g /d ) of EPA -I- DHA for a 22 d period did not 
result in the expected significant hypotriacylglycerolaemic effect. This may have been due
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to the relatively short intervention period and the significant weight gain achieved 
during the n-3-enriched intervention period. However a significant increase in fasting 
HDL-cholesterol concentration and a significant reduction in postprandial NEFA was 
observed after the n-3-enriched period, suggesting that even short periods of low doses of 
n-3 PUFA have potential beneficial effects in normotriacylglycerolaemic middle-aged 
men.
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